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Abstract:
Mutations in RyR2 alter intracellular Ca2+ handling and can result in stress-induced 
arrhythmias. The phenotype resulting from genetic mutations in other ion channels 
(channelopathies) are sometimes influenced by the co-inheritance of common single 
nucleotide polymorphisms (SNPs) in the same gene. Here we provide the first evidence 
that human RyR2 Ca2+ release channel dysfunction associated with an arrhythmogenic 
right ventricular dysplasia type 2 (ARVD2)-linked mutant (L433P) is affected by a 
common, co-inherited RyR2 SNP (Gly1885Glu, G1885E).
Confocal laser scanning microscopy and Ca2+ imaging of human embryonic kidney cells 
(HEK) expressing wild-type (WT) and L433P mutant RyR2 showed that L433P-linked 
Ca2+ handling dysfunction was modulated by the incorporation of WT (non-mutant) RyR2 
into heterotetramers. RyR2 channels formed exclusively from subunits containing only 
the G1885E polymorphism appeared functionally normal. However, G1885E profoundly 
modulated basal and agonist-evoked L433P mutant channel function.
RyR2 homotetramers formed from subunits containing both the G1885E polymorphism 
and the L433P mutation (i.e. in cis) exhibited augmented dysfunction when compared 
with homotetrameric L433P channels during spontaneous and agonist-evoked Ca2+ 
release events. Conversely, heterotetrameric RyR2 channels composed of subunits that 
contained either the L433P or G1885E substitutions (i.e. in trans) displayed a marked 
attenuation of L433P-linked channel dysfunction.
Analysis of basal and post-activation Ca2+ flux levels revealed that complex mechanisms 
underpinned the observed phenomenon, and highlighted that the predominant changes 
were associated with the decay phase of the Ca2+ transient.
This data provides compelling evidence that mutation-linked RyR2 channel dysfunction 
is modulated by common sequence polymorphisms and predicts that a more severe 
clinical phenotype results from the in cis inheritance of G1885E / L433P. Our studies 
also show that co-expression of L433P and G1885E subunits partially restores the 
functionality of the resultant heterotetrameric channels. The potential therapeutic 
benefits of positively modulating RyR2 mutant channel dysfunction via such a trans­
complementation approach remain to be explored.
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Chapter 1
Introduction
1.1. Calcium signalling
Calcium ions (Ca2*) are a ubiquitous intracellular messenger that regulate a multitude of 
cellular processes including muscle contraction, gene expression, energy metabolism, 
cell proliferation and cell death (Laude & Simpson, 2009). The involvement of Ca2* in 
such a variety of cellular processes stems from the interplay of numerous signalling 
proteins that regulate the intracellular availability of Ca2* ions (Bootman et al., 2006). 
Intracellular Ca2* concentration is controlled by a number of processes which increase or 
decrease the level of cytoplasmic Ca2*, a balance of which determines resting cellular 
Ca2* levels (see section 4.1.1 - 4.1.2).
Elevation of intracellular Ca2* concentration is achieved by the influx of Ca2* ions through 
integral plasma membrane (PM) Ca2* channels or through the release of sequestered 
Ca2* from intracellular stores and acts as a trigger for a number of cellular processes 
(Bootman et al., 2001). To allow termination of the cellular event initiated by Ca2*to  
occur, the increased free intracellular Ca2* concentration must decrease in order to 
reduce cytosolic Ca2* availability. This decrease is achieved through a number of ATP- 
dependent or independent mechanisms, namely extrusion of Ca2* from the cell through 
plasma membrane Ca2* ATPases or exchangers, sequestration of Ca2* into intracellular 
stores through sarcoplasmic/endoplasmic reticulum Ca2* ATPases (SERCA), or by 
uptake into mitochondria via the mitochondrial uniporter (Berridge et al., 2000; Bootman 
etal., 2001).
1.1.1. Compartmentalisation of Ca2* signalling
In order for many diverse cellular processes to be regulated by Ca2*, a high level of 
complexity exists in the nature of the Ca2* signal in terms of localisation, amplitude and 
duration. The free diffusion of Ca2* throughout the cell is restricted by cytoplasmic 
buffering and Ca2* extrusion/store uptake, so Ca2* signals must enter the cell in close 
proximity to its target protein or pass through the cell via a process of signal propagation 
(Berridge et al., 2000). In the myocyte, Ca2* release from the sarcoplasmic reticulum 
(SR) stores occurs predominantly through ryanodine receptors (RyRs). Activation of a 
single Ca2* release channel results in a small, localised, increase in cytoplasmic Ca2* 
(~30nM), which lasts for ~200 ms, spreads a distance no more than 2pm and is termed
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a Ca2+ “quark” (Niggli & Shirokova, 2007). The activation of a cluster of several 
neighbouring RyR’s produce elementary Ca2+ release events termed Ca2+ “sparks”. 
These events result in a greater increase in localised Ca2+ of ~200nM, last for ~500ms 
and spread for no more than 6pm. If several Ca2+ sparks occur in close proximity 
simultaneously, it can result in the propagation of a regenerative Ca2+ “wave” which can 
spread rapidly throughout the cell (see Figure 1.1). The magnitude of Ca2+ release is 
important in determining whether these elementary Ca2+ release events can activate 
neighbouring channels and produce a global Ca2+ wave (Cheng et al., 1993). The 
propagation and degeneration of these elementary Ca2+ release events are heavily 
dependent on the buffering capacity of the proteins and organelles encountered by the 
Ca2+ signal (Bootman et al., 2001).
Cytoplasm
SR
t Ca2+ Release Ca2+Uptake
W  RyR2 ( p  SERCA
Figure 1.1. Elementary Ca2+ release events schematic. Ca2+ release from the SR store 
through RyR is indicated by green arrows and uptake through SR Ca2+ ATPases is indicated 
by red arrows. Activation of a single Ca2+ release channel causes the release of a small 
amount of Ca2+ (quark), which is readily sequestered into the ER/SR. Activation of a cluster 
of Ca2+ release channels produces a greater level of Ca2+ release, which can activate 
channels in close proximity (spark). Sequential activation of neighbouring Ca2+ release 
channels can lead to the propagation of a Ca2+ wave that can spread rapidly throughout the 
cell.
The duration of the intracellular Ca2+ signal is also critical in regulating diverse cellular 
functions. Sustained elevated cytoplasm ic Ca2+ can induce cellular apoptosis and as 
such, the majority of Ca2+ signals are presented in a pulsatile or oscillatory manner. 
(Bootman & Berridge, 1995). Furthermore, increased Ca2+ flux between the endoplasmic 
reticulum (ER) and cytoplasm has also been implicated in cell death (George et al., 
2003b). Ca2+ signalling is a critical pathway involved in the correct functioning of many 
different cell types, including amongst others, the cardiac myocyte.
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1.1.2. The cardiac myocyte
The myocardium is made up of many different cell types, although cardiac myocytes are 
the most predominant and fundamental contractile cell in the myocardium. The typical 
cardiac ventricular myocyte (Figure 1.2) is cylindrical in shape and between 10-20pm in 
diameter and 50-100pm in length. Individual myocytes are mainly connected in a 
longitudal direction (end-to-end) and connect at a region termed the intercalated discs, 
which consist of many adhesion proteins and gap junctions (Shimada et al., 2004).
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Figure 1.2. Cardiac muscle ultrastructure. Cardiac muscle comprises of contractile 
myofibrils, each comprised of several sarcomeres. T-tubules penetrate the cell at regular 
intervals to allow rapid depolarisation of the myocyte. Mitochondria provide the energy 
required for dissociation of the myosin head from actin during muscle contraction. 
Adapted from Davies & Novak (2006).
The outer-layer of the myocyte is the sarcolemma, which is a lipid bilayer containing a 
multitude of ion channels allowing the selective ion transport in to and out of the 
myocyte. Highly ordered invaginations of the sarcolemma form structures termed 
transverse tubules (t-tubules) that protrude into the myocyte (Walker & Spinale, 1999; 
Song et al., 2005). T-tubules are between 100-300nm in diameter and occur 
approximately every 1.8pm along the axis of the cell and result in the sarcolemmal L- 
type Ca2+ channels being in close proximity to the intracellular SR calcium release 
channel (Figure 1.3, Song et al., 2005).
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Each individual myocyte is packed with a highly organised array of myofilament proteins 
that form the myocyte contractile apparatus, the sarcomere, comprised of ‘thin’ actin and 
‘thick’ myosin filaments, tropomysin and the troponin complex (troponins T, I and C). 
Both tropomysin and the troponin complex are located within the thin filament and are 
involved in actin stabilisation and regulating the extent of myofibril contraction 
respectively (Walker & Spinale, 1999).
Under resting conditions, when the myocyte is relaxed, tropomysin is wrapped around 
the actin filament, preventing interaction with the myosin filament. Elevated cytoplasmic 
Ca2+ concentration (systole) causes a conformational change in troponin C which results 
in the cross-bridge formation between actin and myosin filaments. The release of ADP 
from the myosin heads causes a change in the angle of the cross-bridge and causes the 
myosin filaments to slide past the actin filaments, shortening the sarcomere and 
resulting in myocyte contraction. Subsequent extrusion of Ca2+ from the myocyte 
dissociates Ca2+ from troponin C, returning the myofilaments to their original positions 
and myocyte relaxation occurs (Purves et al., 2003). This process, whereby the cyclical 
release and re-sequestration of Ca2+ in the SR results in the contraction and relaxation 
of muscle tissue is termed ‘excitation-contraction (EC) coupling’ (Bers, 2002).
1.1.3. Excitation-contraction coupling
Excitation contraction coupling is the process whereby electrical stimulation of the 
cardiac myocyte initiates physical contraction of the heart (Bers, 2002). When the 
heart is relaxed (diastole), intracellular Ca2+ is sequestered in the SR. Membrane 
depolarisation of the myocyte results in an influx of Ca2+ into the cell through 
sarcolemmal voltage-gated L-type Ca2+ channels (LTCC). Due to the localisation of 
the cytoplasmic Ca2+ increase to the sarcolemmal-SR junction and the close 
proximity of RyR2 to the LTCC, this small increase in Ca2+ concentration (200- 
400pM) is sufficient to activate clusters of RyR2 channels (Bers, 2006; Bootman et 
al., 2006). This produces Ca2+ sparks, which subsequently activate neighbouring 
RyR channels, effectively passing the Ca2+ signal through the cell as a propagating 
Ca2+ wave (Figure 1.1) resulting in increased global intracellular Ca2+ levels (Keller 
et al., 2007; Niggli & Shirokova, 2007). The increased availability of intracellular 
Ca2+ causes activation of the cellular contractile machinery and results in
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contraction of the myocyte (systole). The amplitude of the Ca2+ release transient is 
proposed to determine the force of the resulting contraction (Bers, 2006; Eisner et 
al., 2009). Ca2+ is then extruded from the cell via the sodium-calcium exchanger 
(NCX) and plasmalemmal Ca2+ ATPase (PMCA) and is returned to the SR and 
mitochondria by SERCA and the mitochondrial uniporter respectively.
A
B
Figure 1.3. Excitation contraction coupling. Upon membrane depolarisation, an 
influx of Ca2+ (lCa) through LTCC activates RyR2, causing the release of Ca2+ from 
SR stores. Following contraction, Ca2+ dissociates from the myofilaments and is 
removed from the cytoplasm by sequestration in the SR via SERCA modulated by 
phospholamban (PLB), extrusion from the cell via NCX and sarcolemmal Ca + 
ATPase and taken up by the mitochondria via the uniporter. Insert shows the relative 
time course of the action potential, intracellular Ca2+ transient and contraction of a 
rabbit ventricular myocyte. From Bers (2002). Distinct phases of the action potential, 
described in section 1.1.4, are indicated on the representative cardiac action 
potential shown in panel B, adapted from Marban (2002).
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1.1.4. Cardiac action potential
The electrical origin of EC coupling is the cardiac action potential (AP, Figure 1.3A and 
B). Myocytes under diastolic conditions exhibit a resting membrane potential (Em) of 
approximately -85mV (Phase 4). The voltage-dependent activation of fast inward Na+ 
currents results in the rapid depolarisation to approximately +40mV and is represented 
by the sharp upstroke of the action potential (Phase 0). Following complete 
depolarisation, the inward Na+ current becomes inactivated and the efflux of K+ and Cl' 
ions from the cell causes a downward deflection in the AP, indicating slight repolarisation 
(Phase 1). A plateau of the AP follows this downward deflection and is a result of the 
balance between inward Ca2+ currents through LTCCs and the efflux of K+ ions through 
the slow delayed rectifier channel (Phase 2). A rapid repolarisation step follows whereby 
the inward Ca2+ current is stopped by RyR2 mediated Ca2+ efflux, the SR Ca2+ store is 
refilled by SERCA and the outward K+ channels remain open, extruding K+ ions and 
therefore positive charge, from the cell (Phase 3). This continues until the resting 
membrane potential of -85mV is reached, ready for the initiation of the next AP (Phase 
4, Marban, 2002; Bers, 2008)
1.1.5. p-adrenergic stimulation of the cardiac myocyte
Physiological sympathetic stimulation of the heart through the activation of p-adrenergic 
receptors in the myocyte is essential in order to increase cardiac output during periods of 
high metabolic demand and is often termed the “fight-or-flight” response (Marx & Marks, 
2002). p-adrenergic stimulation increases the rate (chronotropy) and force (inotropy) of 
myocyte contraction and accelerates myocyte relaxation (lusitropy), which culminate in 
increased cardiac output (Bers, 2008). p-adrenergic stimulation causes an increase in 
cyclic AMP production which increases protein kinase A (PKA)-mediated 
phosphorylation of several myocyte Ca2+ handling proteins (Figure 1.4, Bers, 2002). 
Inotropic mechanisms upregulated by PKA phosphorylation include Ca2+ influx through 
LTCC (section 1.2.3.3.1) and the release of Ca2+ from the SR through RyR2 (section 
1.2.3.2.4). PKA phosphorylation increases lusiotropic activity through increasing SERCA 
activity (increasing SR Ca2+ uptake, see section 1.2.3.3.2) and the dissociation of 
troponin I from the actin myofilaments (increasing rate of Ca2+ liberation from troponin C, 
section 1.1.2). As such, these processes culminate in an increased level of SR Ca2+ and
27
contribute to a larger Ca2+ transient and increased cardiac output (Bers, 2002). The role 
that PKA phosphorylation on NCX remains highly contentious, with experimental data 
suggesting that PKA phosphorylation increases (Iwamoto et al., 1998) and decreases 
(Ginsburg & Bers, 2005) NCX activity.
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Figure 1.4. p-adrenergic receptor activation and EC-coupling phosphorylation 
targets The p-adrenergic receptor is activated by circulating epinephrine/norepinephrine. 
This triggers the activation of a GTP-binding protein (GJ which stimulates adenylyl- 
cyclase to produce cAMP, which in turn activates PKA. PKA then phosphorylates 
phospholamban (PLB), RyR, LTCC (lCa) and troponin I. CaMKII and the NCX are not 
shown, as uncertainty remains over whether they are regulated by p-adrenergic 
stimulation. From Bers, (2002).
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1.2. The ryanodine receptor (RyR)
The ryanodine receptor (RyR) is a large transmembrane SR Ca2+ channel that regulates 
Ca2+ release from the SR during Ca2+ signalling events, including EC-coupling in 
contractile tissue. The functional RyR channel is a homotetramer, consisting of four 
565kDa subunits with a total molecular mass of ~2.2MDa (Tunwell et al., 1996).
Three tissue-specific isoforms of RyR are encoded by three separate genes. RyR1 is 
primarily expressed in skeletal muscle (Otsu et al., 1990; Zorzato et al., 1990), RyR2 is 
primarily expressed in cardiac tissue, as well as the brain (Lai et al., 1988; Otsu et al., 
1990; Sorrentino & Volpe, 1993; Tunwell et al., 1996) and RyR3 is expressed in smooth 
muscle tissue, the brain and the diaphragm (Hakamata et al., 1992; Sorrentino & Volpe, 
1993; Fill & Copello, 2002). The three isoforms exhibit 66-70% sequence homology, with 
the majority of sequence variation occurring in three regions of sequence diversity: 
divergent regions 1, 2 and 3 (DR1-3), which are thought to be responsible for tissue- 
specific, physiological differences between isoforms (Sorrentino & Volpe, 1993; Zhang et 
al., 2003). For example, RyR1 is activated through a mechanism involving physical 
interaction with the LTCC, whereas RyR2 is activated by CICR in the absence of a 
physical interaction (Fill & Copello, 2002).
In RyR2, DR1 and DR2 encompass residues 4210-4562 and 1353-1397 respectively 
and are located towards the top of the cytoplasmic assembly (Figure 1.6, Liu et al., 
2002; Liu et al., 2004). This region is proposed to be involved in the interaction of RyR1 
with the LTCC, suggesting that sequence variation in this region may be responsible for 
the physiological difference in activation mechanisms between RyR1 and RyR2 (Fill & 
Copello, 2002).
There is also heterogeneity between the Ca2+-dependent activation/inactivation profiles 
of the skeletal muscle and cardiac RyR2 isoforms. RyR2 exhibits a decreased sensitivity 
to inactivation by high concentrations of Ca2+ (>10pM) compared to RyR1, despite 
similar Ca2+-dependent activation profiles (0.1-1 OpM, Chen & MacLennan, 1994; Du et 
al., 1998). Deletion of DR3 (residues 1872-1923 in RyR1, corresponding to residues 
1852-1890 in RyR2) from RyR1 was shown to increase channel sensitivity to Ca2+- 
dependent activation and abolished Mg2* and Ca2+-dependent channel inactivation 
(Hayek et al., 1999). Given that a proposed low-affinity cytosolic Ca2+-binding site is
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located within DR3 of RyR, sequence variation in these regions may contribute to the 
varying Ca2+-dependent activation/inactivation profiles of the RyR isoforms (Sorrentino & 
Volpe, 1993).
Knock-out mouse models that were deficient in each of the specific RyR isoforms 
exhibited extremely detrimental phenotypes. Mice that were deficient in RyR1 exhibited 
respiratory failure and abnormal skeletal and muscular development, (Takeshima et al., 
1994). Those that were deficient in RyR2 exhibited embryonic lethality after 9-10 days 
coupled with impaired heart development (Takeshima et al., 1998). RyR3-deficient mice 
exhibited normal development and muscular function, but exhibited increased locomotor 
activity, suggesting altered neuronal activity in these mice (Takeshima et al., 1996). 
These RyR-deficient mice illustrate the developmental importance of RyR expression.
The work described in this thesis was carried out exclusively on the cardiac RyR 
isoform, RyR2, and although there is a great deal of similarity between the three 
isoforms, RyR2 structure and function will be the focus of the rest of this Introduction.
1.2.1. RyR2 structure
The three-dimensional structure of tetrameric RyR exhibits 4-fold symmetry and appears 
as a mushroom shaped protein comprising of a small C-terminal transmembrane 
assembly (TA, 120 x 120 x 60 A) comprising the channel pore and a larger N-terminal 
cytoplasmic portion (280 x 280 x 120 A, Figure 1.5, Orlova et al., 1996; Samso & 
Wagenknecht, 1998), made up of 10 distinct sub-domains, accounting for approximately 
90% of the protein (Figure 1.5, Wang et al., 2007). Clamp-shaped regions at the corners 
of the RyR tetramer are connected to the centre part of the cytoplasmic assembly by 
part of the protein termed “handle” domains (Figure, 1.5) and are proposed to be 
involved in inter-RyR2 interactions (section 1.2.2).
The cytoplasmic assembly plays a major role in the regulation of RyR channel activity. 
The targeted insertion of the GFP epitope into various locations of RyR2 has revealed 
the location of several primary sequence motifs in the RyR2 three-dimensional structure, 
which are important in channel regulation, the approximate locations of which are 
indicated in Figure 1.6 and summarised in Table 1.1.
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Figure 1.5. Three-dimensional representation o f the RyR channel in the open and 
closed conformation (30 A resolution) Channels are represented in the open (left 
images) and closed (right images) confirmation when viewed from the cytoplasmic face 
(top panels), the side (middle panels) and from the luminal side of the channel (bottom 
panels). The open confirmation o f the channel was induced by incubation o f the purified 
channels with 100pM Ca2+ and 100nM ryanodine. The clamp-shaped structures (C) and 
the handle structure (H) are indicated. The clamp-shaped structures appear to open when 
the channel is in the open state, however this is an artifact of the resolution at which the 
structure was determined. From Orlova (1996)
The divergent regions are all located on the periphery of the RyR2 cytoplasmic 
assembly. DR1 is located on the “handle” domain encompassing subdomain 3 (Liu et al.,
2002). DR2 is located in the subdomain 6, which forms part of the clamp structures (Liu 
et al., 2004), which are proposed to undergo a conformational change during transition 
between the open and closed state of the channel (Orlova et al., 1996), leading to a 
proposed role of DR2 in RyR: RyR interactions (section 1.2.2). DR3 is located in 
subdomain 9, also within the clamp structures (Zhang et al., 2003) and is proposed to be 
critical for correct channel regulation by Ca2+ and Mg2+ (Hayek et al., 1999).
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Figure 1.6. Location o f regulatory motifs in RyR2 3D structure. Top view of RyR2 
from the cytoplasmic assembly (panel A), bottom view o f the channel looking towards 
the SR lumen (panel B), side view o f RyR2 (C), illustrates the disparity in size of the 
cytoplasmic and transmembrane assembly (TA) domains. Numbered regions (1-10) 
indicate distinguishable sub-domains o f the cytoplasmic assembly. Approximate 
locations of important regulatory domains in the cytoplasmic assembly that have been 
identified by targeted GFP insertion are indicated by coloured circles and labels of 
corresponding colour. References for the three-dimensional localisation experiments 
are detailed in section 1.2.1. Adapted from Wang, 2007.
DR3 is located adjacent to the proposed binding site of an important RyR2 regulatory 
protein, FKBP12.6 (section 1.2.3.2.1), which is located in subdomain 3 of the 
cytoplasmic assembly (Sharma et al., 2006) which has recently been corroborated in 
fluorescent energy transfer (FRET) based experiments (Cornea et al., 2010). The 
proposed interaction site of another RyR2 regulatory protein, calmodulin (CaM, section
1.2.3.2.3) has also been mapped to the cytoplasmic assembly. When in its Ca2+-free 
form (apoCaM), difference mapping localises CaM to subdomain 3, although upon Ca2+- 
binding the centre of the mapped difference is shifted by 33 A, although these two areas 
of mapped difference overlap (Samso & Wagenknecht, 2002).
Genetic mutations identified in RyR have been shown to cluster into 3 distinct regions of 
the RyR sequence (section 1.3.2), two of which have subsequently been mapped on the 
3D RyR2 structure. The N-terminal mutation domain has been localised to the clamp 
structure of the cytoplasmic assembly and is located between sub-domains 5 and 9 
(Wang et al., 2007), placing it in relatively close physical proximity to DR3. A second 
mutation domain is located in the centre of the protein sequence and has been mapped
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to the bridge structure between sub-domains 5 and 6 in the cytoplasmic assembly (Liu et 
al., 2005), adjacent to the N-terminal mutational domain, the potential implications of 
which are discussed in section 1.3.4.2.
Two phosphorylation sites involved in the regulation of RyR2 (section 1.2.3.2.4) have 
been mapped to the cytosolic face of the cytoplasmic assembly. A serine residue at 
position 2808 in the RyR2 sequence (Ser2808) is located in subdomain 6 of the 
cytoplasmic clamp region, placing it in close proximity to the central mutation domain 
(Meng et al., 2007). Phosphorylation of S2808 is proposed by some groups to cause the 
dissociation of the RyR stabilising protein FKBP12.6, although this phenomenon remains 
highly disputed (section 1.2.3.2.4). However, the S2808 phosphorylation site is between 
105 and 120 A from the mapped FKBP12.6 binding site, making a direct involvement of 
S2808 phosphorylation in FKBP12.6 binding unlikely (Meng et al., 2007). Similarly, a 
serine residue at position 2030 (S2030) has been proposed as a second 
phosphorylation site (Xiao et al., 2005) and has been mapped to subdomain 4 at the top 
of the cytoplasmic assembly (Jones et al., 2008b), which is also distant from the 
FKBP12.6 binding site. The controversial role of RyR2 phosphorylation in channel 
regulation will be discussed in section 1.2.3.2.4.
Although difference mapping of RyR2 following targeted GFP insertion has been 
extensively used in the localisation of particular motifs in the RyR2 3D-structure, the 
reliability of this procedure is somewhat questionable. Most RyR2 regulatory motifs have 
been mapped to the periphery of the cytoplasmic assembly, particularly to the clamp­
shaped regions (see Figure 1.6). Whether the mapped differences actually constitute the 
inserted GFP epitope, or are a result of GFP insertion within the centre of the molecule 
displacing the flexible clamp regions, remains unknown. However, there is an element of 
reconciliation between difference mapping studies, which place the N and C-terminal 
mutation domains in close proximity in the 3D structure (Liu et al., 2006; Wang et al., 
2007) with FRET-based (Liu et al., 2010) and peptide-competition binding studies 
(Yamamoto et al., 2002), which demonstrate an interaction between these two domains. 
Recent evidence from another FRET based study reconciles the location of the 
FKBP12.6 binding site as determined in these difference mapping studies (Sharma et 
al., 2006; Cornea et al., 2010).
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Regulatory
Motif
GFP insertion location 
(Residue)
Cytoplasmic
Sub-domain Notes References
N-terminal
mutation
domain
S437 Between domains 5 and 9
Domain contains residues 77 - 466 (Medeiros- 
Domingo, 2009). In dose proximity (30A) to central 
mutation domain.
Wang. 2007
Divergent 
Region 2 T1366 6 Localised to “clamp” structure. Liu, 2004.
Divergent 
Region 3 T1874 9
Localised to “damp” structure, adjacent to FKBP12.6 
binding site. Region proposed to contain Ca2YMg2+ 
binding site (Hayek, 1999). Adjacent to FKBP12 .6 
binding site.
Zhang, 2003.
Ser2030 T2023 4 Distant from FKBP12.6 binding site. Jones, 2008.
Central
mutation
domain
S2367 Bridge between domains 5 and 6
Domain contains residues 2246 to 2534 (Medeiros- 
Domingo, 2009). In dose proximity (30A) to N- 
terminal mutation domain.
Liu, 2006.
Ser2808 Y2801 6
Localised to damp structure, 105 - 120A from 
FKBP12.6 binding site. Adjacent to central mutation 
domain.
Meng, 2007.
Divergent 
Region 1 D4365 3 Localised to “handle” domain. Liu, 2002.
FKBP12.6 
binding site
Difference mapping carried 
out in the presence and 
absence of F KBP12.6 
(Proposed T1874 residue)
3, adjacent to 
domain 9.
Adjacent to damp strudures. Displaced 1 -2nm upon 
channel opening.
Wagenknecht.
1996. 
Shanva, 2006.
Calmodulin 
binding site
Difference mapping carried 
out in the presence and 
absence of CaCaM and 
apoCaM 
(Proposed 3630-3638 
residues in RyR1)
3 Shifts -33 ± 5A upon Ca2+ binding.
Samso & 
Wagenknecht, 
2002.
Table 1.1. Summary of motifs mapped in the 3D RyR2 structure. Domain numbers correspond to the sub-domains illustrated in Figure 
1.6. Unless stated, motif localisation was determined through the targeted insertion of the GFP coding sequence into RyR2 cDNA.
The open conformation of RyR contains a C-terminal pore, through which Ca2+ ions are 
released from the SR during CICR (Figure 1.5, Orlova et al., 1996). Although there is 
consensus that the pore region contains several membrane-spanning domains, there 
remains contention over the precise number of transmembrane domains. Models 
containing between 4 and 12 transmembrane domains have been proposed (Takeshima 
et al., 1989; Zorzato et al., 1990; Tunwell et al., 1996; Du et al., 2002). All of these 
models agree that both N and C termini are found on the cytoplasmic side of the SR 
membrane, indicating that the RyR spans the membrane an equal number of times. The 
position of the final pair of transmembrane domains (M8 and M10) and the intervening 
ion-selectivity filter (p-loop, M9) have been confirmed, but ambiguity remains over the 
number of proceeding domains (Du et al., 2002; Meur et al., 2007) with a 6-8 
transmembrane domain being in particular favour (Du et al., 2002; Hamilton & 
Serysheva, 2009).
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Figure 1.7. Proposed RyR membrane topology. The proposed 6 transmembrane 
segment topological model of RyR1. Segments indicated by clashed lines indicate the 
tentative nature of the first predicted helical hairpin loop. The numbers inside each 
transmembrane sequence (M3-M10) are those proposed by Zorzato et al (1990). M9 
represents the selectivity filter, although it is not a transmembrane segment, from Du et al 
2002.
The C-terminus was proposed to contain a conserved peptide sequence located in TM4 
(of the four TM model, corresponding to TM6 of the 6TM model and M10 in Figure 1.7) 
that retains RyR1 within the ER membrane (Bhat & Ma, 2002), although a subsequent 
study showed that a TM1 RyR fragment exhibited a significantly higher degree of ER 
retention, suggesting that the primary retention signal lies within the first TM domain (M5 
in Figure 1.7, Meur et al., 2007). Furthermore, the extreme C-terminal 15 amino acid 
residues of RyR2 have been proposed to be essential for RyR2 tetramerisation (Stewart 
et al., 2003).
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1.2.2. RyR:RyR interaction & coupled gating
As detailed in section 1.1.1, the propagation of an intracellular Ca2+ signal requires the 
coordinated activation of several neighbouring RyR2 channels. As such, RyR2 exists in 
a highly organised lattice-like arrangement with each RyR tetramer interacting with 4 
neighbouring RyR tetramers (Yin & Lai, 2000; Yin et al., 2005b) as depicted in Figure 
1.8 .
Figure 1.8. Physical interaction o f RyR tetramers. Two-dimensional crystallisation of 
RyR on a lipid membrane exhibits a lattice-like appearance as shown in the electron 
micrograph in panel A (Scale bar represents 100pM). A projection map of an RyR 2D array 
is indicated in panel B. The point within the square indicates the RyR pore and the arrows 
indicate the interacting cytoplasmic sub-domain 6 o f neighbouring RyRs. Resolution is ~20 
A. Adapted from Yin (2005b). The “clamp” structure containing sub-domains 3,4,5,6 and 9 
are clearly visible in the projection structure in panel C and corroborate single channel 
structure obtained from previous cryo EM-studies (Radermacher et al., 1994).
This organisation of RyR channels in a “chequerboard” arrangement has functional 
implications, in that interacting channels tend to open and close in unison in response to 
agonist-induced activation. This phenomenon has been termed “coupled gating” and has 
been observed in both RyR1 and RyR2 (Marx et al., 1998; Marx et al., 2001). Marx et al 
have proposed that this interaction is mediated by FKBP12.6 and that dissociation of
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FKBP12.6 from RyR2 disrupts this coupled gating, without causing physical uncoupling 
of RyR tetramers (Marx et al., 2001). However, this has been contested by another 
group who observed no functional consequences of FKBP12.6-dissociation on RyR2 
coupled gating (Hu et al., 2005). Furthermore, modelling of RyR arrays heavily suggests 
that domains 6 and 10 are the regions of the cytoplasmic assembly that interact with 
neighbouring RyR2s (Yin et al., 2005a), making the role of FKBP12.6 in RyR:RyR 
interaction unlikely, given that the proposed FKBP12.6 binding site is located near the 
junction between sub-domains 3 and 9 (Sharma et al., 2006).
Recently, it was demonstrated that luminal Ca2+ regulates the stability of the interaction 
between coupled RyR2 channels in lipid bilayer experiments (Gaburjakova & 
Gaburjakova, 2008). Additionally, the depletion of luminal Ca2* was shown to cause 
greater instability in the RyR2:RyR2 coupling when channels were in the open state, 
which according to the model of Liang et al, leads to the decrease in channel opening 
required for fast RyR2 inactivation (Liang et al., 2007).
1.2.3. Modulation of RyR2
Although RyR2 has a central role in cardiac myocyte Ca2+ signalling, many other 
proteins and cellular processes are involved in the regulation of RyR2 channel function. 
The channel is regulated by many physiological ligands including Ca2* itself, magnesium 
(Mg2*) and ATP (section 1.2.3.1). Some of these modulators are accessory proteins 
which interact directly with RyR2 and constitute the macromolecular complex (section 
1.2.3.2), whereas others indirectly regulate RyR2 activity by altering the intracellular 
ionic environment (section 1.2.3.3). The functional effects of each of these RyR2 
modulators on RyR2 activity will be discussed here. Furthermore, several non- 
physiological compounds, including ryanodine, caffeine and ruthenium red have also 
been shown to alter RyR2 activity and have proved useful tools in investigating RyR2 
function and will be discussed in section 3.1.1.2 and 3.1.5.
1.2.3.1. Physiological ligands
Ca2* itself is the main effecting ligand of RyR2, responsible for both channel activation 
and inactivation, with Ca2* binding sites present on both the luminal and cytosolic sides
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of the channel (Figure 1.9, Laver, 2007). RyR2 is activated by low micromolar 
concentrations of cytoplasmic Ca2+ (1-1 OpM, Rousseau et al., 1986; Rousseau & 
Meissner, 1989; Chen et al., 1998) and in the absence of other regulatory factors i.e. 
Mg2+, ATP (discussed below), RyR2 exhibits a biphasic, bell-shaped 
activation/inactivation curve (Meissner & Henderson, 1987; Li & Chen, 2001) with the 
channel being inactivated by millimolar cytoplasmic Ca2+ concentrations (1-1 OmM). This 
could correspond to the interaction of Ca2+ with the A-site and L-sites described in 
Figure 1.9 (Laver, 2007).
cytoplasm (6a) "■ 
A -s ite ,
lumen
Site Regulatory Role Ligand Ka
L-site Luminal Activation Ca*+ 60pM
A-site Cytoplasmic Activation Caz* 1-10pM
h-site Cytoplasmic Inhibition Caz* and Mg^+ ~10mM
12-site Cytoplasmic Inactivation Caz* 1pM
Figure 1.9. Schematic representation o f RyR2 Ca2* binding sites. RyR2 is 
regulated by the binding of Ca2* to three binding sites. The L-site is the luminal Ca2* 
activation site, the A-site is the cytoplasmic Ca2* activation site, the l2-site is the 
cytoplasmic inactivation site and the /* site is the non-specific Ca2*/Mg2* inhibition 
site. From Laver, (2007).
Single channel analysis of human RyR2 channels demonstrated that raising the 
cytosolic Ca2+ concentration from 1 to 100pM (with 67mM luminal Ca2+) resulted in a 
significant increase in channel opening events (Holmberg & Williams, 1989). In the 
absence of luminal Ca2+ and any RyR2 activating cofactors, increasing cytoplasmic Ca2+
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concentration was shown to increase channel open probability (P0) from 0 to 0.6 with a 
half maximal activating cytoplasmic Ca2* concentration of 5pM (Sitsapesan & Williams, 
1994).
The li site is non-specific for divalent cations (Ca2* and Mg2*) with relatively low affinity 
(~10mM). A C-terminal fragment of RyR1 (residues 4007 to 5037) does not exhibit 
Ca2*/Mg2* inhibition, suggesting the l2-site is in the N-terminal 4007 amino acids, and 
further studies have implicated amino acid residues 1873-1903,1641-2437 and 615 with 
the l2-site (Laver, 2006, 2007)
Luminal Ca2* also plays a major part in regulating RyR2 activity and several models 
have been proposed by which luminal Ca2* regulates RyR2 channel activation and 
inactivation. Although the precise mechanism of luminal Ca2* regulation of RyR2 
remains unknown, it is likely that each of the models described below contributes to 
luminal Ca2*-depedent activation/inactivation of RyR2.
Ca2* feed through hypothesis
Single-channel analysis of RyR2 in lipid bilayers, demonstrated that in the 
absence of cytoplasmic Ca2* or other activating factors, increasing luminal 
Ca2* up 10mM did not cause significant channel activation. (Xu & Meissner, 
1998). It was subsequently proposed that luminal-to-cytoplasmic Ca2* flux 
was required for activation by way of luminal Ca2* binding to the 
cytoplasmic activation site, leading them to term this the Ca2* feed-through 
hypothesis (Tripathy & Meissner, 1996).
Direct Luminal Ca2* activation hypothesis
Another group showed that under conditions which prevented luminal-to- 
cytoplasmic Ca2* flux, increasing luminal Ca2* concentration significantly 
increased channel RyR2 activation (Ching et al., 2000). Furthermore, 
trypsin digestion of the luminal face of RyR2 abolished luminal Ca2* 
activation but did not alter Ca2luminal-to-cytosolic Ca2* flux, questioning the 
feed-through hypothesis and suggesting the presence of a luminal Ca2* 
activation site (L-site).
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Luminal-triggered Ca2* feed-through hypothesis 
The most recently proposed model incorporates both of the other activation 
mechanisms and proposes that RyR2 is activated by Ca2+ binding to either 
a luminal (L-site) or cytoplasmic Ca2* binding site (A site) and is inactivated 
by Ca2* binding to an inhibitory cytoplasmic Ca2* binding site (12-site, Laver, 
2007). This group propose that Ca2*'binding to the L-site causes brief 
channel openings, allowing small amounts of luminal-to-cytoplasmic Ca2* 
flux causing a localised increase in the vicinity of the cytoplasmic A-site. 
Activation of the A-site was proposed to prolong channel openings and 
further SR Ca2* release, which providing that this Ca2* flux is of sufficient 
magnitude, caused channel inactivation by binding to the l2-site.
Luminal Ca2* sensitised cytoso lic  Ca2* activation
This model proposes that luminal Ca2* regulates RyR2 by altering the
sensitivity of channels to activation by cytoplasmic Ca2* (Qin et al., 2008). It
is proposed that an increase in luminal Ca2* concentration leads to an
increase in the maximal channel PQ at a given cytoplasmic Ca2*
concentration, as demonstrated in single channel studies (Qin, 2008, J Gen
Physiol).
Calsequestrin-dependent lum ina l Ca2* activation  
This model proposes that the Ca2*-binding protein, calsequestrin (CSQ, see 
section 1.2.3.2.2) acts as a putative luminal Ca2* sensor. When SR Ca2* is 
low, CSQ is proposed to exert an inhibitory effect on RyR2, preventing 
channel opening and contributing to channel inactivation (Gyorke & 
Terentyev, 2008). As SR Ca2* content increases during SR refilling, CSQ is 
proposed to undergo a conformational change, dissociating it from the 
RyR2 quaternary complex and relieving RyR2 inhibition.
Magnesium inhibits human RyR2 activity in the millimolar concentration range 
(Holmberg & Williams, 1989; Rousseau & Meissner, 1989; Du et al., 1998; Li & Chen, 
2001), most likely through interaction with the lrsite described above. This inhibitory 
effect was most prominent in low cytoplasmic Ca2* concentrations, suggesting that Mg2* 
exhibits its main physiological effects during diastole (Holmberg & Williams, 1989).
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However, Mg2+ has recently been shown to increase RyR2 activation at intermediate 
Ca2+ concentrations (10-100|jM), although this was only observed in rabbit RyR2, which 
does not exhibit the typical biphasic Ca2+-dependence of activation/inactivation (Chugun 
et al., 2007). Mg2+ is thought to result in channel inactivation through competitive binding 
to the non-specific divalent cation ^-binding site and has also recently been proposed to 
compete with luminal Ca2+ to bind the L-site (Laver, 2007).
ATP is a potent RyR2 agonist and has been shown to increase RyR2 P0, but only in the 
presence of cytoplasmic Ca2+ (Witcher et al., 1991; Li & Chen, 2001; Laver, 2007), 
suggesting that ATP sensitises RyR2 to activation by this ligand, rather than directly 
activating the channel.
1.2.3.2. The RyR2 macromolecular complex
Accessory Proteins RyR2 Phosphorylation
CaMKII
Figure 1.10. RyR2 macromolecular complex. A schematic representation o f the known 
components of the RyR2 macromolecular complex. Each tetramer may contain more than 
one interaction site for each accessory protein, as detailed in the text. The right hand side 
of the figure details anchoring proteins and kinases involved in the phosphorylation of 
RyR2. Proteins may not be constitutively bound to RyR2, as their interaction may depend 
on physiological conditions, e.g. phosphorylation status.
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As well as being activated and inactivated by free intracellular ions, RyR2 channel 
activity is also regulated by a number of accessory proteins. The cytoplasmic assembly 
of RyR2 acts as a scaffold to which many of these regulatory proteins bind, some of 
which co-precipitate with RyR2 (Marks et al., 2002; Bers, 2004). The RyR2 channel and 
its associated proteins are commonly referred to as the RyR2 macromolecular complex 
and the proteins that compose this assembly are detailed here.
1.2.3.2.1. FK506-binding protein
The FK506 binding protein (FKBP12.6) is a 12.6kDa accessory protein that directly 
interacts with the cytoplasmic assembly, with a single FKBP12.6 binding site present on 
each RyR2 monomer (Timerman et al., 1996; Sharma et al., 2006). FKBP12.6 is 
described as an immunophillin due to its interaction with the immunosuppressant drugs 
FK506 and rapamycin (Zissimopoulos & Lai, 2005). Although a smaller FKBP12.6 
isoform, FKBP12, is also readily detected in the cardiac myocyte, RyR2 has a 
significantly higher (~600-1000 fold) affinity for FKBP12.6 with which it co-purifies 
(Timerman etal., 1996; Guo etal., 2010). Furthermore, FKBP12.6, but not FKBP12, was 
shown to alter basal RyR2 activity in terms of Ca2+ spark frequency indicating that 
FKBP12 has little functional consequence on RyR2 function (Guo et al., 2010).
The exact mechanism by which FKBP12.6 modulates RyR2 activity remains unclear, 
although it has been proposed to stabilise the closed state of the channel (Marx et al., 
2000; Prestle et al., 2001; George et al., 2003a; Yano et al., 2003; Wehrens et al., 
2005), preventing spontaneous Ca2* release and diastolic Ca2* leak. In accordance with 
this hypothesis, an increased PQ and a number of sub-conductance states were 
observed in single RyR2 channels isolated from FKBP-knockout mice (Wehrens et al.,
2003) or in WT channels treated with drugs that suppressed the FKBP12.6:RyR2 
interaction (rapamycin and FK506, Xiao et al., 2007b). However, these observations 
were contested by results from another FKBP12.6 deficient mouse model, in which the 
absence of FKBP12.6 did not alter single RyR2 channel biophysical properties, agonist- 
sensitivity or the incidence of spontaneous Ca2* release compared to WT mice (Xiao et 
al., 2007b). Other studies have also demonstrated that FKBP12.6 does not have a 
significant effect on RyR2 channel function (Timerman etal., 1996; Barg etal., 1997).
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It has also been proposed that the association of FKBP12.6 with RyR2 is highly 
dependent on RyR2 phosphorylation status and that ‘hyper-phosphorylation’ of RyR2 
can lead to FKBP12.6 dissociation and channel destabilisation (Marx et al., 2000; 
Wehrens et al., 2003). However, this is also a highly contentious observation (Stange et 
al., 2003; Meng et al., 2007; Xiao et al., 2007a; Guo et al., 2010), which will be 
discussed further in section 1.2.3.2.4. Another area of continuing debate is the role of 
FKBP12.6 in arrhythmia caused by mutations in RyR2, which will be discussed in 
section 1.3.4.3.
1.2.3.2.2. Calsequestrin, Junctin and Triadin
It is well established that RyR2 channel activity is regulated by the SR free Ca2* 
concentration, although the precise mechanism by which this occurs remains unknown 
(section 1.2.3.1). Calsequestrin (CSQ, encoded by CASQ1 in skeletal muscle and 
CASQ2 in cardiac muscle) is a 42kDa high-capacity, low-affinity luminal SR Ca2* binding 
protein (MacLennan, 1971) and has been proposed as the RyR luminal Ca2* sensor in 
skeletal and cardiac muscle (section 1.2.3.1, Kim et al., 2007; Gyorke et al., 2009), 
although this role is disputed by other groups (Knollmann et al., 2006). During Ca2* 
uptake and release, CSQ forms a quaternary complex with RyR2 and two “anchoring” 
proteins; junctin and triadin which are 26kDa and 35kDa respectively (Figure 1.10, 
Zhang etal., 1997)
Depending on the ionic environment, CSQ can exist in a range of highly organised 
aggregates ranging from monomers and dimers in the presence of low luminal [Ca2*] to 
long CSQ polymers at high luminal [Ca2*] (Beard et al., 2005; Kim et al., 2007). The C- 
terminal of CSQ is highly negatively charged and allows high capacity binding of Ca2* 
ions (~50 per monomer) and interacts with junctin and triadin bound to the lumenal face 
of RyR (Kim et al., 2007). This effectively ensures that high amounts of Ca2* are stored 
at the RyR pore mouth, ready for Ca2* release during EC-coupling.
Junctin and triadin have been shown to be constitutively bound to RyR2 during EC 
coupling, yet CSQ only interacts with junctin/triadin when free SR Ca2* is low (Zhang et 
al., 1997). Under these conditions, CSQ exerts an inhibitory effect on RyR2, which is 
proposed to allow more efficient SR Ca2* refilling. At high luminal Ca2*, the CSQ Ca2*
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binding sites become occupied causing a conformational change in CSQ and its 
subsequent dissociation from the quaternary complex, abolishing the inhibitory effect of 
CSQ and allowing channel opening and subsequent SR Ca2* release (Kim et al., 2007). 
The presence of all three accessory proteins is required for CSQ to regulate RyR2 
activity in response to changes in luminal [Ca2*] (Gyorke et al., 2004; Gyorke et al., 
2009).
CSQ knockout mice were arrhythmogenic following exercise and exhibited an increase 
in spontaneous SR Ca2* release from the SR coupled with an increased SR volume, 
despite exhibiting a normal systolic Ca2* transient (Knollmann et al., 2006), presenting a 
similar phenotype to that of CPVT patients (sections 1.3.1 and 1.3.4). Furthermore, 
mutations in CSQ, most of which are autosomal recessive, have been identified in 
patients exhibiting a CPVT-phenotype, implicating altered CSQ regulation of RyR2 in 
arrhythmia (section 1.3.4, Lahat etal., 2001a; 2001b; Dirksen etal., 2007).
1.2.3.2.3. Calmodulin
Calmodulin (CaM) is a 16.7kDa, ubiquitously expressed Ca2* binding protein that 
regulates RyR2 channel activity through interaction with sub-domain 3 of the RyR2 
cytoplasmic assembly (Samso & Wagenknecht, 2002; Bers, 2004). CaM consists of two 
pairs of Ca2* binding EF hand domains separated by a flexible peptide linker sequence. 
In its Ca2* free from, CaM appears as a dumbbell-shaped protein and is referred to as 
apoCaM and upon binding Ca2* it undergoes a conformational change and is referred to 
as Ca2*-calmodulin (CaCaM, Chin & Means, 2000). CaCaM has been shown to inhibit 
RyR2 activity at all cytoplasmic Ca2* concentrations (Witcher et al., 1991; Balshaw et al., 
2002; Yamaguchi et al., 2003), and is proposed to do so by desensitising RyR2 to Ca2*- 
dependent activation (Yamaguchi et al., 2003). CaM has been proposed to inhibit 
diastolic RyR2 opening and recently the abolition of CaM binding to RyR2 in a knock-in 
mouse model harbouring a central domain CPVT mutation resulted in an arrhythmogenic 
phenotype (Xu et al., 2010), suggesting CaM has a critical role in regulating RyR2 
function. CaCaM also regulates the activity of Ca2*/Calmodulin-dependent kinase II 
(CaMKII), a serine/threonine kinase involved in RyR2 phosphorylation (section
1.2.3.2.4).
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1.2.3.2.4. Regulation of RyR2 by protein kinases
Although there is consensus that phosphorylation plays a major role in the regulation of 
RyR2 activity, there remains a great deal of contention as to the precise mechanism and 
functional consequences of channel phosphorylation. To date, three phosphorylation 
sites have been identified in RyR2, which are serine residues located at amino acid 
positions 2808, 2814 and 2031 in the human RyR2 sequence (Witcher et al., 1991; 
Wehrens et al., 2004; Xiao et al., 2005; Huke & Bers, 2008). RyR2 is phosphorylated by 
a number of protein kinases, but the most-well documented are protein kinase A (PKA) 
and Ca2+/calmodulin-dependent kinase II (CaMKII).
The serine at residue 2808 (S2808, S2809 in mice) was the first RyR2 phosphorylation 
site to be indentified (Witcher et al., 1991) and has been proposed to be phosphorylated 
by CaMKII (Witcher et al., 1991; Rodriguez et al., 2003) and by PKA (Marx et al., 2000; 
Rodriguez et al., 2003; Wehrens et al., 2003). However, a subsequent study 
demonstrated that CaMKII was unable to phosphorylate this residue, but phosphorylated 
a nearby serine residue, S2814 (S2815 in mice) which was not subject to PKA 
phosphorylation, suggesting that S2814 is an exclusive CaMKII phosphorylation site 
(Wehrens et al., 2004).
The most recently identified phosphorylation site in RyR2 is a serine residue located at 
amino acid position 2030 in mice (S2030, S2031 in humans), which was shown to be 
subject to phosphorylation by PKA (Xiao et al., 2005), but not by CaMKII, leading to the 
proposal that this was a PKA-specific phosphorylation site.
A recent study comparing the residue-specific phospho-antibodies used by different 
research groups in the investigation of RyR2 phosphorylation, has demonstrated that the 
sensitivities of each groups antibodies varied significantly (Huke & Bers, 2008). This 
suggests that these phospho-specific antibodies are not the most reliable indicators of 
RyR2 phosphorylation at specific residues and could explain some of the discrepancies 
in results obtained from different groups.
PKA-mediated phosphorylation of RyR2 has been shown to increase RyR2 P0 and 
cause the channel to exhibit several sub-conductance states (Marx et al., 2000), 
although the observation of sub-conductance states has not been repeated to date.
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Increased P0 following PKA phosphorylation was proposed to be the result of FKBP12.6 
dissociation mediated by PKA phosphorylation of RyR2 (Marx et al., 2000; Wehrens et 
al., 2003). Similarly, CaMKII phosphorylation of RyR2 has also been shown to increase 
channel P0 (Witcher et al., 1991; Wehrens et al., 2004) but did not result in the 
dissociation of FKBP12.6 or in the observation of channel sub-conductance states 
(Wehrens et al., 2004), suggesting that PKA and CaMKII alter RyR2 gating parameters 
through distinct mechanisms.
However, the functional consequences of RyR2 phosphorylation remain highly 
controversial, with several groups reporting that PKA and CaMKII-mediated 
phosphorylation does not cause the dissociation of FKBP12.6 from RyR2 (Jiang et al., 
2002; Stange et al., 2003; Xiao et al., 2005) or alter the biophysical properties of the 
channel (Stange etal., 2003). Additionally, RyR2 has been shown to be phosphorylated 
at S2808 by PKA to approximately 75% of maximal levels under resting conditions, yet 
exhibits low channel activity (Carter et al., 2006). As such, the precise role of 
phosphorylation and FKBP12.6 dissociation remains highly controversial.
The effects of PKA phosphorylation on RyR2 activity are further confounded by the fact 
that PKA phosphorylates a number of other Ca2+ handling proteins e.g. the SR Ca2+ 
ATPase, LTCC, whose effects, such as altered SR Ca2+ load, may alter RyR2 activity 
(Bers, 2002).
1.2.3.2.5. Protein Phosphatases -  PP1 and PP2A
As phosphorylation is generally thought to increase RyR2 activity during periods of p- 
adrenergic stimulation (Marx et al., 2000), there must also be a mechanism to reverse 
the action of RyR2 phosphorylation when p-adrenergic stimulation ceases. Several 
protein phosphatases (PP) reside in the RyR2 macromolecular complex and interact 
with RyR2 indirectly through adaptor proteins e.g. spinophillin, mAKAP (Marx et al.,
2000). Each of these proteins interacts with each other through substrate-specific 
isoleucine/leucine zipper (ILZ) sequences.
Much, like the role of phosphorylation in RyR2 regulation, the involvement of PP1 and 
PP2A in channel regulation remains controversial. PP1 and PP2A have been shown to
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cause a depletion of SR Ca2+ stores and an increase in channel activity (Terentyev et al., 
2003; Carter et al., 2006). This is a rather surprising observation as phosphorylation and 
dephosphorylation of RyR2 are opposing processes and would be expected to result in 
opposite effects on channel activity. A potential explanation could be that deviation from 
75% of maximal S2809 phosphorylation levels increases RyR2 activity and protein 
kinases and phosphatases act in unison to regulate RyR2 activity (Carter et al., 2006).
1.2.3.2.6. Other macromolecular proteins
S100A is 21kDa accessory protein that to date has received little attention in terms of its 
modulatory effect on RyR2 function. However, S100A competitively binds at the CaM 
binding site on RyR2 (Prosser et al., 2008) and ablation of S100A results in a decrease 
in agonist-evoked SR Ca2+ release (Wright et al., 2008), which is proposed to result from 
increased CaM binding in the absence of S100A.
Sorcin is a relatively novel 22kDa Ca2+ binding protein that localises to the RyR2 and 
LTCC junction (Farrell et al., 2003). Upon binding Ca2+, sorcin adopts a membrane 
bound form in which it is proposed to inhibit RyR2 over a wide range of Ca2+ 
concentrations (Valdivia, 1998). Sorcin has also been shown to directly interact with 
CaMKII and inhibit CaMKII activity, while CaMKII has been shown to phosphorylate 
sorcin (Anthony et al., 2007), suggesting a collaborative regulatory effect on RyR2 
activity.
1.2.3.3. Other myocyte Ca2* handling proteins
Together with proteins in the RyR2 macromolecular complex, several other myocyte
Ca2* handling proteins are involved in regulating the availability of intracellular Ca2* in
the myocyte, and as such can indirectly influence RyR2 function.
1.2.3.3.1. L-Type Ca2* channel
Although LTCC is not part of the RyR2 macromolecular complex per se, and there is no 
physical interaction between LTCC and RyR2 (unlike in RyR1, Lu et al., 1994), these
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two proteins exhibit an apparent functional coupling (see section 1.1.3). In order for 
resting Ca2+ homeostasis to be achieved, the LTCC current must be periodically stopped 
to allow cytoplasmic Ca2+ sequestration in intracellular stores, prior to the initiation of the 
subsequent action potential. LTCC is subject to two inactivation mechanisms; voltage- 
dependent inactivation and Ca2+-dependent inactivation. Following SR Ca2+ release, the 
cytoplasmic Ca2+ concentration in the vicinity of the LTCC is dramatically increased and 
results in channel inactivation (Benitah etal., 2010).
The functional LTCC is heterotetrameric and consists of a number of subunits (a,, (3, a2, 
5). Several isoforms of each subunit have been identified and the subunit composition 
of the LTCC varies between tissues (Treinys & Jurevicius, 2008), possibly accounting for 
the functional differences observed between activation mechanisms. Like RyR2, LTCC 
activity is modulated by phosphorylation by a number of kinases (PKA, PKC, PKG), 
which in the case of PKA, is consistent with the observation of altered Ca2+ current 
following (3-adrenergic stimulation (Bodi et al., 2005; Benitah et al., 2010).
1.2.3.3.2. Sarco-endoplasmic Ca2+ ATPase and phospholamban
The human cardiac sarco-endoplasmic reticulum Ca2+ ATPase (SERCA), a 110kDa 
protein encoded for by the SERCA2a gene, is located in the SR membrane of the 
myocyte and is responsible for the sequestration of cytoplasmic Ca2+ in to the SR 
following myocyte contraction (Verboomen etal., 1992). Each SERCA molecule contains 
two Ca2+ binding domains in the transmembrane region, a phospholamban (PLB) 
binding site in the cytoplasmic “head” and a thapsigargin binding site at the cytoplasmic 
face of the SR membrane (Toyoshima et al., 2000).
SERCA activity is modulated by an SR membrane bound protein; phospholamban 
(PLB), which is a 22kDa protein comprising of a single transmembrane domain and a 
cytoplasmic “head” domain connected by a flexible linker sequence (Smith et al., 2001). 
In its unphosphorylated state, PLB binds and inhibits SERCA, reducing the rate of Ca2+ 
uptake into the SR. PLB is readily phosphorylated by PKA and CaMKII and becomes 
dissociated from SERCA upon phosphorylation, increasing the rate of Ca2+ uptake into 
the SR and explaining the observed increase in Ca2+ transient amplitude following |3-AR 
stimulation (Bers, 2008). The interaction between PLB and SERCA can also be
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interrupted in the absence of PLB phosphorylation by increasing cytosolic Ca2+ above a 
certain threshold level, causing the loss of SERCA inhibition and an increase in the rate 
of Ca2+ uptake into the SR (Periasamy & Huke, 2001). Furthermore, PLB knockout mice 
displayed significantly increased SR Ca2* load and rate of SR Ca2* uptake and a 
decreased relaxation time (Chu et al., 1998), indicative of increased SERCA activity in 
the absence of PLB.
SERCA Ca2+ uptake activity is Ca2*-dependent, as demonstrated by the increase in rate 
of radio-labelled 45Ca ion uptake by microsomes over-expressing SERCA2a in the 
presence of increasing Ca2+ concentrations, with a half maximal rate of Ca2+ uptake 
(K o .s ) at 0.34pM (Verboomen et al., 1992). This infers that the rate of Ca2+ uptake into 
the SR is fastest during periods of elevated cytoplasmic Ca2*, such as immediately 
following transient Ca2* release during EC-coupling. There is evidence that SERCA 
expression and Ca2* transfer activity is down-regulated in several experimental models 
of HF (reviewed by Bers, 2006).
1.2.3.3.3. Sodium-calcium exchanger (NCX)
Following CICR, the majority of cytoplasmic Ca2* is resequestered in to the SR by 
SERCA (~75% in humans, Figure 4.1, Piacentino et al., 2003), however, Ca2* is also 
extruded from the cell, predominantly through a plasma membrane sodium-calcium 
exchanger (NCX, Bers, 2002; Piacentino et al., 2003). NCX activity is electrogenic, in 
that a single Ca2* ion is extruded from the cell in exchange for 3 Na* ions, resulting in a 
net decrease in membrane potential. As such the outward Ca2* current through NCX is 
evident throughout the majority of the action potential and is critical for myocyte 
repolarisation.
The role of phosphorylation in the regulation of NCX activity remains controversial with 
several groups reporting that PKA phosphorylation increases NCX activity, whereas 
others report that PKA-mediated phosphorylation has no effect on NCX (reviewed by 
Reppel etal., 2007). However, given that a macromolecular complex containing protein 
kinase and phosphatase anchoring proteins (e.g. mAKAP) and the protein phosphatases 
PP1 and PP2 is present on the cytoplasmic face of NCX, a potential role of 
phosphorylation on NCX regulation is likely.
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Over-expression of NCX in knock-in mouse models resulted in increased LTCC current 
amplitude, suggesting an element of compensation by LTCC following increased 
cytoplasmic Ca2+ extrusion (Reuter et al., 2004). In contrast, knock-out mice deficient in 
NCX exhibited embryonic lethality, with myocytes isolated from 9.5 day post-coitum 
embryos displaying normal Ca2* transients under resting conditions (Reuter et al., 2003). 
However, following p-adrenergic or agonist stimulation when SR Ca2* transient 
magnitude was increased, normal Ca2* homeostasis was unable to be achieved, 
indicating a critical role of NCX in intracellular Ca2* handling.
1.2.3.3.4. Slow Ca2* extrusion mechanisms
Together with SERCA and NCX-mediated cytoplasmic Ca2* removal, relatively small 
amounts of Ca2* are extruded from the cell by a plasmalemmal Ca2* ATPase (PMCA) or 
sequestered in the mitochondria via a uniporter. These two mechanisms of Ca2* removal 
are collectively termed “slow mechanisms” and are proposed to account for 
approximately 1-2% of cytoplasmic Ca2* removal following Ca2* induced Ca2* release 
(Bers, 2002), meaning that their functional impact on myocyte Ca2* cycling and CICR is 
negligible compared to the other Ca2* extrusion mechanisms.
Like SERCA, PMCA-mediated Ca2* extrusion is an energy-driven process, with a single 
Ca2* ion being removed from the cell for each molecule of ATP that is hydrolysed. PMCA 
activity is regulated by CaM which upon binding the ATPase causes a slight increase in 
PMCA Ca2* affinity (Di Leva et al., 2008). The uptake of Ca2* into the mitochondrial 
uniporter is a passive process, in that Ca2* moves down the electrochemical gradient 
from the cytoplasm during systole when cytoplasmic Ca2* concentration is high. The 
uptake of Ca2* into the mitochondria is believed to be involved in determining the rate of 
energy production, the spatio-temporal nature of intracellular Ca2* signals and the 
regulation of cell death (Kirichok et al., 2004).
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1.3. Dysfunctional Ca2* signalling and disease
Given the highly orchestrated nature of myocyte Ca2* signalling and the integral role that 
RyR2 plays in this pathway, it is unsurprising that dysfunctional SR Ca2* release through 
RyR2 is implicated in cardiac pathology.
Alterations in SR Ca2* store load have been associated with many aspects of myocyte 
Ca2* handling dysfunction and SR Ca2* load can be altered through perturbed activity of 
many of the Ca2* handling proteins discussed in sections 1.1.3. An increase in SR Ca2* 
content can increase the sensitivity of RyR2 to activation and can result in increased 
spontaneous Ca2* release i.e. Ca2* sparks (Bers, 2006; Gyorke & Carnes, 2008). If such 
Ca2* release is of sufficient amplitude, it can activate inward Na* currents through NCX, 
which can lead to early and delayed after depolarisations (EADs and DADs, see section 
5.1.1) which can cause the initiation of premature action potentials and lead to 
arrhythmia (Bers, 2006). Contrarily, downregulation of SERCA or upregulation of NCX 
causes a decrease in Ca2* transient amplitude and can result in impaired cardiac 
contractility, as observed during HF (Bers, 2006, Phsyiol). Decreased SR Ca2* load can 
also occur as a result of Ca2* leak from the SR resulting from destabilised or “leaky” 
RyR2 channels (Marx et al., 2000). Not only can this Ca2* leak result in decreased 
transient amplitude, but if the leak is sufficient it could potentially activate inward Na* 
currents through NCX and cause premature APs as described above.
Over the last decade, a great deal of evidence has demonstrated that mutations in the 
gene encoding RyR2 alter many parameters of SR Ca2* release and have been 
associated with two arrhythmia-linked conditions, which are described in section 1.3.1.
1.3.1. CPVT and ARVD2
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic 
condition characterised by the occurrence of syncopal episodes and sudden cardiac 
death under conditions of physical or emotional stress. CPVT does not cause structural 
aberrations of the heart and the patients present a normal ECG pattern under resting 
conditions, making the disorder relatively difficult to diagnose (Leenhardt et al., 1995; 
Priori et al., 2002). Only after increased (3-adrenergic stimulation do patients exhibit
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bidirectional ventricular tachycardia, which if persistent can result in arrhythmia. Males 
who have inherited a mutation in RyR2 have been reported to be at slightly higher risk of 
exhibiting CPVT than females (Priori et al., 2002; Medeiros-Domingo et al., 2009), 
although this difference is only observed in some earlier cohorts (George et al., 2007).
CPVT has been linked to chromosome 1q42-q43 (Swan et al., 1999), a region which 
encompasses the locus for RyR2. Mutations in this gene have since been associated 
with CPVT (Priori et al., 2001). These mutations are inherited in an autosomal dominant 
fashion, meaning that inheritance of a single disease-linked allele is sufficient to result in 
a CPVT phenotype and exhibits a high mortality rate (30-50% by the age of 30 years old, 
Fisher et al., 1999). Arrhythmogenic right ventricular dysplasia type 2 (ARVD2) is a 
similar condition to CPVT, in that it presents as stress-induced arrhythmias on a 
background of a normal resting ECG (Rampazzo et al., 1995) and is an autosomal 
dominant disease caused by genetic mutations in RyR2 (Tiso et al., 2001). However, 
ARVD2 is distinguishable from CPVT due to the observation of partial replacement of 
the sub-epicardial right-ventricular myocardium with fatty-fibrous tissue in affected 
patients (Rampazzo et al., 1995).
CPVT has also been linked to a distinct second chromosomal location, 1p13-21 (Lahat 
et al., 2001a; Lahat et al., 2001b) and was subsequently shown to result from mutations 
in the CASQ2 gene (Lahat et al., 2002). Unlike the autosomal dominant form of CPVT 
caused by mutations in RyR2, mutations in CASQ2 are autosomal recessive in nature 
(Lahat et al., 2002), meaning that inheritance of a CASQ2 disease-linked mutation on 
both alleles is required to result in a CPVT phenotype.
1.3.2. Identification of disease-linked RyR2 mutations
The onset of CPVT was first attributed to mutations in RyR2 through the genotyping of a 
number of patients who exhibited bidirectional ventricular tachycardia on a background 
of a normal resting ECG and a structurally normal heart (Leenhardt et al., 1995; Priori et 
al., 2001; Postma et al., 2005).
The majority of CPVT patients demonstrate a family history of CPVT symptoms, such as 
syncope or sudden cardiac death, suggesting the inheritability of the condition. However
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in some cases the patient was the only symptomatic family member and neither parent 
carried the mutant allele, suggesting that CPVT mutations can also arise in a de novo 
manner (Priori et al., 2001; Laitinen et al., 2003; Postma et al., 2005; Marjamaa et al., 
2009). CPVT-associated mutations tend to be located in regions of the gene that are 
highly conserved between species and isoforms, suggesting that they are of particular 
functional importance (Laitinen et al., 2001; Priori et al., 2001; Postma et al., 2005; 
Marjamaa etal., 2009). RyR2 mutations also appear to cluster in three distinct regions of 
the protein, that correspond to regions of RyR1 in which mutations have been shown to 
be associated with malignant hypothermia (MH) and central core disease (CCD, Priori & 
Napolitano, 2005). These domains are located towards the cytoplasmic N-terminus 
(residues 77-466, CPVT I), the central domain (residues, 2246-2534, CPVT II) and the 
C-terminal channel region (residues 3778-4959), which is sometimes split into two 
domains, CPVT III and IV, Figure 1.11, (George et al., 2007; Medeiros-Domingo et al., 
2009).
Genotyping studies are often targeted to these regions of RyR2, resulting in screening of 
only a portion of the coding exons (Priori et al., 2001; Laitinen et al., 2003; Choi et al., 
2004; Postma et al., 2005; Nishio et al., 2008). This infers that substitutions that reside 
outside of these mutational “hot-spots” may sometimes be overlooked and can result in 
a CPVT patient being described as genotype-negative, despite the possibility that a 
mutation may be present outside of these mutation clusters (Creighton et al., 2006). 
Although the majority of studies in which sequencing of the entire RyR2 coding 
sequence has been carried out tend not to report disease-linked mutations outside of 
these mutational “hot-spots” (Laitinen et al., 2001; Tiso et al., 2001; Bagattin et al., 2004; 
Marjamaa et al., 2009b), there are exceptions to this in which mutations have been 
identified at the peripheries of these clusters (Marjamaa et al., 2009a; Medeiros- 
Domingo et al., 2009). Furthermore, common polymorphisms have been identified in the 
regions between these mutational clusters which may or may not have functional 
significance (section 1.4.4.2.2 and 1.4.4.2.3, Laitinen etal., 2001; Tiso etal., 2001).
Cases of ARVD2 have been reported, in which symptomatic individuals have inherited 
two RyR2 disease-linked mutations on the same allele i.e. R176Q/T2504M (Tiso et al., 
2001), with subsequent functional characterisation in a heterologous system revealing 
that either mutation alone was sufficient to perturb intracellular Ca2+ handling (Thomas et 
al., 2004). However, the homotetrameric co-expression of R176QM/T2504M exhibited
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different intracellular Ca2+ handling characteristics compared to when either mutation 
was expressed alone (Thomas et al., 2004), suggesting a complex phenotype of the 
“double” mutant. CPVT mutations exhibit a variable degree of penetrance between 
individuals, both in the same and different affected families (Bauce et al., 2002; Thomas 
et al., 2007; Marjamaa et al., 2009b). A CPVT-affected family has been identified in 
which all affected individuals harboured a P2328S mutation. However, two family 
members who had inherited this mutation were completely asymptomatic (Laitinen et al.,
2001). Similarly, the R420W substitution was identified in two CPVT-affected families, 
with a variable penetrance being observed between mutation carriers in each of these 
families. In the first family, all R420W carriers exhibited a CPVT phenotype, whereas two 
members of the second family had inherited the R420W mutation, but were 
asymptomatic despite the SCD of several other family members (Bauce et al., 2002).
Recently, the N3308S polymorphism and R3570W mutation were identified in CPVT- 
affected families, in which carriers of the mutation displayed highly varying degrees of 
CPVT phenotype, despite inheriting the same RyR2 mutation (Marjamaa et al., 2009a; 
Marjamaa et al., 2009b). Furthermore, the age of pathological onset of CPVT-mutations 
has also been shown to vary significantly within family members who have inherited 
identical CPVT-linked RyR2 mutations (Priori et al., 2001; Marjamaa et al., 2009a). 
These observations taken together suggest that RyR2 mutations exhibit a variable 
penetrance between individuals of the same family, further implicating the role of 
epigenetic factors in determining the severity of the resulting mutant phenotype. This 
proposal was strengthened by the observation that the clinical penetrance of six 
mutations identified through genetic screening of CPVT patients varied between 25 and 
100%, with no obvious relationship between mutation locus and the degree of 
penetrance (Bauce et al., 2002).
1.3.3. RyR2 mouse models of CPVT and ARVD2
Knock-in mouse models heterozygous for CPVT/ARVD2-linked RyR2 mutations have 
been generated and used to investigate the mechanisms of mutant RyR2 pathogenesis 
(Cerrone et al., 2005; Kannankeril et al., 2006; Goddard et al., 2008; Lehnart et al., 
2008; Fernandez-Velasco et al., 2009; Uchinoumi et al., 2010). These models allow 
investigation into the effects of RyR2 mutations in the intact heart of a mammalian
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organism, although considerations must be made for differences in cardiac physiology 
between species e.g. heart rate, relative contributions of Ca2* extrusion mechanisms, 
cardiac output etc.
A knock-in mouse, heterozygous for the C-terminal R4496C mutation (R4496C+/), the 
mouse equivalent to the human R4497C CPVT-linked mutation (Priori, 2001), displayed 
no structural aberrations of the heart and exhibited a normal ECG under resting 
conditions (Cerrone et al., 2005), in agreement with the CPVT phenotype observed in 
humans. However, R4496C*7' mice displayed a significantly increased susceptibility to 
bidirectional and polymorphic VT in response to exercise stress-testing or ^-adrenergic 
stimulation and caffeine administration, a phenomenon characteristic of CPVT (Priori et 
al., 2002). The treatment of R4497C+/‘ mice with (3-blockers did not prevent the onset of 
arrhythmia in these mice (Cerrone et al., 2005), which is reflective of only the partial 
success of (3-blocker administration in preventing arrhythmia in CPVT patients carrying 
this mutation. A phenomenon that was first described in R4496C*'" mice, was the 
observation that myocytes isolated from these mice exhibited increased spontaneous 
SR Ca2* release under basal, non-stimulated conditions, which was exacerbated 
following (3-adrenergicstimulation (Liu etal., 2006; Femandez-Velasco etal., 2009). This 
provides the first evidence that CPVT-linked RyR2 mutations cause an underlying defect 
in intracellular Ca2* handling at rest, which is worsened following p-adrenergic 
stimulation, corroborating observations made through heterologous expression and 
subsequent functional characterisation of R4496C (section 3.1.1.6, Jiang etal., 2002).
Another mouse model has been generated, which is heterozygous for the R2474S 
central domain CPVT-linked RyR2 mutation (Lehnart et al., 2008). As in other mouse 
models, R2474S+/" mice displayed a normal heart rate and rhythm at rest, but exhibited 
bidirectional and polymorphic VT following exercise stress-testing and epinephrine 
administration. Myocytes isolated from these mice also exhibited an increased 
spontaneous Ca2* release event frequency following p-adrenergic stimulation, an 
observation that was not evident at rest or in WT myocytes. Interestingly, these mice 
also exhibited spontaneous brain seizures, independently of cardiac arrhythmias 
(Lehnart et al., 2008), providing evidence that mutant RyR2 dysfunction is not limited to 
cardiac disorders, although this has not been observed in humans suggesting this 
phenotypic manifestation may be species-specific. Unlike the other mouse models, 
these mice displayed a reduced RyR2-FKBP12.6 interaction under resting conditions,
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which was exacerbated following PKA-mediated RyR2 phosphorylation, which is 
consistent with the model proposed by Marx (2000, section 1.3.4.3) and Wehrens 
(2003). Conversely, a second mouse model harbouring the same R2474S mutation has 
been generated and characterized by another group (Uchinoumi et al., 2010) who 
observed a slightly different phenotype. Although these mice presented bidirectional or 
polymorphic VT in response to exercise or caffeine/epinephrine administration, they also 
exhibited increased spontaneous polymorphic ventricular contractions under resting 
conditions. The increase in the occurrence of VT was attributable to an observed 
increase in spontaneous SR Ca2* release events in myocytes isolated from the 
R2474S*/'mouse, both at rest and following p-adrenergic stimulation. However in 
contrast to Lehnart’s R2474S heterozygous mouse, Uchinoumi et al did not observe 
spontaneous seizures in their R2474S mouse model, nor did they observe the increase 
in PKA-mediated hyper-phosphorylation of RyR2 and subsequent FKBP12.6 
dissociation (Uchinoumi etal., 2010), illustrating phenotypic differences between the two 
heterozygous mouse models harbouring the same R2474S mutation (Lehnart et al., 
2008; Uchinoumi et al., 2010), which could be attributable to differences in the genetic 
background of the mice (Cook et al., 2009).
Similarly, a knock-in mouse heterozygous for the N-terminal R176Q ARVD2/CPVT- 
linked RyR2 mutation (R176Q+/) has been produced (Kannankeril et al., 2006). These 
mice exhibited a normal resting ECG and exhibited premature ventricular beats following 
P-adrenergic stimulation, which developed into bidirectional VT under pacing conditions 
(Kannankeril et al., 2006), similar to the phenotype observed in ARVD2 and CPVT 
patients. However, there was no evidence of the ARVD2-characteristic fibro-fatty 
infiltration of the right ventricle (Rampazzo et al., 1995) in hearts isolated from R176Q*A 
mice, although a decrease in systolic function was observed. This suggests this mouse 
model is a more representative of the CPVT phenotype and suggests the co-inherited 
T2504M mutation may be responsible for the ARVD2 phenotype observed in some 
patients (Tiso et al., 2001).
Recently, a central domain CPVT-linked RyR2 mutation, P2328S, was investigated in 
mice that were both homozygous (P2328S*/+) or heterozygous (P2328S+/‘) for the 
mutation (Goddard et al., 2008). Compared to either WT or P2328S+/' mice, P2328S+/* 
mice exhibited a much more severe arrhythmogenic phenotype, displaying increased VT
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Mutation Disease Location Knock-in Mouse Phenotype Isolated Myocyte Phonotypo References
R176Q ARVD2 N-terminus Developed arrhythmia upon caffeine/epinephrine 
administration
Increased Spontaneous Ca2* release at rest 
and upon catecholamine treatment.
Kannankeril,
2006
P2328S
(homozygote)
CPVT Central
Domain
Higher VT incidence than heterozygote.
EADs and arrhythmia at rest (6/11 hearts)
Developed arrhythmia upon catecholamine treatment 
(11/11 mice).
Increased spontaneous Ca2* release at rest, 
enhanced by catecholamine treatment.
Decreased SR Ca2* upon catecholamine 
treatment.
Goddard, 2008
P2328S
(heterozygote)
CPVT Central
Domain
Developed arrhythmia upon catecholamine treatment 
(5/7 mice).
Normal phenotype at rest and upon 
catecholamine treatment
Goddard, 2008
R2474S (i) 
(homozygote)
CPVT Central
Domain
Lethal developmental phenotype
-  S107 treatment prevented embryonic lethality.
n/a Lehnart, 2008
R2474S (i) 
(heterozygote)
CPVT Central
Domain
Exhibited tonic-clonic seizures spontaneously and in 
response to weak stimuli i.e. arousal from sleep.
Developed arrhythmia upon exercise /  catecholamine 
treatment (8/9 mice)
-  S107 treatment prevented arrhyth mia and 
decreased seizure propensity.
Increased spontaneous Ca2* release at rest, 
enhanced by catecholamine treatment.
Decreased RYR2-FKBP12.6 interaction
S107 restored FKB P12.6 binding and 
stabilized channel.
Lehnart, 2008
R2474S (il) CPVT Central
Domain
No observed tonic-clonic seizures.
Developed arrhythmia In response to weak stimuli i.e. 
light and sound as well as cafTeine/catecholamine 
treatment.
Prolonged SR Ca2* transient and lower SR 
Ca2* load.
Increased spontaneous Ca2* release at rest, 
enhanced by catecholamine treatment.
Uchinoumi,
2010
Xu, 2010
R4496C CPVT C-terminus Developed arrhythmia upon exercise/catecholamine 
treatment (5/14 mice)
-  p-blockers did not prevent arrhythmia (4/5 mice)
-  K201 did not prevent DAD's or VT (5/5 mice)
Increased spontaneous Ca2* release at rest, 
enhanced by catecholamine treatment.
Increased DADs at rest (21/33 myocytes) and 
upon catecholamine treatment (29/33)
- not prevented by K201 treatment.
- Increased Ca2* sparks and waves 
following oubain-induced SR Ca2* 
overload.
Cerrone, 2005, 
Uu, 2006, 
Femandez- 
Veriasco, 2009
Secfej, 2010
Table 1.2. CPVT/ARVD2-linked RyR2 mutant knock-in mouse models. Summary of the currently available RyR2-mouse models 
carrying CPVT/ARVD2-associated mutations. Mice containing the same mutation which were generated by different groups are denoted 
by (i) and (ii).
under resting conditions (6/11, 55%) or following p-adrenergic stimulation (11/11, 100%, 
(Goddard et al., 2008). This is the first instance in which an RyR2 mutation has been 
characterised both homozygously and heterozygously in a mouse model and suggests 
that the relative prevalence of the mutant allele is imperative in determining the severity 
of the disease phenotype, although homozygous CPVT mutation inheritance is not 
observed in vivo. Interestingly, cross-breeding of R2474S+/’ mice did not produce 
offspring in accordance with Mendelian inheritance patterns with only 3.5% of offspring 
exhibiting an R2474S+/+genotype after 16.5 days of embryonic development (Lehnart et 
al., 2008). This suggests that homozygous inheritance of R2474S results in a more 
severe or lethal developmental phenotype. Taken together, these observations 
corroborate the autosomal dominant nature of CPVT and ARVD2 mutations in vivo.
These data provide confirmation that CPVT/ARVD2-linked RyR2 mutations expressed in 
a murine model replicate the disease phenotype observed in the human condition to 
some extent, although some different phenotypic characteristics were observed 
(KannankerH et al., 2006). Furthermore, there were differences of the phenotype of two 
different mouse models which expressed the same CPVT-linked R2474S mutation. 
However, there are obviously physiological differences between mouse and human, 
including altered ion channel expression levels, decreased heart size and significantly 
increased heart rate of mice (Cook et al., 2009), which may or may not alter the 
phenotypic manifestation of the disease-linked mutation when compared across species.
1.3.4. Pathogenic mechanisms of RyR2 mutations
Given that disease-linked mutations are located throughout the RyR2 protein in several 
functionally important regions (Figure 1.11) and exhibit a degree of variable penetrance 
(Bauce et al., 2002; Marjamaa et al., 2009b), it is highly unlikely that all mutations result 
in an arrhythmogenic phenotype through a single unifying mechanism. Furthermore, as 
the number of functionally characterised arrhythmia-linked RyR2 mutations is increasing, 
it is hardly surprising that several mechanisms by which RyR2 mutations result in an 
arrhythmogenic phenotype have been proposed, each of which will be described here.
59
1.3.4.1. Altered RyR2 Ca2* sensitivity
Arrhythmia-linked mutations have been shown to alter RyR2 sensitivity to both luminal 
and cytoplasmic Ca2*, which can result in perturbed channel gating and dysregulated 
Ca2* release.
Several N-terminal and central domain mutations have been shown to alter the Ca2* 
dependence profiles of channel activation and inactivation in a heterologous cell system 
(Thomas et al., 2005). The majority of characterised RyR2 disease-linked mutations 
have been shown to result in an increase in sensitivity to activation by cytoplasmic Ca2*, 
when examined in single channel experiments, (S4565R, R3570W, Tester et al., 2007; 
Marjamaa et al., 2009b), in [3H] ryanodine binding experiments (Jiang et al., 2002) and 
when expressed in heterologous systems (Thomas et al., 2005). However, an exception 
to this is the L433P ARVD2-linked RyR2 mutation which caused a decrease in Ca2* 
sensitivity (Thomas et al., 2005), suggesting that this mutation results in a decrease in 
channel activity, an observation that will be discussed further in section 3.1.3.
The effect of RyR2 mutations on Ca2* sensitivity is further confounded by the fact that 
many mutations exhibit a similar cytoplasmic Ca2* dependent activation profile compared 
to WT RyR2 (Jiang et al., 2005; Tester et al., 2007; Marjamaa et al., 2009b) and has led 
to the emergence of the hypothesis that disease-linked RyR2 mutations preferentially 
alter the sensitivity of RyR2 to activation by luminal Ca2* (Jiang et al., 2004; Jiang et al., 
2005). Mutations from regions spanning the length of RyR2 were shown to increase 
RyR2 luminal Ca2* sensitivity (Jiang et al., 2005; Uchinoumi et al., 2010), which 
manifested as an increase in spontaneous Ca2* release coupled with a decrease in the 
levels of ER Ca2* load when examined in heterologous systems (Jiang et al., 2005; 
Jones et al., 2008a). These observations have also been corroborated in single channel 
analysis and [3H] ryanodine binding experiments (Jiang et al., 2004; Jiang et al., 2005). 
Although the majority of RyR2 disease-linked mutations increase luminal Ca2* sensitivity, 
some mutations have been shown to decrease or completely ablate luminal Ca2* 
sensitivity (Jiang et al., 2007), suggesting the location and nature of the mutation can 
have profound effects on the extent of Ca2* dysregulation. However, this is further 
complicated by the potential coupling between luminal and cytoplasmic Ca2* activation 
and inactivation of RyR2 (section 1.2.3.1).
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Although it may be difficult to envisage how a mutation located on the cytoplasmic face 
of the channel, such as R176Q, can alter luminal Ca2* sensitivity, this could potentially 
be explained according to the disruption of RyR2 intra-molecular interactions described 
below. However, such mutations have been demonstrated to alter luminal Ca2* 
sensitivity to a lesser extent than those located in the transmembrane region e.g. 
A4860G (Jiang et al., 2007). The role of altered luminal Ca2* regulation of RyR2 and the 
resulting effects on spontaneous SR Ca2* release will be discussed in more detail in 
Chapter 5. The implication of dysfunctional luminal Ca2* sensitivity also complements the 
implication of CSQ mutations in CPVT pathogenesis (CPVT2, see section 1.3.5).
1.3.4.2. Disruption of RyR2 inter-domain interactions
It has been proposed that regions of the RyR2 cytoplasmic assembly participate in inter­
domain interactions, which are important in stabilising the closed state of the channel 
(Yamamoto & Ikemoto, 2002). Under resting conditions, a region of the N-terminus 
(residues 1-600) has been proposed to interact with a region of the central domain 
(residues 2000-2500), in a process termed domain “zipping” (Ikemoto & Yamamoto,
2000). Following stimulation of the channel, this interaction is proposed to be weakened, 
causing “unzipping” of this domain interaction and allowing channel opening and 
subsequent Ca2* release (Ikemoto & Yamamoto, 2002). In support of this model, it has 
been shown that these two domains lie in close proximity to each other in sub-domain 5 
of the cytoplasmic assembly (Figure 1.6, Liu et al., 2005; Wang et al., 2007). A recent 
FRET-based study confirmed that this interaction takes place between the N-terminal 
and central domains of separate RyR2 subunits rather than an intra-subunit interaction 
(Liu etal., 2010). Furthermore, in support of this model, a short peptide corresponding to 
a region of the central domain (DPc10, G2460-P2495), has been shown to competitively 
bind the N-terminal domain, reversibly increasing channel activity and Ca2* leak (Oda et 
al., 2005), indicative of RyR2 destabilisation and this peptide was also shown to disrupt 
the FRET signal described above (Liu etal., 2010).
Notably, these two interacting-domains correspond to regions of RyR2 in which disease- 
linked mutations have been shown to cluster (Medeiros-Domingo et al., 2009). This led 
to the hypothesis that RyR2 mutations result in a CPVT/ARVD2 phenotype through the 
“unzipping” of these intramolecular interactions destabilising the channel and increasing
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Figure 1.12. Schematic o f peptide probe competition hypothesis o f inter-domain 
interaction. The N-terminal domain (green) interacts with the central domain (yellow). A 
central domain mutation results in the partial “unzipping” of the intra-domain interaction. 
DPc10-R2474S does not cause the disruption o f this interaction. WT DPc10 competes for 
the N-terminal binding site, inducing domain unzipping and channel instability. Domain 
unzipping is involved in channel activation in CICR and partial unzipping facilitates further 
unzipping by Ca2+ activation. From Yang, (2006).
RyR2 activity. This was supported by the observation that insertion of a CPVT-linked 
central domain RyR2 mutation, R2474S, into DPc10 prevented channel destabilisation. 
By extrapolation, this suggests that the presence of R2474S in RyR2 disrupts the 
interaction between the N-terminal and central domain, resulting in channel 
destabilisation and increased channel activity attributed to CPVT (Oda et al., 2005; Yang 
et al., 2006) and is consistent with recent results from an R2474S knock-in mouse 
(Uchinoumi et al., 2010). In addition, the destabilisation of the channel caused by DPc10 
resulted in an increase in RyR2 luminal Ca2+ sensitivity which was not observed when 
R2474S was present in the peptide, in accordance with the proposal that CPVT-linked 
mutations alter luminal Ca2+ sensitivity (section 1.3.4.1). Similar findings were obtained 
when DPc10 (10-50pM) was introduced into cardiac myocytes, in that D PdO  caused a 
sustained increase in resting cytoplasmic Ca2+ levels pertaining to increased SR Ca2+ 
leak and an increase in Ca2+ spark frequency associated with increased spontaneous 
Ca2+ release (Yang et al., 2006).
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DPcIO increased RyR2 luminal Ca2+ sensitivity, which is consistent with the observed 
consequences of heterologous expression of a number of other CPVT/ARVD2-linked 
RyR2 mutations (Jiang et al., 2002; 2004; 2005). Furthermore, this increase in luminal 
Ca2+ sensitivity coupled with increased SR Ca2+ refilling as a result of p-adrenergic 
stimulation, provides an attractive explanation of why CPVT-associated channel 
dysfunction is more apparent during periods of stress. Furthermore, the disruption of this 
interaction was shown to be independent of FKBP12.6 interaction (Uchinoumi et al., 
2010) and is contrary to earlier work by the same group (Oda et al., 2005).
Similar findings have recently been described using another N-terminal peptide 
(residues 163-195) containing the R176Q mutation and a peptide targeted to a region on 
the cytoplasmic side of the transmembrane domain (residues 4090 to 4123) containing 
the N4104K mutation (Tateishi et al., 2009). This latter region is proposed to be involved 
in RyR2 autoregulation and is termed the l-domain (George, 2004, Mol. Biol. Cell). Both 
WT peptides resulted in increased Ca2+ leak manifesting as increased Ca2+ spark 
frequency, which was not observed with the mutated peptides, suggesting that these 
mutations also cause channel destabilisation by altering domain-domain interactions. 
Similarly, mutations in the l-domain (N4104K and R4497C) of the full-length channel 
were also shown to cause channel destabilisation and augmented Ca2* release following 
agonist-evoked channel activation (George et al., 2006), suggesting that disruption of 
interactions between the C-terminal and central domains can also result in channel 
dysfunction. This also provides a potential mechanism by which mutations in the 
cytoplasmic domain can alter luminal Ca2* sensitivity.
1.3.4.3. RyR2 hyper-phosphorylation and FKBP12.6 dissociation
As described in section 1.2.3, the mechanism by which phosphorylation alters RyR2 
activity (section 1.2.3.2.4) and the role of FKBP12.6 in RyR2 regulation (section 
1.2.3.2.1) remains highly contentious, as do their roles in mutant RyR2 pathogenesis.
Marx et al proposed that CPVT-linked RyR2 mutations exhibit an increased sensitivity to 
p-adrenergic mediated PKA phosphorylation, resulting in a decreased affinity for 
FKBP12.6 and increased RyR2 destabilisation and SR Ca2* leak (Marx et al., 2000; 
Wehrens et al., 2003). However, whether PKA hyperphosphorylation of CPVT-linked
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mutant RyR2 channels causes the dissociation of FKBP12.6 and whether mutations 
alter the RyR2-FKBP12.6 interaction has been highly disputed by a number of other 
laboratories.
CPVT-linked m utations do no t a lter RyR2 phosphorylation status:
Firstly, equivalent levels of RyR2 phosphorylation were observed in heterologously 
expressed mutant and WT RyR2 using pan-phospho-specific (George et al., 2003c) and 
a S2809-specific phospho-antibody (Tester et al., 2007). Similarly, RyR2 isolated from 
heterozygous R4497C and R2474S knock-in mice exhibited equivalent S2809 
phosphorylation levels compared to RyR2 isolated from WT mice (Fernandez-Velasco et 
al., 2009; Sedej et al., 2010; Xu et al., 2010), providing further evidence that mutant 
RyR2 channels are not disproportionately phosphorylated or hyperphosphorylated. 
Recently, it was shown that R4497C myocytes exhibited spontaneous Ca2+ release and 
DADs independently of PKA phosphorylation as a result of oubain-induced SR Ca2+ 
overload (Sedej et al., 2010), further questioning the role of RyR2 phosphorylation at 
S2808/S2809 in CPVT.
CPVT-linked m utations do no t a lter FKBP12.6 a ffin ity:
There is also ambiguity over whether RyR2 mutations lead to the dissociation of 
FKBP12.6 from RyR2, as proposed by Marks and colleagues (Lehnart et al., 2004; 
Sedej et al., 2010). Several groups have shown that mutations from distinct regions of 
RyR2 exhibit a similar affinity for FKBP12.6 as that observed with WT RyR2 in 
heterologous expression systems (George et al., 2003a; Jiang et al., 2005; Tester et al., 
2007; Jones et al., 2008a; Zissimopoulos et al., 2009) and the R4497C knock-in mouse 
(Liu et al., 2006). A recent study has also demonstrated that the N-terminal and central 
domain mutations, R176Q and S2246L, respectively, resulted in an increase in 
FKBP12.6 binding to RyR2 (Zissimopoulos et al., 2009), adding further complexity to the 
effects of RyR2 mutations on RyR2-FKBP12.6 interaction.
Arrhythmia-associated phenomena are independent o f  FKBP12.6 interaction:
To further contest the role of FKBP12.6 dissociation in RyR2 mutant pathogenesis, 
CPVT/ARVD2-linked mutations have been shown to perturb intracellular Ca2+ handling 
without altering the RyR2-FKBP12.6 interaction or in the complete absence of FKBP12.6 
from the experimental system. The R2474S and R4497C mice exhibited an unaltered 
RyR2-FKBP12.6 interaction, yet displayed increased susceptibility to DADs and
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arrhythmia (Fernandez-Velasco et al., 2009; Zissimopoulos et al., 2009; Uchinoumi et 
al., 2010). Similar results were obtained through heterologous expression of RyR2 
containing several CPVT mutations, in that several RyR2 mutations altered luminal Ca2+ 
sensitivity or agonist-evoked SR Ca2* release magnitude, despite normal levels of 
FKBP12.6 interaction (George etal., 2003a; Jiang etal., 2005).
These observations suggest that RyR2 is not hyperphosphorylated following (3- 
adrenergic stimulation and CPVT/ARVD2 linked mutations do not cause increased 
FKBP12.6 dissociation from RyR2, making it highly unlikely that these are the 
mechanisms of RyR2 mutant pathogenesis.
1.3.5. Identification and pathogenic mechanisms of CSQ mutations
A CPVT-associated mutation in the cardiac isoform of CSQ (D307H) was first identified 
in a Bedouin family, in which several members exhibited stress-induced polymorphic VT 
on a background of a normal resting ECG (Lahat et al., 2001a; Lahat et al., 2001b). 
CPVT arising from mutations in the CASQ2 gene is termed ‘CPVT2’, as opposed to 
CPVT (or CPVT1) arising from RyR2 mutations.
Homozygous R33Q and D307H knock-in mouse models presented similar phenotypes 
to those observed in human CPVT2, with myocytes isolated from these mice exhibiting 
decreased SR Ca2* content and increased spontaneous Ca2* release leading to DADs 
(Houle et al., 2004; Dirksen et al., 2007; Song et al., 2007). These mutations were both 
shown to alter the tertiary structure of CSQ, disrupting polymerisation (Houle et al., 
2004; Song et al., 2007; Bal et al., 2010), suggesting that this is a common mechanism 
which contributes to the observed CPVT phenotype. Interestingly, similar observations 
were also made in CSQ-deficient mice, suggesting the homozygous inheritance of CSQ 
mutations causes near-complete ablation of normal CSQ function (Song etal., 2007).
The precise mechanism by which mutations in CSQ result in a similar CPVT phenotype 
to that caused by RyR2-mutations remains unsolved, although there are two prominent 
hypotheses; a SR store-overload model proposed by Chen and colleagues and the 
ablation of CSQ-mediated RyR2 regulation model proposed by Gyorke et al. The first 
model of mutant CSQ pathogenesis is akin to the “SOICR” model (described in chapter
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5), whereby the increase of SR Ca2* load above a particular threshold level is proposed 
to result in spontaneous Ca2* release through mutant RyR2 (MacLennan & Chen, 2009). 
In terms of mutant CSQ, this model proposes that the decreased Ca2* binding affinity of 
mutant CSQ increases the level of free luminal Ca2* above the threshold for diastolic 
Ca2* leak (MacLennan & Chen, 2009). The level of SR Ca2* is further increased during 
p-adrenergic stimulation, following an increase in PKA-mediated SERCA activity. This is 
proposed to result in increased spontaneous Ca2* release, which can lead to DADs and 
arrhythmias observed in the autosomal recessive from of CPVT. The model proposed by 
GyOrke et al hypothesised that mutations in CSQ alter the protein-protein interactions 
between CSQ, junctin and triadin with RyR2, leading to dysfunctional regulation of RyR2 
opening (Gyorke et al., 2009). Like CPVT-linked mutations in RyR2, there does not 
appear to be a unifying mechanism by which CSQ mutations result in a CPVT 
phenotype i.e. D307H alters CSQ Ca2* binding properties, whereas R33Q perturbs inter 
and intramolecular interactions between CSQ and RyR2.
1.3.6. Treatment of CPVT and ARVD2
The predominant therapeutic strategy currently employed to treat CPVT 
arrhythmogenesis is the administration of p-adrenergic receptor antagonists (p- 
blockers), including propranolol and atenolol (Priori et al., 2002). This is intended to limit 
the stimulatory effect of circulating catecholamines on the p-adrenergic pathway (section 
1.1.5), which has been widely implicated in models of arrhythmogenesis, with varying 
degrees of success. Some studies report high p-blocker efficacy in preventing further 
episodes (65%, Bauce et al., 2002; 98%, Postma et al., 2005), whereas others report a 
much lower success rate (Lahat et al., 2001a), with ablation of arrhythmic episodes in 
just 41% of a Japanese CPVT cohort and 22% of patients dying during the 10 year 
follow-up period (Sumitomo et al., 2003). The disparity in the success of p-blocker 
treatment in different patients could suggest that not all mutations result in CPVT 
through the same pathogenic, p-adrenergic-dependent mechanism or that other factors 
are involved in determining the penetrance of a particular mutation. The use of 
implantable cardioverter defribillators (ICD) is the usual course of treatment in patients in 
which p-blocker therapy is ineffective, although this treatment is also not always 
successful (Pizzale et al., 2008).
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K201 (also know as JTV-519) and S107 are compounds that have displayed several 
cardio-protective and anti-arrhythmic properties in the hands of a number of research 
groups, although there remains contention over the precise mechanism by which it elicits 
these benefits. K201 and S107 have been proposed to prevent arrhythmia by inhibiting 
spontaneous Ca2* release from the SR by restoring the interaction between FKBP12.6 
and RyR2 (Wehrens et al., 2003; Yano et al., 2003; Lehnart et al., 2008), resulting in the 
stabilisation of the channel. Marks et al showed that K201 prevented arrhythmia in 
heterozygous FKBP12.6 knock-out mice, but not in FKBP12.6 null mice (Wehrens et al., 
2003; Lehnart et al., 2006), suggesting that FKBP12.6 was essential for the therapeutic 
action of K201. However, given the ambiguity over the involvement of FKBP12.6 in 
CPVT, this hypothesis has been challenged by several other groups. K201 
administration did not alter the FKBP12.6 interaction or the occurrence of DADs or 
arrhythmia in the R4496C heterozygous mouse model (Liu et al., 2006). Furthermore 
K201 abolished the spontaneous Ca2* release observed in myocytes and RyR-deficient 
cell lines, independently of FKBP12.6 association (Hunt et al., 2007). It has also been 
suggested that SERCA is the main target of K201 (Loughrey et al., 2007). Together, 
these findings indicate that further clarification is needed on the effects of K201 and 
S107 on RyR2 dysfunction.
Verapamil, an LTCC antagonist, has also been used to treat CPVT, although with limited 
success as it did not prevent arrhythmia, but increased the threshold of arrhythmia 
occurrence during exercise-stress testing (Sumitomo et al., 2003). Verapamil has been 
shown to reduce spontaneous Ca2* release when administered at high concentrations 
(intraperitoneal, 8pg/g mouse body weight, Wakimoto et al., 2007), although this 
exceeded the toxic level in plasma and lower concentrations (0.5mM) had no observable 
effect on mutant RyR2 channel stabilisation (Liu et al., 2010). A recent study 
demonstrated that verapamil did not affect disrupted intra-domain interactions between 
the N-terminal and central domains of RyR2 (Liu et al., 2010).
Flecainide is a Na* channel antagonist and has recently been shown to be effective in 
preventing arrhythmia in both CPVT1 and CPVT2 patients who were non responsive to 
|3-blocker and verapamil therapy (Watanabe et al., 2009) Flecanaide was demonstrated 
to decrease the frequency of spontaneous Ca2* waves release in a CPVT2 mouse 
model (Watanabe et al., 2009), which is proposed to be the result of a decreased in Ca2* 
spark magnitude, despite an increase in spark frequency (Hilliard et al., 2009).
67
Dantrolene is a compound that is used to treat malignant hypothermia in patients 
harbouring mutations in RyR1. A recent study demonstrated that dantrolene prevented 
diastolic Ca2* leak and spontaneous Ca2* release through RyR2 isolated from failing 
canine hearts (Kobayashi et al., 2009), by restoring the defective inter-domain 
interactions in RyR2. Recently, the extent of the stabilising effect of dantrolene has been 
proposed to be dependent on the location of the mutation. Dantrolene was shown to 
stabilise inter-domain interactions weakened by a central domain mutation (R2474S, 
(R2474S, Liu et al., 2010; Uchinoumi et al., 2010), but had no effect on spontaneous 
Ca2* release observed in cells expressing a C-terminal mutation (N4104K, Jiang et al., 
2008).
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1.4. Single nucleotide polymorphisms in cardiac channelopathies.
Although both DIMA polymorphisms and mutations are essentially changes in DNA 
sequence away from the “normal” or wild-type sequence, there are several differences 
between the precise definitions of these terms. Firstly, in order for a nucleotide 
substitution to be classified as a single nucleotide polymorphism (SNP), the least 
common allelic variant must be present in at least 1% of the population; otherwise the 
substitution is classed as a mutation. Secondly, SNPs are not usually causative of 
disease and although they may be identified in affected-individuals, they are also likely 
to be prevalent in the control population (Roses, 2000). For purposes of clarity in this 
thesis, missense nucleotide substitutions resulting in a disease-linked amino acid 
substitution will be referred to as “mutations”, whereas substitutions that are not 
exclusively related to a disease-phenotype and are present in the healthy population will 
be referred to as “polymorphisms” or SNP’s.
There is substantial evidence that rare nucleotide substitutions (mutations) in genes 
encoding several cardiac ion channels result in cardiomyopathies. Many of these 
mutations have been demonstrated to result in the alteration of ion channel structure and 
function, resulting in an arrhythmogenic phenotype (Zimmer & Surber, 2008; Medeiros- 
Domingo etal., 2009).
However, since the advent of high throughput genotyping technologies such as SNP 
microarrays and genome wide association studies, common polymorphisms have 
received an increasing amount of interest. Genotyping of 29 cardiac genes in a large 
cohort (n = 1468) revealed three genes in which common SNPs were associated with 
subtle, but detectable, alterations in heart rate (cardiac sodium channel; SCN5A, 
calsequestrin; CASQ1 and |3-adrenergic receptor; ADRB1, Wilton et al., 2008), 
demonstrating that common sequence variants can modulate cardiac function. 
Furthermore, the inheritance of common SNPs in a number of cardiac ion channel genes 
has been demonstrated to cause subtle variation in QT interval (Pfeufer et al., 2005).
There is an extremely strong link between a family history of HF and the likelihood of 
SCD and VT onset during myocardial infarction, suggesting that inherited genetic factors 
may pre-dispose to arrhythmia (Spooner et al., 2001; Kaikkonen et al., 2006). In support 
of this, genetic association studies have identified relationships between arrhythmia
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susceptibility and SNPs in a number of genes encoding cardiac ion channels (Napolitano 
et al., 2005; Albert et al., 2010). SNPs in genes associated with long QT syndrome 
(LQTS) and related arrhythmogenic disease have been the focus of many of these 
studies and have revealed that these common sequence variants can have significant 
functional consequences on disease phenotype.
1.4.1. Congenital and acquired long QT syndrome
LQTS is a cardiac disorder which presents as a prolonged QT interval on an ECG, 
resulting from the prolongation of myocyte repolarisation during the cardiac action 
potential (Phase 0, Figure 1.3). Sustained myocyte repolarisation can result in the onset 
of early after-depolarisations (EADs), which can lead to Torsades de pointes (TdP), a 
specific variant of polymorphic VT. There are two variants of LQTS; termed congenital 
and acquired LQTS which exhibit a similar disease phenotype but are triggered by 
somewhat different mechanisms (van Noord et al., 2010).
Congenital LQTS is caused by the inheritance of rare genetic mutations, predominantly 
in an autosomal dominant fashion, in a number of genes encoding proteins involved in 
myocyte repolarisation. The vast majority of congenital LQTS cases are due to 
mutations in cardiac Na* or K* channel genes (SCN5A, KCNQ1 and KCNH2, Tester et 
al., 2005), however, there is emerging evidence that mutations in structural proteins e.g. 
AKAP9, caveolin-3 result in LQTS, although this has been observed in significantly fewer 
cases (Schulze-Bahr, 2006, 2008). Different subtypes of LQTS are described according 
to the gene in which the causative mutation is identified (LQT1-12), accompanied by 
differences in clinical phenotype e.g. Brugada syndrome, Timothy syndrome etc, 
(Schulze-Bahr, 2008; Webster & Berul, 2008). Congenital LQTS-associated mutations 
have been reported to have a variable penetrance (Priori et al., 1999; Napolitano et al.,
2005), suggesting that like CPVT-associated mutations in RyR2, the inheritance of a 
LQTS-associated mutation does not necessarily result in a disease-phenotype, inferring 
that other genetic factors may be involved in modulating congenital LQTS pathogenesis.
Acquired LQTS (aLQTS) is significantly more prevalent than its congenital counterpart 
and aLQTS patients do not tend to inherit rare LQTS-associated genetic mutations. 
Instead, aLQTS onset is dependent on other mitigating factors including, but is not
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limited to, female gender, congestive heart failure and ventricular hypertrophy, although 
by far the most common trigger is an adverse reaction to medication (Yang et al., 2002; 
Schulze-Bahr, 2006, 2008). Many drugs have been linked to LQTS-onset including both 
anti-arrhythmic and non-anti-arrhythmic medications, with the majority of these drugs 
altering the duration of the QT interval by blocking repolarising current (van Noord et 
al., 2010). Given that aLQTS is observed in patients with no evidence of LQTS- 
associated mutations (Koo et al., 2007), it is hypothesised that common sequence 
variation in the genes associated with congenital LQTS may pre-dispose individuals to 
QT prolongation and arrhythmia in response to other triggering factors. As such, it is 
regularly quoted that aLQTS is a “forme fruste” or masked variation of congenital LQTS.
1.4.2. Association of SNPs with LQTS
Genetic association and linkage studies have provided a great deal of evidence to 
support the above hypothesis and have demonstrated an apparent association of 
aLQTS with common SNPs (Yang et al., 2002), some of which occur in up to 1 in 3 
healthy individuals (Nof et al., 2010). The relative abundance of these SNPS compared 
to rare congenital LQTS-associated mutations is a plausible explanation for the higher 
prevalence of aLQTS compared to the congenital form. Examples of the association of 
cardiac ion channel SNPs with LQTS and the functional consequences of SNP 
inheritance will be discussed in this section.
Splawski et al identified a SNP in the gene encoding the cardiac sodium channel, 
SCN5A (see section 1.4.4.1), encoding the S1102Y amino acid substitution, which was 
present in 11-13% of healthy African-Americans (Splawski et al., 2002; Van Norstrand et 
al., 2008). A subsequent study demonstrated that this SNP was more prevalent in an 
SCD-patient cohort of African origin, suggesting that S1102Y was associated with an 
increased risk of arrhythmia (Burke et al., 2005). Functional characterisation of this SNP 
showed that S1102Y caused a slight prolongation of the QT interval by causing a 
modest negative shift in voltage dependence of channel activation (Splawski et al., 
2002). Another group demonstrated that S1102Y channels behaved comparably to WT 
channels under normal conditions, with a positive shift in channel inactivation only 
observed following cellular acidosis (Plant et al., 2006). Taken together, these findings 
suggest that although the inheritance of the S1102Y SNP alone is not sufficient to result
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in arrhythmia, it may pre-dispose carriers to acquired arrhythmia in response to 
secondary “trigger” factors.
Similarly, a SNP resulting in a non-synonymous K897T substitution in the gene encoding 
the cardiac potassium channel (KCNH2, hERG), responsible for the rapid inward 
rectifying K+ current (ta) during phase 3 of the AP, has been associated with a modest 
decrease in QT interval duration (1.6-1 Oms, Bezzina et al., 2003; Marjamaa et al., 
2009c), which translated as a modest shift in l^ activation voltage dependence (-7mV, 
Bezzina et al., 2003). This alteration in both QT duration and channel activation voltage 
dependence are comparatively small compared to those observed in congenital LQTS- 
associated mutations (30-40ms, Sanguinetti et al., 1996) suggesting that K897T 
inheritance alone is unlikely to be of sufficient magnitude to result in EADs and TdP. This 
further suggests that the inheritance of common SNPs that cause subtle alterations in 
QT interval, may increase patient susceptibility to factors that also augment the QT 
interval e.g. QT interval prolonging drugs and LQTS associated mutations.
Of course, this could also suggest that the combinational effect of several co-inherited 
SNPs that each cause subtle alterations in QT interval, either in a single or several 
LQTS associated genes, could culminate in severe QT interval augmentation and 
arrhythmia. This proposal has been supported by a study in which affected members of 
several families suffering from congenital LQTS had not inherited a disease-linked 
mutation, but had inherited several common SNPs in several LQTS associated genes 
(Koo etal., 2007).
1.4.3. Ethnicity-dependent variation in SNP prevalence
Association studies have also demonstrated that the prevalence of SNPs that are 
associated with increased arrhythmia-susceptibility vary significantly between 
populations of different ethnicity. Although, the S1102Y SCN5A polymorphism was 
relatively prevalent in individuals of African descent (section 1.4.2), this SNP was absent 
in large Asian, Caucasian or Hispanic control cohorts (n = 123 - 511, Splawski et al., 
2002). Interestingly, this same polymorphism was identified in SCD-affected individuals 
of a single Caucasian family (Chen et al., 2002), but due to its absence from the healthy 
Caucasian population was classified as a mutation, rather than a SNP in this case. The
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increased prevalence of S1102Y in populations of African descent (Splawski et al., 2002; 
Van Norstrand et al., 2008) could be a contributing factor to the observation that SCD is 
more frequent in African-descended populations compared to Caucasians (Zheng et al.,
2001). Furthermore, the K897T SNP in KCNH2 that was present in ~32% of the 
Caucasian population was only found in 2% of a healthy Japanese cohort (Iwasa et al., 
2000).
In light of these observations, and the apparent susceptibility of certain populations to 
particular genetic arrhythmia-linked diseases i.e. increased prevalence of sudden 
unexplained death syndrome (SUDS) in Asian populations (Lizotte et al., 2009), 
increased SCD in African-Americans etc (Zheng et al., 2001), further suggests ethnicity- 
specific SNPs may predispose to arrhythmia.
1.4.4. Modulatory effects of SNPs on disease-linked mutations
Although association and linkage studies demonstrate that many SNPs are associated 
with increased arrhythmia susceptibility, an understanding of the mechanistic basis by 
which they result in arrhythmia pre-disposition is only obtained through their biophysical 
and intracellular characterisation.
Heterozygous inheritance of a KCNH2 SNP (K897T) was shown to exacerbate the 
reduction in inward K+ current caused by co-expression of a predicted stop codon 
(P926Ax14) in the same gene (Nof et al., 2010). Interestingly, heterozygotic inheritance 
of either one of these alterations had no effect on clinical phenotype, yet co-inheritance 
of both alterations resulted in a severe arrhythmogenic phenotype (Nof et al., 2010), 
suggesting the common K897T predisposes to arrhythmia caused by the co-inheritance 
of the stop codon mutation.
As well as increasing arrhythmia susceptibility by exacerbating the detrimental effects of 
ion channel mutations, common SNPs have been also been shown to offer protection 
against mutant phenotype (Viswanathan et al., 2003; Ye et al., 2003; Poelzing et al.,
2006). Although this phenomenon has been described in a number of cardiac ion 
channel genes, mutations and SNPs in SCN5A have been subjected to the most
73
rigorous combinatorial characterisation, and will be the focus of the next part of this 
introduction.
1.4.4.1. Cardiac sodium channel (hNav1.5)
The a-subunit of the human cardiac Na+ channel (hNav1.5) is encoded for by the 
SCN5A gene and is expressed as a 260kDa transmembrane protein which constitutes 
the pore-forming region of the channel. The sodium channel (3-subunits (NaV(31 - 4) are 
much smaller, single transmembrane domain proteins that are proposed to be involved 
in the regulation and intracellular localisation of hNav1.5 (Abriel, 2010). hNav1.5 is 
responsible for the rapid depolarisation of the myocyte during phase 0 of the cardiac 
action potential, in which there is a rapid influx of Na+ ions into the myocyte, causing the 
activation of the LTCC (Figure 1.3, Bers, 2008).
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l40X X A
D1275N
T512I Voltage
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Voltage
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Figue 1.13. Schematic representation o f the cardiac sodium channel protein 
(hNav1.5) a-subunit encoded for by the SCN5A gene. The channel consists of four 
domains (DI-IV) connected by cytoplasmic linker sequences. Each domain contains six 
transmembrane segments (S1-S6) and a domain specific pore-forming loop (p-loop) 
between segments 5 and 6. S6 comprises the voltage sensor and the intracellular Dlll- 
DIV loop comprises the inactivation gate. The common H558R SNP is indicated in green. 
Red residues are those whose functional consequences are exacerbated by H558R, 
whereas those whose normal function is restored by H558R (see section 1.4.4.1.2) are 
indicated in blue. Adapted from Balser (1999)
hNav1.5 consists of four homologous transmembrane domains (l-IV) connected by 
cytoplasmic linker sequences, with each domain containing six transmembrane 
segments (S1-S6) as depicted in Figure 1.13. Residues between S5 and S6 of each
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domain turn back into the protein to form the channel pore structure, which is termed the 
P-loop. (Balser, 1999; Grant, 2001) and is highly conserved between species and 
isoforms.
Depolarisation causes 
opening of the sodium 
channel and results in 
Na* influx.
Re polarisation causes 
channel closure.
Figure 1.14. Proposed mechanism o f hNavl. 5 activation /  inactivation. A schematic 
representation the activation and inactivation mechanism of hN avl.5 as detailed in 
section 1.4.4.1.1.
The S4 segment is proposed to contain the voltage sensor motif and undergoes a 
conformational change upon membrane depolarisation, resulting in protrusion of S4 into 
the cell and subsequent channel opening (Figure 1.14, Balser, 1999). The channel is 
inactivated within a few milliseconds of opening and the conformational change in S4 is 
proposed to act as the trigger for “fast-inactivation” of Nav1.5. The flexible intracellular 
loop between domain III and IV contains a cluster of hydrophobic amino acids which act 
as a pore-lid flanked by glycine and proline residues which function as molecular hinges 
and is collectively termed the “fast-inactivation gate”. The flexibility of these flanker 
sequences allow the hydrophobic lid to bind to the its receptor site in the intracellular 
mouth of the pore, terminating inward Na+ current and allowing membrane 
repolarisation. Repolarisation results in further conformational changes in S4, causing it
Inactivation gate 
closes soon after 
channel opening 
(1-2ms, fast- 
inactivation)
 ►
Fast
Inactivation
Gate
Slow
Inactivation
Gate
Channel closure causes 
the opening of the 
inactivation gate, 
priming the channel for 
depolarisation-evoked 
activation
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described above i.e voltage sensor, fast-inactivation gate and inactivation gate receptor 
sites (Zimmer & Surber, 2008).
Conversely, SCN5A mutations associated with BrS, SSS or CCD tend to confer a loss- 
of-function phenotype and have been shown to decrease or abolish inward Na+ current 
by several mechanisms ( Gui et al., 2010a). Some mutations e.g. R282H, M1766L, 
R1232W/T1620M prevent correct hNavl.5 channel trafficking to the sarcolemmal 
membrane, retaining the protein within intracellular compartments (Baroudi et al., 2002; 
Ye et al., 2003; Poelzing et al., 2006; Gui et al., 2010a), completely ablating or 
decreasing inward Na+ current as shown in Figure 1.15., indicating that different SCN5A 
mutations can affect the same mechanism to varying degrees.
Other loss-of-function SCN5A mutations correctly localise to the sarcolemmal 
membrane, but reduce inward Na+ current by altering Navi .5 biophysical properties. The 
G1406R mutation correctly localised to the sarcolemmal membrane, but caused 
complete ablation of Na+ current (Kyndt et al., 2001), presenting a severe cellular 
phenotype. The T512I CCD-linked mutation caused a hyperpolarisation of hNavl.5 
activation and inactivation and enhanced slow channel inactivation, delaying channel 
recovery (Viswanathan et al., 2003).
Interestingly, whether SCN5A mutations are expressed alone or are co-expressed with 
another SCN5A mutation can have a major impact on the severity of the resulting 
cellular phenotype. Both the R1232W and T1620M BrS-linked mutations have been 
shown to correctly localise to the sarcolemmal membrane, and both mutations exhibit 
enhanced channel inactivation properties when expressed alone. However, the co­
expression of both R1232W and T1620M mutations resulted in complete ablation of Na+ 
current and was attributable to incorrect membrane trafficking of the channel (Baroudi et 
al., 2002), suggesting a detrimental combinational effect of some SCN5A mutations.
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Figure 1.15. The H558R SCN5A SNP can restore normal lNa current by correcting 
defective mutant channel trafficking, see section 1.4.4.1.1 and 1.4.4.1.2.. Heterologously 
expressed WT hNavl.5 and hNavl.5-H558R correctly localises to the cell periphery and 
exhibit normal Ina current (panel A and B). Several LQTS-associated mutations in SCN5A 
cause hNavl.5 to be retained in the ER, preventing correct membrane trafficking and 
abolishing lNa. (panel C). Co-expression of H558R has been shown to correct membrane 
trafficking of several LQTS associated mutants and restore lNa to normal levels. Each panel 
contains brightfield and immunofluorescent confocal images of recombinantly expressed 
hNavl.5, peak Na+ density charts and schematic representation of hNavl.5 intracellular 
trafficking. Confocal images from Ye, (2003). Peak current traces from Poelzing, (2006).
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1.4.4.1.2. Effects of SNPs on mutant hNavl .5 function
SCN5A mutations exhibit a high level of variable penetrance, with some mutations 
resulting in a disease phenotype in 100% of carriers (Vatta et al., 2002), whereas other 
mutations, particularly those associated with BrS, may exhibit a significantly low 
penetrance (~20%, Priori etal., 2002a). Furthermore, different disease phenotypes have 
been observed in carriers of the same SCN5A mutation, even within affected families 
(Kyndt et al., 2001); a phenomenon that is most prevalent with BrS/CCD-associated 
mutations. This further suggests that other environmental or genetic factors may have an 
important role in determining the penetrance of SCN5A mutations in different individuals. 
Common SNP’s in SCN5A are one such genetic factor that has received a great deal of 
attention over the last decade with regard to their involvement in arrhythmia 
susceptibility.
There is increasing experimental evidence that co-inheritance of common SCN5A SNPs 
can alter the phenotypic manifestation of disease-linked SCN5A mutations. Although 
several SCN5A SNPs have been shown to exhibit this modulatory effect on mutant 
hNavl .5 function, one particular SNP, resulting in a histidine to arginine substitution at 
residue 588 (H558R) located in the DI-DII cytoplasmic linker (Figure 1.13), has received 
the most attention. H558R exhibits a relatively high prevalence (~20% of the population, 
Yang et al., 2002; Chen et al., 2007; Doolan et al., 2008) and has been shown to be co­
inherited with many disease-linked SCN5A mutations. Unlike the S1102Y polymorphism 
described by Splawski et al, H558R has been reported to exhibit a similar allelic 
frequency between Caucasian populations and those of African descent (Splawski et al.,
2002), suggesting that this polymorphism is not specific to a particular ethnic group, 
although it was less common in a separately examined Asian cohort (8%, Iwasa et al., 
2000).
Furthermore, heterologous expression of H558R alone consistently results in a similar 
biophysical phenotype to the WT channel (Makielski et al., 2003; Viswanathan et al., 
2003; Poelzing et al., 2006; Saito et al., 2009; Gui et al., 2010b). In addition, a cohort of 
SCN5A mutation carriers who had also inherited H558R, tended to exhibit improved 
ECG characteristics and fewer symptoms than subjects who did not carry this SNP 
(Lizotte et al., 2009), suggesting a protective effect of this substitution, although this 
could very well be on a mutation-by-mutation basis. In contrast, a single genotyping
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study identified a link between H558R inheritance and AF susceptibility (Chen et al.,
2007), questioning whether H558R is truly functionally benign in the absence of other 
SCN5A mutations.
The first experimental evidence that H558R altered the phenotypic manifestation of an 
SCN5A mutation was demonstrated through the heterologous co-expression of an LQTS 
mutation, M1766L, with H558R on the same recombinant protein (Ye et al., 2003). Here, 
the presence of the H558R substitution was shown to restore correct trafficking of the 
protein to the sarcolemmal membrane and restored inward sodium current (as illustrated 
in Figure 1.15), although this current was persistent and characteristic of LQTS (Ye et 
al., 2003). This suggests that although H558R was able to restore trafficking of the 
M1766L Nav1.5 to the sarcolemmal membrane, it did not restore the biophysical 
properties of the M1766L channel to normal levels.
This same polymorphism was able to restore the correct membrane trafficking and Na+ 
current of another BrS-associated SCN5A mutation, R282H, which is found in the p-loop 
of Dl (Poelzing et al., 2006). The probands daughter, who had inherited R282H and 
H558R in a composite heterozygous fashion (Figure 1.16, patient D), was asymptomatic 
and displayed a normal ECG, whereas the proband did not co-inherit H558R and 
exhibited a BrS phenotype. In this case, the extent to which H558R restored normal 
channel function in heterologous systems was dependent on the precise mode of 
mutation and SNP co-expression and will be discussed further in section 3.1.2.
HSSSR M5S8R
Figure 1.16. Pedigree of a family 
with Brugada syndrome, BrS
Affected individuals indicated in 
black. Patients A and B were 
heterozygous for the R282H 
mutation, patient C was homozygous 
for the H558R polymorphism and 
patient D was heterozygous for both 
R282H and H558R , with both 
substitutions on opposite alleles. 
From Poelzing, (2006).
M5S8R
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As well as restoring correct membrane trafficking of mutant Nav1.5 channels, H558R 
has been shown to alter the biophysical properties of mutant channels that exhibit 
normal membrane trafficking. The first example of this modulatory behaviour of H558R 
was demonstrated on the T512I mutation, which had been identified in CCD patient 
(Viswanathan et al., 2003). In this case, the proband was homozygous for the H558R 
polymorphism and heterozygous for the T512I mutation, whereas the mother, who was 
asymptomatic, was heterozygous for both T512I and H558R, with both substitutions on 
the same allele (Figure 1.17).
Heterologous expression of Nav1.5 containing the T512I mutation altered activation and 
inactivation voltage-dependence and enhanced the level of channel slow-inactivation. 
These altered parameters were partially restored to normal levels when H558R was co­
expressed with T512I on the same recombinant protein, inferring that this SNP was able 
to attenuate the detrimental biophysical effects of the T512I mutation (Viswanathan et 
al., 2003). The fact that the mother of the proband had also inherited both substitutions 
on the same allele, but was asymptomatic, reiterates the variable penetrance of 
mutations occurring in SCN5A and the potential benefit of the inheritance of this SNP.
DrO
H558R
■
T512I
H558R
H558R
T512I
H558R H558R H558R
Figure 1.17. Family pedigree of a cardiac 
conduction disorder-affected proband 
who inherited H558R with a disease- 
linked SCN5A mutation, A CCD affected 
patient was homozygous for the H558R 
polymorphism and heterozygous for the 
T512I mutation. The patients mother was 
asymptomatic and was heterozygous for 
both H558R and T512I, with both 
substitutions on the same allele. The 
probands father and siblings were 
asymptomatic and were heterozygous for 
H558R and did not carry T512I. Adapted 
from Viswanathan (2003).
Recently, a comprehensive investigation into the effects of H558R on all known SSS- 
associated SCN5A mutations further demonstrated that this SNP resulted in both 
aggravation or amelioration of several disease causing mutations (Gui et al., 2010b), 
further suggesting that the modulatory effects of H558R are mutation-specific.
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Mutation AssociatedDisease
Control
Frequency
Patient
Frequency
Effect of mutation on 
phenotype
Functional consequence of 
H558R co-expression Reference
E161K SSS Not known Not known Decreased peak In# current. Exacerbates decrease in current Gui, 2010.
R282H BrS 0%(0/60)
9%
(1/11)
Complete ablation of In,  
current through abolition of 
membrane trafficking
Restores correct membrane 
trafficking and In*
Pitzalis, 2003; 
Poelzing, 2006.
G298S IBS n%(0/1500)
2%
(1/50)
Decreased peak In* current 
and prolonged time to 
peak.
Exacerbates decrease in In» 
current and prolongation of 
time to peak.
Saito, 2009.
G400A
Acute
myocardial
infarction
0%
(0/364)
5.3%
(1/19)
Decreased peak ^  current, 
hyperpolarised inactivation 
voltage-dependence.
Exacerbates decrease in peak 
Ifta current to near complete 
ablation.
Hu, 2007.
T512I AV conduction block Not known Not known
Hyperpolarised voltage- 
dependent inactivation, 
decreased peak Ins
Partial restoration of voltage- 
dependent inactivation and 
peak In* to WT levels
Viswanathan, 2003.
123A572D LQT3 0.49% 0.45% Similar to WT Persistent late Sodium Current Tester, 2010.
D1275N SSS Not known Not known Decreased peak W  current Fuly restores In& current Gui, 2010.
P1298L SSS Not known Not known Decreased peak current Exacerbates decrease in tua current Gui, 2010.
R1632H SSS Not known Not known Prolonged channel recovery from inactivation
Exacerbated delay in channel 
inactivation Gui, 2010.
M1766L LQT3 0%(0/200)
n/a 
Single post­
mortem
Decreased peak Inb current 
through decreased 
membrane trafficking.
Fuly restores correct 
membrane trafficking and W  
current
Valdivia, 2002; 
Ye, 2003.
Table 1.3. Summary of the effects of H558R on mutant hNavl.5 channel function. Several disease-linked SCN5A mutations have been 
characterized in the presence and absence of the H558R polymorphism, the functional consequences of which are indicated here. SSS = sick 
sinus syndrome, BrS = Brugada syndrome, IBS = irritable bowel syndrome, LQT3 -  long WT syndrome type 3.
Taken together, these examples suggest that depending on the specific nature of the co­
inherited mutation and the precise mode of expression, the same common H558R 
polymorphism is able to restore normal channel function to varying degrees (see Table 
1.3). However, the precise mechanism by which H558R can modulate the effects of an 
amino acid substitution that can be distant in the primary or 3D protein structure or on a 
separate protein monomer altogether remains unknown.
These examples of the effects of H558R on mutant channel function, clearly 
demonstrate that this polymorphism is capable of modulating mutant channel 
functionality through a variety of mechanisms, both when it is found on the same or 
opposite allele as the disease-linked mutations. Furthermore, this provides evidence that 
this SNP modulates the activity of several different mutations to a varying degree, 
depending on the precise mode of co-inheritance.
1.4.4.2. SNPs in CPVT-associated genes
There is increasing evidence that common SNPs in genes associated with CPVT and 
ARVD2 i.e. CASQ2 and RyR2, constitute rather more than benign natural sequence 
variation and such SNPs are sometimes associated with these disorders (de la Fuente 
et al., 2008; Wong et al., 2009), mirroring the implication of SNPs in other cardiac 
channelopathies.
1.4.4.2.1. CPVT-associated SNPs in CASQ2
Since the implication of CSQ mutations in CPVT pathogenesis (section 1.3.5), several 
non-synonymous mutations have been identified (de la Fuente et al., 2008; Kirchhefer et 
al., 2010). Recently, a study indentified a CPVT patient who had inherited two CSQ 
amino acid substitutions (Y55C and P308L) in a composite heterozygous manner (de la 
Fuente et al., 2008). The inheritance of either of these mutations alone did not result in a 
CPVT phenotype and neither substitution was found in a large healthy cohort, 
suggesting that these substitutions are only pathogenic when co-inherited. This provides 
the first evidence that not all CSQ mutations are autosomal recessive and that co­
inheritance of two apparently benign CSQ substitutions, can potentially alter protein 
function; however there is no biophysical evidence to support or refute this possibility.
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Conversely, genetic screening of CASQ2 of a CPVT cohort identified a CPVT-patient 
heterozygous for two non-synonymous SNPs resulting in T66A and V76M substitutions, 
both of which were located on the same allele (Laitinen et al., 2003). This mode of SNP 
inheritance was also observed in 18 further CPVT patients and a large control cohort, 
suggesting that another confounding factor may be involved in this particular case. 
Subsequently, when expressed alone, T66A was shown to exhibit a similar Ca2+-binding 
capacity and polymerisation Ca2+ dependency to WT CSQ (Kim et al., 2007), whereas 
V76M decreased Ca2+ binding capacity and altered dimerisation propensity, but to a 
lesser degree than CPVT-linked mutations i.e. R33Q, L167H, D307H. This could 
suggest a combinatorial modulatory role of T66A and V76M SNPs in CPVT2 
pathogenesis observed in vivo (Laitinen etal., 2003). Like CPVT-linked mutations, V76M 
occurs at a residue highly conserved between species, suggesting that although it only 
has a modest role on CSQ function, V76M may evoke a predisposition to arrhythmia, 
questioning whether it should be classed as a SNP or a mutation.
1.4.4.2.2. Emerging role of SNPs in RyR2 function
There is little documented evidence of the prevalence and functional consequences of 
SNPs in RyR2, however there appears to be emerging interest in the roles that common 
sequence variation in RyR2 may have on channel function.
A rare non-synonymous RyR2 mutation located between the central and C-terminal 
mutation domains, N3308S, was recently identified in a patient exhibiting a typical CPVT 
phenotype (Figure 1.11, Marjamaa et al., 2009a), suggesting this substitution is 
causative of the disease. However, this substitution was also identified in 1 out of 300 
healthy individuals, suggesting that N3308S exhibits a variable penetrance or is 
mitigated by other, possibly genetic, factors. Biophysical characterisation of this 
substitution did not identify altered channel activity compared to WT RyR2, when 
subjected to increasing cytoplasmic Ca2+ (Marjamaa et al., 2009a), providing an 
indication this is a rare, functionally benign substitution, however the extent of functional 
characterisation of N3308S was limited.
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Figure 1.18. G4662S and H4726P 
result in a CPVT phenotype when 
inherited in a composite 
heterozygous fashion. Grey symbols 
represent carriers of either 
asymptomatic G4662S or H4762P- 
carrying individuals. The black symbol 
represents the CPVT-affected patient 
harbouring both substitutions. Adapted 
from Postma (2005).
A recent comprehensive genotyping study of a cohort of CPVT and gene-negative LQTS 
patients identified several RyR2 SNPs that were present in both patients and control 
subjects e.g. G1885E, G1886S, Q2958R, (Medeiros-Domingo et al., 2009). However, 
this study provided no evidence that these SNPs exert any functional effects on the 
mutations with which they were co-inherited, and due to their prevalence in the control 
population they may just represent natural sequence variation. However, Postma et al 
(2005) identified a family in which a CPVT-affected individual inherited two rare 
substitutions (G4662S and H4726P) in a composite heterozygous manner i.e. one 
mutation from each parent (Figure 1.18). However, the probands parents and children 
had only inherited either one of these mutations and were completely asymptomatic 
(Postma et al., 2005), suggesting that G4662S and H4726P are rare SNPs that only 
exhibit a detrimental phenotype when co-inherited.
Similarly, there is a reported case of ARVD2, whereby the affected individuals did not 
harbour a disease-linked RyR2 mutation, but had inherited the common G1885E and 
G1886S SNPs in a composite heterozygous fashion (Milting et al., 2006). These 
polymorphisms are relatively common in the healthy Caucasian population (G1885E = 
6% of individuals, G1886S = 20% of individuals, n=100-463, Milting et al., 2006; 
Medeiros-Domingo et al., 2009), but the inheritance of both SNPs simultaneously was 
only observed in an ARVD2 cohort (3.5%, 3/85 patients). Like the SNPs described by 
Postma et al, this suggests that inheritance of either SNP alone is not sufficient to result 
in an ARVD2 phenotype, yet these apparently benign SNPs are causative of disease 
when inherited in a composite heterozygous fashion. Subsequent biophysical
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characterisation of single channels isolated from an ARVD2 patient harbouring both 
SNPs exhibited several sub-conductance states and an increased PQ at diastolic Ca2+ 
levels (Milting et al., 2006), indicative of channel destabilisation and diastolic Ca2+ leak. 
The heterologous expression of recombinant RyR2 harbouring the G1885E and G1886S 
SNPs have further shown that these substitutions alter spontaneous Ca2+ release (Koop 
et al., 2008), which will be discussed in greater detail in section 5.1.4.
These SNPs were also identified in Asian and African-American populations, although 
they were observed at different frequencies between populations. G1885E was only 
identified in a single SUDS patient (1/28) of Asian origin and was not present in the 
control population (0/95), whereas G1886S was present in 10.7% of SUDS cases (3/28 
patients) and at similar levels in the control population (13.7%, 13/95 patients, (13.7%, 
13/95 patients, Wong et al., 2009). Similarly, G1885E was not identified in an African- 
American cohort, whereas G1886S present in 20% of healthy African-Americans 
(Medeiros-Domingo et al., 2009). Although limited in number and cohort size, these 
studies suggest that there are differences between the prevalence of these SNPs 
between different ethnic populations, particularly in the Asian population.
1.4.4.2.3. Co-inheritance of SNPs with RyR2 mutations
Genotyping studies have identified several cases in which CPVT/ARVD2 patients 
carrying disease-linked RyR2 mutations have also inherited common, apparently 
functionally benign polymorphisms (Tiso et al., 2001; Medeiros-Domingo et al., 2009). 
The first documented case of this phenomenon describes three Italian families who 
inherited common, non-synonymous SNPs on the same allele as a disease-linked RyR2 
mutation (Tiso et al., 2001). In the first family identified, all ARVD2-affected individuals 
harboured a leucine to proline amino acid substitution at RyR2 residue 433 (L433P). 
Interestingly, all affected individuals also harboured a glycine to glutamate amino acid 
substitution at residue 1885 (G1885E) on the same allele as the L433P-coding 
nucleotide substitution, as shown in Figure 1.19. Similarly, affected members of two 
families harbouring an asparagine to isoleucine substitution at residue 2386 (N2386I) 
had also inherited the G1885E substitution described above, together with another RyR2 
missense SNP encoding a glutamine to arginine substitution at residue 2958 (Q2958R). 
Neither disease-linked mutation was identified in a healthy control population (n = 200,
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(n = 200, Tiso et al., 2001), whereas the SNPs were, further suggesting that inheritance 
of these SNPs alone does not result in CPVT/ARVD2 pathogenesis. Both of these 
residues are highly conserved among species (Appendix 1, Figure 1), further suggesting 
a functional importance of both substitutions.
The Q2958R amino acid substitution was also co-inherited homozygously in all CPVT 
affected individuals from four Finnish families harbouring a range of RyR2-disease linked 
mutations: P2328S, V4653F and Q4201R (Laitinen et al., 2001). Two individuals from 
one of these families (2/13 mutation carriers, 15.4%), who were heterozygous for the 
P2328S mutation and homozygous for the Q2958R polymorphism, were completely 
asymptomatic, whereas other family members with the same haplotype exhibited CPVT 
symptoms. The SNP encoding Q2958R exhibited an allelic frequency of 0.26 in the 
control population, confirming that the Q2958R amino acid substitution alone is not 
sufficient to cause a disease phenotype, which is not surprising considering that the 
Q2958R is the most common RyR2 polymorphism, particularly among Caucasians 
(34%, Medeiros-Domingo et al., 2009).
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Figure 1.19. ARVD2 pedigrees o f Italian families harbouring L433P and N2386I 
mutations and G1885E and Q2958R SNPs. Asterisks indicate individuals whose DNA 
was not available for genotyping. Affected members o f family A harboured the G1885E 
polymorphism on the same allele as the ARVD2-linked L433P mutation. Affected 
individuals o f families B and C harboured both G1885E and Q2985R polymorphisms on the 
same allele as the N2386I mutation. Results o f single strand conformation polymorphism 
analysis was used to detect substitutions and is indicated in panels B and C. Adapted from 
Tiso, (2001)
87
Although the reported co-incidence of RyR2 polymorphisms with disease-linked RyR2 
mutations appears to be relatively low, this could be artefactual due to targeted 
sequencing of mutation “hot-spots” in RyR2 (Laitinen et al., 2001; Tiso et al., 2001; 
Bagattin et al., 2004; Marjamaa et al., 2009b). Because the majority of CPVT cases do 
not undergo sequencing of the entire open reading frame, the prevalence of mutations 
and polymorphisms outside of the three “conventional” mutational domains remains 
unknown. The 61 exons that fall outside of the commonly targeted mutational domains 
encode 2570 amino acids, accounting for over half of the RyR2 protein. (Medeiros- 
Domingo et al., 2009). Similarly, in some cases where SNP’s are co-inherited with 
disease linked mutations, they are not always reported due to their incidence within the 
control population (Bauce etal., 2002).
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1.5. General Aims:
Some common SNPs in cardiac ion channel genes, exert a modulatory effect on 
disease-causing mutations within the same gene (Viswanathan et al., 2003; Nof et al., 
2010). A group of ARVD2 patients were identified, in which all affected individuals had 
inherited the common G1885E SNP on the same allele as the ARVD2-linked RyR2 
L433P mutation (Tiso et al., 2001). The general aim of this thesis was to investigate the 
effects of G1885E co-expression on L433P mutant channel function.
Most functional characterisations of RyR2 mutations expressed in heterologous systems 
have been carried out on homotetrameric channels but this does not accurately 
represent the autosomal dominant nature of CPVT and ARVD2-linked RyR2 mutations. 
Furthermore, as is the case with other ion channels, SNPs often dictate the resultant 
channel behaviour depending on the precise mode of their co-inheritance i.e. in cis or in 
trans (Poelzing et al., 2006). In light of these observations, characterisation of co­
expressed WT, L433P and G1885E RyR2 was also carried out in RyR2-null HEK cells to 
better control the relative recombinant expression levels and subunit stoichiometry.
ARVD2 and CPVT-linked mutations in RyR2 have been shown to profoundly alter 
characteristics of agonist-evoked Ca2+ release when expressed in heterologous systems 
(George et al., 2003a; Jiang et al., 2005). Here, live-cell Ca2+-imagining experiments 
were carried out to systematically analyse several parameters of caffeine-evoked Ca2+ 
release in HEK cells expressing L433P (Chapter 3). A major focus of this thesis was to 
determine whether these parameters were altered by G1885E co-expression. Analysis 
of small cytoplasmic Ca2+ fluxes is a useful tool for interrogating Ca2+ release dysfunction 
promoted by CPVT-linked RyR2 mutations (George et al., 2003b; 2006; Fry, 2008). By 
quantifying these small Ca2+ fluxes using the index of Ca2+ signal variability the effects 
of L433P on basal and agonist-evoked Ca2+-signalling were examined. This thesis 
investigated the influence of the G1885E SNP on Ca2+ handling mediated by L433P 
channels (Chapter 4). RyR2 mutations have also been reported to alter the propensity 
for spontaneous ER/SR Ca2+ release (Jiang etal., 2005; Liu etal., 2006), a phenomenon 
linked to DADs and arrhythmia. To this end, the extent and mode of spontaneous Ca2+ 
release of cells expressing L433P and the effects of G1885E co-expression were also 
examined (Chapter 5).
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Chapter 2
Materials & Methods
2.1. Materials
2.1.1. General Lab Chemicals and Reagents
All chemicals and reagents used were of analytical grade and were obtained from 
Sigma-Aldrich, unless otherwise stated. All solutions were dissolved in deionised H20  
and stored at room temperature (RT) unless otherwise stated. All filtration was carried 
out using 0.2pM filters (Sartorious).
2.1.2. Molecular Biology Reagents
• QuikChange® site-directed mutagenesis Kit, obtained from Stratagene, stored at 
-20°C.
• Miniprep resuspension solution -  50mM Tris, 10mM EDTA, 100pg/ml RNAse A, 
pH adjusted to 7.5 with hydrochloric acid and filter sterilised.
• Miniprep Lysis solution -  0.2M sodium hydroxide, 1% (w:v) sodium dodecyl 
sulphate (SDS). Filter sterilised.
• Miniprep Neutralisation solution -  4.09M Guanidine-HCI, 0.759M acetic acid, pH 
adjusted to 4.2 with glacial acetic acid. Filter sterilised.
• Miniprep Column wash solution -  60mM potassium acetate, 8.3mM Tris-HCI (pH
7.5), 0.04mM EDTA, pH adjusted to 8.0, 60% (v:v) ethanol.
• Restriction enzymes -  all enzymes and appropriate buffers were acquired from 
New England Biolabs (BamHI, Bglll, EcoRI, HinDIII, Kpnl) and Stratagene 
(SanDI). Stored at -20°C.
• Molecular Biology Grade Agarose -  supplied by Eurogentec.
• EDTA -  0.5M stock prepared. 186.12g/L EDTA. pH adjusted to 10.0 with sodium 
hydroxide to dissolve EDTA. Once dissolved, pH adjusted to 7.5 using 
hydrochloric acid.
• TAE (50x) -  2M Tris, 2M acetic acid, 50mM EDTA.
• 1Kb DNA molecular weight ladder -  supplied by Invitrogen, mixed with 2x Gel
loading buffer and aliquots were stored at -20°C.
• Gel loading buffer (2x) -  5ml Glycerol, 5ml 1x TAE and 0.25% (w:v) Orange G to
allow visualisation the progress of agarose gel electrophoresis.
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• Maxiprep Resuspension Buffer (Buffer P1) - 50mM Tris, pH adjusted to 8.0, 
10mM EDTA, 100pg/ml RNase A. Stored at 4-8°C.
• Maxiprep Lysis Buffer (Buffer P2) -  200mM sodium hydroxide, 1% SDS (w:v)
• Maxiprep Neutralisation Buffer (Buffer P3) -  3M potassium acetate, pH adjusted 
to 5.5.
• Column equilibration buffer (Buffer QBT) -  750mM NaCI, 50mM MOPS, pH 
adjusted to 7.0,15% isopropanol (v:v) and 0.15% Triton® X-100 (v:v).
• Column wash buffer (Buffer QC) -  1M NaCI, 50mM MOPS, pH adjusted to 7.0 
and 15% isopropanol (v:v).
• Elution buffer (Buffer QF) -  1.25M NaCI, 50mM Tris, pH adjusted to 8.5 and 15% 
isopropanol (v:v).
• QIAEX II gel extraction kit (Qiagen) -  for the purification of DNA fragments 
resolved by agarose gel electrophoresis 2.2.1. Briefly, a slice of agarose gel 
containing resolved DNA is solubilised in a high salt buffer and is incubated with 
silica beads, to which the DNA binds. DNA-containing beads are collected and 
washed in another high salt buffer to remove residual agarose and are also 
washed with an ethanol containing buffer to remove salt contaminants. DNA was 
eluted from the silica beads in SDW.
• DNA sequencing Kit -  BigDye terminator V5 obtained from Applied Biosystems. 
Briefly, DNA to be sequenced is incubated with standard deoxynucleotides as 
well as fluorescently-labelled, chain-terminating dideoxynucleotides which 
terminate DNA strand extension when incorporated into the newly synthesised 
DNA. This random incorporation of fluorescently-labelled dideoxynucleotides 
produces DNA fragments of varying lengths which can be resolved by high- 
resolution electrophoresis. Labelling of the dideoxynucleotides with fluorophores 
with distinct excitation/emission properties allows the determination of the 
specific terminating nucleotide.
2.1.3. Protein Biochemistry Reagents
• Protease inhibitor cocktail tablets -  obtained from Roche. Contains several 
inhibitors of serine proteases (Pefabloc SC, aprotinin and leupeptin) proteases 
and inhibitors of cysteine proteases (E-64). Tablets were stored at 4-8°C. 1x
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protease inhibitor cocktail tablet dissolved in 20mM Tris, 5mM EDTA and 0.05% 
(v:v) Triton-X-100 (25ml total volume), adjusted to pH7.4 with HCI.
• Hypo-osmotic cell lysis buffer -  20mM Tris, 1mM EDTA, pH adjusted to 7.4 with
hydrochloric acid, protease inhibitor tablet (1 per 25ml, Roche) and 1% (v:v) 
Triton-X-100.
• Micro BCA™ protein assay kit -  obtained from Thermo Scientific.
• BSA standards -  1 mg/ml stock diluted to 200, 100, 50, 20 and 10pg/ml in sterile 
deionised H20. Stored at -20°C
• SDS-PAGE Stack buffer (1x) - 0.5M Tris, pH adjusted to 6.8 with hydrochloric 
acid.
• SDS-PAGE Separating buffer -  1.5M Tris, pH adjusted to 8.8 with hydrochloric 
acid.
• 40% Acrylamide / bis-solution 37.5:1 -  BioRad.
• Sodium Dodecyl Sulphate -1 0 %  (w:v) solution prepared immediately before use.
• Ammonium persulphate (APS) -  10% (w:v) solution prepared immediately before 
use.
• Molecular weight markers -  pre-stained (Kaleidoscope), obtained from BioRad.
• SDS-gel loading buffer (2x) 100mM Tris pH 6.8, 20% (v:v) glycerol, 4% (w:v) 
SDS, 0.2% (w:v) bromophenol blue, 10% (v:v) (3-mercaptoethanol and filter 
sterilised. Prepared immediately prior to use.
• Running Buffer (1x) -  25mM Tris, 250mM Glycine, 0.1% (w:v) SDS
• Transfer Buffer (Semi-dry) - 48 mM Tris, 39 mM glycine, 0.037% (w/v) SDS.
• Tris-buffered saline (TBS, 1x) 20mM Tris, 137mM NaCI and pH adjusted to 7.6 
with hydrochloric acid.
• TBS-T Buffer (1 x) -  1 x TBS, 0.1 % (v:v) Tween-20.
• Blocking solution -  5% (w:v) non-fat dried milk (Marvel) dissolved in 1x TBS-T 
buffer
2.1.4. Oligonucleotides
SDM primers obtained from VH Bio were purified using reverse-phase HPLC and were 
supplied as lyophilised pellets. Pellets were resuspended in 250pl SDW and stored at - 
20°C. Primers were diluted to a concentration of 150ng/pl for use in site-directed
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mutagenesis reactions (as detailed in manufacturers instructions). A list of all of the 
primers used in this study are detailed in Appendix I, Tables 2 and 3.
2.1.5. Plasmid Vectors
2.1.5.1. Mammalian Expression Vector
The mammalian expression vector, pcDNA3 (see Appendix I, Figure 3) containing full- 
length, human RyR2 which is tagged with eGFP at the N-terminus (pcDNA3-eGFP- 
hRyR2) was obtained from Dr. Christopher H. George. pcDNA3-eGFP-hRyR2 
harbouring the CPVT-linked L433P mutation (pcDNA3-eGFP-hRyR2-L433P) was 
obtained from Dr. N. Lowri Thomas (see Appendix I, Table 1 and Figure 2 for construct 
nomenclature).
2.1.5.2. Intermediate Vector
The pSL1180 superlinker vector (GE Healthcare, see appendix 1, Figure 3) was used to 
clone fragments of RyR2 to undergo subsequent site-directed mutagenesis (George et 
al., 2003c). This vector was used solely for the generation and propagation of 
mutagenised RyR2 and was not used for the expression of protein. pSL1180 containing 
the 2.1 kb SanDI/Kpnl fragment (pSL1180-SK1, hRyR2 DNA residue 5540-7678) was 
obtained from Dr. N. Lowri Thomas.
2.1.6. Microbiology
All growth media and antibiotics were obtained from Sigma-Aldrich. Sterile plasticware 
and glassware were obtained from Greiner and Fisher. All glassware was washed in 
detergent-free water and autoclaved prior to use. Aseptic technique was employed in all 
bacterial cell culture work and where possible work was carried out in a Class I 
containment safety cabinet.
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• LBAmp agar -  10g/L tryptone, 5g/L yeast extract, 10g/L NaCI, 15g/L agar. Autoclaved 
and allowed to cool before the addition of lOOpg/ml of ampicillin. Stored at 4-8°C.
• LBAmp broth -  10g/L Tryptone, 5g/L yeast extract, 10g/L NaCI. Autoclaved and
allowed to cool prior to the addition of 100pg/ml of ampicillin. Stored at 4-8°C.
• NZY broth -  16g/L NZ, 5g/L yeast extract. Autoclaved and stored at 4-8°C.
• SOC medium -  20g/L Tryptone, 5g/L yeast extract, 0.5g/L NaCI, 0.18g/L KCI,
0.95g/L MgCI. Autoclaved and allowed to cool prior to the addition of glucose at 2% 
(w:v) from the stock solution.
• Glucose -  20% (w:v) in deionised H20, filter sterilised.
• Ampicillin -  100mg/ml stock prepared in deionised H20, filter sterilised, and aliquots 
were stored at -20°C.
2.1.7. Bacterial Cell Lines
Several strains of Escherichia coli and Epicurian coli were used in the generation and
propagation of wild type and mutagenised eGFP-tagged hRyR2.
• XL1-Blue competent cells were obtained from Stratagene and were used solely 
for the transformation of single-stranded mutagenised plasmid DNA. XL1-Blue 
cells are deficient in endonuclease (endA) and recombination (recA), which 
improves the quality of purified DNA and insert stability. The hsdR mutation 
eliminates a methylation-specific restriction site, preventing cleavage of cloned 
DNA by the endogenous EcoK endonuclease system.
• XL10-Gold Ultracompetent cells were also obtained from Stratagene and were 
used for several stages of cloning of full length, pcDNA3-eGFP-RyR2 and 
pSL1180-SKI constructs. XL10-Gold cells are deficient in endonuclease (endA-) 
and recombination (recA-) genes, increasing plasmid quality and insert stability. 
These cells carry the Hte phenotype, which increases the transformation 
efficiency of large DNA molecules
• MAX Efficiency® Stbl2 competent cells were obtained from Invitrogen and are 
optimised for the transformation of unstable inserts with increased yield and and 
were used for the propagation of full-length mutagenised RyR2 plasmid. These 
cells contain the endA- and recA1 phenotype described above.
• Aliquots of all bacterial stocks (25-50(jl) were stored at -80°C.
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2.1.8. Human Embryonic Kidney (HEK) 293 cell culture media and reagents.
HEK-293 cells (ATCC accession number CRL-1573) are derived from human embryonic 
kidney cells that have been immortalised through their transformation with sheared 
Adenoviral 5 DNA. They are an adherent cell line that exhibit epithelial morphology, in 
that they grow as a cellular monolayer, with a tendency to continue dividing after 
reaching confluency, forming aggregates or clumps of cells (Graham et al., 1977). The 
phenotype of HEK-293 cells and the justification for the use of them in this study is 
discussed further in section 3.1.1.5.
All cell culture media and reagents were obtained from Invitrogen. All chemicals were 
obtained from Sigma-Aldrich, unless otherwise stated. Cell culture flasks and plates 
were obtained from Nunc (Fisher Scientific). Poly-D-Lysine coated glass coverslips were 
obtained from MatTek Corporation (www.mattek.com). All mammalian cell culture work 
was earned out under sterile conditions in Class I containment cabinets (Microflow).
• Foetal bovine serum (FBS) -  heat-inactivated, filter sterilised and aliquots were 
stored at -20°C.
• Complete Dulbecco’s Modified Eagles Medium (cDMEM) -  DMEM containing 
4.5g/L glucose and supplemented with 10% (v:v) foetal bovine serum (FBS), 
2mM glutamine and 100pg/ml penicillin/streptomycin (all filter sterilised prior to 
addition). Stored at 4-8°C.
• Minimal Dulbecco’s Modified Eagles Medium (mDMEM) -  DMEM containing 
5.4g/L glucose and supplemented with 2mM glutamine and 100pg/ml 
penicillin/streptomycin (all filter sterilised prior to addition). Stored at 4-8°C.
• Trypsin-EDTA -  1x in HBSS without Ca2+ or Mg2+. Aliquots were made and 
stored at -20°C. Filter sterilised immediately prior to use.
• Saline solution -  0.9% (w/v) supplied by Baxter Medical Supplies.
• Phosphate buffered Saline (PBS) -  Prepared a 10x stock, 1.37M NaCI, 27mM 
KCI, 100mM Na2HP04 and 18mM KH2P04. Diluted to 1x PBS and pH adjusted to
7.4.
• Effectene transfection reagent -  obtained from Qiagen, stored at 4-8°C.
• Hepes buffered saline (HBS) 2x -  280mM NaCI, 10mM KCI, 1.5mM Na2HP04, 
10mM glucose, 50mM Hepes, pH adjusted to 7.05, filter sterilised and aliquots 
were stored at -20°C.
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• Calcium chloride -  2M CaCI2.6H20  was prepared, filtered and aliquots were 
stored -20°C.
2.1.9. Antibodies
• Ab-GFP (B-2), mouse monoclonal IgG, raised against the entire Green 
Fluorescent Protein of Aequorea victoria, and cross reacts with enhanced GFP. 
Obtained from Santa Cruz. Used at 1:5000 dilution for western blotting.
• pAb-1093, rabbit polyclonal antiserum, raised to residues 4454-4474 of the 
cardiac ryanodine receptor (EDKGKQKLRQLHTHRYGEPEC), and does not 
cross react with RyR1. Used a 1:5000 dilution for Western blotting, 1:100 for 
immunocytochemistry.
2.1.10. Ca2+ Imaging reagents and agonists
• Fluo3-AM -  50pg of Fluo-3 AM calcium dye dissolved in 15pl 20% (w:v) pluronic 
acid in DMSO to obtain a stock concentration of 3mM. Pluronic acid prevents 
aggregation of Fluo3-AM and increases loading efficiency. The 3mM solution 
was diluted 1:200 in mDMEM to obtain a working stock at 15pM. Fluo3-AM was 
prepared immediately prior to use.
• Caffeine solution -  100mM caffeine working stock was prepared in mDMEM. All 
subsequent dilutions were generated from this stock by dilution with mDMEM. 
Caffeine causes RyR2 activation by sensitising the channel to activation by 
luminal/cytoplasmic Ca2+ (section 3.1.5)
• Thapsigargin -  1mM stock solution prepared in DMSO, aliquots were stored at - 
20°C. Thapsigargin a sesquiterpene lactone isolated from the plant, Thapsia 
garganica. Thapsigargin raises cytoplasmic Ca2+ concentration by way of SERCA 
inhibition, leading to passive depletion of the ER Ca2+ store and is regularly used 
to estimate ER Ca2+ content (Lytton et al., 1991; Tong et al., 1999).
• lonomycin -  1mM stock solution prepared in DMSO. Diluted 1/10 to prepare a 
100pM stock and aliquots were stored at -20°C. lonomycin is an ionophore that is 
produced by Stmptomyces conglobatus and increases the permeability of the cell
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membrane to Ca2+ ions, resulting in increased cytoplasmic Ca2+ levels if sufficient 
Ca2+ is present in the external medium.
• EGTA -  100mM stock solution of Na2EGTA (ethylene glycol-bis (p- 
aminoethylether)-N,N,N\N’-tetraacetic acid) was prepared, pH adjusted to 10.0 
with KOH until dissolved, pH adjusted to 7.0 with HCI and stored at 4-8°C. EGTA 
is a Ca2+ chelating agent that is routinely used to buffer Ca2+ in experimental 
systems and has a significantly higher affinity for Ca2+ than EDTA, which is a 
chelator of all divalent cations e.g. Ca2+, Mg2+, Mn2+ etc.
2.1.11. Data Analysis
DNA sequencing analysis was carried out on an Applied Biosystems DNA sequencing 
source file using Chromas Version 1.5 (Technelysium, 
http://www.technelysium.com.au). Homology alignments to the WT human RyR2 
nucleotide sequence were performed using NCBI BLAST 
(http://blast.ncbi.nlm.nih.QOv/Blast.cqi).
The analysis of Ca2+ imaging data will be discussed in further detail in sections 3.2, 4.2 
and 5.2. Briefly, numerical data corresponding to the intensity of Ca2+-dependent Fluo3- 
AM signal from defined cellular regions of interest were generated using Leica LAS AF 
software. Raw Ca2+-imaging data was exported in a Microsoft Excel compatible format 
and was stored and manipulate using Microsoft Excel before graphical plotting and 
statistical analyses were performed using GraphPad Prism software 
(http://www.qraphpad.com). Initial analyses of spontaneous Ca2+ oscillation parameters 
were carried out using synchrony -  amplitude -  length -  variability of oscillations 
(SALVO) software (Silvester et al., 2009), prior to data being transferred to Microsoft 
Excel. Appropriate statistical tests were performed using Microsoft Excel and GraphPad 
Prism software as detailed in section 2.2.4.
98
2.2 Methods
2.2.1. Molecular biology techniques
2.2.1.1. Agarose gel electrophoresis
DNA fragment size was analysed by agarose gel electrophoresis and comparison 
against concurrently run DNA molecular weight markers. All analysis of DNA fragments 
was carried out using a 1% (w:v) agarose gel prepared by dissolving the appropriate 
amount of agarose in TAE (1x) buffer and boiling in a microwave oven. The agarose was 
allowed to cool to ~50°C, before the addition of ethidium bromide to a final concentration 
of 0.1pg/ml and was then poured into a gel-tray according to manufacturer’s instructions 
(Hoefer, Biorad). Once the gel was set, DNA samples were mixed with an equal volume 
of DNA loading buffer (2x) and loaded onto the gel and ran alongside a 1kB DNA 
molecular weight marker. Electrophoresis was typically carried out at constant voltage 
(80V) until the dye front had migrated two thirds of the way down the gel, which was 
sufficient to result in resolution of all DNA fragments. DNA was visualised using UV 
trans-illumination and imaged using a gel documentation system and Quantity One 
software.
2.2.1.2. Cloning of DNA fragments
Plasmid DNA (1-2pg) was digested with the appropriate restriction enzymes (5-10U per 
20pl reaction) for 4 hours at 37°C to which ensured complete digestion. Concurrent 
double digests were carried out in the most appropriate buffers, as determined by the 
Double Digest Finder tool (New England Biolabs, http://tools.neb.com/NEBcutter2). 
Digest products were run on a 1% agarose gel (section 2.2.1.1). DNA fragments were 
physically excised from the agarose gel and purified using the QIAEX II gel extraction kit 
(Qiagen) according to the manufacturers instructions. The agarose-gel slice was 
weighed and nuclease free water (2x, v:w, 1pl:1mg of agarose), QX1 buffer (3x, v:w, 
1(jl:1mg of agarose) and 20pl of silica bead solution were added to the agarose gel 
containing the DNA fragments, which were then incubated at 50°C for 10 mins to 
solubilise the agarose. The mixture was centrifuged (20,000 xg, 1 min) and the 
supernatant was discarded. The resulting pellet was resuspended in 500pl QX1 buffer
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and centrifuged (20,000 xg, 1 min). The supernatant was discarded and the pellet 
underwent two washes with 500pl PE buffer, centrifuging (20,000 xg, 1 min) after each 
wash. The supernatant was discarded and the pellet was incubated at RT for 10 mins to 
dry. DNA was eluted from the silica beads by the addition of 30pl elution buffer (10mM 
Tris, pH 8.8), which was incubated at 50°C for 5 mins before centrifugation (20,000 xg, 1 
min) to remove the silica beads from solution. Product (5pl) was run on a 1% (w:v) 
agarose gel and visualized to validate purification (section 2.2.1.1 and section 2.2.1.4).
Although column-based purification methods tend to yield higher levels of DNA recovery, 
they are limited to DNA fragments between 0.1-10kb making them unsuitable for RyR2 
purification. The amount of DNA recovered was estimated by visual comparison with the 
signal intensity of bands on an agarose gel corresponding to known amounts of pre - 
linearised DNA (Figure 2.1). Typically, ~150-200ng of DNA would be recovered from the 
restriction digest and QIAEX II purification of 4pg of plasmid DNA. Although there was a 
large loss of DNA, the remaining amount of DNA was sufficient to carry out ligations of 
mutagenesis cassettes into full-length RyR2.
D N A (nM )
1kb 1kb
Ladder 1000 500 250 200 100 75 50 30 20 10 Ladder
Figure 2.1. DNA dilution series for estimation of amount of DNA recovered from 
QIAEX II purification. pSL1180 containing the SanDI/Kpnl mutagenesis cassette (1pg) 
was digested with EcoRV for 4 hours at 37°C. EcoRV cuts the plasmid at a single site and 
linearises the plasmid DNA, preventing the effects o f super-coiling on DNA fragment 
migration. A range of amounts of digest product (0.01 -  1pg) were run on an agarose gel 
(1%) containing ethidium bromide (1pl per 100ml of agarose) and were imaged by UV 
trans-illumination. The intensity o f the resulting band of known molecular mass was used to 
estimate the amount o f DNA recovered from QIAEX II purification.
Ligations were carried out using the Rapid Ligation Kit (Roche) according to the 
manufacturer’s instructions. The insert fragment was mixed with the plasmid vector 
(50ng) in a 3:1 molar ratio together with T4 DNA ligase and Ligase Buffer and was 
incubated at 4-8°C for 16 hours. Ligation product (15pl) was used to transform XL10- 
Gold cells (50pl) according to the protocol in section 2.2.1.3.
1 0 0
2.2.1.3. Transformation of competent bacterial cell lines
Three strains of Escherichia coli were used in this study: XL10-Gold (Stratagene), XL1- 
Blue (Stratagene) and MAX Efficiency Stbl2 (Invitrogen) competent cells (see section 
2.1.7). The adherence to stringent protocols was essential for successful propagation of 
full-length RyR2 plasmid cDNA, as the large plasmid (~21kb) is fragile and prone to 
spontaneous intra-plasmid recombination. Bacteria transformed with full-length RyR2 
plasmid were cultured at 30°C for less than 18 hours to minimize the likelihood of 
spontaneous plasmid DNA rearrangements (George etal., 2003c). Bacteria transformed 
with the smaller intermediate vector containing mutagenesis cassettes were cultured at 
37°C. All bacteria were cultured in LB media containing ampicillin (100pg/ml, LBAmp) for 
transformant selection, either in suspension with shaking at 225rpm or on LB-agar 
plates.
Propagation of full-length RyR2 plasmid DNA and the intermediate vector containing 
mutagenesis cassettes was carried out by the transformation of XL10-Gold cells. Briefly 
competent cells (25pl) were thawed on ice and treated with (3-ME (1pl, 0.5M) for 10 mins 
prior to the addition of ligation mix (15pl) or 100ng of plasmid DNA for retransformation. 
Cells were incubated on ice for 30 mins, prior to hear shock treatment at 42°C for 30 
secs and immediate transfer to ice for 2 mins. NZY medium (900pl) was added to the 
cells which were then incubated at 37°C for 1 hour with shaking at 225rpm. Cells were 
plated onto LB^p agar plates and were incubated overnight at 30°C or 37°C for cells 
transformed with full-length RyR2 or intermediate vector containing mutagenesis 
cassette DNA respectively.
Site-directed mutagenesis products (5pl) were treated with Dpnl to digest the 
methylated, non-mutated DNA template (see section 2.2.1.7 and Figure 2.2) and were 
transformed into XL-1 Blue supercompetent cells (25pl). A similar method was employed 
to that used in the transformation of XL10-Gold cells, although (3-ME treatment of cells 
was not carried out in this protocol. XL1-Blue cells are capable of repairing the resulting 
'nicks’ in plasmid DNA resulting from site-directed mutagenesis primer elongation.
MAX Efficiency Stbl2 cells were used for the propagation of full-length RyR2 plasmid 
DNA, as they produced a significantly higher yield and no observable differences in 
restriction digest patterns compared to plasmid DNA propagated in XL10-Gold cells.
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Full-length RyR2 plasmid DNA (200pg) was added to Stbl2 cells (50pl) and incubated on 
ice for 30 mins. Cells were heat-shocked at 42°Cfor 25 secs before being returned to ice 
for a further 2 mins. SOC medium (900|jl) was added to the cells, which were incubated 
at 30°C for 90 mins with shaking at 225rpm. Bacteria were spread onto LBAmp plates and 
incubated overnight at 30°C, before being examined for colony growth. Stbl2 cells 
tended to produce slightly smaller and significantly more individual colonies, when 
compared XL10 Gold cells.
2.2.1.4. Small scale plasmid isolation (“Miniprep”)
Individual bacterial colonies were picked into L B ^  medium (4ml) and incubated for 16h 
at 30°C (full-length RyR2 plasmid DNA) or 37°C (intermediate vector containing 
mutagenesis cassettes).
A proportion of the bacterial culture (3mls) was subsequently centrifuged (20,000 xg, 1 
min) to pellet the bacteria. Plasmid DNA was then purified using the Wizard Mini-Prep 
System (Promega) according to the manufacturer’s instructions. Briefly, the bacterial 
pellet was resuspended in resuspension solution (250pl) containing RNase A. Cell lysis 
solution (250pl) was added to the resuspended cells which were incubated at RT for 2 
mins. Neutralisation solution (350pl) was added to the lysed bacteria which were then 
centrifuged (20,000 xg, 1 min) RT to pellet insoluble material. The clear lysate was 
transferred to a Wizard Mini-Prep spin column, containing a silica membrane to which 
the DNA became bound after centrifugation (20,000 XG, 1 min). The flow-through was 
discarded and the column was washed with wash solution (700pl) and centrifuged 
(20,000 xg, 1 min). The supernatant was discarded and the column underwent a further 
wash with wash solution (250pl) and was centrifuged (20,000 xg, 1 min). The column 
flow-through was discarded and the column was centrifuged (20,000 xg, 2 mins) to dry 
the silica membrane. The column was transferred to a collection tube and plasmid DNA 
was eluted in dH20 (30pl) by centrifugation (20,000 xg, 1 min).
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2.2.1.5. Large scale plasmid isolation (“Maxiprep”)
The remaining miniprep culture was refreshed with 3ml LBAmp broth and incubated at 
30°C (full-length RyR2 constructs) or 37°C (intermediate vector containing mutagenesis 
cassette) with shaking at 225 rpm for 1 hour prior to seeding a larger culture (200ml) at a 
1 in 400 dilution. Larger cultures were incubated at 30°C (full-length RyR2 constructs) or 
37°C (intermediate vector containing mutagenesis cassettes) with shaking at 225rpm for 
16 hours before being centrifuged at 15,000 xg for 10 mins at 4°C to pellet the bacterial 
cells. Plasmid DNA was isolated from the bacteria using the Qiagen Maxi-prep kit 
according to the manufacturer’s instructions. The supernatant was discarded and the cell 
pellet was resuspended in 10ml of resuspension buffer (Buffer P1). Cells were lysed by 
the addition of 10mls of lysis buffer (Buffer P2) followed by inversion of the tube until the 
lysate became clear. Neutralisation buffer (Buffer P3, 10ml) was added to the solution 
which was incubated on ice for 30 mins to precipitate insoluble material. The lysate was 
centrifuged at 20,000 xg for 30 mins to remove the insoluble material. A Qiagen-tip 500 
was equilibrated with 10ml of column equilibration buffer (Buffer QBT), prior to the 
addition of the cleared supernatant to the column. The supernatant was allowed to flow 
through the column before undergoing two washes with 30mls of wash buffer (Buffer 
QC). The column was transferred to a 30ml collection tube and DNA was eluted in 15ml 
of elution buffer (Buffer QF). 10.5mls of isopropanol was added to the DNA which was 
allowed to precipitate for 16 hours at -20°C. DNA was collected by centrifugation at 
20,000 xg, 4°C for 30 mins. The DNA pellet was washed with 5ml of 80% ethanol and 
was centrifuged for a further 10 mins at 20,000 xg at 4°C. The supernatant was 
discarded and the pellet was allowed to air-dry for 10 mins before being resuspended in 
500pl of SDW. DNA was incubated at 37°C for 2 mins to aid resuspension, before being 
transferred to a 1.5ml micro-centrifuge tube. Plasmid DNA was quantified (see 2.2.1.6) 
and 1 pg of “Maxiprep” DNA was analysed for sequence integrity (see 2.2.1.3) and stored 
at -20°C.
2.2.1.6. Analysis of recombinant plasmid DNA
DNA concentration was determined using a spectrophotometer to measure the 
absorbance at 260nm (Abs26o) of a 1:50 dilution of “Maxiprep” DNA in SDW. Duplicate
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measurements were made to allow the calculation of the average Abs^o. which was 
used to calculate DNA concentration according to the following formula:
Abs26o x dilution factor x 50 = DNA Concentration (ng/pl)
An AbS26o value of 1 corresponds to 50pg/ml double stranded DNA, hence this 
multiplication step is incorporated into the above formula. Tyrosine and tryptophan 
residues absorb strongly at 280nm, and as such the absorbance at 280nm (Abs28o) is 
measured and used as an indicator of contaminating protein levels. The Abs26o ' Abs28o 
ratio was determined and used as a measure of the purity of the DNA prep, with a ratio 
of >1.8 being indicative of a preparation of high purity.
Restriction enzyme mapping was used to confirm that transformations were successful 
and that no gross plasmid rearrangement events had occurred during transformation, 
which would be presented as an altered DNA fragment banding pattern when run on an 
agarose gel. Several restriction enzymes were available for the mapping of full-length 
human RyR2 due to the presence of multiple restriction sites for an individual restriction 
enzyme in the RyR2 DNA sequence. HinDill was used for restriction mapping of 
pSL1180-SK1 constructs, due to the presence of numerous Hin Dill restriction sites in 
this construct.
2.2.1.7. Site-directed mutagenesis of pSL1180-SK1
The site-directed mutagenesis (SDM) method employed in the generation of full-length 
RyR2 cDNA constructs containing the single nucleotide polymorphisms utilises the 
polymerase chain reaction (PCR) and is limited to DNA sequences of ~6-8kb in length 
(Figure 2.2). The pcDNA3-eGFP-RyR2 plasmid is approximately 21 kb making it too 
large for PCR amplification. Therefore, a method utilising an intermediate vector, 
pSL1180, containing the SanDI/Kpnl hRyR2 mutagenesis cassette (psL1180-SK1) was 
adopted for the generation of constructs containing the G1885E polymorphism. The 
cassette in the intermediate vector is only 5,455bp, a suitable length for reliable PCR 
amplification.
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Site-directed mutagenesis was carried out on the pSL1180 intermediate vector 
containing the SanDI/Kpnl RyR2 fragment using the QuikChange® SDM kit (Stratagene) 
according to the manufacturers instructions (Figure 2.2). A schematic overview of the 
methods employed in the incorporation of single nucleotide substitutions and their 
subsequent verification is shown in Figure 2.3. Complementary oligonucleotide primers 
were designed that complemented the WT RyR2 DNA sequence, apart from a single 
mis-matched nucleotide that resulted in the required amino acid substitution.
When designing primers for use in SDM reactions, there are several factors that need to 
be considered. Firstly, both mutagenic primers need to contain the proposed base 
substitution and anneal to the same sequence on opposite strands of the template 
plasmid. Secondly, primers need to be between 25 and 45 base pairs long, with the 
mutation site as central as possible, to ensure complete specific annealing of the primer 
to the template DNA. Thirdly, the primers must have a melting temperate (Tm) of >78°C 
and should terminate with a guanine or cytosine base to ensure primer stability. Finally, 
the primers must have a high level of purity, such as that obtained by HPLC purification, 
as a decrease in primer purity results in a significant decrease in mutation efficiency. 
The primers used are detailed in Appendix 1, Table 2. The SDM reaction mix was 
prepared as detailed in Table 2.1. and underwent thermal cycling according to the 
protocol in Table 2.2.
Reagent Volume Final Concentration
10x Reaction Buffer 5pl 1x
DNA Plasmid Template 0.5|jl of 90ng/pl stock 45ng total (0.9ng/Ml)
Forward Primer (G1885E For) 1 ul of 150ng/ul stock. 150ng total (3ng/Ml)
Reverse Primer (G1885E Rev) 1 |jl of 150ng/|jl stock. 150ng total (3ng/pl)
dNTP Mix 1pl of 10mM stock 0.2mM
PfuTurbo DNA Polymerase 1 pi of 2.5U/mI stock 2.5U (0.5U/MD
Nuclease Free H20 To total volume of 50ul 40.5m!
Table 2.1. G1885E Site-directed mutagenesis reaction mix.
Step Temperature Duration Cycles
Initial Denaturation 95°C 30 secs 1
Denaturation 95°C 30 secs
18Annealing 55°C 1 min
Elongation 68°C 6 mins
Hold 4°C Indefinitely 1
The length of the elongation step is determined by the size of the 
template plasmid, requiring 1 min per 1kb to be amplified.
Table 2.2. Site-directed mutagenesis thermal cycling protocol.
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Following thermal cycling, 1 |jl of the restriction endonuclease, Dpn/, was added to the 
reaction product, which was then incubated at 37°C. Dpn/ is specific for methylated and 
hemimethylated DNA and digests the template plasmid, whereas the PCR product is 
non-methylated and remains intact following Dpn I digestion, effectively selecting for 
mutation-containing synthesised DNA.
2.2.1.8. Sequencing of restriction boundaries and SDM site
Direct automated sequencing was used to confirm that the SDM reaction was successful 
and that the appropriate nucleotide substitution had been made. DNA sequencing was 
performed using the chain-terminating BigDye™ sequencing kit (Applied Biosystems, 
brief description in section 2.1.2) using the ABI Prism Genetic Analyzer 3130x1 
sequencer. The sequencing reaction was prepared according to Table 2.3. and thermal 
cycling was carried out according to the protocol in Table 2.4.
Reagent Volume
PSL1180-SK1-G1885E plasmid DNA 1M9
Big Dye Buffer 2ul
Big Dye 2pl
Sequencing Primer 1 pi of 3.2pmol/ul
Nuclease Free H20 To total volume of 10mI
Table 2.3. BigDye term inator sequencing reaction formulation.
Step Temperature Duration Cycles
Initial Denaturation 96°C 30 secs 1
Denaturation 96°C 30 secs
25Annealing 50°C 1 min
Elongation 60°C 4 mins
Hold 4°C Indefinitely 1
Table 2.4. BigDye term inator sequencing reaction thermal cycling protocol.
Following thermal cycling, DNA incorporating the sequence-dye was precipitated prior to 
automated sequencing. The sequencing reaction product was made up to a total volume 
of 20pl with dH20, to which 80pl of freshly prepared 75% ethanol was added. The 
reaction mix was then incubated in the dark, at RT for 1 hour. The sequencing reaction
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Figure 2.3. Cloning strategy for inserting nucleotide substitutions into full-length RyR2 cDNA. Site directed mutagenesis was used to insert a 
SNP (G1885E) into the SanDI/Kpnl mutagenesis cassette (SK1) in the intermediate vector (panel A, section 2.2.1.7). The expression vector containing 
full-length RyR2 and intermediate vector containing the mutagenesis cassette were both digested with SanDI/Kpnl (panel B, section 2.2.1.2) and DNA 
fragments corresponding to the RyR2 “vector" and mutagenesis cassette containing G1885E were purified (panel C). The cassette containing G1885E 
was ligated into the full-length RyR2 “vector” (panel D), which was then propagated in XL10-Gold or Stbl2 cells (section 2.2.1.3 - 2.2.1.5). Successful 
ligation was confirmed by restriction mapping (panel E) and direct sequencing of the SDM site. The resulting codon change is indicated in red. (panel 
F, section 2.2.1.8).
was then centrifuged at 20000 xg for 30 mins at RT to pellet the DNA and the 
supernatant was discarded. The resulting pellet was washed with 180pl of freshly 
prepared 75% ethanol and centrifuged for a further 15 mins. The supernatant was 
discarded and residual ethanol was removed by incubation at 95°C for 2 mins. The 
precipitated DNA was then sequenced using the ABI Prism Genetic Analyzer 3130x1 
sequencer.
Sequencing data was analysed using NCBI BLAST (www.ncbi.nlm.nih.aov/BLAST) and 
was compared to the human RyR2 sequence (accession number NM__001035.2) using 
the nucleotide sequence homology alignment tool.
2.2.2. Cell biology techniques
2.2.2.1. HEK-293 cell culture
Human Embryonic Kidney 293 (HEK) cells were maintained in Dulbecco’s Modified 
Eagles Medium (DMEM) supplemented with 10% (v:v) FCS, 2mM glutamine and 
100pg/ml penicillin/streptomycin (complete DMEM, cDMEM). They were routinely 
cultured in 75cm2 tissue culture flasks with filter caps (Greiner Bio-one) in a 37°C, 5% 
C 02 incubator (Sanyo). Routine passaging of cells was carried out by detaching the cells 
from the flask by incubation with 2mls Trypsin-EDTA for 2 mins, inhibited by the addition 
of 10mls cDMEM. Cell number was calculated using a haemocytometer and adjusted to 
the appropriate density. Briefly, a glass coverslip was firmly affixed to the 
haemocytometer to ensure correct counting chamber depth. Cell suspension was mixed 
well to disrupt cellular aggregates before being added to the haemocytometer counting 
chamber by way of capillary action. The average number of cells in each of the four 4x4 
corner squares, each with a volume of 1 x 10"4 ml was determined. The average cell 
count was multiplied by 1x105 to determine cell density (cells / ml). Cell density was 
adjusted by pelleting a known number of cells by low-speed centrifugation (1000 xg) for 
5 min and resuspension in the appropriate volume of DMEM.
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2.2.2.2. Heterologous RyR2 expression
In order to heterologously express full-length recombinant RyR2 in HEK-293 cells, two 
methods of transfection were employed with the downstream experimental application 
being the deciding factor of which methodology was used. Calcium phosphate (CaP04) 
mediated transfection was used for the transfection of cells from which RyR2 protein 
was to be used in SDS-PAGE and western blot-analysis as this method results in high 
levels of RyR2 expression per individual cell. However, high-levels of RyR2 expression 
can be cytotoxic and result in increased cell-death (George et al., 2003a) and also 
leaves a residual precipitate on the cells, which is not ideal for live-cell Ca2+ imaging. 
CaP04 transfection also tended to exhibit a high level of variation between separate 
transfection experiments, possibly due to the sensitivity to variation in transfection 
reagents e.g. HBS, CaCI. Furthermore, CaP04-mediated transfection requires a 
significantly greater amount of DNA (~10 fold) for successful transfection compared to a 
commercially available lipid-mediated transfection reagent, Effectene (Qiagen).
Effectene Reagent (Qiagen) was more suitable for the transfection of cells for live cell 
imaging, as it produced highly reproducible transfection efficiencies (40-45 %, Figure
3.10), did not leave a precipitate and was less cytotoxic than CaP04-mediated 
transfection, possibly due to lower levels of RyR2 expression per individual cell. 
However, transfection of large numbers of cells for RyR2 with Effectene reagent was not 
feasible due to the expense of sufficient reagent for large scale transfection. Also, when 
large scale transfection was attempted, the amount of RyR2 that was isolated was not 
sufficient to exhibit sufficient signal for accurate determination of relative levels of RyR2 
expression by SDS-page and western blot analysis.
2.2.2.2.1. Calcium phosphate-mediated transfection of HEK cells
HEK cells (1x106) were seeded into a T75 flask and were incubated for 24 hours at 
37°C, 5% C 02 prior to transfection with full-length, pcDNA3-eGFP-RyR2 plasmid DNA. 
Plasmid DNA (28pg) was mixed with sterile dH20  and 259pl of 2M CaCI2 to a total 
volume of 1050pl and vortexed vigorously. This mixture was added a drop at a time to 
1050pl of warmed 2x HBS in a sterile 14ml capacity polypropylene tube (Greiner) with 
continuous mixing to achieve a final CaCI2 concentration of 125mM and a volume of
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2050|jl. Transfection complexes were incubated at RT for no longer than 30 mins to 
allow precipitates to form. These were subsequently mixed by vortexing and added a 
drop at a time to cells in cDMEM (20ml), which were incubated at 37°C, 5% C 02 for 24 
hours. Transfection media was then removed and replaced with cDMEM and cells were 
incubated for a further 24 hours before harvesting by trypsinisation as in section 2.2.2.1.
2.2.2.2.2. Effectene-mediated transfection of HEK cells
Transfection of HEK cells for subsequent live-cell Ca2+-imaging using confocal 
microscopy was achieved using the lipid-based Effectene Reagent (Qiagen) according 
to manufacturer’s instructions. HEK cells were seeded onto 154mm2, poly-D-lysine 
coated coverslips (154mm2 growth area, MatTek) at a density of 1x10s cells/coverslip in 
a meniscus volume of 150pl. Cells were incubated at 37°C, 5% C 02 for 1 hour prior to 
transfection, to allow them to adhere to the coverslip. To transfect 14 coverslips, 3.2pg of 
pcDNA3-eGFP-RyR2 plasmid DNA was made up to a total volume of 400pl With EC 
Buffer, to which 25.6pl enhancer solution was added to “condense” the DNA. The 
solution was mixed by vortexing and incubated at RT for 4 mins. 80pl of Effectene 
reagent was added to the solution, which was mixed by vortexing and incubated at RT 
for 10 mins to produce condensed Effectene-DNA complexes. 2.4mls of cDMEM was 
added to the transfection solution containing the Effectene-DNA complexes, 200pl of 
which was added to the meniscus on each coverslip. Cells were incubated at 37°C, 5% 
C 02 for 24 hours before being topped up with 2mls cDMEM and returned to the 
incubator for a further 24 hours (48 hours total incubation post-transfection). Cells were 
then examined for eGFP fluorescence using fluorescent microscopy (Zeiss) for 
confirmation of successful protein expression.
2.2.2.2.3. Co-transfection with multiple RyR2 cDNAs
To investigate the functional consequences of co-expression of two distinct recombinant 
RyR2s, cells were transfected with equimolar ratios of two distinct RyR2 cDNAs using 
Effectene reagent as detailed in section 2.2.2.2.2. When transfecting cells on 14 
coverslips for single-cell Ca2+ imaging, 1.6|jg of each RyR2 cDNA (3.2pg total) was 
mixed, prior to incubation with enhancer and Effectene reagents. Transfection with a
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Figure 2.4. Schematic representation o f recombinant RyR2 tetramerisation. HEK cells 
transfected with a single RyR2 result in the formation of homotetramers, with each monomeric 
subunit containing identical amino acid substitutions (panel A). Co-transfection of HEK cells with 
equimolar ratios of two distinct RyR2 cDNAs likely results in the formation of heterotetramers 
containing a mixture of RyR2 subunits (panel B). Although tetramers consisting of 2 of each type 
of RyR2 subunit are illustrated here, RyR2 tetramers will likely be of varying stoichiometry, 
including the formation of homotetrameric channels, although this can not be determined in these 
experiments. Tetramers described as "in cis’’ indicate the mode of expression replicative of 
inheritance of the two substitutions on the same allele in vivo, whereas those described as “in 
trans” are representative of the inheritance of two substitutions on opposite alleles in vivo. The 
hypothetical modes of inheritance i.e. (in cis and in trans) are indicated in each case.
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single RyR2 cDNA variant i.e. WT, G1885E, L433P or L433P-G1885E, results in the 
formation of homotetramers due to the absence of endogenous RyR2 in HEK cells 
(Figure 3.11). However co-transfection with equal amounts of two RyR2 cDNAs is likely 
to result in the formation of heterotetramers of varying stoichiometry, consisting of a 
mixture of the two different monomeric subunits in varying ratios. This is summarised in 
Figure 2.4, although it must be considered that the ratios of each subunit type will vary 
between tetramers i.e. 4 WT: 0 Mutant, 3 WT:1 mutant, 2 WT:2 mutant, 1 WT:3 mutant, 
0 WT:4 mutant. This also assumes that there is no difference in expression levels and 
relative tetramerisation affinity of the two co-expressed RyR2s. However, this mode of 
co-expression has been used previously in the heterologous expression of RyR (Tong et 
al., 1999; Lehnart et al., 2008) and the cardiac Na* channel (Baroudi et al., 2002; 
Poelzing etal., 2006).
2.2.2.2.4. Immunofluorescent detection of RyR2 protein expression
HEK cells were seeded in to 6 well plates (9.6cm2 per well) at a density of 8x105 
cells/well and were incubated at 37°C, 5% C 02 for 1 h prior to transfection with each 
RyR2 construct using Effectene transfection reagent (Qiagen, section 2.2.22.2). After 48 
hours, cells were examined for eGFP expression using fluorescent microscopy to 
confirm that the transfection was successful. Cells were detached with 1ml trypsin 
‘inactivated’ with cDMEM (4ml) and cell density was adjusted to 7.5x10s cells/ml. HEK 
cells (1.5 x 10s cells) were added to a sterile glass coverslip in volume of 200pl and were 
incubated at 37°C, 5% C 02 for 24 hours.
Cells were washed with PBS (3x) and were fixed in 4% (v:v) paraformaldehyde in PBS 
for 10 mins in the dark at RT. Cells were washed with PBS and rehydrated in PBS for 24 
hours at 4-8°C. Following rehydration, cells were washed with PBS and permeabilised 
with 0.1% (v:v) Triton-X-100 diluted in PBS for 30 mins at RT. Cells were incubated in 
10% (v:v) FCS diluted in PBS for 30 mins at RT. Following washing with PBS, cells were 
incubated with an anti-hRyR2 antibody (pAb1093, 1:100 v:v) at RT for 90 mins. 
Following three 10 min washes in PBS, cells were incubated with the secondary Alexa546 
goat anti-rabbit antibody (1:250) in PBS in the dark at RT for 90 mins. Coverslips were 
washed in PBS and SDW and mounted on glass slides using a drop of Fluorsave and 
were allowed to dry for 30 mins. Cells were imaged using an SP5 confocal microscope
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(Leica) with an oil immersion, 63x objective. eGFP fluorescence was excited with an 
Argon laser (peak excitation of 488nm) and emission between 520±28nm was detected. 
Alexa546 fluorescence was excited at 561 nm with a diode-pulsed solid state (DPSS) laser 
was detected over 655±65nm range.
The direct overlay of eGFP- and Alexa546 images was used to determine the extent of 
co-localisation of eGFP and antibody signals (calculated for each construct and 
expressed as the ‘percentage overlap’ as described previously (George et al., 2003a)
2.2.2.3. Confocal microscopy
HEK cells transfected with full-length pcDNA3-eGFP-hRyR2 constructs using Effectene 
reagent, were examined using a SP5 confocal microscope (Leica). 48 hours post­
transfection {2.2.22.2) cells were loaded with Fluo3-AM (15pM in mDMEM, see section
2.1.10) for 1h at 37°C, 5% C 02> before addition of excess mDMEM. Cells were returned 
to the incubator for a further 15 mins to allow de-esterification of Fluo3-AM. Media was 
aspirated from the coverslip and was replaced with mDMEM (1ml) prior to examination 
using the confocal microscope using an oil-immersion, 63x magnification objective, using 
an Argon laser. Excitation was at 488nm and fluorescence was detected over the range 
of 525±25nm. Data was acquired from regions of interest representing global 
intracellular environments using Leica LAS AF confocal software. Analysis of exported 
Ca2+ imaging data was performed using Microsoft Excel and GraphPad Prism software.
2.2.3. Protein biochemistry techniques
2.2.3.1. Preparation of mixed membranes from transfected HEK cells
Following CaP04 mediated transfection of HEK cells (as in section 2.2.2.2.1) cells were 
harvested by trypsinisation and pelleted by centrifugation (1,000 xg, 5 mins). Cells were 
resuspended in hypo-osmotic buffer (see section 2.1.3, 1ml buffer per 1x106 cells). Cells 
were homogenized by 10 strokes with a glass homogenizer on ice, before passing the 
cells through a 23G needle ten times. Lysed cells were centrifuged at low speed (1,000 
xg, 15 mins) to remove un-lysed cells and nuclei. The supernatant was collected and
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centrifuged at high speed (30,000 xg, 90 mins, 4°C) to pellet a microsomal fraction. 
Supernatant was removed and the microsomal pellet was resuspended in 0.4M sucrose, 
20mM HEPES solution (20pl per 1x106 cells). Microsomal preparations were aliquoted, 
snap frozen and stored at -80°C.
2.2.3.2. Micro-BCA protein assay
The first step of the micro bicinchoninic acid (BCA) protein assay is the chelation of 
copper with protein in an alkaline environment to form a blue-coloured complex. 
Peptides containing three or more amino acid residues form a coloured chelate complex 
with cupric ions in an alkaline environment containing sodium potassium tartrate. The 
second step of the colour development process involves the reaction of BCA, a highly 
sensitive colourimetric detection reagent, with the cupric cation formed in the first stage 
of the assay. The purple coloured reaction product is formed by the chelation of two 
molecules of BCA with one cuprous ion. The BCA/copper complex is water-soluble and 
exhibits a strong linear absorbance at 562nm directly proportional to increasing protein 
concentration.
Protein samples were diluted 1:200 (v:v) in SDW and 100pl was added in duplicate to a 
96 well plate. This dilution of sample proteins was necessary to ensure that protein 
concentrations were in the linear range of the relationship between protein concentration 
and absorbance as demonstrated by the generation of a BSA standard curve (Figure
2.5). Bovine serum albumin (BSA) was diluted to a range of concentrations (10, 25, 50, 
75, 100, 200 pg/ml) and added in duplicate to the 96 well plate. BCA solution was 
prepared by combing reagents A, B and C in a ratio of 50:49:1 respectively and 100pl of 
the prepared solution was added to each well. The samples were incubated at 37°C for 1 
hour before reading the absorbance at 560nm on a plate reader (Labsystems, Multiskan 
Ex). A standard curve of BSA protein concentration was generated using the 
absorbance at 560nm of the range of known BSA concentrations (Figure 2.5). The 
equation of the linear regression line was used to determine the protein concentration 
from the OD560 of sample protein. Typical protein yields from 1x106 cells harvested 48 
hours post-transfection with full-length RyR2 was typically between approximately 8mg- 
10mg and approximately 5-6mg in 1x106 untransfected HEK cells.
115
0.75n
s  0.50-
10
Q
O
0.25-
y = 0.00293x + 0.0638 
r2 = 0.9950.00
0 50 100 150 200 250
BSA (pg/Ml)
Figure 2.5. Linear regression analysis of the relationship between BSA 
concentration and absorbance at 560nm. Linear regression analysis was used to 
generate a standard curve from which sample protein concentration (pg/pl) could be 
estimated. Absorbance readings at each BSA concentration were taken in duplicate.
2.2.3.3. SDS Polyacrylamide gel electrophoresis
RyR2 protein expression levels were analysed by discontinuous SDS-polyacrylamide gel 
electrophoresis (Laemmli, 1970, Nature) and subsequently, by western blot analysis. A 
4% (v:v) acrylamide separating gel was prepared according to Table 2.5. A 4% gel is 
suitable for the resolution of proteins greater than 500 kDa. It was imperative that 
TEMED and APS were added to the separating gel immediately prior to the pouring of 
the gel to prevent premature acrylamide polymerization. A fresh working stock of APS 
was made immediately prior to preparation of the separating gel.
Reagent Volume Final Concentration
40% bis-Acrylamide 3ml 4% (v:v)
Tris 1.5M pH8.8 7.5ml 25% (v:v)
SDS, 10% (w:v) 3ml 1 % (v:v)
Ammonium persulphate, 
10% (w:v)
150pl 0.5% (v:v)
TEMED 15(j| 0.05% (v:v)
dH20 16.335ml 60.45% (v:v)
Total 30ml
Table 2.5.4% SDS-PAGE separating gel formulation.
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The polyacrylamide gel mixture was poured into the gel casing (Hoefer), which had been 
assembled according to the manufacturer’s instructions, and covered with a 1 cm layer of 
SDW and allowed to set. Once the polyacrylamide gel had set, the water was removed 
and replaced with 4% stacking gel prepared according to Table 2.6.
Reagent Volume Final Concentration
40% bis-Acrylamide 2ml 4% (v:v)
Tris 0.5M pH6.8 5ml 25% (v:v)
SDS, 10% (w:v) 200pl 0.1%
Ammonium persulphate, 
10% (w:v)
100yl 0.5%
TEMED 20pl 0.1% (v:v)
dH20 16.28ml 69.4% (v:v)
Total 20ml
Table 2.6.4% SDS-PAGE stacking ge l formulation.
While the stacking gel was setting, mixed membrane protein samples (lOOpg) were 
incubated with equal volumes of 2x SDS-gel loading buffer at 42°C for 30 mins to 
linearise proteins. Once the stacking gel had set, mixed membrane protein samples 
(100pg) were loaded alongside protein molecular weight markers (Invitrogen). 
Electrophoresis was carried out at constant current (10mA) until only the two largest 
markers (150 and 250 kDa) remained on the gel. The RyR2 monomer is 565 kDa and 
migrates through the gel at a slower rate than even the largest Kaleidoscope protein 
molecular weight markers, and presents as a band above those corresponding to these 
markers following western blot analysis.
2.2.3.4. Transfer of proteins onto a PVDF membrane
Proteins separated on SDS-PAGE gels were transferred onto a polyvinylidene difluoride 
(PVDF) membrane (Millipore) using a semi-dry blotting system (Bio-Rad). PVDF 
membranes were prepared by soaking in methanol for 1 min and subsequently in semi­
dry transfer buffer for 30 mins. The semi-dry transfer apparatus was assembled 
according to the manufacturers instructions and transfer was carried out at constant 
current (400mA, limited to 25V) for 2 hours at 4°C.
117
2.2.3.5. Western blot analysis of RyR2 protein
Following protein transfer, the membrane was incubated in 5% (w:v) non-fat dried milk 
protein (Marvel) in TBS-T buffer (5% blocking buffer) overnight at 4°C. An RyR2-specific 
primary antibody (pAb1093) was diluted 1:5000 (v:v) in blocking buffer and was applied 
to the membrane for 2 hours at RT or overnight at 4°C. The membrane was then washed 
three times (10 mins each wash) in 1% blocking buffer. A horseradish peroxidase 
(HRP)-conjugated secondary antibody (raised against the species corresponding to 
source of primary antibody was produced) was applied in a 1:10000 dilution in 1% 
blocking buffer for 2 hours at RT. The blot was then washed with TBS-T buffer (5x 
10mins). Immunoreactive protein bands were visualised by enhanced 
chemiluminescence detection (ECL, GE Healthcare) according to manufacturer’s 
instructions (Figure 2.6). Briefly, HRP conjugated to the secondary antibody catalyses 
the peracid-mediated oxidation of luminol. Oxidation causes luminol to enter an excited 
state which decays to a ground state via a light emitting pathway (428nm). The presence 
of enhancer molecules, including phenols, enhances this light emission up to 1000-fold, 
making it readily detectable by exposure to blue-light sensitive autoradiography film. The 
blot was exposed to X-ray film (Hyperfilm, GE Healthcare) for a suitable length of time 
which was determined by the level of the chemiluminescence signal.
Primary Ab
Hybond ECL
Oxidized
product
Peracid
luminol
enhancer
Hyperfilm ECL
Figure 2.6. Principle o f Enhanced Chemiluminescent (ECL) protein detection, from 
GE healthcare ECL Western Blotting Detection Manual. Horseradish peroxidase on the 
secondary antibody catalyses the peroxidase-mediated oxidation of luminol, which emits 
low levels of light (428nm) which is enhanced by the presence of phenols. This enhances 
emitted-light levels up to 1000-fold and is readily detectable by exposure to blue-light 
sensitive autoradiography film.
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2.2.4. Statistical analysis
Appropriate statistical analyses were carried out using Microsoft Excel and GraphPad 
Prism software. Data was assessed for Gaussian distribution by way of Kolmogorov- 
Smirnoff test (p>0.10 indicating a normal distribution) and through investigation of the 
frequency histogram. Homogeneity of variance testing of normally distributed data was 
carried out using Bartlett’s test for equal variances. Comparison of independent sample 
means from normally distributed data was carried out using Students T-test to compare 
two means, or by One-Way analysis of variance (ANOVA) to compare multiple sample 
means. Tukey-Kramers post-hoc test was used to compare multiple sample means to 
each other, providing that the ANOVA result indicated a significant difference between 
sample means (p<0.05). Comparison of independent sample means from data which did 
not fit a Gaussian distribution were carried out using non-parametric tests. The Mann- 
Whitney test was used to compare two sample medians and the Kruskal-Wallis test with 
Dunn’s post-hoc tests were used to compare median values of multiple samples. Unless 
otherwise stated, the level of significance reported as a result of statistical testing is 
reported by a number of asterisks with a single asterisk representing p < 0.05 (*), two 
asterisks representing p < 0.01 (**) and three asterisks representing p < 0.001 (***). The 
absence of an asterisk represents that p > 0.05, indicating that no significant difference 
at the 95% confidence level was observed.
2.2.5. Linear regression analysis
Linear regression analysis was used to determine whether relationships existed between 
two variables and to determine the nature of any relationships. All linear regression 
analysis was carried out using the least-squares method using GraphPad Prism 
analytical software. Several key statistics were determined from the linear regression 
analysis, which are detailed below and were used to examine the relationship between 
two variables.
Gradient: The gradient (A) quantifies the steepness of the line-of-best-fit and
indicates the change in one variable (y) for each unit change in another 
variable (x). If the gradient is positive, it indicates that an increase in
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variable x results in an increase in variable y (positive relationship). If the 
gradient is a negative value, it infers that as variable x increases, variable 
y decreases (negative relationship).
r2: This is the goodness-of-fit value and represents how well the data fits the
line-of-best-fit. This value is always between 0 and 1, with values a value 
of 1 indicating that all data points lie exactly on the line-of-best-fit. A value 
of 0 indicates that there is no linear relationship between two variables. 
An arbitrary threshold value of 0.3 was chosen to represent a weak 
significant relationship, 0.5 - 0.7 to represent a moderate relationship and 
greater than 0.7 to represent a strong relationship.
p-value: The null hypothesis predicts that the slope of the linear regression line is
zero. If this the p-value was less than 0.05, the null hypothesis is rejected 
and it would suggest that the slope of the linear regression line is 
significantly different to zero and there is a significant positive or negative 
relationship between the two variables, x and y.
The r2 and p-values must be interpreted together to determine whether a significant
relationship between two variables exists.
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Chapter 3
Functional characterisation of the L433P 
ARVD2 linked mutation and associated 
G1885E polymorphism in a heterologous
cell system.
3.1. Introduction
To date, there have been over 124 single nucleotide substitutions identified in the RyR2 
gene of patients diagnosed with CPVT/ARVD2 (Medeiros-Domingo et al., 2009). Despite 
the continuing identification of arrhythmogenic disease-linked RyR2 mutations (Thomas 
et al., 2010), the precise mechanism by which these mutations result in an 
arrhythmogenic phenotype remains unknown, although several mechanisms have been 
proposed (section 1.3.4). Although the majority of RyR2 mutations that have been 
functionally characterised have been shown to increase channel activity under various 
experimental conditions, there is emerging evidence that not all mutations confer a gain- 
of-functionality (Thomas et al., 2004; 2005; Jiang et al., 2007). This suggests that there 
may not be a unifying mechanism by which RyR2 mutations result in channel 
dysfunction. Together with the fact that the location of the mutation in the RyR2 protein 
sequence does not dictate the resulting phenotype (Jiang et al., 2005), this reiterates the 
need to functionally characterise mutations on an individual basis.
3.1.1. RyR2 functional characterisation methodologies
Given that the number of identified RyR2 mutations is increasing dramatically (Thomas 
et al., 2010), comprehensive functional characterisation tends to be prioritised to those 
mutations which present an ‘interesting’ phenotype i.e. R4497C, R2474S etc. The 
characterisation of disease-linked RyR2 mutations has been carried out using several 
experimental systems, each capable of investigating different pathophysiological 
mechanisms of mutant channel function, several of which will be discussed here.
3.1.1.1. Lipid bilayer single channel analysis
Unlike whole-cell patch-clamp analysis of cell-surface ion channels which measures 
multiple channel currents, the reconstitution of channels into lipid bilayers allows the 
investigation of the gating and conductance properties of single RyR2 and other 
intracellular membrane channels (Holmberg & Williams, 1989). These experiments allow 
the precise control of the ionic environment surrounding the cytoplasmic and luminal 
face of the channel and as such can be used to monitor RyR2 biophysical properties
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under a range of physiological conditions i.e. high luminal Ca2+ and low cytoplasmic 
Ca2+, concentrations characteristic of diastole. As such, lipid bilayer analysis of single 
RyR2 channels has allowed the investigation into the effects of physiological and non- 
physiological ligands, regulatory proteins, cellular processes and RyR2 mutations on 
channel gating and conductance properties (Rousseau et al., 1986; Holmberg & 
Williams, 1989; Tester etal., 2007; Kong etal., 2008).
Although this methodology allows for the precise control of the ionic conditions 
surrounding the channel, it is not without its limitations. Isolation of RyR2 channels from 
a cellular environment is likely to subject the channel to non-physiological conditions, 
such as oxidative stress, which may alter channel properties (Meissner, 2004). Similarly, 
detergent lysis of cellular expression systems may lead to the dissociation of accessory 
proteins from the RyR macromolecular complex or alteration of inter- and intramolecular 
interactions.
3.1.1.2. [3H]ryanodine binding assays
Ryanodine is a highly toxic plant alkaloid found in the Ryania speciosa plant and binds 
all three RyR isoforms with high affinity. The radio-labelling of ryanodine has provided an 
indispensible tool that was used in the identification and isolation of RyR2 (Inui et al., 
1987) and has been used extensively in the functional characterisation of RyR2. Given 
that ryanodine only binds RyR2 when the channel is in the open state, the measurement 
of the level of bound ryanodine is an accurate measure of channel activity. In this sense, 
the [3H]ryanodine binding assay has been used to investigate the effects on RyR 
channel activity of physiological ligands e.g. Ca2+, Mg2+, ATP (Holmberg & Williams, 
1989; Du et al., 1998) non-physiological ligands e.g. caffeine, K201 (Holmberg & 
Williams, 1989; Hunt et al., 2007) and accessory proteins e.g. FKBP12.6 (Yano et al.,
2003). Furthermore ryanodine binding analysis has been instrumental in elucidating the 
mechanisms by which CPVT/ARVD2 linked mutations alter RyR2 gating parameters. 
Typical gain-of-function mutations that are proposed to exhibit diastolic Ca2+ leak are 
regularly characterised by an increase in sensitivity to Ca2+-dependent [3H]ryanodine 
binding (Jones et al., 2008a; Fernandez-Velasco et al., 2009) due to the increased open 
probability compared to WT RyR2.
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3.1.1.3 SR vesicle Ca2* uptake and leak assays
Given the proposed role of diastolic Ca2* leak in RyR2 mutant pathogenesis, assays 
have been developed to measure the rates of Ca2* uptake and release into and out of 
the SR (Yano et al., 2000; Doi et a/., 2002; Yano et al., 2003; Oda et a/., 2005). Briefly, 
isolated SR vesicles are loaded with Ca2* through incubation in a Ca2+-containing buffer, 
with SERCA-mediated Ca2* uptake being initiated through the addition of ATP. By 
monitoring the decrease in Ca2*-indicator signal intensity (e.g. Fluo3, see section 
3.1.1.4), the rate of Ca2* uptake into the SR can be monitored. Once Ca2* uptake had 
plateaued, a small amount of thapsigargin (typically 1pM) was added to the SR vesicles 
to inhibit SERCA activity and cause a passive release of Ca2* from the SR through 
RyR2, which can be measured by monitoring the increase in Fluo3 signal intensity (Yano 
et al., 2000). This approach has been used to examine the effects of both RyR2 
accessory proteins e.g. FKBP12.6 (Yano et al., 2000; Yano et al., 2003), and 
arrhythmia-linked mutations e.g. R2474S (Oda et al., 2005), on the rates of Ca2* uptake 
and release, with decreased rates of Ca2* uptake and increased rates of Ca2* release 
pertaining to SR Ca2* leak.
3.1.1.4 Ca2* imaging in intact cells
Since the advent of Ca2* sensitive fluorescent dyes and improvements in microscopy 
and computing technology, intracellular Ca2* imaging has become a powerful and widely 
used technique in the investigation of RyR2 function. Although the examination of RyR2 
in intact cells does not allow the precise control of the environment surrounding the 
channel, as afforded in experiments where RyR2 is isolated from the cell (section 
3.1.1.1), this method allows the characterisation of RyR in more physiologically relevant 
setting. Of course, the precise nature of this cellular environment is entirely dependent 
on the cell-line in which Ca2* imaging experiments are carried out (see section 3.1.1.5).
High-powered laser scanning confocal microscopy is widely used in the characterisation 
of RyR2, as by utilising fluorescent Ca2*-indicator dyes e.g. Fluo3, fura-2, it allows the 
direct monitoring of free intracellular Ca2* levels in intact cells in a relatively non-invasive 
fashion. Confocal microscopy has many advantages over conventional fluorescence 
microscopy in that it:
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Removes light that has not originated from the focal plane, resulting in the 
generation of a sharper image.
Causes sample excitation on a point-by-point basis, decreasing the effects of 
global photo-bleaching.
Allows 3D reconstruction of samples by computationally assembling “stacks” of 
2D images.
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Figure 3.1. Schematic representation o f the workings o f a confocal microscope.
Briefly, “excitation light” from a high-powered laser of known wavelength emission 
passes through a pinhole filter and is directed towards a series of horizontally and 
vertically rotating mirrors by the acousto-optical beam splitter (AOBS). These mirrors 
allow the excitation light to be systematically scanned across the sample, causing 
excitation of the fluorescent indicator on a point-by-point basis. Emitted fluorescent light 
is descanned by the same rotating mirrors and is ‘tuned’ to a particular wavelength by 
the AOBS. Light that did not originate from the focal point is removed by passing the 
emitted light through a pinhole filter, prior to detection by a photomultiplier tube (PMT). 
The PMT effectively amplifies the fluorescent signal through a process termed 
“secondary emission” and converts it to a measurable current pulse that is indicative of 
the magnitude of the initial fluorescence level.
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There are many Ca2* indicator dyes that are commercially available, each with unique 
excitation and emission profiles. These dyes fall in to two categories; ratiometric or 
single-wavelength, the properties of which are detailed in Table 3.1.
Ratiometric Dyes Single Wavelength Dyes
Examples Fura-2, Fura Red, lndo-1. Fluo-3, Fluo-4, Ca2* Orange.
Excitation Normally in UV range Normally in visible spectrum range
Emission Ca2+-bound and Ca2+-free forms are excited at distinct 
wavelengths and the ratio of emissions at each excitation 
wavelength is directly correlated to the amount of 
intracellular Ca2+ i.e. Fura-2.
Ca2+-bound and Ca2+-free forms are excited at a single 
wavelength, but emit at distinct wavelengths i.e. lndo-1. 
The ratio of emitted fluorescence at each wavelength is 
directly correlated to the amount of intracellular Ca2+.
Single wavelength, dependent on 
free (Ca2+],
Advantages Corrects for differential indicator loading, dye leakage, 
photobleaching.
Provides more accurate indication of free [Ca2+]
Excitation energy is low, reducing 
photodamage
Emission of multiple indicators can 
be carried out in the same cell.
Data analysis is comparatively 
simple
Disadvantages UV can be detrimental in live-cell imaging. 
Data analysis is more complex.
Expensive equipment costs.
Can be influenced by differential 
indicator loading.
Table 3.1. Comparison ratiometric and single wavelength Ca** indicator properties.
Acetoxymethyl (AM)-conjugated forms of Ca2* dyes are able to traverse the cell 
membrane and are passively taken up by cells into the cytoplasm. The Ca2*-sensitive 
form of the dye is liberated through hydrolysis of the AM-conjugated form by the action 
of endogenous esterases. As well as rendering the dye sensitive to Ca2*, this restores 
the hydrophobic properties of the dye, preventing it from leaking from the cell (Kao et al.,
1989). In the case of single-wavelength Ca2* indicators, an increase in cytoplasmic Ca2* 
concentration results in dramatic increase in indicator emission intensity (Kao et al., 
1989; Gee et al., 2000).
Live-cell Ca2*-imaging has been widely used to investigate many aspects of the 
consequences of arrhythmia-linked RyR2 mutations on intracellular Ca2* handling. In 
cardiac myocytes, spontaneous Ca2* release events associated with arrhythmia, namely 
Ca2* sparks and waves, manifest as localised and propagating increases in intracellular 
Ca2*-dependent signal intensity respectively (Lehnart et al., 2008; Fernandez-Velasco et
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al., 2009; Uchinoumi et al., 2010). Although sparks and waves are not observed in non­
myocyte cells expressing RyR2, similar spontaneous ER Ca2+ release events have been 
observed in HEK cells recombinantly expressing RyR2 and have been implicated in 
CPVT pathogenesis (see Chapter 5, (Jiang et al., 2002; 2004; 2005; Koop et al., 2008). 
The quantification and characterisation of all of these types of spontaneous Ca2* release 
events are measured as an indication of the propensity for mutations to increase DAD 
susceptibility.
Intracellular Ca2*-imaging is also routinely used to measure parameters of agonist- 
evoked ER/SR Ca2* release to determine differences in sensitivity between WT and 
mutant RyR2 (George et al., 2003a; Thomas et al., 2004; Jiang et al., 2005; Thomas et 
al., 2005). Unlike in experiments where RyR2 is isolated from the cellular environment, 
in order for agonists to directly activate RyR2, they must be able to rapidly traverse the 
cell membrane or activate RyR2 via receptor-coupled mechanisms. Such RyR2 agonists 
that are routinely used include Ca2* itself, caffeine (section 3.1.5) and 4-chloro-m-cres 
(4-cmc). Additionally, RyR2 in cardiomyocytes is also indirectly activated by the addition 
of activators of the (3-adrenergic signalling cascade such as isoproterenol and 
epinephrine.
3.1.1.5. Heterologous expression in mammalian cell lines
There are many cell lines in which human RyR2 can be recombinantly expressed, 
although it could be argued that none of them provide the perfect system in which to 
characterise the functional effects of RyR2 mutations. Perhaps the preferred cell type in 
which to characterise RyR2 mutations would be the primary cardiac myocyte, as this cell 
type retains the contractile phenotype exhibited In vivo and expresses a multitude of 
cardio-specific regulatory proteins e.g. FKBP12.6, junctin, triadin, etc (section 1.2.3.2 -  
1.2.3.3). However, transfection of primary cardiac myocytes with recombinant RyR2 has 
proved problematic due to the size (~20kb) and fragility of the plasmid and tends to yield 
low levels of protein expression (George et al., 2005), making the study of mutant RyR2 
function in primary myocytes difficult. Immortalised myocyte cell lines, such as HL-1 cells 
(Claycomb et al., 1998), have been developed, as have transgenic mice harbouring 
RyR2 mutations (section 1.3.3, Cerrone et al., 2005; Kannankeril et al., 2006; Goddard 
et al., 2008; Lehnart et al., 2008), which go some way to alleviating this problem. Like
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primary cardiac myocytes, HL-1 cells retain a contractile phenotype and express the full 
complement of cardio-specific accessory proteins (Claycomb et al., 1998), although they 
are not without their disadvantages in terms of studying RyR2 mutant channel function. 
Due to the endogenous expression of RyR2 in cardiac myocytes, transfection with RyR2 
cDNA may result in the expression of either two discrete populations of recombinant and 
endogenous RyR2 or the formation of heterotetramers of unknown stoichiometry, adding 
an undefined element to RyR2 mutation functional characterisation. Furthermore, work 
carried out in this laboratory has shown that the contractile phenotype exhibited by HL-1 
cells tends to be ablated following transfection with RyR2.
Another cell line that has been used in the functional characterisation of RyR1 and RyR3 
is the dyspedic skeletal myotube, 1B5, cell line (Moore et al., 1998). These cells have 
been engineered to be deficient in all three RyR isoforms, yet they express the full 
complement of skeletal muscle RyR accessory proteins that are involved in RyR1 
regulation e.g. FKBP12, CSQ etc (Moore et al., 1998). However, a similar cell line from a 
transgenic cardiac lineage has not been developed to date, meaning alternative 
expression systems must be used in the investigation of RyR2.
RyR2-deficient cell lines provide another attractive system in which to investigate the 
functional effects of RyR2 mutations. The lack of endogenous RyR2 protein in such cell 
lines means that transfection with RyR2 cDNA results in the expression of a 
homotetrameric population of recombinant RyR2 channels. This effectively abolishes the 
possibility of heterotetramerisation and reduces the complexity of RyR2 mutant 
characterisation. Furthermore, the investigation of RyR mutations in a manner replicative 
of heterozygotic inheritance has been carried out by co-transfecting RyR-deficient cells 
with equimolar ratios of WT and mutant RyR2 (Tong et al., 1999; Wehrens et al., 2003; 
Lehnart et al., 2008), which is likely to result in the formation of RyR heterotetramers. 
This is supported by the finding that an [3H]ryanodine-binding-deficient RyR2 mutant, 
I4827T, co-precipitated with WT RyR2 and restored [3H]ryanodine binding, suggesting 
heterotetramerisation of WT and I4827T mutant subunits (Xiao et al., 2002). 
Furthermore, single-channel analysis of ho motetrameric G48 24A ch annels exhibited 
near-complete ablation of channel conductance, yet RyR2 purified from cells co­
expressing G4824A and WT RyR2 subunits exhibited a range of conductances, which 
were proposed to represent channels consisting of each possible combination of WT 
and mutant subunits (Zhao et al., 1999).
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immortalised Cardiac 
Myocytes (HL-1) 
(Claycomb, 1998)
CHO
0 VO, 1958)
COS 
(Jensen, 1964)
HEK-293 
(Graham, 1977)
Species Mouse Hamster African Green Montey Human
Tissue Cardiac Myocyte Ovary Kidney Kidney
Endogenous RyR2 
expression Yes No No No
Contractile Phenotype Contractile Non-confractile Non-corrtractHe Non-confractile
RyR2 accessory 
proteins Full complement n/a n/a n/a
Advantages
Full complement of cardiac - 
specfic accessory proteins.
Recombinant RyR2 co­
expression reflects autosomal 
dominant n ature or RyR2 
mutations.
Human-derived cel line
Allows homotetrameric 
expression of recombinant 
RyR2.
Effects of recombinant RyR2 
expression separated from 
effects of accessory proteins.
Effects of recombinant RyR2 
expression separated from 
modulation by accessory 
proteins.
Allows homotetrameiic 
expression cf recombinant 
RyR2.
Effects of recombinant RyR2 
expression separated from 
effects of accessory proteins.
Effects of recombinant RyR2 
expression separated from 
modulation by accessory 
proteins.
Can express RyR2 to relatively 
high levels.
Allows homotetrameric 
expression of recombinant 
RyR2.
Widely used inRyR2 
characterisation.
Functional RyR2 data 
produced complements that 
from other experimental 
systems (section 3.1.1.6).
Effects of recombinant RyR2 
expression separated from 
modulation tty accessory 
proteins.
Human derived cell Ine.
Disadvantages
Endogenous RyR2 expression 
complicates interpretation of 
effects of recombinant RyR2 
expression.
Exhibit a variable contractile 
phenotype.
Loses contractile phenotype 
folowing transfection.
Non-human derived cell Ine.
Low levels of stable RyR2 
expression (Imagaw, 1998).
High levels of RyR2 expression 
decreased cel viability 
(George, 2003).
Non-human derived cell Ine.
Lacks many RyR2 accessory 
proteins and myocyte ultra- 
structure.
Little functional RyR2 
characterisation data avalable.
Non-human derived celt ine
Lacks many RyR2 accessory 
proteins and myocyte ultra­
structure e.g. FKBP12.6, 
Junctin.Triadii.
Table 3.2. A summary of cell-lines used in the heterologous expression and functional characterisation of RyR2.
Several RyR2-deficient cell lines have been used in the functional investigation of RyR2 
mutations including Chinese hamster ovary cells (CHO, (CHO, Imagawa et al., 1992; 
George et al., 2003b), African Green Monkey cells (COS) and human embryonic kidney 
cells (HEK-293 cells). CHO cells are routinely used in the investigation of recombinantly 
expressed proteins. However, stable RyR2 expression has been shown to result in 
limited RyR2 expression levels (Imagawa et al., 1992) whereas driving transient RyR2 
expression in CHO cells dramatically decreased cell viability (George et al., 2003b), 
making these cells less than ideal for RyR2 expression and subsequent characterisation. 
HEK-293 cells are the most widely used RyR2-deficient cell line in the study of 
recombinant RyR2 in single-channel electrophysiological studies (Jiang et al., 2002; 
2004; 2005; 2010) or for the investigation of RyR2 Ca2+-handling dynamics in a 
mammalian cell environment (Jiang et al., 2002; 2004; Thomas et al., 2004; 2005). 
Although HEK cells are lacking in many of the regulatory RyR2 accessory proteins 
expressed in cardiac myocytes, functional data produced from experiments in which 
RyR2 is expressed in HEK cells complements that produced from experiments carried 
out in cardiac myocytes (section 3.1.1.6). Similarly, functional characterisation of 
recombinant RyR2 isolated from HEK cells also appears to be highly comparable to 
those results obtained using RyR2 isolated from native tissue (Du et al., 1998). It is for 
the reasons described above, coupled with the fact that the majority of RyR2 mutation 
characterisation has been carried out in HEK cells by several groups, that this cell line 
will be used in this study of the effects of L433P and G1885E expression on intracellular 
Ca2+ handling.
3.1.1.6. Comprehensive characterisation of R4497C, R2474S and R176Q RyR2 
mutations.
The R4497C mutation was one of the first and more severe CPVT-linked mutations 
identified through the genetic screening of a CPVT-affected cohort (Priori et al., 2001) 
and as such has been subjected to extensive functional investigation in a variety of 
experimental systems (summarised in Table 3.3). Patients who inherited the R4497C 
mutation presented structurally normal hearts and bidirectional VT that was reproducibly 
induced by exercise-stress testing or isoproterenol infusion (Priori et al., 2001).
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Heterologous expression of R4496C (mouse equivalent of R4497C) in HEK-293 cells 
increased the propensity of spontaneous ER Ca2* release, which was associated with an 
increased sensitivity to activation by luminal Ca2* and increased single channel P0 at low 
cytosolic Ca2* concentrations, compared to WT RyR2 (Jiang et al., 2002; 2004). 
Furthermore, R4496C expression resulted in an increase in caffeine sensitivity, 
indicating that the R4496C channel was sensitised to both Ca2* and caffeine-activation 
(Jiang et al., 2004). Similarly, immortalised cardiomyocytes (HL-1 cells) transfected with 
RyR2 containing the R4497C mutation displayed an increased Ca2* transient amplitude 
following agonist-evoked RyR2 activation, whereas comparable intracellular Ca2* 
transient amplitudes were observed following p-adrenergic stimulation. However, both 
modes of channel activation produced significantly prolonged Ca2* transients (George et 
al., 2003a), which can result in the prolongation of elevated cytoplasmic Ca2* 
concentration, which can create a premature inward depolarising current through the 
NCX, increasing the likelihood of DAD occurrence (Bers, 2008; Gyorke & Carnes, 2008).
The R4496C+/' mouse exhibited a similar phenotype to that observed in CPVT patients 
(section 1.3.3), with an increased susceptibility to VT under conditions of physical stress 
or p-adrenergic stimulation, despite a structurally normal heart and normal resting ECG 
(Cerrone et al., 2005). Myocytes isolated from R4496C+/'mice and subjected to electrical 
pacing or p-adrenergic stimulation displayed an increased frequency of DAD’s compared 
to WT mice (Liu et al., 2006; Femandez-Velasco et al., 2009). This was attributed to an 
observed increase in Ca2* spark frequency and an increase in sensitivity to Ca2*- 
dependent activation of RyR2, which culminated in an increase in intracellular Ca2* wave 
propagation (Fernandez-Velasco et al., 2009). Myocytes isolated from these mice also 
displayed increased Ca2* spark frequency under non-stimulated conditions and an 
increased level of basal activity at low Ca2* concentrations. Not only does this reconcile 
with the increase in R4496C basal activity observed in channels isolated from HEK cells 
(Jiang et al., 2002), but this suggests that the effects of the R4496C mutation are evident 
at rest and are exacerbated following p-adrenergic stimulation (Liu et al., 2006; 
Femandez-Velasco eta!., 2009).
Similar findings have been observed for a central domain mutation (R2474S), that was 
identified in a single, CPVT-affected individual who suffered from syncope and exhibited 
non-sustained VT during exercise-stress testing, despite exhibiting a normal resting 
ECG (Priori et al., 2002). Heterologous expression of R2474S demonstrated that this
131
mutation had no effect on the Ca2+-dependence of [3H]ryanodine binding, but 
significantly increased spontaneous Ca2+ release propensity attributed to an observed 
increase in luminal Ca2+ sensitivity (Jiang et al., 2005). Myocytes isolated from two 
R2474S heterozygous mouse models (section 1.3.3), exhibited an increase in 
spontaneous Ca2* sparks and waves following p-adrenergic stimulation (Lehnart et al., 
2008; Uchinoumi et al., 2010; Xu et al., 2010), corroborating the increase in 
spontaneous Ca2* release observed through heterologous R2474S expression and the 
stress-induced nature of human CPVT.
Although there were similarities in Ca2* handling observed in myocytes isolated from 
each of these mouse models, there were several differences between findings from each 
group (section 1.3.3, summarised in table 1.2) i.e. normal phosphorylation vs 
hyperphosphorylation, normal FKBP12.6:RyR2 interaction vs decreased 
FKBP12.6:RyR2 interaction). As such, Uchinoumi et al proposed that R2474S resulted 
in an increase in spontaneous Ca2* release through the destabilisation of an inter- 
domain interaction coupled with a decrease in CaM-binding, leading to increased Ca2* 
leak and arrhythmia (section 1.3.4.2) (Uchinoumi et al., 2010; Xu et al., 2010). However, 
Lehnart et al proposed R2474S caused SR Ca2* leak through PKA-mediated “hyper­
phosphorylation” of the mutant RyR2 causing increased FKBP12.6 dissociation and 
channel destabilisation (section 1.3.4.3, Lehnart et al., 2008). There is extensive 
evidence supporting the destabilisation of the domain-interaction hypothesis which is 
discussed in greater detail in section 1.3.4.2.
Similar findings have been observed for an N-terminal RyR2 mutation (R176Q) that has 
been identified in a number of ARVD2-affected individuals, both as the only identified 
mutation (Tester et al., 2005) or on the same allele as a second T2504M mutation (Tiso 
et al., 2001; Bauce et al., 2002; Tester et al., 2005). The equivalent mutation in RyR1 
(R163C) has been shown to result in both MH and CCD disease phenotypes in different 
individuals, without the presence of a second RyR1 mutation (Robinson et al., 2002), 
suggesting R176Q alone is likely to result in the ARVD2 phenotype. Interestingly, R163C 
was shown to result in different disease phenotypes (i.e. MH or CCD) in different 
individuals, as was R176Q in RyR2 (Bauce et al., 2002) which has been implicated in 
both ARVD2 and CPVT, suggesting other genetic or environmental factors are important 
in determining the resulting disease phenotype of these mutations.
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R176Q R2474S R4497C (R4496C)
Patient Phenotype ARVD2, fibro-fatty infiltration of the right ventricle, stress induced pVT. (Tiso, 2001).
CPVT, structurally normal heart and ECG, stress- 
induced bVT or pVT (Priori, 2002)
CPVT, structurally normal heart and ECG. 
exercise-induced bVT (Priori, 2001).
Mouse Phenotype
Structurally normal heart and resting ECG. 
Decreased RV end-diastolic volume. 
Stress, P-AR stimuation or agonist-induced bVT. 
(Karmankerii, 2006. Mathur, 2009)
Structurally normal heart.
Stress or p-AR induced bVT and pVT. (Lehnart, 
2008, Uchinoumi, 2010). 
Spontaneous clonic/tonic seizures (Lehnart, 2008)
Structurally normal heart and resting ECG. 
Stress or P-AR stimulation-induced VT 
(Cerrone, 2005)
Isolated myocyte 
characteristics
Increased basal and P-AR induced spontaneous 
Ca2* release. (Kannankerii, 2006)
Increased P-AR-induced spontaneous Ca2* 
release (Uchinoumi, 2010) and Ca2* wave 
propagation, (Lehnart, 2008)
Increased basal and P-AR-induced spontaneous 
Ca2* release and Ca2* wave propagation (Liu 
2006. Veriasco. 2009).
Recombinant 
expression in 
immortalised 
myocytes
n/a n/a
Increased caffeine-evoked Ca2* release 
magnitude and duration. (George, 2003). 
Prolonged Ca2* release transient duration 
following B-AR stimulation. (George. 2003)
Recombinant 
expression in 
RyR2 deficient 
cell lines 
(HEK293)
Increased caffeine-evoked Ca2* release 
magnitude (Thomas. 2004) 
Homotetramaric txprassion with T2504M:
Increased caffeine-evoked Ca2* release 
magnitude (Thomas, 2004) and spontaneous Ca2* 
release (Jiang, 2005).
Increased spontaneous Ca2* release in cells 
expressing mouse RyR2 (Jiang, 2005)
Increased spontaneous Ca2* release (SOICR) 
Increased luminal Ca2* sensitivity. 
Increased sensitivity to caffeine-evoked channel 
activation. (Jiang, 2002, Jiang, 2004)
Single Channel 
Analysis
Homotetrameric expression with T2504M:
Increased luminal Ca2* sensitivity. 
(Jiang, 2005)
Increased luminal Ca2* sensitivity. (Jiang. 2005, 
Uchinoumi, 2010).
P-AR stimulation increased P0 (Wehrens, 2003, 
Lehnart, 2008), restored to WT after S107 
treatment (Lehnart, 2008).
Increased P0 at low [Ca2*].
Slight increase in luminal Ca2* sensitivity. 
(Jiang, 2004)
PH] Ryanodine 
binding
Homotetrameric expression with T2504M:
Normal Ca2* dependent activation (Jiang, 2005) Normal Ca2* dependent activation (Jiang, 2005)
Increased basal activity at low [Ca2*]©. Increased 
Ca2* sensitivity and caffeine sensitivity.(Jiang, 
2002, Jiang, 2004)
Effects on RyR2 
phosphorylation 
level
n/a
Equal phosphorylation levels (Wehrens. 2003, 
Lehnart, 2008), but increased sensitivity to 
phosphorylation activation (Uchinoumi. 2010)
No effect on RyR2 phosphorylation in HL1 cells. 
(George, 2003)
Effects on 
FKBP12.6 
interaction
Homotetrameric expression with T2504M:
No alteration in FKBP interaction when 
heterologously co-expressed (Jiang. 2005).
Decreased interaction in heterozygous mouse, 
exacerbated by P-AR stimulation, restored to WT 
after S107 treatment (Lehnart, 2008) No 
alteration in heterozygous myocytes (Ucinoumi, 
2010)
Interaction in heterologous expression:
No alteration (Jiang, 2005), but P-AR causes 
dissociation (Wehrens, 2003).
FKBP interaction similar to WT at rest and after P- 
AR stimulation. (George, 2003).
P-AR dissociates FKBP 12.6 (Wehrens, 2003). 
Normal FKBP12.6 interaction in knock-in mouse 
(Uu. 2006, Veriasco. 2009)
Table 3.3. A summary of the functional characterisation of three CPVT/ARVD2-linked mutations in a variety of experimental systems.
R176Q was first identified in a patient who also inherited a T2504M mutation, as such characterisation of R176Q is often carried out in the presence 
of this second mutation. SIDS = Sudden infant death syndrome, RV = right ventricle, VT = ventricular tachycardia pVT = polymorphic ventricular 
tachycardia, bVT = bi-directional ventricular tachycardia
When heterologously expressed in HEK-293 cells, R176Q increased the magnitude of 
caffeine-evoked Ca2+ release compared to that observed in cells expressing WT RyR2 
(Thomas et al., 2004). When both R176Q and T2504M were co-expressed on the same 
RyR2 subunits in HEK293 cells, there was an increase in channel sensitivity to caffeine 
activation compared to WT RyR2 (Thomas et al., 2004) and an increase in spontaneous 
Ca2* release frequency (Jiang et al., 2005). This was associated with an increased 
sensitivity to luminal Ca2* and suggests the increased spontaneous Ca2* release 
observed in HEK cells is due to a decreased luminal Ca2* activation threshold (Jiang et 
al., 2005). Mice heterozygous for the R176Q mutation (R176Q+/) exhibited a normal 
resting ECG and exhibited bidirectional VT in response to p-adrenergic stimulation or 
caffeine and epinephrine administration (section 1.3.3, Kannankeril et al., 2006; Mathur 
et al., 2009). Myocytes isolated from the R176Q*7' mouse displayed increased 
spontaneous Ca2* release under both non-stimulated conditions and following p- 
adrenergic stimulation (Kannankeril et al., 2006), similar to observations in HEK cells 
expressing recombinant R176Q.
The comprehensive functional characterisation of the R176Q, R4497C and a central 
domain mutation, R2474S, in a multitude of experimental systems reveals the benefit of 
such complementary investigation in determining the mechanism of mutant channel 
dysfunction (Table 3.3). The fact that data derived from each experimental system 
exhibits similarities with that obtained from other methodologies and results in similar 
mechanistic conclusions being made, suggests that cell based assays can be reliably 
used to gain an insight into how the specific RyR2 mutations result in a disease- 
phenotype in vivo.
3.1.2. The effects of SNP expression on mutant hNav1.5 function depends on the 
mode of co-inheritance
As described in section 1.4.4.1.2, the common H558R SCN5A SNP exhibited profound 
effects on mutant hNav1.5 functionality and has been shown to both alleviate or 
exacerbate the detrimental consequences of several disease-linked SCN5A mutations 
(Ye et al., 2003; Poelzing et al., 2006; Gui et al., 2010b). Furthermore, H558R was also 
shown to ameliorate mutant channel function to varying degrees (Viswanathan et al., 
2003; Poelzing et al., 2006; Gui et al., 2010b), suggesting that the precise nature and
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location of the co-inherited mutation may be an important factor in determining the extent 
to which H558R altered mutant channel function. This hypothesis has been supported 
through the biophysical characterization of recombinant hNav1.5 channels containing 
the H558R SNP in combination with several disease-linked mutations.
WT-SCN5A R282H-SCN5A H558R-SCN5A
H558R-SCN5A + 
R282H-SCN5A
B cf? G *J  j r
rST A ?/ / / /
0"
-100-
& -200“wc
-300-
■400-
— 3
(0 -500-0)0- -600-
-700
c5
Figure 3.2. H558R restores R282H lNa current only when both substitutions are on 
the same protein. R282H abolished lNa current, which was partially restored (-50%) 
when H558R was co-expressed on separate protein to the mutation (panel A). Co­
expression of H558R on the same protein as R282H had no restorative effect on lNa 
current (panel B). These findings corroborate those observe in vivo (panel C). From 
Poelzing, (2006).
Poelzing et al demonstrated that the H558R SNP was able to restore lNa current through 
R282H channels by restoring correct membrane trafficking, as illustrated schematically 
in Figure 1.15. lNa currents were only completely restored to normal levels when H558R 
and R282H were expressed on separate hNav1.5 molecules through co-transfection 
with equimolar ratios of H558R-SCN5A and R282H-SCN5A cDNA (Figure 3.2, Poelzing
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et al., 2006). These findings correlate with the observation that individuals who inherited 
R282H and H558R in a composite heterozygous fashion, did not exhibit a LQTS-related 
phenotype, whereas those who inherited R282H were symptomatic. This restoration of 
lNa current was not observed when H558R and R282H were expressed on the same 
protein, was partially restored when co-expressed with WT hNav1.5.
Viswanathan et al showed that the co-expression of H558R on the same protein as the 
T512I LQTS-associated SCN5A mutation completely restored the voltage-dependence 
of hNavl .5 activation and partially restored that of channel inactivation (Viswanathan et 
al., 2003). This group only characterised the effects of H558R when it was expressed on 
the same protein as the T512I mutation and reported a partial restoration of voltage- 
dependent channel inactivation. In this case it was not clear whether co-expression of 
H558R and T512I from separate cDNAs would alter T512I gating properties to a similar 
extent. Furthermore, the method of T5121 and H558R co-expression in this study did not 
replicate the modes of inheritance observed in vivo (Figure 1.17), so it remains unknown 
if such modes of expression i.e. T512I+H558R, exhibit normal hNavl.5 gating.
These two examples support the hypothesis that whether H558R is inherited on the 
same or opposite alJele as the disease-linked SCN5A mutation has a critical impact on 
the extent to which the SNP alters mutant channel function. This observation reiterates 
the importance of characterising disease-linked ion channel mutations in a manner 
representative of the mode of inheritance in vivo, to gain a more accurate understanding 
of the precise nature of mutation pathogenesis. This is particular pertinent in terms of 
RyR2 mutations, which are predominantly investigated when expressed as 
homotetramers which is representative of autosomal recessive inheritance, although 
RyR2 mutations exhibit autosomal dominant pathogenesis. The few studies that have 
investigated the functional consequences of heterologous co-expression of mutant RyR 
with WT RyR, observe a diluted form of the mutant cellular phenotype (Tong et al., 1999; 
Wehrens et al., 2003; Lehnart et al., 2008). As described in section 3.1.1.5, the 
transfection of RyR-null cell lines with equimolar ratios of mutant and WT RyR2 cDNA 
allows the greatest control over the relative levels of mutant and WT RyR2 protein 
expression. However, at present it is difficult to accurately determine relative levels of 
each recombinant protein and precise RyR2 channel stoichiometry.
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3.1.3. Characterisation of homotetrameric L433P and G1885E
Although a group of ARVD2 patients were identified who were heterozygous for both 
L433P and G1885E, functional characterisation has only been carried out when either 
one of these substitutions were heterologously expressed. Furthermore, both L433P and 
G1885E have only been characterised when expressed as homotetramers, which is not 
truly representative of the autosomal dominant nature of CPVT/ARVD2-linked RyR2 
mutations (see section 1.3.2)
Functional characterisation of L433P revealed that it does not exhibit the typical 
phenotype associated with gain-of-function RyR2 disease-linked mutations (Thomas,
2004). Heterologous expression of human RyR2 channels harbouring the L433P 
mutation exhibited a decreased sensitivity to caffeine activation (EC50 = 4.84 ± 0.58mM) 
compared to WT RyR2 (EC50 = 1.56 ± 0.2mM). Furthermore, L433P increased the rate 
at which Ca2* was released from the ER and decreased the rate at which Ca2* was 
removed from the cytosol following caffeine-evoked Ca2* release from the ER (Thomas 
et al., 2004) and a caused a modest decrease in ER Ca2* levels. Taken together, these 
data suggest that L433P is not a typical gain-of-function mutation in terms of channel 
activation and that the decreased Ca2* store load and rate of Ca2* removal and 
increased rate of Ca2* release could be indicative of “leaky” RyR2 channels associated 
with delayed after depolarisations and arrhythmia (Bers, 2006, 2008; Gyorke & Carnes, 
2008; Santiago etal., 2010).
However, another group has disputed that L433P is associated with a different 
intracellular Ca2* handling phenotype compared to that observed through the 
heterologous expression of other gain-of-function RyR2 mutations (Jiang et al., 2005). 
They demonstrated that single channel analysis of isolated mouse RyR2 channels 
harbouring L433P exhibited an increase in channel sensitivity to caffeine-induced 
activation (EC50 = 2.4mM) compared to cells expressing WT RyR2 (EC50 = 4.5mM, Jiang 
et al., 2005). They also observed an increase in “store-overload induced Ca2* release”, 
as well as a decrease in ER Ca2* store load after heterologous expression of L433P 
(Jiang et al., 2005), both of which are phenomena characteristic of gain-of-function 
mutations. This disparity between findings could be a result of the different experimental 
systems in which the data was obtained (single-cell Ca2*-imaging versus mixed- 
membrane [3H]ryanodine binding), RyR2 species differences (mouse vs human),
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different HEK cell lineage and the different functional end points being measured 
(magnitude of Ca2+ release rather than channel activation).
Single RyR2 channels isolated from a CPVT patient who inherited G1885E and G1886S 
in a composite heterozygous fashion exhibited several subconductance states (Figure 
3.3, Milting et al., 2006), indicative of a destabilised channel with altered conduction 
properties. The recent heterologous expression and functional characterisation of 
G1885E and G1886S revealed that expression of either one of these substitutions alone 
exhibited similar Ca2+ and caffeine sensitivity to W T channels accompanied by a normal 
store load (Koop et al., 2008). However, expression of homotetrameric G1885E also 
increased the occurrence of spontaneous Ca2+ release, which was suggested to be a 
result of an increased sensitivity to luminal Ca2+ (Koop et al., 2008) although this remains 
to be verified directly. This is the only characterisation that has been carried out on 
G1885E expressed alone and provides the first indication that G1885E has mutation-like 
properties.
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Figure 3.3. Composite heterozygotic inheritance o f G1885E/G1886S results in 
channel sub-conductance states. An ARVD2 patient inherited G1885E and G1886S on 
opposite alleles as shown in panel A. Single channel analysis of RyR2 isolated from this 
patient, shown in panel B, illustrated that this mode of G1885E and G1886S inheritance 
resulted in 4 sub-conductance states under conditions representative of systole. The open 
probabilities of each sub-conductance state are detailed above the trace. From Milting, 
(2006)
Interestingly, expression of homotetramers containing both G1885E and G1886S 
substitutions resulted in near-complete ablation of spontaneous Ca2+ release and 
severely augmented Ca2+ and caffeine sensitivity (Koop et al., 2008), accompanied by 
an increase in ER Ca2+ levels pertaining to a decrease in luminal Ca2+ sensitivity (see
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section 5.1.3). However, this mode of homotetrameric expression is not representative of 
the observed mode of expression in vivo, where heterotetramers containing G1885E and 
G1886S monomeric subunits would be present. The fact that homotetrameric expression 
of the two substitutions exhibited a ‘loss-of-function’ phenotype, whereas single channel 
studies of heterotetrameric RyR2 made up of G1885E and G1886S subunits exhibited a 
phenotype more characteristic of gain-of function RyR2 mutations. This disparity in 
findings between the two modes of expression highlights the importance of functionally 
characterising RyR2 mutations when expressed in a manner more closely representative 
of the mode of inheritance observed in vivo.
A common finding from these studies is the G1885E SNP is able to modify the function 
of another nearby SNP, G1886S, in terms of agonist activation and spontaneous Ca2* 
release. Furthermore, the fact that inheritance of G1885E and G1886S in a composite 
heterozygous fashion exhibited an ARVD2 phenotype, yet association studies did not 
establish a link between the inheritance of either one of the SNPS and ARVD2 suggests 
that G1885E is also capable of modulating G1886S when on separate subunits.
3.1.4. Visualising recombinant RyR2 using eGFP
Several protein expression tags have been developed which can act as markers of 
recombinant gene expression and can therefore be used to monitor the efficiency of 
transfection. Perhaps the most ubiquitous marker of gene expression in cellular systems 
is the green fluorescent protein (GFP) epitope (Chalfie et al., 1994; 2009). The GFP 
protein comprises 238 amino acid residues (26.9 kDa) and was first isolated from the 
jellyfish Aequorea victoria in which it was coupled with a bio-luminescent Ca2+-sensing 
protein, aequorin. Native GFP has two excitation peaks: a maximal peak at 395nm (UV 
light) and a smaller excitation peak at 470nm (blue light) and has an emission peak at 
509nm (green light). In vivo, in the presence of Ca2*, aequorin emits blue light (469nm), 
which causes the emission of green light from the neighbouring GFP chromophore 
(Chalfie eta l, 1994).
Subsequently, work was carried out to show that isolated GFP was a relatively stable 
protein, was active as a monomer, fluoresced independently of any cofactors or 
accessory proteins, was not easily photo-bleached and retained functionality in all 
species in which it was examined. More importantly, GFP fluorescence can be examined
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in both live and fixed cells using fluorescent or confocal microscopy and can be detected 
by an anti-GFP antibody during western blotting, making it a versatile fluorescent 
biomarker (Cubitt et al., 1995). Since its discovery and isolation, GFP has undergone 
significant refinement to alter and improve its photo-properties. By introducing specific 
amino acid substitutions into GFP, a whole palette of chromophores have been 
developed with varying excitation and emission wavelengths (Zimmer, 2009). Enhanced 
GFP (eGFP) was one of the first derivatives and was developed by inserting P64L and 
S65T amino acid substitutions into the WT chromophore, causing a shift in the maximal 
excitation peak to 488nm and a 35-fold increase in fluorescence intensity compared to 
WT GFP (Zhang et al., 1996). The coding sequence of eGFP has also been altered to 
contain 190 silent-base substitutions corresponding to human codon-usage preferences, 
as opposed to jellyfish, increasing expression levels in mammalian cell systems (Zhang 
etal., 1996).
Determining the successful transfection of RyR into mammalian cells with a relatively 
high efficiency has proved difficult due to the high molecular weight of the RyR2 plasmid 
DNA. As such, Treves et al generated a number of full-length eGFP-tagged recombinant 
RyR1 proteins, with the eGFP chromophore fused to the N and C termini and 
subsequently characterised them in COS cells (Treves et al., 2002). Fusion of eGFP to 
the extreme C-terminus ablated channel caffeine sensitivity. However, eGFP-tagging at 
the extreme N-terminus retained correct channel trafficking to the ER and formed 
functional channels as determined by way of caffeine-sensitivity when heterologously 
expressed in COS and CHO cells (Bhat et al., 1999; Treves et al., 2002). Taken together 
this suggests that the precise location of GFP in RyR is critical in determining whether 
the channel retains functionality.
As such, a mammalian expression vector containing the human RyR2 gene with eGFP 
fused to the extreme N-terminus (pcDNA3-eGFP-hRyR2) has been created, as 
described previously (George et al., 2003c), which allows the monitoring of RyR2 
transfection efficiency. This construct has been used in the functional studies of RyR2 
mutations in mammalian cell systems in which the resulting RyR2 protein that was 
expressed formed functional, tetrameric channels which correctly localised to the 
endoplasmic reticulum (Thomas et al., 2004; 2005) and exhibited similar functionality to 
untagged RyR2. GFP has also been used in the mapping of particular amino acid 
residues in the 3D structure of RyR2 (section 1.2.1). GFP has been introduced into
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several regions of the cytoplasmic domain of RyR2, with the resulting channels retaining 
functionality by way of caffeine and [3H]ryanodine sensitivity (Zhang et al., 2003; Wang 
et al., 2007; Jones et al., 2008b). This is somewhat surprising, as the intra-molecular 
insertion of eGFP doesn’t appear to significantly alter RyR2 function, yet the insertion of 
a single point mutation can be catastrophic.
3.1.5. Caffeine as an RyR2 agonist
Caffeine is an RyR2 agonist that is regularly used to examine Ca2* handling properties of 
RyR2 in many experimental methods described in section 3.1.1. It is widely believed that 
rather than directly activating RyR, caffeine sensitises the channel to activation by Ca2* 
(Sitsapesan & Williams, 1990; Kong et al., 2008). Despite the RyR-activating properties 
of caffeine first being described in 1985 (Fabiato, 1985), the precise mechanism of 
caffeine activation of RyR is still uncertain. Analysis of sheep RyR2 in planar lipid 
bilayers in physiological cytoplasmic Ca2* (0.1 pM), demonstrated that addition of 
caffeine (1 mM) to the cytosolic side of RyR2 in lipid bilayers, resulted in an increased 
open probability from effectively 0 to 0.25, but did not alter channel conductance 
(Sitsapesan & Williams, 1990). This increase in channel PQ was due to an increase in the 
frequency of channel opening events and a reduction in the duration of channel closed
A B
+ 2mM 
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No caffeine (O)
+ 2mM caffeine ( • )
No caffeine
Luminal Ca2+ (pCa) Cytosolic Ca2+ (pCa)
Figure 3.4. Caffeine preferentially increases the sensitivity o f RyR2 to activation by 
luminal Ca2*. Single channel activities were recorded with increasing luminal or cytosolic 
Ca2* concentration in the presence and absence of caffeine (2mM). Cytosolic or luminal 
Ca2* concentrations were 46nM in panel A and B respectively. Data represents the mean 
(± S.E.M) channel open probabilities ( n -  5 -9  channels). From Kong, (2008).
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Figure 3.5. Caffeine activation profiles o f rabbit RyR2 heterologously expressed in 
HEK-293 cells. HEK-293 cells transiently expressing rabbit RyR2 were loaded with the 
ratiometric Ca2*-indicator dye, Fura-2, and were examined using microfluoriometry. 
Individual peak amplitudes of 340/380nm ratio (of peak fluorescence divided by basal 
fluorescence) following activation with 0.03 - 30mM, with a wash step between sequential 
caffeine additions to restore resting SR Ca2* levels, as shown in panel A. Resulting data 
was normalised to the peak Fura-2 340/380nm ratio obtained at 30mM caffeine and was 
expressed as mean ± S. E.M and was used to plot a caffeine activation profile, shown in 
panel B. Half maximal channel activation (ECSo) was observed at 1.00mM. From Du et al, 
(1998).
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events. In the presence of subactivating cytoplasmic Ca2* (80pM) and extremely high 
free-luminal Ca2* (80mM), caffeine (<10mM) was not sufficient to induce channel 
openings, although 40mM caffeine increased the P0 to 0.1 (Sitsapesan & Williams,
1990). Similarly, experiments on canine RyR2 showed that the addition of caffeine 
(6mM) on the cytosolic side of the channel in 60nM cytosolic Ca2* and 50mM luminal 
Ca2* increased the channel P0 from practically zero to 0.22 (Rousseau & Meissner, 
1989). Addition of caffeine to the luminal side of RyR2 had no effect on channel open 
probability (Rousseau & Meissner, 1989), suggesting that the site of interaction of 
caffeine with the channel is found on the large cytoplasmic domain. These data propose 
that caffeine enhances channel activation by sensitising the channel to activation by 
cytosolic Ca2*, although a recent study has suggested the mechanism of caffeine 
activation is not entirely straightforward.
By directly measuring ER Ca2* concentration of HEK-293 cells expressing recombinant 
RyR2, the exposure of cells to increasing concentrations of caffeine decreased the 
luminal Ca2* threshold at which spontaneous ER Ca2* release occurred (Kong et al., 
2008). Subsequently, single channel analysis of RyR2 in 46nM cytosolic Ca2* and 
300nM luminal Ca2* (reflecting diastolic cellular conditions), caffeine was shown to 
preferentially sensitise the channel to activation by luminal, rather than cytosolic Ca2* 
(Figure 3.4), demonstrated by a ~100 fold increase in channel sensitivity to activation by 
luminal Ca2* compared to a ~2 fold increase in sensitivity to activation by cytoplasmic 
Ca2* (Figure 3.4, Kong et al., 2008). Whether this is due to a direct increase in sensitivity 
of the luminal Ca2* binding site to activation or a result of increased luminal Ca2* flow­
through-dependent activation at the cytoplasmic activation site remains unknown (Laver, 
2007).
Despite the uncertainty of the precise mechanism of caffeine activation of RyR2, it has 
been widely used in functional studies of RyR2 mutations to measure both channel 
activation properties and ER/SR Ca2* store load in heterologous systems. The 
expression of recombinant rabbit RyR2 in HEK-293 cells demonstrated an increase in 
cytoplasmic Ca2* concentrations in response to caffeine, as indicated by a substantial 
increase in Ca2*-dependent Fura-2 fluorescence ratio (Figure 3.5, Du et al., 1998). 
These experiments demonstrated that in HEK-293 cells, rabbit RyR2 exhibited a half 
maximal level of channel activation in response to approximately 1mM caffeine, slightly 
lower than that observed in HEK cells expressing eGFP-tagged human RyR2 (1.5mM,
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Thomas et al., 2004) and that peak caffeine-induced Ca2+ release was achieved at 
approximately 10mM caffeine.
In light of the potency of caffeine in activating RyR2, and the prevalence of its use in 
functional characterisation of RyR2, particularly of the L433P and G1885E substitutions, 
caffeine will be used as an activating ligand to monitor RyR2 Ca2* release parameters in 
this study.
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3.1.6. Chapter aims
It is evident from recent studies of RyR2 and other cardiac ion channels that in some 
cases, SNPs exert a modulatory effect on mutant channel function. In some instances 
the SNP rescues mutant channel function, whereas in others it exacerbates the 
detrimental effects of the co-inherited mutation. Furthermore, whether the SNP is 
present on the same protein subunit as the mutation or on separate subunits (i.e. in cis 
or in trans, see Figure 2.4) can influence the extent to which the SNP modifies mutant 
channel function. The G1885E polymorphism has been shown to modulate the effects of 
another RyR2 SNP, G1886S, and has also been identified in cis of the ARVD2-linked 
L433P mutation in an affected family.
It is hypothesised that:
• HEK-293 cells provide a suitable heterologous system in which to investigate 
intracellular Ca2* handling dynamics following expression of recombinant eGFP 
tagged human RyR2 using single-cell Ca2* imaging techniques.
• Expression of L433P and G1885E RyR2 alter intracellular Ca2* handling 
parameters to varying degrees depending on whether they are expressed as 
homotetramers or heterotetramers.
• The G1885E SNP modulates the detrimental effects of L433P on intracellular 
Ca2* handling characteristics and the mode of co-expression ( ‘in cis’ or ‘in trans) 
influences the extent of this modulatory effect.
In summary, this chapter will aim to determine whether the heterologous expression of 
L433P and G1885E substitutions alters intracellular Ca2* handling characteristics and 
subsequently, whether the presence of G1885E alters the cellular Ca2* handling 
phenotype of cells expressing the L433P ARVD2-linked mutation.
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3.2. Methods
3.2.1. Cloning and Site-Directed Mutagenesis
Full-length RyR2 cDNA constructs containing the nucleotide substitution that results in 
the G1885E substitution were generated using the cassette-based mutagenesis strategy 
summarised in Figure 2.3. This strategy was adopted for the generation of constructs 
containing the G1885E polymorphism alone (pcDNA3-eGFP-RyR2-G1885E) or on the 
same cDNA construct as the L433P mutation (pcDNA3-eGFP-RyR2-L433P-G1885E). 
Construct nomenclature is detailed in Appendix I, Table 1 and Figure 2).
The SDM reaction to introduce the appropriate codon change into the SanD\/Kpn\ 
mutation cassette (SKI) resulting in the G1885E substitution (GGG to GAG at nucleotide 
5454) was carried out using the oligonucleotide primers detailed in Appendix 1, Table 2, 
according to the thermal cycling protocol in Table 2.2. The G1885E substitution was 
introduced into the full-length WT and hRyR2-L433P sequence by purifying the SK1- 
G1885E mutagenesis cassette and ligating it into pcDNA3-eGFP-hRyR2 and pcDNA3- 
eGFP-hRyR2-L433P respectively (section 2.2.1.2).
Constructs were verified at each stage of cloning by restriction digest mapping of 1 pg of 
plasmid DNA using a battery of restriction enzymes: BamH\t Bg/ll, EcoRI and HinD\\\ 
(section 2.2.1.6). Correct nucleotide-substitution insertion and the SK1-G1885E 
mutagenesis cassette 5’ and 3' insertion boundaries were verified by direct-automated 
sequencing and subsequent nucleotide-nucleotide sequence homology alignment 
(section 2.2.1.8). Sequencing primers are detailed in Appendix 1, Table 3.
3.2.2. Single-cell Ca2* imaging of HEK cells expressing hRyR2
HEK-293 cells on poly-D-lysine coated glass coverslips were loaded with Fluo3-AM as 
detailed in section 2.2.2.3. The volume of minimal DMEM on the coverslip was adjusted 
to 1ml immediately prior to imaging. Cells were imaged with a 63x oil immersion lens on 
a Leica SP5 confocal microscope controlled by Leica LAS AF software. Excitation of 
Fluo3 was achieved using an Argon laser at 488nm and emitted Fluo3 fluorescence was 
collected over the range 525 ± 25nm.
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Figure 3.6. Heterogeneous caffeine-induced Ca2+ release in HEK cells transfected with 
RyR2. HEK cells expressing eGFP-hRyR2 were loaded with Fluo3-AM and examined using 
confocal microscopy (panel A). Cells were imaged before and after caffeine (0.1-40mM) addition, 
denoted by i and ii respectively. The Ca2* -dependent increase in Fluo3 signal intensity following 
caffeine activation of RyR2 can be seen in the numbered traces (panel B1-4) corresponding to 
the highlighted cells in the confocal images (panel A, ii 1-4).
Images were acquired every 200ms for a period of 2 minutes 30 seconds (750 frames 
total). Basal Fluo3 signal intensity was measured for the first 30 seconds of the series 
before a caffeine addition (0.1-10mM) was made to activate RyR2. A single addition of
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caffeine was made to each individual coverslip to remove the effects of sequential 
caffeine additions on ER Ca2* load (Figure 3.6). It is important to note that the addition of 
caffeine as a bolus to the cells is likely to alter RyR2 inactivation properties, which will 
have implications on store refilling and subsequent intracellular handling. These effects 
will be discussed in more detail throughout this chapter. ‘Global’ regions of interest 
representing whole single-cell environments were generated using Leica LAS AF 
software and there was no significant difference between ROI area in cells expressing 
each RyR (45 - 46.5pm2, p=0.96, ANOVA). Data analysis was carried out using 
Microsoft Excel and GraphPad Prism software.
3.2.3. Boltzmann curve generation to determine if Fluo3 signal intensity was 
influenced by PMT voltage gain
A Boltzmann curve was generated to examine the effects of increasing PMT voltage 
gain on Ca2*-dependent Fluo3 signal intensity in HEK cells under basal conditions. 
Untransfected HEK cells were loaded with Fluo3-AM and examined using the Leica SP5 
confocal microscope as detailed in section 2.2.2.3. Images of a single field of view 
containing between 29 and 39 HEK cells was taken at incremental voltages (500 - 
1250V). The mean Ca2*-dependent Fluo3 signal intensity values from three separate 
experiments were fitted to a Boltzmann equation, on to which the mean, minimum and 
maximum voltages at which data was acquired were indicated.
3.2.4. Measuring of Ca2*-handling parameters of HEK cells expressing hRyR2
Several parameters of the caffeine-induced Ca2*-transient were measured in HEK cells 
expressing each of the RyR2 constructs which are described below and illustrated in 
Figure 3.7. Single-cell Ca2* imaging data was exported from Leica LAS AF confocal 
software and Ca2* transient parameters were determined using Microsoft Excel.
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Figure 3.7. Measurement of intracellular Ca2* handling parameters. The average basal 
Ca2*-dependent Fluo3 signal intensity (F0) was determined over a period of 60 seconds prior 
to caffeine addition (0.1-40mM). The amplitude of Ca2* release (F), time to peak Ca2* and 
time to decay to half maximal Ca2* were determined and used to determine rates of Ca2* 
release and Ca2* extrusion as described in section 3.2.4.
Basal Ca2*-dependent signal intensity
The average basal Ca2+-dependent Fluo3 signal intensity (F0) was measured by 
calculating the mean average signal intensity of the first 300 frames (60 seconds) of the 
time series. This provided an indication of the relative level of basal cytoplasmic Ca2* 
prior to caffeine activation of RyR2 in cells expressing each mutation/polymorphism and 
was integral in determining the other Ca2* transient parameters.
Magnitude of Ca2* release
The magnitude of Ca2* release following caffeine activation was determined by 
measuring the height of the peak Fluo3 signal (F) and subtracting the average basal 
Fluo3 signal (F0) from this. As peak magnitude may be influenced by differences in basal 
signal intensity, the magnitude of Ca2* release was normalised to the average basal 
intensity, i.e. [ (F-F0) / F0].
Rate of Ca2* Release (AF-F(/F0)sec'1
The rate of Ca2* release was determined by first measuring the time from caffeine 
addition at which peak Fluo3 signal intensity was achieved. This allowed the subsequent 
calculation of the rate at which Ca2* released i.e. [(F-F0) / F0] / T Peak.
Rate of Ca2* removal from the cytoplasm
The rate of removal of Ca2* from the cytoplasm was determined by first measuring the 
time taken for the Fluo3 signal to decrease to that of half the maximal signal intensity
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achieved following caffeine addition. The half maximal value was used rather than the 
time taken for the signal intensity to return to resting levels, as not all Ca2+ transients 
returned to baseline levels following caffeine addition. This was then used to calculate 
the rate at which the Fluo3 signal decreased and represents the removal of Ca2+ from 
the cytosol by extrusion from the cell via plasma membrane pumps and exchangers or 
uptake into intracellular stores.
3.2.5. Estimation of ER Ca2+ store load
ER Ca2+ load was estimated by the measurement of peak Ca2+ release following the 
addition of thapsigargin (10pM) to HEK cells expressing recombinant RyR2 (Figure 3.8). 
Thapsigargin is a selective and irreversible blocker of the sarco-endoplasmic reticulum 
Ca2+ ATPase (SERCA) and upon inhibition of SERCA by thapsigargin, the ER store is 
passively emptied (Lytton et al., 1991). As only a proportion of cells in a particular field of 
view were expressing RyR2, transfected cells were first identified by the addition of a low 
concentration caffeine bolus (0.5mM).
Thaps
Caff
ER Ca = Fcaff Thaps
C TG
Figure 3.8. Estimation o f ER Ca2* store load. HEK cells expressing recombinant RyR2 
were loaded with Fluo3-AM and examined using con focal microscopy. The mean basal 
Ca2*-dependent Fluo3 signal was determined for the 40 second period prior to exposure of 
cells to a low concentration of caffeine (0.5mM, C) to identify transfected cells. 
Thapsigargin (10pM, TG) was added to the cells after approximately a further 10 seconds. 
The magnitude of caffeine (FCan) and thapsigargin (FThaps) evoked Ca2* release were 
combined to determine the total ER store Ca2* load. Cells were imaged every 200ms for a 
total of 5 minutes.
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To minimise the effects of Ca2* reuptake into the ER, thapsigargin addition was made 
immediately after the caffeine addition. The same method of loading cells with Fluo3-AM 
and single-cell Ca2* imaging was used as detailed in section 2.2.2.3. Thapsigargin was 
used to estimate store load instead of caffeine, as the ER store in HEK cells is 
functionally compartmentalised and contains a significant caffeine-insensitive component 
(Tong et al., 1999). However, it is important to note that caffeine and thapsigargin only 
allow the indirect estimation of ER Ca2* load by measuring the amount of Ca2* release 
following their application, rather than directly measuring ER Ca2* content in situ.
3.2.6. Determination of resting cytoplasmic Ca2* concentration.
Increased cytosolic basal Ca2* levels can be indicative of Ca2* leak from the ER/SR and 
as such, resting cytosolic Ca2* levels were determined in HEK cells expressing each 
recombinant RyR2. Cells were loaded with Fluo3-AM as detailed in section 2.2.2.3. and 
the intracellular fluorescence signal was used to determine the basal Ca2* concentration 
using the Grynkiewicz equation (Grynkiewicz et al., 1985) below:
[Ca2*] = K<i (F-Fmlll) / (Fm,* -  F)
Kd represents the Fluo3 Ca2* dissociation constant that was previously determined in 
Fluo3-AM loaded HEK cells (Thomas et al., 2005), F represents the initial basal 
fluorescence, Fmin represents the minimum fluorescence achieved following the addition 
of a Ca2* chelator, EGTA (20mM) and Fmax represents the maximum fluorescence 
achieved through the addition of the ionophore, lonomycin (5 pM).
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3.3. Results
3.3.1. Generation of ARVD2-linked RyR2 mutant/polymorphism constructs
GFP-tagged RyR2 mutants harbouring the G1885E polymorphism (pcDNA3-eGFP- 
hRyR2-G1885E), the L433P mutation (pcDNA3-eGFP-hRyR2-L433P) or both 
substitutions (pcDNA3-eGFP-hRyR2-L433P-G1885E) were successfully generated and 
propagated. Restriction digest mapping and direct automated sequencing of the 5’ and 
3’ restriction boundaries were carried out to confirm correct ligation of mutated cassettes 
into full-length pcDNA3-eGFP-hRyR2 constructs (Figure 3.9B and 3.9C respectively). 
Restriction digests of all pcDNA3-eGFP-hRyR2 constructs with a battery of restriction 
enzymes produced the correct banding pattern of fragments with expected molecular 
weights as determined by in silico digestion using NEBcutter. (Figure 3.9A)
Direct automated sequencing of the mutagenesis site and sequence homology 
alignment to the WT sequence was carried out to confirm that the correct nucleotide 
substitution had taken place (Figure 3.9C). This was also used to verify that no 
additional base substitutions had inadvertently been inserted into the cDNA sequence. 
Taken together, these data confirm that full-length, eGFP-tagged human RyR2-encoding 
constructs containing the nucleotide substitutions resulting in the L433P and G1885E 
amino acid substitutions have been successfully cloned and propagated.
3.3.2. Expression of recombinant RyR2 in HEK Cells
HEK-293 cells were routinely transfected with full-length RyR2 cDNA constructs 
according to the method described in section 2.2.2.2.2. Calculation of the percentage of 
cells exhibiting eGFP fluorescence following transfection with each RyR2 construct 
demonstrated equivalent efficiencies of transfection (40 - 45%, p = 0.88, ANOVA, Figure
3.10). SDS-PAGE and western blot analysis was carried out as detailed in section 2.2.3 
in order to determine relative expression levels of each RyR2 construct and to ensure 
that the full-length protein was being expressed. Western blot analysis using an antibody 
probe targeted to the C-terminus of RyR2 (pAb1093) and a goat, anti-rabbit HRP- 
conjugated secondary antibody produced a single, high molecular weight protein band in
152
GFP
BamHI
RyR2
7683 bp
GFP
EcoRI
RyR2
GFP
Bglll
RyR2
0197
GFP
HinDIII
RyR2
BamHI Bglll EcoRI HinDIII
10664bp 5182bp 7683bp 11759bp
4871 bp 3805bp 5741 bp 5700bp
3461 bp 2632bp 
261Obp 
2573bp*
3952bp 3770bp
2199bp 1905bp
1873bp*
3015bp
34bp 649bp 838b p
B
O)m
— ©9 3£ -c
X  »
A
12.2kb
5 1 kb
4 1 kb
3 1 kb
1.6 kb
G 1885E SDM site
i
G C T G AGCAf t GAACCCA 0 C C AC C G C A A C C G
/^ jA /v#vA w w W W V w vV W t
G E E E A K e G K  
GE GGT GAGGAAGAAGCCAAGG GGGCAAG
I I I I I I I I I I I I I I I I I I I I I I I I I I
GGT GAGGAAGAAGCCAAGGGGGGCAAG 
G E  E E  A K G G K
SDM
W T
SanDI Restriction Site
i 1---- 1
GE SarrDt CCT CCAACT GGGT CCCGGGCATGAAGACT
II I I I I I I I I I I II I I I I I I I I I I I II I I
W T SanDI CCT CCAACT GGGT CCCGGGCATGAAGACT
Kpnl Restriction Site
i 1 i
T T G G C C C T C l i T C G G T A C C T T T G C A C i G C C
MWaWAaaA/\A»a«/MAAAi
GE Kpnl TTGGCCCTCAATCGGTACCTTTGCACAGCC
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
W T Kpnl TTGGCCCTCAATCGGTACCTTTGCACAGCC
Figure 3.9. Restriction digest mapping o f full-length eGFP-hRyR2 plasmid. Full-length WT 
and mutant pcDNA3-eGFP-hRyR2 cDNA (1pg) were digested with restriction enzymes (BamHI, 
Bglll, EcoRI and HinDIII), the products of which were run on a 1% agarose gel with a 1 kb DNA 
ladder (Panel B). The restriction digest pattern was compared to the expected fragment sizes, as 
determined by in silico digest of the WT and mutant RyR2 cDNA sequence using NEBcutter 
(Panel A). Asterisked fragments are of similar molecular weight and appear as a single band on a 
1% agarose gel. DNA sequencing of the G1885E mutagenesis site and the SanDI/Kpnl restriction 
sites was carried out and compared to the WT sequence by nucleotide homology alignment as 
shown in panel C. Nucleotide substitutions did not disrupt any restriction sites. (Panel C).
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Figure 3.10. Expression o f recombinant GFP- 
tagged hRyR2 in HEK cells following Effectene- 
mediated transfection. Transfection efficiencies 
were calculated using fluorescence (panel A, lower 
panels) and phase (Panel B, upper panels) 
images. Untransfected HEK cells did not exhibit 
intracellular eGFP fluorescence. Similar 
transfection efficiencies (40-45%) were achieved 
with all RyR2 constructs, (panel B, ANOVA, 
p>0.05). Data was obtained from between 7 and 
15 separate transfections with 554±11.5 cells per 
coverslip. Scale bar represents 100/jm.
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each case. Each RyR2 produced a band of equal molecular weight (565 kDa) and there 
was no significant difference in relative levels of expression (p > 0.35, ANOVA, Figure
3.11). There was no RyR2 protein detected in untransfected HEK cells, which is 
consistent with this being an RyR2-deficient cell line.
Figure 3.11. A ll recombinant RyR2 
expressed to equivalent levels.
Mixed membrane vesicles isolated 
from HEK cells transiently expressing 
WT and mutant/polymorphism were 
resolved by SDS-PAGE as shown in 
panel A. Western blotting with a RyR2 
specific rabbit-polyclonal antibody 
(pAb1093) produced a single, high 
molecular weight band was detected 
for each RyR2 construct. Densitometric 
analyses were carried out on 5 
experiments, the results of which are 
presented in panel B. There was no 
significant difference in RyR2 
expression levels of any mutant RyR2 
(one-way ANOVA, p>0.05). 
Untransfected HEK cells did not 
display RyR2 this large molecular 
weight band. Data is presented as 
mean ± S.E.M. and is from 5 
experiments.
3.3.3. Localisation of recombinant RyR2 to the endoplasmic reticulum
The intracellular visualisation of recombinant RyR2 protein was performed by examining 
the cells for inherent GFP fluorescence and also via immunodetection using an antibody 
targeted to the C-terminus (pAb1093) and Alexa546-conjugated secondary antibody 
detection (Figure 3.12). The appearance of the characteristic lattice-like fluorescence 
pattern indicates that all recombinant RyR2s correctly localised to the ER. Consistent 
with the results of the immunoblotting analysis, the high degree of colocalisation (89.1 to 
93.6%) of GFP and Alexa546 fluorescence, targeted to the amino and carboxyl regions 
respectively, would suggest the full-length protein is being expressed.
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Figure 3.12. L433P and G1885E exhibit correct ER trafficking. Cells expressing 
recombinant eGFP-hRyR2 were examined for endogenous eGFP fluorescence (top 
panels, excitation 488nm, emission collection = 525±25nm) and immunofluorescence of 
Alexa546 secondary antibody used with an anti-RyR2 primary antibody targeted to the C- 
terminus (pAB1093, middle panels, excitation = 546nm, emission 572±30nm) as shown in 
panel A. Both GFP and Alexa546 signals were localised to the ER as characterised by the 
lattice-like appearance. The scale bar represents 10pM. Extent of antibody and GFP 
colocalisation was quantified as the percentage of GFP pixels (green) that were directly 
coincident with Alexa546 pixels (red), presenting as yellow pixels when the two images 
were overlayed (‘Merged’, bottom panels, George, 2003). The mean ± S.E.M. extent of 
colocalisation is presented in panel B. Data was collected from between 7-11 cells.
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3.3.4. Voltage-independent measurement of Fluo3 signal intensity
The examination of the effects of PMT voltage gain on the Ca2+-dependent Fluo3 signal 
intensity demonstrated a clear positive relationship between the two parameters, 
indicating that increasing PMT voltage resulted in an increase in signal intensity. In HEK 
cells loaded with Fluo3-AM, the effects of increasing voltage on Fluo3 signal intensity 
was fitted to a Boltzmann distribution, as illustrated in Figure 3.13. The Boltzmann curve 
exhibited a flat section when voltage gain was between approximately 0-750V, where 
the Ca2+-dependent Fluo3 signal was relatively voltage-independent. This was followed 
by a steep section where Fluo3 signal intensity exhibited a high voltage-dependence, 
between voltages of approximately 800 and 1200V. The Boltzmann curve appears to 
begin to plateau at voltages in excess of 1250V, although the plateau phase was not 
completely observed here due to the maximum voltage gain in this experimental system 
being limited to 1250V.
Given the voltage-dependence of Fluo3 signal intensity (Figure 3.13A), variation in 
voltage gain at which data was collected could lead to artefactual differences in signal 
intensity being misinterpreted as having biological significance. In light of this it was 
essential to determine whether all experimental data was collected at comparable 
voltages. The mean voltage at which all Ca2+-imaging data was acquired was normally- 
distributed about a mean of 730 ± 3.2V (Figure 3.13). The average voltage at which 
Ca2+-imaging data was acquired from cells expressing each recombinant RyR2 was 
between 717.2 and 739.6 V  and the minimal and maximal voltages at which data was 
acquired were 643 and 815 V  respectively.
There were significant differences between the voltage gain at which Ca2+-imaging data 
was acquired from HEK cells expressing each RyR2 (Figure 3.14, ANOVA, p < 0.05). 
However, this was likely attributable to the high sample number (216-760 cells, 34-70 
coverslips per RyR2 construct) coupled with the fact that the majority of data was 
collected at voltages close to the mean, although some data was collected at extreme 
voltages.
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Figure 3.13. Boltzmann curve o f HEK cells loaded with Fluo3-AM. A Boltzmann curve was 
generated to examine the effects of increasing voltage gain (V) on Ca2-dependent Fluo3 signal 
intensity in untransfected HEK cells. The mean ± S.E.M. signal intensity of HEK cells loaded with 
Fluo3-AM was determined at each voltage gain, increasing voltage in 10V increments from 500 -  
1250V and is plotted in panel A. Data was generated from between 29-39 cells in 3 separate 
experiments. Solid black lines represent the lowest and highest average data acquisition voltages 
(714.9 and 739.6V respectively). Dotted black lines represent the minimal and maximal voltage at 
which Ca2+-imaging data was acquired. Panel B shows the portion of the Boltzmann curve across 
which Ca2+ imaging data was collected. The portion of the linear regression line between the 
minimal and maximal voltages at which data was collected (dotted lines) approximates to a 
straight line represented by the formula y = 0.05013x -  26.14.
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Figure 3.14. Ca2*imaging data was acquired at comparable PMT voltage gain. Voltage gain 
at which Ca2* imaging data was acquired was normally distributed. The mean voltage gain at 
which data was acquired is displayed in panel A and ranged from between 717.2 -  737.7 V for 
cells expressing each RyR2. Asterisked data indicates a significant differences to the mean 
voltage gain (p < 0.05) The voltage gain at which Ca2* imaging data was collected followed a 
Gaussian distribution about the mean of 730 ± 3.2V. Although data were collected at significantly 
different voltages to the mean, the majority of data was collected at voltages within 2% of the 
mean voltage gain and 96% of experiments were carried out at voltages within the normal 
distribution voltage range. Data was collected from a total of 457 separate coverslips.
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The mean voltages at which Ca2+-imaging of cells expressing each recombinant RyR2 
was carried out were within 2% of the mean voltage of the entire data set, with this level 
of error falling within the 95% confidence interval. The voltage range over which data 
was collected was located in a region of the Boltzmann curve where Fluo3 signal 
intensity was relatively voltage-independent, as demonstrated by linear-regression 
analysis of the region between the minimal and maximal acquisition voltages (643-815 
V) revealing a relatively shallow relationship gradient (A=0.05±0.006 FA/, Figure 3.13B). 
Taken together, the similarity between the mean acquisition voltage and the fact that 
data was acquired at a range of voltages that had little effect on Fluo3 signal intensity, 
there was no need to normalise data to voltage gain and it was possible to directly 
compare the nature of the Ca2*-dependent Fluo3 signal intensity between cells 
expressing each recombinant RyR2.
3.3.5. Recombinant RyR2s form functionally heterogeneous Ca2* release channels.
Transfection of HEK cells with all RyR2 constructs resulted in the expression of 
functional Ca2* release channels, demonstrated by way of an increase in intracellular 
Ca2* following exposure of transfected cells to caffeine. Figure 3.15A shows 
characteristic Ca2* imaging traces from HEK cells expressing WT RyR2, exposed to 
caffeine (0.1 -  40mM). The characteristic caffeine-evoked transient has a relatively flat 
baseline, followed by a sharp increase in intracellular Ca2* immediately after caffeine 
addition (indicated by an arrow in Figure 3.15A) followed by a slow decrease in signal 
intensity as intracellular Ca2* as is removed from the cytosol. The magnitude of caffeine- 
induced Ca2* release appeared to be dose dependent, with a larger intracellular Ca2* 
transient being observed following activation with increasing concentrations of caffeine.
The average magnitude of Ca2* release following activation of WT RyR2 with each 
concentration of caffeine was calculated and used to generate a caffeine-activation 
curve (Figure 3.15B). The magnitude of Ca2* release (F-F0) was normalised to the basal 
signal intensity to account for differences in resting Ca2* levels (F-F0 / F0). Under these 
experimental conditions, WT RyR2 produced half maximal caffeine-activation (EC50) at 
1.28±0.19mM caffeine, which is comparable to data produced from a study using a 
similar experimental system (1.56 ± 0.24mM, Thomas et al., 2004).
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Figure 3.15. WT RyR2 exhibits a sigmoidal caffeine activation curve when expressed in 
HEK cells. Representative Ca2* transients following the addition of caffeine (0.1 -40mM) at the 
points indicated in A. The average magnitude of Ca2* release following activation with each 
caffeine concentration was used to produce a caffeine-activation curve (Panel B). The EC50 value 
(1.27mM) was calculated from a non-linear regression sigmoidal dose response curve and 
represents the caffeine concentration evoking half-maximal Ca2* release. The 40mM caffeine 
data point (*) was excluded from non-linear regression due to quenching of Fluo3 signal as the 
fluorescence at this caffeine concentration was typically 10-40% lower than that observed 
following activation with 10mM caffeine. Data was collected form between 11 and 49 cells per 
caffeine concentration from 12 separate experiments.
Although the majority of caffeine sensitive cells exhibited these “normal” transients, a 
significant percentage (~ 15-40%) of cells expressing each RyR2 construct exhibited 
spontaneous basal Ca2* oscillations prior to caffeine addition. Cells exhibiting 
spontaneous basal Ca2+ oscillations were analysed as a separate data set and will be 
discussed in Chapter 5 of this thesis and are excluded from the analysis described in 
this chapter (see Figure 3.16).
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Figure 3.16. Single cell Ca2* imaging analysis work-stream. Data from non-oscillating cells underwent analysis of caffeine-evoked 
Ca2* release parameters (Chapter 3) and analysis of basal and post-activation Ca2* signal variability (Chapter 4). Data from cells that 
exhibited spontaneous basal Ca2* oscillations were analysed as a separate data-set and the incidence and characteristics of 
spontaneous Ca2* release events were determined (Chapter 5).
Identical Ca2* imaging experiments were carried out on cells expressing each 
recombinant RyR2, alone or co-expressed with WT RyR2. These experiments 
demonstrated significant heterogeneity in terms of the magnitude of caffeine-induced 
Ca2* release and channel sensitivity to caffeine activation. Figure 3.17 shows the 
caffeine-activation curves of cells expressing RyR2 homotetramers containing L433P, 
G1885E or L433P-G1885E (LP, GE or LPGE respectively). Figure 3.18 shows the 
caffeine activation curves obtained from cells co-expressing WT RyR2 with L433P 
(WT+LP), G1885E (WT+GE) or L433P-G1885E (WT+LPGE) or co-expressing L433P 
with G1885E on separate subunits (LP+GE), in a fashion mimicking the expression of 
heterotetramers (see Figure 2.4 for visual representation of RyR2 homo- and 
heterotetramers). For clarity in describing the various combinations of recombinant RyR2 
expression, the nomenclature described in Figure 2.4 will be adopted for the duration of 
this thesis.
From the EC50 values produced (Figures 3.17 and 3.18) it is evident that the expression 
of GE homotetramers or WT+GE heterotetramers produced channels with similar 
caffeine-sensitivity to WT (1.00 ± 0.15mM and 1.61 ± 0.42mM respectively, Figure 3.17 
and Figure 3.18). Cells expressing LP homotetramers exhibited a significantly higher 
EC50 value (2.17 ± 0.35mM) than cells expressing WT RyR2 (p < 0.05, Figure 3.17), 
indicating that LP channels are desensitised to caffeine activation compared to WT 
RyR2, reaffirming the notion that L433P is a not a typical gain-of-function RyR2 
mutation. Expression of LPGE homotetramers produced an EC50 value of 0.11 ± 
0.07mM, which would suggest that homotetrameric LPGE channels are sensitised to 
caffeine activation compared to WT RyR2 (p < 0.01, Figure 3.17). However, the inclusion 
of G1885E on the same subunit as L433P (LPGE) appears to have abolished the 
sigmoidal caffeine dose response that was exhibited in cells expressing all other RyR2s, 
suggesting this EC50 may be artefactual. Additionally, the only significant difference 
between the magnitudes of Ca2* release at a particular activating caffeine concentration 
in cells expressing LPGE compared to those expressing LP alone was observed 
following activation by 0.1 mM caffeine (p < 0.05, Figure 3.17).
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Figure 3.17. Homotetrameric 
L433P or L433P-G1885E alter 
the RyR2 caffeine activation 
profile. Caffeine-activation dose 
response curves (0.1-10mM 
caffeine) were generated using 
HEK cells expressing G1885E, 
L433P or L433P-G1885E, 
homotetramerically. Data is 
represented as the mean ± 
S.E.M. magnitude of caffeine- 
induced Ca2* release (AF-FO /  
F0) and was obtained from 
between 1 0 - 8 4  cells at each 
caffeine concentration from >3 
experiments. WT data is 
represented by open circles (o) 
and a dashed line and 
mutant/polymorphism data is 
represented by closed squares 
(■) and a solid line. The EC50 
value of WT RyR2 is 1.27mM as 
shown in Figure 3.11. Asterisked 
data points denote a significant 
difference to WT (p < 0.05).
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Figure 3.18. G1885E negates the altered caffeine activation profile of WT+LP co­
expression. Caffeine-activation dose response curves (0.1-1 OmM caffeine) were generated 
using HEK cells co-expressing WT RyR2 with G1885E, L433P or L433P-G1885E or co­
expressing L433P with G1885E. Data is represented as the mean ± S.E.M. magnitude of 
caffeine-induced Ca2* release (AF-FO /  F0) and was obtained from between 11-67  cells at each 
caffeine concentration from >3 experiments. WT data is represented by open circles (o) and a 
dashed line and mutant/polymorphism data is represented by closed squares (m) and a solid line. 
The ECso value of WT RyR2 is 1.27mM as shown in Figure 3.11. Asterisked data points and EC50 
values denote a significant difference to WT (p < 0.05).
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Co-expression of L433P with WT RyR2 (WT+LP), appeared to cause the caffeine 
activation curve to shift in the opposite direction to when LP was expressed alone, 
producing a significantly lower EC50 value than of WT RyR2 (0.75 ± 0.2mM, p < 0.05, 
Figure 3.18), inferring increased sensitivity to caffeine activation. Interestingly, the co­
expression of L433P-G1885E with WT RyR2 (WT+LPGE, representative of ‘in cis’ 
inheritance) produced a caffeine-activation curve that was significantly right-shifted (1.58 
± 0.2mM, p < 0.05, Figure 3.18) compared to that observed in cells co-expressing 
WT+LP, indicating that the presence of the G1885E polymorphism prevented the 
sensitisation of the channel to caffeine activation caused by WT+LP expression. 
Similarly, the increased caffeine-sensitivity of heterotetrameric WT+LP channels was not 
observed when G1885E was co-expressed on separate subunits to L433P (LP+GE, 
representative of ‘in trans' inheritance). This mode of expression resulted in a caffeine 
activation profile that was similar to that obtained from cells expressing WT RyR2 (p = 
0.70), indicating the presence of G1885E restored normal caffeine sensitivity to WT+LP 
channels.
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Figure 3.19. Heterogeneity in peak caffeine-induced Ca2* release magnitude. The average 
peak magnitude of Ca2* release following activation with caffeine (10mM), representing maximal 
RyR2 activation was determined in HEK cells expressing each combination of recombinant RyR2. 
Data is presented as the mean magnitude of Ca2* release ± S.E.M. Data was acquired from 
between 29 and 62 cells expressing each RyR2 construct. * indicates a statistically significant 
difference compared to WT RyR2 (p < 0.05). ### indicates a statistically significant difference 
compared to the homotetrameric counterpart of heterotetrameric substitution (p < 0.001) i.e. 
WT+GE vs GE or WT+LP vs LP or WT+LPGE vs LP.
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Heterogeneity between caffeine-induced Ca2+-release was observed between cells 
expressing each construct following maximal RyR2 activation with 10mM caffeine 
(Figure 3.19). Expression of GE or WT+GE exhibited similar peak Ca2+ release 
magnitude compared to WT RyR2 (p=0.62). Homotetrameric expression of LP or LPGE 
exhibited a significantly decreased peak Ca2+ release compared to cells expressing WT 
RyR2 (p < 0.05), although the magnitude of this decrease did not differ between cells 
expressing LP or LPGE (p = 0.96). This suggests that inclusion of G1885E on the same 
sub-unit as L433P had no significant effect on peak caffeine-induced Ca2* release 
compared to that observed when L433P was expressed alone. Co-expressing WT+LP 
resulted in a significant increase in the magnitude of peak caffeine-induced Ca2* release 
compared to WT RyR2 (p < 0.05), although this increase did not reach statistical 
significance when compared to other G1885E or L433P containing RyR2s (p = 0.07, 
Figure 3.19). However, co-expression of WT+LPGE resulted in a non-significant 
decrease in the peak magnitude of Ca2* release compared to cells co-expressing 
WT+LP (p = 0.07), indicating that G1885E caused modest alterations in L433P peak 
Ca2* release magnitude, but only in the heterotetrameric state.
3.3.6. Rates of Ca2* release and cytoplasmic Ca2* removal
Expression of each RyR2 mutation/polymorphism resulted in differences in the peak rate 
at which Ca2* was released from the ER Ca2* store into the cytosol, following activation 
with 10mM caffeine (Figure 3.20). The G1885E substitution did not alter the peak rate of 
Ca2* release, irrespective of whether it was expressed alone or co-expressed with WT 
RyR2 (p = 0.31). Cells expressing LP or LPGE homotetramers displayed a similar peak 
rate of Ca2* release compared to eachother and to WT RyR2 (p = 0.06 and p = 0.07 
respectively). Interestingly, co-expression of WT+LP resulted in a significant, 
approximately 2-fold increase in the peak rate of Ca2* release (p < 0.001) compared to 
WT, the opposite effect to that observed when LP was expressed alone. However, this 
increase in peak rate of caffeine-induced Ca2* release was not observed following 
WT+LPGE or LP+GE co-expression. Taken together, these data suggest that the 
G1885E polymorphism has a modulatory effect on the peak rate of caffeine-induced 
Ca2* release of WT+LP mutant channels, but not on homotetrameric L433P channels 
(Figure 3.20).
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Figure 3.20. Mean peak rate o f Ca2+ release following caffeine (10mM) activation. The
mean peak rate of Ca2* release was measured following channel activation with caffeine 
(10mM), representing maximal channel activation. Data is presented as mean rate of Ca2* 
release ± S.E.M. Data comprises of between 29 and 67 cells expressing each RyR2 
construct. *** indicates a statistically significant difference compared to WT RyR2 
(p<0.001). # indicates a statistically significant difference compared to the homotetrameric 
counterpart of heterotetrameric substitution i.e. WT+GE vs GE or WT+LP vs LP or 
WT+LPGE
Linear regression analysis was carried out to determine if there was a relationship 
between the rate of Ca2+ release and the concentration of activating caffeine in cells 
expressing each recombinant RyR2 (Figure 3.21). Cells expressing WT RyR2 exhibited 
a strong, positive correlation between the concentration of activating-caffeine and the 
average rate of resulting Ca2+ release (r2 = 0.89, A = 0.019 ± 0.003, p < 0.001). 
Expression of the G1885E polymorphism produced a similar relationship between 
activating caffeine concentration and the rate of Ca2+ release compared to WT, both 
when homotetrameric GE (r2 = 0.89, A = 0.024 ± 0.003, p < 0.0001) or heterotetrameric 
WT+GE (t2= 0.89, A = 0.027 ± 0.004, p < 0.0001) were expressed.
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Figure 3.21. Homotetrameric expression of L433P and L433P-G1885E disrupt the 
relationship between activating-caffeine concentration and the rate of Ca2* release. The
average rate o f Ca2* release following caffeine activation (0.1-10mM) was measured in cells 
expressing WT (open circles, dotted line) and mutant/polymorphism (closed squares, solid line) 
RyR2. Asterisked data points are significantly different to WT (p < 0.05). A linear regression line 
was fitted to the same data from which the goodness o f fit (r2) and the gradient of the regression 
line were calculated (GraphPad Prism). Gradients significantly different to zero are indicated by 0 
(p < 0.05). Gradients significantly different to WT are asterisked. The WT r2 value is 0.8653 and 
the gradient is 0.01887 ± 0.0028. Data was collected from between 13 and 84 transfected HEK 
cells per caffeine concentration.
Expression of LP homotetramers produced a similar gradient of the line-of-best-fit (A = 
0.014 ± 0.004, p < 0.05) compared to that of WT RyR2. This suggests that the rate of 
Ca2+ release through LP channels increases to the same extent as WT, in response to 
an increase in activating caffeine concentration. However, the LP data did not fit the 
linear regression model so well, which manifests as a lower goodness-of-fit value (r2 = 
0.62). This decrease in the robustness of the relationship between activating caffeine 
concentration and the rate of Ca2* release was exacerbated in cells expressing LPGE 
homotetramers. Cells expressing LPGE homotetramers did not exhibit a relationship 
between activating caffeine concentration and the rate of Ca2* release as demonstrated 
by a gradient that was not significantly different to zero (A = 0.0065, p = 0.12) and a low 
goodness-of-fit value (r2 = 0.32). This suggests that the presence of the G1885E SNP 
has a detrimental modulatory effect on the dysfunctional Ca2* release caused by 
homotetrameric L433P expression.
The co-expression of WT+LP resulted in a much steeper gradient than when WT or LP 
were expressed alone (A = 0.033 ± 0.006, p < 0.001), and the data was a good fit to the 
linear regression line (r2 = 0.82). Interestingly, when WT+LPGE was expressed, cells 
exhibited a relationship between activating caffeine concentration and the rate of Ca2* 
release (r2 = 0.82, A = 0.02263, p < 0.001) similar to that observed in cells expressing 
WT RyR2 or co-expressing WT+LP.
Furthermore, heterotetrameric co-expression of LP+GE, exhibited a similar relationship 
between activating caffeine concentration and rate of Ca2* release compared to that 
observed in cells expressing WT RyR2, although with a decreased goodness of fit value 
(r2 = 0.61, A = 0.028 ± 0.009, p < 0.05). This suggests that G1885E only alters the 
relationship between activating caffeine concentration and the rate of Ca2* release when 
expressed with L433P in a homotetrameric state.
Expression of most recombinant RyR2 variants displayed a similar rate of Ca2* removal 
from the cytosol following caffeine-evoked Ca2* release (10mM) compared to WT (Figure 
3.22). Cells expressing GE homotetramers or WT+GE heterotetramers, exhibited a 
similar rate of Ca2* removal as cells expressing WT RyR2. Expression of 
homotetrameric LP or LPGE had no significant effect on the rate of Ca2* removal from 
the cytosol compared to cells co-expressing WT RyR2.
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Figure 3.22. WT+LP heterotetrameric expression increases the rate o f Ca2* removal 
from the cytoplasm following RyR activation. Data presented is the mean rate of Ca2* 
removal following RyR2 activation with 10mM caffeine ± S.E.M., representing the rate of 
Ca2* removal from the cytosol following maximal RyR2 activation. Data was collected from 
between 29 and 62 cells expressing each RyR2 construct. * indicates a statistically 
significant difference in the mean peak rate of Ca2+ release compared to WT RyR2. # 
indicates a statistically significant difference compared to the homotetrameric counterpart 
of heterotetrameric substitution i.e. WT+GE vs GE or WT+LP vs LP or WT+LPGE vs LP.
However, co-expression of WT+LP resulted in a significant increase in the rate of Ca2+ 
removal from the cytosol, compared to WT or LP homotetramers were expressed (p < 
0.05). Co-expression of WT+LPGE exhibited a similar rate of Ca2+ removal compared to 
that observed in cells expressing WT RyR2. It is important to note that differing 
magnitudes of caffeine-induced Ca2+ release observed in cells expressing each 
recombinant RyR2 may contribute to the varying rates of Ca2+ removal from the cytosol. 
Also worth noting is that the addition of a caffeine bolus to the cells may alter RyR2 
gating following Ca2+ release (Gaburjakova et al, 2006) and may presumably perturb ER 
store refilling with the majority of Ca2+ likely being removed from the cell through various 
cell membrane bound Ca2+ pumps and exchangers.
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3.3.7. Differential ER Ca2+ store load
Caffeine and thapsigargin depletion of the ER Ca2+ store was used to estimate the 
relative levels of Ca2+ in intracellular ER stores of cells transfected with each RyR2 
construct (Figure 3.8 and 3.23). Cells expressing WT RyR2 demonstrated an increased 
store load compared to untransfected HEK cells, which is consistent with previous data 
(Tong et al, 1999). Cells expressing GE homotetramers or WT+GE heterotetramers 
displayed a similar Ca2+ store load compared to cells expressing WT RyR2 (p=0.69). 
However, homotetrameric expression of LP caused a significant decrease in ER Ca2+ 
store load which was exacerbated by the inclusion of G1885E on the same RyR2 
subunits as the mutation (LPGE, p<0.05), both of which were significantly decreased 
compared to WT RyR2 (p < 0.05). This decrease in ER Ca2+ levels could potentially be 
indicative of diastolic Ca2+ leak.
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Figure 3.23. Heterogeneity in ER Ca2* load as estimated by thapsigargin depletion of 
ER Ca2*. Transfected cells were indentified by caffeine-sensitivity (0.5mM). Passive ER 
store depletion was achieved by thapsigargin (10pM) inhibition of SERCA, preventing store 
refilling. Data represents mean ± S.E.M magnitude of thapsigargin and caffeine induced 
Ca2* release. Data was obtained from 20-74 cells per recombinant RyR2, or from 272 
untransfected cells. * indicates a statistically significant difference compared to WT RyR2. # 
indicates a statistically significant difference compared to the homotetrameric counterpart 
of heterotetrameric substitution i.e. WT+GE vs GE or WT+LP vs LP or WT+LPGE vs LP. ¥ 
indicates a statistically significant difference compared to the respective recombinant RyR2 
without G1885E co-expression, i.e. LP-GE vs LP or WT+LPGE vs WT+LP or LP+GE vs 
WT+LP.
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Co-expression of heterotetrameric WT+LP had the opposite effect to when 
homotetrameric LP was expressed, exhibiting a significantly increased ER Ca2* store 
load compared to cells expressing WT (p < 0.05). Conversely, co-expression of 
WT+LPGE heterotetramers resulted in a significant decrease in ER Ca2+ levels 
compared to cells expressing either WT or WT+LP (p < 0.05). Heterotetrameric LP+GE 
expression exhibited a comparable ER Ca2* store load to WT RyR2, although this was 
significantly decreased compared to that of cells co-expressing WT+LP (p < 0.05).
In summary, the presence of G1885E appears to alters ER Ca2* load irrespective of 
whether it is expressed on the same or separate subunits as L433P in a 
heterotetrameric fashion or whether it is expressed with homotetrameric L433P. 
Homotetrameric expression of LPGE appeared to exacerbate the effects of L433P on 
Ca2* store load, whereas co-expression of G1885E with L433P in a heterotetrameric 
fashion appeared to alleviate the increase in store load caused by the co-expression of 
WT+LP. Furthermore, the heterogeneity in ER Ca2* levels can potentially explain some 
of the observed differences in intracellular Ca2* handling between cells expressing each 
recombinant RyR2 and will be discussed in section 3.4.
3.3.8. Heterogeneity in basal Ca2* levels
The free cytoplasmic Ca2* concentration was measured in cells expressing each 
recombinant RyR2 according to the method detailed in section 3.2.6. Expression of 
recombinant RyR2 resulted in an increase in basal cytoplasmic Ca2* concentration 
compared to untransfected HEK cells (p < 0.05, Figure 3.24), an observation that has 
previously been made through the heterologous expression of RyR1 (Tong et al., 1999). 
Expression of WT RyR2 resulted in a basal cytoplasmic Ca2* concentration (108 ± 
19nM, Figure 3.24) comparable to that of previously published data (80 ± 13nM, Thomas 
et al., 2005). Expression of homotetrameric GE or heterotetrameric WT+GE did not 
significantly alter the basal cytoplasmic Ca2* concentration compared to that of cells 
expressing WT RyR2. When homotetrameric L433P was expressed, a basal cytoplasmic 
Ca2* concentration of 110 ± 14nM (101.8±13% of WT) was observed, which is similar to 
WT (p = 0.94) and previously published data (86 ± 13mM, 107.5±15%, Thomas et al., 
2005). However, expression of homotetrameric LPGE resulted in a significant increase 
in basal cytoplasmic Ca2* concentration (268±37nM, 248±13.8% of WT) compared to
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that observed in cells expressing homotetrameric LP, which suggests that the presence 
of G1885E increases the level of cytoplasmic Ca2+ and coupled with the observed 
decreased Ca2+ store load, could be indicative of ER Ca2+ leak.
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Figure 3.24. Heterogeneity in basal cytoplasmic Ca2+ levels in cells expressing each 
recombinant RyR2. Transfected cells were indentified by caffeine-sensitivity (0.5mM) 
before determination of the maximal (lonomycin 10pM) and minimal (EGTA, 20mM) Ca2+- 
dependent signal intensities. These values were used to determine the basal cytoplasmic 
Ca2+ concentration of cells expressing each RyR2. Data is plotted as mean ± S.E.M. which 
is and was generated from between 21 and 73 transfected cells and 130 untransfected 
cells. * indicates a statistically significant difference compared to WT RyR2. # indicates a 
statistically significant difference compared to the homotetrameric counterpart of 
heterotetrameric substitution i.e. WT+GE vs GE or WT+LP vs LP or WT+LPGE vs LP. ¥ 
indicates a statistically significant difference compared to the respective recombinant RyR2 
without G1885E co-expression, i.e. LP-GE vs LP or WT+LPGE vs WT+LP or LP+GE vs 
WT+LP.
Co-expression of WT+LP also significantly increased basal cytoplasmic Ca2+ levels 
compared to WT RyR2 (184.4 ± 32.5nM, 170.7±17.6% of WT, p < 0.05). Interestingly, 
co-expression of WT+LPGE restored basal cytoplasmic Ca2+ levels to those observed in 
cells expressing WT RyR2 or homotetrameric LP, as did the expression of LP+GE 
heterotetramers. Taken together this data indicates that the G1885E also alters the 
basal cytoplasmic Ca2+ levels of cells expressing the L433P mutation, both when it is 
expressed in a homotetrameric or heterotetrameric manner. Given that altered 
cytoplasmic Ca2+ concentration has been implicated in impaired cardiac function, the 
differences in cytoplasmic Ca2+ levels observed here may be an indication that L433P 
and G1885E have a role in arrhythmia pathogenesis.
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RyR2
ER Ca2* Store Load 
[(Foafi + Fth»p»)-Fo] i Fo
Cytoplasmic 
[Ca2*] (mM)
Peak Ca2* 
release
Minimal Ca2* 
release
Caffeine 
ECflo (mM)
Peak Rate of 
Ca2* release 
A(F-Fo/Fo) sec1
Rate of Ca2* 
removal 
A(F-Fo/F0) sec1
Untransfected 1.21 ± 0.03 * 67.2 ± 3.7 * N/A N/A N/A N/A N/A
Wild Type 1.51 ±0.19 108.7 ±16.2 0.68 ± 0.09 0.15 ±0.02 1.27 ±0.19 0.25 ± 0.06 0.25 ± 0.04
G1885E 1.58 ±0.26 88.5 ±16.8 0.63 ± 0.07 0.19 ±0.03 1.00 ±0.15 0.33 ± 0.05 0.3 ± 0.06
L433P 1.1 ±0.1 * 110.7 ±13.2 0.43 ± 0.06 * 0.25 ±0.05 * 2.17 ± 0.35 * 0.17 ±0.02 0.28 ± 0.03
L433P - G1885E 0.89 ±0.11 * 193.4 ±13.8* 0.43 ± 0.04 * 0.21 ±0.02* 0.11 ±0.07* 0.16 ±0.02 0.27 ± 0.03
WT+G1885E 1.27 ±0.18 145.1 ± 14.0 0.61 ±0.07 0.15 ±0.03 1.6 ±0.42 0.26 ± 0.03 0.32 ± 0.03
WT+L433P 2.29 ± 0.39 * 180.0 ±28.0* 0.92 ±0.1* 0.37 ±0.09* 0.75 ±0.2* 0.53 ± 0.1 * 0.41 ±0.04*
WT+L433P-G1886E 1.11 ±0.06* 114.2 ± 18.0 0.64 ± 0.07 0.11 ±0.02 1.58 ±0.2 0.35 ± 0.06 0.35 ± 0.04
L433P + G1886E 1.21 ±0.14 114.2 ±18.5 0.68 ±0.11 0.22 ± 0.03 1.6 ±0.35 0.28 ± 0.08 0.28 ± 0.04
Table 3.4. A summary of the Ca2* handling parameters observed in cells expressing each recombinant RyR2. Asterisked data 
indicates a significant difference to WT RyR2 (p < 0.05). Green values indicate a significant increase and red values indicate a significant 
decrease compared to WT RyR2.
3.4. Discussion
3.4.1. RyR2 constructs harbouring ARVD2-linked mutations/polymorphisms were 
successfully generated and expressed in HEK-293 cells.
Non-liposomal lipid-mediated transfection was shown to be an effective method of 
transiently expressing recombinant RyR2 in HEK cells. This method of transfection 
routinely resulted in transfection efficiencies of ~40-45% for all cDNA constructs, as 
determined by monitoring cells for eGFP expression. Co-transfection of cells with two 
different RyR2 cDNAs in a 1:1 molar ratio produced comparable transfection efficiencies 
to when cells were transfected with a single RyR2 construct. This suggests that 
transfection with two distinct RyR2 cDNA constructs results in the same number of cells 
expressing RyR2 protein and there is no obvious detrimental effect of co-transfection on 
eGFP expression. This method of co-transfection has been routinely used in the 
investigation of cardiac sodium channel gene (SCN5A) mutations (Viswanathan et al., 
2003; Poelzing et al., 2006), RyR1 CCD/MH-linked mutations (Tong et al., 1999; Du et 
al., 2004) and RyR2 mutations (Wehrens et al., 2003; Lehnart et al., 2008). HEK-293 
cells transfected with each RyR2 construct exhibited eGFP fluorescence, indicating that 
the chromophore was correctly folded, as eGFP only fluoresces when the correct 
secondary structure has been adopted.
Western blot analysis of mixed membrane vesicles isolated from HEK cells transfected 
with each RyR2 construct, and subsequently probed with an anti-RyR2 antibody 
confirmed that the full-length 565kDa protein was being expressed, since the pAb1093 
antibody binds to RyR at the C-terminus (residues 4455-4474). The densitometric 
analysis of western blots also showed that the relative levels of expression did not differ 
between cells expressing each RyR2 mutation/polymorphism, consistent with published 
data in the cases of G1885E (Koop et al., 2008) and L433P (Thomas et al., 2004). As all 
RyR2 mutants/polymorphisms were expressed to comparable levels, any observed 
functional consequences of RyR2 mutations/polymorphisms do not stem from 
differences in relative expression levels.
The high degree of co-incident localisation (89-94%) of endogenous eGFP fluorescence 
with pAb1093 immunofluorescence also suggests that the full-length RyR2 protein is 
being expressed. This is corroborated by the fact that the eGFP epitope is located at the 
extreme N-terminus of the protein and the pAb1093 antibody is targeted to a region near
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the C-terminus, with the two signals exhibiting high levels of co-localisation. Interestingly, 
all recombinant RyR2’s exhibited an expression pattern similar to that characteristic of 
immunofluorescent markers targeted to other ER proteins i.e. sarcolipin (Gramolini et al.,
2004), SERCA (Bobe et al., 2004). This confirms the correct membrane trafficking of 
recombinant RyRZs to the ER, meaning that any observed functional consequences of 
mutant channel expression are not caused by protein mis-trafficking. The correct 
trafficking of RyR2 to the ER also confirms that the fusion of the eGFP chromophore to 
the N-terminus of the RyR2 peptide does not prevent correct protein targeting. The lack 
of pAb1093-dependent signal demonstrated by western blot analysis of membrane 
vesicles isolated from untransfected HEK cells, coupled with the absence of pAb1093 
immunofluorescence confirms that HEK cells do not endogenously express RyR2.
Transfection of HEK-293 cells with each of the RyR2 cDNAs resulted in the formation of 
functional recombinant RyR2 channels, as demonstrated by caffeine-evoked Ca2* 
release in single-cell Ca2*-imaging experiments. This confirms that the fusion of the 
eGFP epitope at the extreme N-terminus does not prevent the formation of functional 
Ca2* release channels. This is consistent with previous functional studies using similar 
N-terminal eGFP-tagged RyR2 cDNA constructs in HEK-293 cells (Thomas et al., 2004;
2005) and 3D-mapping studies in which the GFP epitope was inserted into various 
locations within the RyR2 protein (Zhang et al., 2003; Liu et al., 2005; Wang et al., 
2007). Insertion of GFP into regions spanning the length of the protein (Figure 1.6, 
regulatory motif localisation), including at the N-terminus (Wang et al., 2007), resulted in 
channels that presented similar Ca2* and caffeine activation sensitivities to untagged WT 
RyR2 channels. This makes it unlikely that the insertion of a GFP tag at the extreme N- 
terminus will cause gross perturbation of channel function. Untransfected HEK cells did 
not exhibit caffeine-induced Ca2* release, reconfirming that HEK cells do not 
endogenously express RyR2.
Cells expressing WT RyR2 exhibited similar basal cytoplasmic Ca2* levels and ER Ca2* 
store load compared to previously published data produced from a similar experimental 
system (Thomas et al., 2004; 2005). Similarly, the resting cytoplasmic Ca2* levels of 
cells expressing RyR2 (108.7±16.2nM) were comparable to those observed as a result 
of expression of RyR1 in a HEK-293 cell model (112.1±11nM, Tong et al., 1999). Also in 
accordance with this study, cells expressing recombinant RyR2 exhibited a marked 
increase in cytoplasmic Ca2* concentration compared to untransfected HEK cells
177
(97±5nM, 15.5% increase, Tong et al., 1999), although this increase was not as 
pronounced as that observed here (67.2±3.7nM, 38.2% increase). Tong et al proposed 
that expression of RyR1 causes an increase in the permeability of the ER Ca2+ store, 
accounting for the observed rise in basal cytoplasmic Ca2* levels and also observed a 
compensatory increase in SERCA expression levels and activity, culminating in an 
increased store load (Tong et al., 1999), similar to observations made here.
The caffeine activation profile of cells expressing recombinant WT RyR2 was also similar 
to previously published data obtained from the heterologous expression of recombinant 
human (Thomas et al., 2004) and rabbit (Du et al., 1998) RyR2. Cells expressing WT 
RyR2 also displayed a strong relationship between activating caffeine concentration and 
the rate of subsequent Ca2* release, suggesting that increasing the level of channel 
activation increases the rate at which Ca2* is released from the ER.
All of this data taken together would suggest that HEK-293 cells provide a suitable 
model system in which to express human RyR2 and study the functional consequences 
of mutant channel expression on intracellular Ca2* handling. The similarities observed 
between the Ca2* handling properties of HEK-293 cells expressing WT RyR2 in this 
study and that of Thomas et al suggest that direct comparison of experimental data from 
the two studies is plausible. The measurement of the intracellular Ca2* handling 
parameters discussed here were determined for cells expressing each recombinant 
RyR2 and the data generated is summarised in Table 3.4.
3.4.2. G1885E channels are functionally similar to WT RyR2
Single-cell Ca2* imaging of HEK cells expressing RyR2 containing G1885E indicates that 
this polymorphism did not cause gross perturbation of RyR2 Ca2* handling in a cellular 
environment. Unlike the vast majority of CPVT/ARVD2-associated mutations and 
consistent with previous investigation of this polymorphism (Koop et al., 2008), G1885E 
expression did not result in a decreased ER Ca2* store load. This, coupled with the fact 
that it did not lead to increased basal cytoplasmic Ca2* levels, suggests that it is unlikely 
that G1885E results in diastolic Ca2* leak, one of the mechanisms by which RyR2 
mutations are proposed to result in arrhythmia. The magnitude of caffeine-induced Ca2* 
release in cells expressing G1885E was similar to that observed in cells expressing WT
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mRyR2 across the entire caffeine concentration range (0.1-10mM), which suggests the 
G1885E channel had a similar activation profile to that of WT RyR2. This is corroborated 
by the similarity between WT and G1885E EC50 values in previously published data of 
mouse RyR2-G1885E caffeine activation profiling (Koop et al., 2008). The similarity in 
the rates of Ca2* release and subsequent Ca2* removal, coupled with the comparable 
magnitudes of Ca2* release suggests that following channel activation, the cytoplasmic 
Ca2* concentration profile is comparable between cells expressing G1885E or WT RyR2. 
Similarly, when G1885E was co-expressed with WT RyR2 there was no significant 
difference in ER Ca2* store load, basal cytoplasmic Ca2* levels, caffeine activation profile 
and the rates of Ca2* release and subsequent Ca2* removal when compared to WT or 
G1885E data. Collectively, these data suggest that G1885E does not cause any gross 
perturbation of intracellular Ca2* handling parameters, regardless of whether it is 
expressed as homotetramers or heterotetramers.
The G1885E polymorphism is located in DR3 (Zhang et al., 2003), a region of the 
cytoplasmic domain that has been proposed to be involved in the Ca2* dependent 
regulation of RyR activity (Hayek et al., 1999). Given the role of DR3 in RyR2 
inactivation (Hayek et al., 2000), the substitution of the non-polar glycine residue for a 
negatively charged glutamate residue (G1885E) could potentially alter the Ca2* binding 
affinity of this domain and subsequently alter Ca2*-dependent regulation of the channel. 
However, in these experiments G1885E did not appear to exhibit an altered caffeine 
activation profile, suggesting that the G1885E substitution is unlikely to alter Ca2* 
dependent channel activation when it is the only substitution present, however this would 
need to be examined in single channel studies. The effects of G1885E on Ca2* 
dependent channel inactivation could not be accurately determined in this experimental 
system as the addition of caffeine as a bolus is likely to alter channel gating parameters 
following activation (Gaburjakova et al., 2006).
Although several groups have demonstrated that CPVT/ARVD2-linked RyR2 mutations 
do not reduce FKBP12.6 binding (George et al., 2003a; Stange et al., 2003; 
Zissimopoulos et al., 2009), G1885E is in a region directly adjacent to the proposed 
FKBP12.6 binding site (Zhang et al., 2003; Sharma et al., 2006), meaning that functional 
consequences of G1885E on FKBP12.6 binding or activity cannot be ruled out. If 
G1885E did alter FKBP12.6 regulation of RyR2, it would not have been observed in 
these experiments as HEK-293 cells do not endogenously express FKBP12.6. The
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potential effects of the G1885E substitution on FKBP12.6 activity would therefore need 
to be investigated when co-expressed with FKBP12.6 or in a cardiac system in which 
FKBP12.6 is endogenously expressed.
3.4.3. L433P functional consequences depend on mode of expression
The L433P ARVD2-linked mutation resulted in significant perturbation of intracellular 
RyR2 Ca2+ handling dynamics compared to G1885E. Cells expressing L433P 
homotetramers exhibited a decrease in Ca2* store load and similar basal cytoplasmic 
Ca2* levels to cells expressing WT RyR2, in agreement with findings from several 
studies (Thomas et al., 2004; Jiang et al., 2005) and observations made through 
heterologous expression of RyR1 MH-linked mutations (Bobe et al., 2004; Brini et al.,
2005). Interestingly, when L433P channels were fully activated by high concentrations of 
caffeine, the magnitude of Ca2* release was significantly decreased compared to cells 
expressing WT RyR2. The caffeine activation profile of L433P appeared to be right 
shifted compared to WT (EC50 = 2.17 ± 0.35), suggesting that L433P caused a 
desensitisation of the channel to caffeine activation, which is in accord with previous 
work (Thomas et al., 2004), although the extent of caffeine desensitisation was more 
pronounced in their experiments (EC50 = 4.86 ± 0.58mM).
The observed decrease in Ca2* store load could be indicative of passive Ca2* leak from 
the ER, as has been observed through heterologous expression of several MH and 
CCD-linked RyR1 mutations (Brini etal., 2005), resulting in a decreased level of ER Ca2* 
available for release following caffeine activation of RyR2 (Bers, 2008). Although the 
Ca2* store load was decreased, the level of cytoplasmic Ca2* was unchanged compared 
to WT, suggesting that a compensatory mechanism of Ca2* extrusion may have come 
into effect. However, the precise mechanism of extrusion of cytoplasmic Ca2* from HEK 
cells remains unknown as HEK cells do not endogenously express NCX (Hurtado et al.,
2006). Coupled with the fact that ER Ca2* store refilling may be chronically perturbed by 
the activating-caffeine bolus, this suggests that Ca2* is most likely removed from the 
cytoplasm by the “slow” mechanisms described in section 1.2.3.3.4. The observed 
increase in the magnitude of Ca2* release at low activating caffeine concentrations could 
be a result of increased L433P sensitivity to caffeine activation, which is not presented at
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higher activating caffeine concentrations due to the decreased Ca2* availability resulting 
from the reduced ER store load.
The significant decrease in the rate at which Ca2* was released from the ER following 
caffeine activation of RyR2 could potentially be due to the observed decrease in peak 
Ca2* release magnitude, both of which are likely attributable to the decreased ER Ca2* 
load. The decreased ER Ca2* store load coupled with the unaltered basal cytoplasmic 
Ca2* concentration would result in a decreased Ca2* gradient from the ER to the 
cytoplasm, potentially decreasing the rate of calcium release from the ER. Alternatively, 
the L433P mutation may alter channel conductance properties, although this would not 
have been evident in these experiments and was not observed in previous biophysical 
characterisation of L433P (Jiang et al.t 2005). The L433P mutation did not alter the rate 
of Ca2* removal from the cytoplasm following caffeine-evoked Ca2* release compared to 
that of WT, suggesting under these experimental conditions, this mutation has little 
observable effect on Ca2* extrusion or channel inactivation. However, subtle differences 
in channel inactivation properties pertaining to ER Ca2* leak through incomplete 
activation may well be masked by the continued presence of caffeine following channel 
activation. Data presented in Chapter 5 of this thesis, which examines Ca2* handling 
parameters in the absence of caffeine-evoked channel activation, will discuss the effects 
of mutations on channel inactivation in further detail. However, collectively this data is 
consistent with the view that L433P is not a typical gain-of-function mutation (Thomas et 
al., 2004; Thomas et al., 2005).
It is extremely important to note that the homotetrameric expression of L433P in HEK- 
293 cells is not truly representative of the mode of mutant RyR2 protein expression in 
vivo (Tiso et al., 2001). All CPVT/ARVD2-linked RyR2 mutations are inherited in an 
autosomal dominant fashion (apart from a single case of compound heterozygosity, 
Postma et al., 2005), meaning that all patients express both WT and mutant RyR2 
subunits, which are likely to form heterotetramers of varying stoichiometry. To replicate 
this in vitro, HEK-293 cells were co-transfected with equimolar amounts of WT and 
L433P plasmid DNA, leading to the expression of both WT and L433P RyR2 monomers. 
Whether the distinct RyR2 monomers tetramerise to form two distinct homotetrameric 
channel populations or form heterotetramers of varying stoichiometry remains unknown. 
However, the fact that co-expression of WT+LP or WT+LPGE didn’t simply result in a 
“diluted” cellular phenotype half way between that observed in cells expressing either
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WT, LP or LPGE, suggests that heterotetramers are being expressed which present a 
rather complex phenotype. Furthermore, it has been demonstrated that RyR1 and RyR2 
monomers, which have a certain degree of sequence divergence (~30%) are capable of 
heterotetramerisation (Xiao et al., 2002), making it likely that recombinant RyR2 with a 
single amino acid substitution will form heterotetramers with WT RyR2.
Regardless of the stoichiometry of the RyR2 channels resulting from WT RyR2 and 
L433P co-expression, there were drastically different functional consequences 
compared to those observed in cells expressing homotetrameric L433P. Here, WT+LP 
co-expression resulted in a dramatically increased Ca2* store load, the complete 
opposite effect of that observed in cells expressing L433P alone, and was coupled with 
an increase in basal cytoplasmic Ca2* levels. Co-expression of WT+LP not only resulted 
in an increased caffeine sensitivity as demonstrated by the left-shifted caffeine activation 
curve (EC50 = 0.75 ± 0.2mM), but also significantly increased the magnitude of caffeine- 
evoked Ca2* release across the range of activating caffeine concentrations. This is most 
likely a consequence of the increased ER Ca2* store load, as increasing SR store load 
has been shown to result in Ca2* transients of increased amplitude. It would be useful to 
determine whether SERCA activity is upregulated in cells co-expressing WT+LP, to 
determine whether this causes the observed increase in ER Ca2*, which likely drives the 
increased channel sensitivity to activation and the increased magnitude of Ca2* release.
The increase in peak rate of Ca2* release is likely attributable to the observed increase in 
ER Ca2* load, resulting in increased Ca2* transient magnitude. Similarly, the rate of Ca2* 
removal following caffeine-evoked Ca2* release was significantly increased, perhaps 
driven by upregulation of Ca2* extrusion mechanisms due to the increased cytoplasmic 
Ca2* concentration, rather than a functional consequence of the presence of the L433P 
mutation. An alternative hypothesis could be that Ca2* extrusion mechanism activity is 
somehow down-regulated and/or SERCA activity is upregulated, resulting in a net 
decrease in Ca2* removal from the cell and enhanced store refilling. However, without 
measuring the activity of the various Ca2* extrusion/sequestration proteins it is 
impossible to draw conclusions on the precise mechanism responsible for the increased 
Ca2* store load and basal cytoplasmic Ca2*.
Given the disparity between the basal cytoplasmic Ca2* level, ER Ca2* load and Ca2* 
release parameters in cells co-expressing WT+LP compared to cells expressing L433P
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or WT RyR2 homotetramers, the experimental system was scrutinised to ascertain 
whether these results were artefactual or biologically significant. However, after further 
experimentation using fresh DNA preparations, cell culture and transfection reagents, 
lower passage HEK cells etc., comparable results were consistently obtained from cells 
expressing WT+LP, confirming that the observed phenotype is functionally relevant.
The differences between the results observed in cells expressing L433P homotetramers 
expressing WT+LP suggest the mechanisms by which RyR2 mutations perturb RyR 
Ca2+ handling dynamics are a complex phenomenon. Co-expression of L433P with WT 
RyR2 did not simply result in a “diluted" response of L433P channel perturbation, but 
displayed a shift in the opposite direction in terms of ER Ca2+ store content, magnitude 
of caffeine-evoked Ca2* release, caffeine-sensitivity etc. This provides an indication that 
co-transfection of HEK cells with distinct RyR2 cDNAs results in the formation of 
heterotetramers that convey a complex functional phenotype. This is consistent with the 
recent observation that heterotetrameric expression of two SCN5A mutations presented 
very different lNa current characteristics to when either mutation was expressed alone 
(Medeiros-Domingo et al., 2009). Furthermore the inheritance of two apparently benign 
RyR2 mutations in a composite heterozygotic manner was demonstrated to result in 
CPVT/ARVD2 pathogenesis (Postma et al., 2005), although cellular characterisation of 
this particular case has not been carried out. Interestingly, although homotetrameric LP 
expression appeared to result in a decreased ER store load and a decrease in Ca2* 
transient amplitude, when co-expressed with WT RyR2 the resulting phenotype was 
more characteristic of the gain-of-function phenotype exhibited by the majority of 
CPVT/ARVD2-linked mutations i.e. increased caffeine sensitivity, increased peak Ca2* 
release.
3.4.4. G1885E alters L433P Ca2* handling properties.
To determine whether the G1885E SNP had any beneficial or detrimental consequences 
on L433P mutant channel function, several modes of L433P and G1885E co-expression 
were investigated (see Figure 2.4), namely; L433P and G1885E on every subunit of the 
RyR2 tetramer (LPGE, homozygous ‘in cis’), L433P and G1885E on the same RyR2 
construct co-expressed with WT RyR2 (WT+LPGE, heterozygous ‘in cis') which is most 
representative of the observed mode of inheritance in ARVD2 patients (Tiso et al., 2001)
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and finally, L433P co-expressed with G1885E on distinct RyR2 subunits (LP+GE, 
heterozygous 'in trans’). This co-expression of LP+GE on different sub-units would have 
the most relevance in terms of the potential therapeutic benefits of polymorphism gene 
transfer in patients who inherited the disease linked-mutation.
3.4.4.1. Homotetrameric co-expression of L433P and G1885E exacerbates 
L433P mutant channel function.
Homotetrameric expression of G1885E on the same subunit as L433P (LPGE) appeared 
to modulate the severity of channel dysfunction caused by the L433P mutation. The 
decrease in ER Ca2* levels caused by the expression of LP homotetramers was 
exacerbated when G1885E was expressed on the same RyR2 subunits as the mutation 
in a homotetrameric fashion (LPGE). A dramatic increase in basal cytoplasmic Ca2* 
concentration was observed in cells expressing homotetrameric LPGE, which coupled 
with the decreased luminal Ca2* concentration, could suggest a Ca2* leak more severe 
than that caused by L433P alone.
L433P is located in the N-terminal mutation domain (Wang et al., 2007) and is in close 
proximity to the central mutation domain (Liu et al., 2005). It has been proposed that 
mutations in the central and N-terminal domains destabilise the channel by disrupting an 
interaction between these two domains (Yang et al., 2006). In line with this model, it is 
plausible that the N-terminal L433P mutation causes unzipping from the central domain, 
resulting in a destabilised channel prone to Ca2* leak, resulting in the decreased ER 
Ca2* load seen here.
Although not in the central mutation domain, G1885E is in sub-domain 9 in relatively 
close proximity to the L433P-containing N-terminal mutation domain (between sub- 
domains 5 and 9) in the RyR2 3D structure (Zhang et al., 2003; Wang et al., 2007). The 
presence of G1885E on the same subunit as L433P may cause further channel 
destabilisation and increased Ca2* leak, resulting in the observed further decrease in ER 
Ca2* load and increased basal cytoplasmic Ca2* in cells expressing LPGE 
homotetramers. Although it appears that homotetrameric LPGE expression resulted in 
sensitisation of the channel to caffeine activation (ECSo = 0.11 ± 0.07), this is likely to be 
artefactual as LPGE expression caused the abolition of the sigmoidal caffeine activation
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profile exhibited by all other RyR2 mutations investigated in this study. It would appear 
that having both G1885E and L433P on every RyR2 subunit perturbs the activation 
profile of RyR2 and results in an “all-or-nothing” release of ER Ca2+ following caffeine 
activation of RyR2. This observation is corroborated by the fact that the relationship 
between the activating caffeine concentration and the rate of caffeine induced Ca2* 
release was weakened in cells expressing L433P alone, but was completely abolished in 
cells expressing both substitutions on every subunit (Figure 3.21).
The significantly lower magnitude of Ca2* release observed in response to minimal 
caffeine activation (0.1 mM) in cells expressing LPGE compared to those expressing LP 
is likely due to a proportion of RyR2 channels remaining insensitive to this low 
concentration of caffeine, resulting in a decreased magnitude of Ca2* release in 
response to 0.1 mM caffeine. Expression of homotetrameric LPGE did not alter the rate 
at which Ca2* was removed from the cytoplasm or released from the ER, compared to 
when L433P was expressed alone, suggesting that the G1885E polymorphism doesn’t 
further alter L433P Ca2* handling kinetic parameters when expressed in this manner.
3.4.4.2. Heterotetrameric WT+LPGE and LP+GE expression restores normal 
intracellular Ca2* handling
Despite the presence of G1885E only causing subtle differences in homotetrameric 
L433P Ca2* handling parameters, when the two substitutions were expressed in a 
heterotetrameric manner (WT+LPGE or LP+GE), the modulatory effect of G1885E on 
L433P channel function was much more pronounced.
Perhaps the most relevant heterologous RyR2 expression pattern results from the co­
expression of WT+LPGE, as the ARVD2 patients expressing these substitutions were 
heterozygous for both L433P and G1885E, with both encoding nucleotide substitutions 
on the same allele (Tiso et al., 2001). Co-expression of WT+LPGE caused a dramatic 
difference in intracellular Ca2* handling compared to that observed through 
heterotetrameric WT+LP expression i.e. without the G1885E polymorphism. When 
WT+LPGE heterotetramers were expressed, despite exhibiting a significant decrease in 
Ca2* store load compared to WT, the basal cytoplasmic Ca2* levels, caffeine activation 
profile (EC50 = 1.58 ± 0.2mM) and kinetic parameters of caffeine induced Ca2* release
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same or separate subunits appeared to have little bearing on the extent to which 
G1885E modified L433P Ca2+ handling.
A recent study has demonstrated that the central and N-terminal domains participate in 
an inter-subunit interaction (Liu et al., 2010). This makes it easier to envisage how 
G1885E alters L433P function when the two substitutions are expressed on separate 
subunits (LP+GE) or on all subunits (LPGE), which likely places the two substitutions in 
relatively close proximity in the RyR2 structure. However, this makes it harder to 
visualise how G1885E alters L433P function when it is expressed in a manner 
representative of heterozygous inheritance of both substitutions on the same allele i.e. 
WT+LPGE, which presumably increases the physical distance between the two 
substitutions. However, the fact that G1885E has previously been shown to alter RyR2 
functionality when found on the opposite allele to another substitution, G1886S (Milting 
et al., 2006), or when expressed on the same subunits as this SNP (Koop et al., 2008), 
adds credence to the hypothesis that G1885E can modulate the functional 
consequences of a mutation that is not in close proximity in the RyR2 structure.
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3.4.5. Chapter Summary
The data produced through the heterologous expression of WT RyR2, G1885E and 
L433P was comparable to that obtained in previous functional studies, suggesting that 
the experimental system employed here is suitable for the characterisation of these 
substitutions.
The results of the characterisation of L433P are consistent with the notion that L433P is 
not a typical gain-of-function mutation, as it exhibited decreased caffeine sensitivity, 
decreased ER Ca2* store load and decreased kinetic parameters of ER Ca2* release. 
However, when co-expressed with WT RyR2, L433P presented an intracellular Ca2* 
handling phenotype more characteristic of a gain-of-function mutation.
These observed differences between LP and WT+LP expression suggests the mode of 
expression is critical in determining the extent of channel dysfunction and highlights the 
importance of characterising RyR2 mutations in a homotetrameric and heterotetrameric 
form, with the latter being a more faithful representation of the autosomal dominant 
nature of CPVT-linked RyR2 mutation inheritance.
G1885E exhibited a highly comparable intracellular Ca2* handling phenotype compared 
to WT RyR2, both when expressed as homotetramers (GE) and heterotetramers 
(WT+GE). This suggests that when expressed alone, G1885E is more characteristic of a 
SNP, rather than a disease-linked mutation.
Although G1885E appeared functionally benign when expressed alone, this SNP was 
shown to alter the functional consequences of L433P co-expression. This provides the 
first documented evidence that a common RyR2 SNP can modulate the severity of 
mutant RyR2 Ca2* handling dysfunction.
Furthermore, G1885E was shown to modulate the effects of L433P to varying degrees 
depending on the precise mode of co-expression. Homotetrameric expression of LPGE 
appeared to exacerbate the decrease in ER Ca2* store load caused by homotetrameric 
LP expression, but had little effect on intracellular Ca2* handling parameters. 
Conversely, heterotetrameric expression of WT+LPGE or LP+GE appeared to restore 
the majority of intracellular Ca2* handling parameters that were perturbed by WT+LP
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expression, to WT levels. This suggests that heterotetrameric co-expression of G1885E 
may offer protective benefits against dysfunctional Ca2+ handling caused by WT+LP 
expression.
However, the work detailed in this chapter does not provide a clear mechanism by which 
the co-expression of WT+LPGE, representative of the ARVD2-assoicated genotype in 
vivo, results in a disease-phenotype. Recent reports have demonstrated that CPVT- 
linked mutations alter basal and post-activation cytoplasmic Ca2* flux and display subtle 
alterations in basal Ca2* handling (Jiang et al., 2002; Liu etal., 2006; Fernandez-Velasco 
et al., 2009). In light of this, the next chapter of this thesis will investigate whether there 
are any subtle, underlying alterations in intracellular Ca2* handling and whether these 
can explain the differences in agonist-evoked Ca2* release parameters observed here.
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Chapter 4
Characterisation of the effects of L433P 
and G1885E on cytoplasmic Ca2* flux.
4.1 Introduction
4.1.1. Myocyte Ca2+ homeostasis
In order to maintain the relatively low level of cytoplasmic Ca2+ (~100nM) in the cardiac 
myocyte, an extensive network of interplaying Ca2+ channels, pumps and exchangers 
work together to move Ca2+ ions in and out of the cell and it’s intracellular Ca2+ 
compartments (Bers, 2002; Dibb et al., 2007). Even though the level of cytoplasmic Ca2+ 
appears to remain relatively constant during diastole, this apparent steady state is 
maintained by equilibrium in the influx and efflux of Ca2+ into and out of the cytoplasm 
during the period between CICR events (Figure 4.1, Piacentino et al., 2003). Even at 
peak cytoplasmic Ca2+ concentrations (~1-2pM), the extracellular Ca2+ concentration 
(~1mM) is much greater, creating a steep inward Ca2+ gradient (Schaub et al., 2006). 
Cells hydrolyse ATP to generate the energy required to extrude Ca2+ from the cell 
against the direction of the Ca2+ gradient through PMCA, whereas the NCX utilises the
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Figure 4.1. Proteins involved in CICR and maintaining myocyte Ca2* homeostasis. Inotropic 
mechanisms and their approximate relative contribution to increasing cytoplasmic Ca2* levels in 
human myocytes are indicated in blue. Lusitropic mechanisms and their relative contribution to 
removing cytoplasmic Ca2* are indicated in red (Piacentino et al., 2003). Under resting conditions, 
the net influx and efflux of Ca2* are in equilibrium.
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electrochemical Na+ gradient to drive Ca2+ removal from the cell (3 Na+ ions: 1 Ca2* ion, 
Berridge et al., 2000; Laude & Simpson, 2009). It is imperative that myocyte Ca2+ 
release and extrusion mechanisms work in a highly orchestrated manner to ensure that 
intracellular Ca2* homeostasis and correct Ca2* cycling are maintained (Dibb et al.,
2007), to ensure correct functioning of the heart on a beat-to-beat basis. Abnormal basal 
Ca2* cycling and perturbation of intracellular Ca2* homeostasis have implications in 
terms of cardiac pathology which will be discussed later in the chapter (section 4.1.3).
4.1.2 Basal Ca2* cycling
In order to lower cytoplasmic Ca2* concentration following CICR, several extrusion 
pathways come into effect; namely SR and sarcolemmal Ca2*-ATPases, sarcolemmal 
NCX and the mitochondrial uniporter (Bers, 2008). Selective inhibition of the activity of 
each of these Ca2* handling proteins allowed the elucidation of the approximate 
contribution of each of these mechanisms to cytoplasmic Ca2* removal (Figure 4.1, 
(Bassani etal., 1994; Piacentino et al., 2003). In mouse myocytes approximately 90% of 
transiently released cytoplasmic Ca2* was re-sequestered in the SR by SERCA, 
approximately 9% was extruded through NCX and the remaining 1% was removed by 
the sarcolemmal Ca2*-ATPase and mitochondrial uniporter (‘slow mechanisms’, Li etal., 
1998; Bers, 2002). Rather unsurprisingly the influx of Ca2* through the L-type Ca2* 
channel has been shown to be equivalent to the amount of Ca2* removed from the cell 
through NCX and PMCA(Diaz et al., 2004), indicating that under resting conditions there 
is negligible net change in total intracellular Ca2*. There is variation in the relative 
contributions of cytoplasmic Ca2* extrusion mechanisms between species, with 23% of 
systolic Ca2* being removed by NCX and ~75% being re-sequestered in the SR via 
SERCA in human myocytes and ~2% taken up by the mitochondrial uniporter and 
extruded from the cell by the plasma membrane Ca2* ATPase (Piacentino et al., 2003). 
By the same token that the amount of Ca2* entering and leaving the cytoplasm are in 
equilibrium from beat-to-beat, under resting conditions the amount of Ca2* sequestered 
in the SR following CICR is comparable to the amount that was released during the 
previous CICR event (Trafford et al., 2001). Together this provides a mechanism by 
which intracellular Ca2* homeostasis is maintained, allowing the myocyte to achieve a 
constant resting state between each heart beat.
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However, this assumes that the myocyte is subject to consistent conditions, which is not 
always the case i.e. following (3-AR stimulation during periods of physical or emotional 
stress, in which a temporary amplification of Ca2* fluxes is evident (Bers, 2008). In such 
situations, the presence of a compensatory negative feedback mechanism is apparent, 
which is briefly described here. (3-AR stimulation causes an increase in the uptake of 
Ca2* into the SR though PKA-mediated dissociation of PLB from SERCA (Periasamy & 
Huke, 2001). The PKA-mediated increase in Ca2* influx through the L-type Ca2* channel, 
coupled with the increased SR Ca2* content, results in a larger systolic Ca2* transient 
during CICR (Bers, 2002). The increased systolic Ca2* transient amplitude results in a 
greater increase in cytoplasmic Ca2* concentration. Consequently, this increases the 
amount of Ca2* extruded from the cell via the NCX and results in a smaller influx of 
“trigger” Ca2* due to increased Ca2*-dependent inactivation of the L-type Ca2* channel 
(Dibb, 2007). Collectively, this results in a net increase in the amount of Ca2* removed 
from the cell and consequently reduces the amount of subsequent SR Ca2* uptake. This 
decrease in SR Ca2* content results in a slightly smaller systolic Ca2* transient than that 
of the previous CICR event, causing a slight decrease in Ca2* extrusion by NCX and a 
slight increase in inward L-type Ca2* current. This auto-regulative process continues until 
a steady state of intracellular Ca2* and SR Ca2* content is re-established (Trafford et al., 
2001; Dibb et al., 2007).
4.1.3. Chronic Ca2* flux imbalance in cardiac pathology
In HF, it is widely accepted that the altered characteristics of the systolic Ca2* transient 
are pathogenic, with several HF models demonstrating a significant decrease in systolic 
Ca2* transient magnitude (Piacentino et al., 2003). Selective inhibition of several Ca2* 
extrusion mechanisms demonstrated that in a model of left ventricular hypertrophy, the 
rate of Ca2* uptake into the SR by SERCA was decreased and the rate of Ca2* removal 
from the myocyte through NCX and the sarcolemmal Ca2*-ATPase was increased (Diaz 
et al., 2004), an observation that has been described by several groups (Bassani et al., 
1994; Piacentino et al., 2003; Dibb et al., 2007). Ultimately, this net Ca2* efflux resulted 
in a decrease in SR Ca2* content, accounting for the observed decrease in systolic 
transient amplitude observed in HF (Bers, 2006).
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Although the mechanisms by which they do so remain contentious, it is generally 
reported that gain-of-function CPVT/ARVD2-linked RyR2 mutations increase channel 
open probability resulting in diastolic SR Ca2* leak or spontaneous Ca2* release (Jiang et 
al., 2005; Tester et al., 2007; Lehnart et al., 2008; Marjamaa et al., 2009b; Tateishi et al., 
2009), suggesting basal Ca2* handling dysfunction. Although the majority of this leaked 
Ca2* would be re-sequestered by SERCA (Piacentino et al., 2003), the increased 
cytoplasmic Ca2* levels resulting from this diastolic leak could increase the net Ca2* 
efflux from the myocyte through increased NCX activity and increased L-type Ca2* 
channel inactivation. This could potentially result in the decreased steady state SR Ca2* 
levels observed in CPVT mouse models (Fernandez-Velasco et al., 2009; Uchinoumi et 
al., 2010) or through the heterologuous expression of RyR2 containing CPVT/ARVD2- 
linked mutations (Jiang etal., 2004; Jiang etal., 2005).
It has been demonstrated in single channel experiments that increased RyR2 open 
probability alone is not sufficient to maintain diastolic Ca2* leak (Dibb et al., 2007), 
presumably due to the adaptation of SR Ca2* levels to a lower steady state through the 
mechanisms described above (section 4.1.2). However, the maintenance of increased 
SR Ca2* content, such as that which occurs during PKA-mediated dissociation of PLN 
from SERCA during p-AR stimulation (Periasamy et al., 2008), results in sustained 
diastolic Ca2* leak between systolic Ca2* transients (Dibb et al., 2007). It is the 
persistence of this altered SR-to-cytoplasmic Ca2* flux that can lead to DADs through 
increased NCX activity, potentially resulting in arrhythmia. Furthermore, the dependence 
of this persistent diastolic Ca2* leak on increased SR Ca2* content corroborates the fact 
that CPVT/ARVD2 mutations only result in arrhythmia following p-AR stimulation when 
SERCA activity and SR Ca2* levels are increased (Leenhardt et al., 1995; Priori et al., 
2001; 2002b).
Interestingly, the comprehensive functional characterisation of the R4497C mutation has 
demonstrated that this mutation results in subtle alterations in basal Ca2* cycling, (Jiang 
et al., 2002; Liu et al., 2006; Fernandez-Velasco et al., 2009) which are exacerbated 
following p-AR stimulation. This suggests that underlying alterations in basal cytoplasmic 
Ca2* handling are likely to originate from the diastolic Ca2* leak caused by this mutation, 
providing a rationale for the further investigation into the alterations in the subtleties of 
basal Ca2* cycling caused by RyR2 mutations.
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4.1.4. Effects of altered basal Ca2* signal variability in heterologous systems
Although there is little published data detailing the investigation of basal Ca2* signal 
variability in heterologous systems expressing RyR2, a handful of studies have 
demonstrated that subtle variations in basal cytoplasmic Ca2* variability have profound 
cellular consequences.
The stable expression of RyR2 in CHO cells was shown to result in an increase in cell 
death and was associated with an increase in resting Ca2* flux, manifesting as an 
increase in resting Ca2*-dependent signal variability or ‘noise’, set against a background 
of normal cytoplasmic Ca2* concentration (Figure 4.2, George et al., 2003b). 
Interestingly, the co-expression of FKBP12.6 with RyR2 was shown to decrease the 
level of Ca2* flux, restoring the level of cell viability to those observed in untransfected 
cells, implicating the level of SR-to-cytoplasmic Ca2* flux in cell death.
Relative signal variability (RSV) is a measure of relative change in Ca2* dependent 
signal variability before and after agonist-evoked RyR2 channel activation in the same 
cell (George et al., 2006). George et al subsequently used this method of signal 
variability or “noise” analysis to examine the effects of CPVT-linked mutations (R4497C 
and N4104K, George etal., 2007b) on basal and post-activation cytoplasmic Ca2* fluxes. 
Using fluorescence energy transfer (FRET) analysis, they demonstrated that CPVT- 
linked RyR2 mutations caused destabilisation of an int ra-RyR2 interaction following 
agonist-activation of the channel, which was accompanied by an increase in Ca2*- 
dependent signal RSV. Given that the disruption of this interaction is proposed to result 
in increased Ca2* leak from the ER/SR, it is likely that the increase in Ca2* leak and 
subsequent extrusion or reuptake is responsible for this increase in Ca2* signal 
variability.
Together these data suggest that the analysis of subtle variations in basal and post 
activation Ca2*-dependent signal variability can provide mechanistic insights into altered 
RyR2 mutant channel function.
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Figure 4.2. Increased Ca2* signal variability associated with RyR2 expression results in 
decreased cell viability. CHO cell lines stably expressing discrete levels of hRyR2 wereWT
generated, confirmed by western blot analysis and designated CHO (untransfected CHO cells), 
CHO (low levels of relative RyR2 expression) and CHO (high levels of relative RyR2 
expression), as shown in panel A. Resting Ca2+ dependent Fluo3 signal intensity was measured 
in each cell line with and without transient FKBP or FKBP12.6 expression as shown in panel B. 
Rapamycin (5pM, 15 hour exposure) was used to dissociate FKBP12.6. Data presented in panel 
C shows that despite comparable resting cytoplasmic Ca2+ levels (i), expression of RyR2 
increased the level o f cytoplasmic Ca2+ signal variability, which was restored to normal levels 
following FKBP12.6 interaction (F-ratio, ii). In panel C, * represents p<0.005 compared to CHOm  
and CHOl cells, ** represents p<0.001 compared to CHO and CHOh cells. The increase in F- 
ratio resulting from RyR2 expression and absence of FKBP12.6 interaction were associated with 
decreased cell viability, as determined by Alamar Blue cell viability assays, shown in panel D (* 
represents p<0.005 compared to CHOm  and CHOL cells and ** represents p<0.01 when 
compared with C H O ^ and CHOh cells. From George, (2003b).
196
4.1.5. Chapter aims
Data presented in Chapter 3 clearly indicates that the recombinant expression of RyR2 
containing combinations of L433P and G1885E alter intracellular Ca2+ handling 
dynamics following caffeine-evoked Ca2+ release. This was particularly evident when 
cells expressed homotetrameric LP or LPGE or heterotetrameric WT+LP. Surprisingly, 
the heterotetrameric expression of WT+LPGE, representing the heterozygous mode of 
L433P and G1885E inheritance observed in an ARVD2 patient, did not grossly perturb 
Ca2+ handling parameters, with the notable exception of decreasing ER Ca2+ levels. This 
suggests that the mechanism underpinning L433P-G1885E and WT co-expression 
pathogenicity is distinct from the other modes of L433P/G1885E expression or manifests 
through a more subtle underlying mechanism such as defective adaptation to altered 
Ca2* handling parameters. In light of this, the level of cytoplasmic Ca2* signal variability 
in cells expressing each combination of L433P and G1885E will be examined. 
Furthermore, Ca2* removal from the cytoplasm comprises the major part of the ER Ca2*- 
release transient and is instrumental in the reestablishment of intracellular Ca2* 
homeostasis and as such the effects of L433P and G1885E on post-activation Ca2* 
cycling will be examined.
It is hypothesised that:
• L433P alters cytoplasmic Ca2*-flux following channel activation, and has little 
effect under resting conditions, consistent with mutant RyR2 dysfunction tending 
to manifest following channel activation.
• The level of basal signal variability predicts the level of cytoplasmic Ca2* flux 
following channel activation, and this coupling is modified by L433P.
• There is variation in the level of cytoplasmic Ca2* flux during re-establishment of 
Ca2* homeostasis following channel activation and this is perturbed by L433P.
• G1885E has little effect on basal and post-activation cytoplasmic Ca2* flux when 
expressed alone, but modulates the level of Ca2* flux in cells expressing L433P.
• Alterations in cytoplasmic Ca2* flux may reconcile the alterations in Ca2* handling 
parameters caused by L433P described in Chapter 3.
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4.2. Methods
4.2.1. Ca2+-imaging data collection
The same Ca2+ imaging data set as that described in Chapter 3 was used to investigate 
the effects of expressing combinations of WT, L433P and G1885E on the relative levels 
of cytoplasmic Ca2+ signal variability as that described in Chapter 3. Analysis of Ca2+ 
signal variability was only carried out on cells that exhibited characteristic Ca2+ transients 
and did not exhibit spontaneous Ca2+ oscillations prior to caffeine-evoked channel 
activation which will be discussed in Chapter 5 (see Figure 3.1.6). Together, this allowed 
direct comparison of the results obtained from the noise analysis experiments detailed in 
this chapter with the observations following the measurement of intracellular Ca2+ 
handling parameters following caffeine-evoked Ca2+ release, as detailed in Chapter 3.
4.2.2. Calculation of SV and SVm
There are several commonly used measures of signal variation in Ca2+ signal intensity 
including RSV, F-ratio and the coefficient of variation (CoV), all of which require a 
variance-based component. Previous work from this laboratory has demonstrated that 
variance based measurements of signal variability are not appropriate for determining 
the level of Ca2+-dependent signal variation in these experiments (Fry, 2008).
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Figure 4.3. Correlation 
between mean signal 
intensity and variance 
based noise-analysis 
parameters. Increased 
basal signal intensity
was associated with an 
increase in standard 
deviation and variance. 
This positive relationship 
was abolished by
normalising variance to 
the mean signal
intensity (CoV) or log 
transforming the data 
prior to calculating the 
variance. Adapted from 
Fry, (2008)
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Both standard deviation and variance of Ca2+-dependent signal intensity were highly 
dependent on the mean level of Ca2*-dependent fluorescence (Figure 4.3A-B), indicating 
that these measurements of signal variability would not account for differential Ca2* 
indicator loading nor variation in cytoplasmic Ca2* levels, which inevitably occur in single 
cell Ca2* imaging experiments. Although the effect of mean signal intensity on these 
values was mitigated by normalisation to the mean signal intensity, (coefficient of 
variance, CoV, Figure 4.3C) or by log transformation of the data (Figure 4.3D), these 
measurements were also highly biased by the gradient or ‘drift’ of the signal trace 
(Figure 4.4A-B), which was another inevitable factor in Ca2* imaging experiments. In 
light of this CoV and variance (Log10) were deemed unsuitable for the analysis of Ca2*- 
depedent signal variability in these experiments (Figure 4.4C-D). Similarly, the F-ratio 
was unsuitable for analysis of Ca-dependent signal variability in these experiments, due 
to its derivation from signal variance.
A B
Figure 4.4. Correlation 
between signal gradient and 
variance based noise-analysis 
parameters. Increased basal 
signal gradient was associated 
with an increase in standard 
deviation, variance, CoV and log 
transformed variance. Adapted 
0.06 0.01 002 ooo oo« ooo ooi 002 o.o9 o.o« from Fry, (Fry, 2008).
O radiant (dF/dT) Gradient (dF/dT)
Signal variability (SV) is used as a measure of the level of variability or “noise” in the 
Ca2* dependent Fluo3 signal and is determined by calculating the sum of the magnitude 
of the differences between consecutive signal intensity measurements (George et al.,
2006). This group utilised this method of noise analysis to compare the levels of “noise” 
under resting conditions to those following channel activation by calculating RSV and is 
represented by a percentage change in SV. SV can be normalised to the length of the 
time series to generate a single value representing the level of signal noise in a given 
time series, allowing the direct comparison of SV of data collected over different time 
periods. The method by which Ca2* SV is calculated is detailed in Figure 4.5.
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Figure 4.5. Determining Ca2*-dependent Fluo3 signal variability (SV). Total signal 
variability (SV) was determined by measuring the average magnitude of the difference 
between consecutive data points i.e. (n2- nrf + (n3 - n j  + ... + (n10 - n9). The average 
SV for a given series was determined by dividing the total SV by the number of data 
points in the series. Panel A illustrates an example of a series exhibiting relatively high 
SV compared to that illustrated in panel B. SV is represented by the formula described 
in panel C.
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However, SV is dependent on mean signal intensity, but not Ca2+ signal gradient (Figure 
4.6A-B), meaning that the direct comparison of SV between several experiments is only 
possible when the mean Ca2+-dependent Fluo3 signal is identical, as increasing the 
mean signal intensity causes an inherent increase in SV. In practice, mean signal 
intensities will never be identical between cells and/or coverslips, due to the variability in 
cellular loading with Fluo3 and variation in cytoplasmic Ca2+ levels.
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Figure 4.6. SV normalised to mean signal intensity (SVm) is independent of mean 
fluorescence and basal signal gradient. SV is dependent on mean signal intensity and 
basal signal gradient (panel A and B), whereas SVm is independent of mean signal 
intensity and basal gradient (C and D). Adapted from Fry, (2008).
To circumvent this problem, the average SV is normalised to the mean signal intensity 
(SVm) to take into account differential Ca2* indicator loading and the subsequent 
necessity to record data using different PMT voltage gain to alter Fluo3 signal intensity. 
SVm is independent of both mean signal intensity and the Ca2*-dependent signal 
gradient (Figure 4.6C-D) and is a robust indicator of Ca2*-dependent signal variability in 
these experiments.
The level of basal SVm was determined for the period 30 seconds prior to the addition of 
caffeine to the cells. In order to examine whether SVm varied following caffeine-evoked
2 0 1
Ca2+ release (as intracellular Ca2+ concentration returned to a steady state), the post­
activation data was divided into groups representing the period immediately after 
caffeine activation (early, 0-30 seconds post-activation), an intermediate period (middle, 
30-60 seconds post-activation) and the final section when Ca2+-dependent signal 
intensity was approaching basal levels (late, 60-90 seconds post-activation), as 
demonstrated in Figure 4.7. The sub-division of the post activation time series was 
carried out to determine whether there were changes in the level of cytoplasmic Ca2+ flux 
from peak caffeine-evoked Ca2+ release to the restoration of a steady-state representing 
a relative equilibrium of the movement of Ca2+ ions into and out of the cytoplasm.
Post-Caffeine A ctiva tion  SVm 
________
Early SVm Middle SVm Late SVm 
0 - 3 0  secs : 3 0 - 6 0  secs : 6 0 - 9 0  secs
Time (s)
Mean Basal 
SVm
30 secs pre­
caffeine 
addition
C affe ine
Figure 4.7. Division o f post-activation intracellular Ca2+ recovery period into early, 
middle and late phases. To determine whether the level of SVm differed over the period 
in which cytoplasmic Ca2+ levels returned to a steady, resting state the post-activation 
data was split into three distinct groupings representing the period immediately after peak 
signal intensity was reached (Early, 0-30 sec post-activation, red), an intermediate period 
(Middle, 30-60 sec post-activation, blue) and the period when intracellular Ca was 
approaching the steady resting state (Late, 60-90 sec post-activation, green). The mean 
basal SVm was determined for the 30 second period prior to caffeine-evoked activation of 
RyR2 to allow direct comparison of SVm levels between each time grouping.
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4.2.3. Examination of the relationship between basal and post-activation SVm
To ascertain whether the level of RyR2 activation and the magnitude of subsequent Ca2+ 
release influenced the level of post-activation Ca2+ signal variability, linear regression 
analysis was carried out on caffeine concentration and SVm at each of the post­
activation time points. Regression analysis was also carried out to identify whether 
relationships existed between the level of basal SVm and the level of SVm following 
caffeine activation (0.1-1 OmM), to determine whether L433P or G1885E altered the 
coupling between basal and post-activation SVm. Linear regression analysis was also 
carried out between the levels of basal SVm and caffeine-evoked Ca2+ release 
magnitude, rate of Ca2+ release and subsequent rate of Ca2+ removal to determine 
whether basal SVm levels were influential in determining the nature of the subsequent 
caffeine-evoked Ca2+ release transient.
4.2.4. Visual representation of statistical comparison data as heat maps
Given the large number of experimental conditions arising from the investigation of SVm 
at 4 separate time points in cells expressing 9 different combinations of RyR2, subjected 
to exposure to 9 concentrations of activating caffeine (a total of 324 conditions), a 
suitable method of data representation is required. Rather than representing the large 
amount of data graphically, the results of statistical comparison have been presented as 
heat maps similar to those employed in the visual representation of DNA microarray 
data, with the observed degree of change compared to the control group being 
represented on a colour scale (Figure 4.8).
To generate the heat map, the mean SVm value at a given time point and activating 
caffeine concentration was compared to the corresponding mean SVm value in the 
control group i.e. WT, to determine whether there was a significant difference between 
the two SVm values. The observed difference between SVm in cells expressing mutant 
RyR2 was expressed as a percentage change compared to the level of SVm observed 
in cells expressing WT RyR2. If statistically significant (p < 0.05), this percentage change 
in SVm was allocated a colour according to the scale illustrated in Figure 4.8. Statistical 
comparison of relationship gradients observed when comparing the linear relationships 
between basal and post-caffeine activation SVm were also summarised using heat
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maps, through statistical comparison of linear regression gradients. Only statistically 
significant differences were illustrated on the heat maps (p < 0.05).
> +50%
+20%
<-50%
Figure 4.8. Heat map colour scale. The
percentage change between SVm or linear 
regression gradient was represented in heat 
maps according to the heat map colour scale 
bar. The white-to-red transition represents an 
increase in SVm or linear regression gradient, 
whereas the white-to-blue transition represents a 
decrease.
Only statistically significant data (p < 0.05) is 
indicated on heat maps and white tabular cells 
indicate that there was no significant difference 
between the compared values.
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4.3. Results
4.3.1. L433P and G1885E do not grossly perturb basal signal variability.
Linear regression analysis of SVm data produced in HEK cells expressing recombinant 
WT RyR2 corroborated the findings of Fry et al (2008), in that SVm was independent of 
both mean Fluo3 signal intensity and the basal Fluo3 signal gradient (Figure 4.9). The 
mean Ca2+ signal intensity-independence of SVm was evident for both raw and log- 
transformed mean Ca2+ signal intensity data, however, only data produced when mean 
basal Ca2+ signal intensity was log-transformed prior to linear regression exhibited a 
normal distribution. In light of this, to allow statistical comparison of mean basal signal 
intensities using parametric tests, only Log transformed basal Ca2+ signal intensity data 
were further analysed and described in this chapter.
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Figure 4.9. SVm is independent of mean basal signal intensity and signal gradient.
Linear regression analysis of data produced in HEK cells expressing recombinant RyR2 
demonstrated that SVm was independent of mean signal intensity (both untransformed and 
log transformed data) and basal Ca2* signal gradient. Data was collected from 299 cells.
Representative traces of basal Ca2+ levels for the 30 second period prior to channel 
activation in untransfected HEK cells and those expressing RyR2 are illustrated in Figure 
4.10 and basal signal intensity, SV and SVm values are summarised in Figure 4.11. 
Consistent with the measurement of absolute basal cytoplasmic Ca2+ levels described in 
section 3.3.8, cells expressing recombinant RyR2 exhibited an increase in basal Ca2+- 
dependent Fluo3 signal intensity compared to that observed in untransfected HEK cells 
(Figure 4.11 A, p <0.001). This increase in mean signal intensity was coupled with a 
significant decrease in basal SV (Figure 4.11B, p < 0.001), which manifested as a 
decrease in basal SVm (p < 0.05, Figure 4.11C) in cells expressing recombinant RyR2. 
Also consistent with the measurement of basal Ca2+ levels, homotetrameric expression 
of WT RyR2, GE or LP all exhibited comparable mean basal Ca2+-dependent signal
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intensities (Figure 4.11A) and comparable basal SVm (Figure 4.11C), indicating these 
substitutions had little effect on basal Ca2+ flux. Despite homotetrameric LPGE 
expression causing a significant increase in mean basal signal intensity (Figure 4.11 A), 
which could pertain to increased ER Ca2+ leak, an equivalent SVm was observed (Figure 
4.11C) due to an observed increase in basal SV (Figure 4.11B). This suggests that 
although homotetrameric LPGE expression increases basal Ca2* flux, this increase is 
not apparent when taking into account the increase in resting cytoplasmic Ca2* levels. 
The same observation was made in cells expressing WT+LP or WT+LPGE 
heterotetramers, which exhibited an increase in resting signal intensity but an equivalent 
cytoplasmic Ca2+ SVm levels compared to WT RyR2 (Figure 4.11A and C).
Conversely, heterotetrameric LP+GE expression resulted in a significant increase in 
mean basal signal intensity (p<0.001, Figure 4.11 A), indicating a higher level of 
cytoplasmic Ca2*, which was coupled with a significant decrease in the level of 
cytoplasmic Ca2* SVm (Figure 4.11C). This decrease in SVm was attributed to a 
decrease in basal SV coupled with the increased mean Ca2* signal intensity. This 
suggests that LP+GE expression causes a significant decrease in the level of 
cytoplasmic Ca2* flux, although this may be attributable to the observed increase in 
basal signal intensity. However, this increase in cytoplasmic Ca2* signal intensity was 
not apparent when directly measuring the cytoplasmic Ca2* concentration as detailed in 
section 3.3.8, suggesting that the observed increase may be artefactual and possibly 
due to other factors, i.e. differential Ca2* indicator loading.
G1885E only appeared to alter L433P mean basal signal intensity or basal SVm, when 
co-expressed as heterotetrameric LP+GE and not when expressed on the same RyR2 
monomers as the mutation (LPGE or WT+LPGE, Figures 4.10 and 4.11). However, the 
mean signal intensity and SVm levels in cells expressing LP+GE were not significantly 
different from those observed in cells co-expressing WT+LP or WT+LPGE, suggesting 
that G1885E only exerts a modest effect on L433P basal Ca2* cycling.
In summary, L433P and/or G1885E did not cause gross perturbation of the level of basal 
cytoplasmic Ca2* flux in HEK cells expressing recombinant RyR2, when accounting for 
mean cytoplasmic Ca2* levels under resting conditions.
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Figure 4.11. Variation in mean 
basal Ca2* signal intensity and 
signal variability do not grossly 
perturb basal SVm levels. The
mean basal signal intensity of 
untransfected HEK cells and HEK 
cells expressing each 
recombinant RyR2 was 
determined and is plotted in panel 
A. The mean basal signal 
variability (SV) was determined 
and is plotted in panel B. The 
basal SV was normalised to the 
mean signal intensity and is 
presented in panel C. The results 
of statistical comparisons are 
indicated on the graphs according 
to the key above. Data was 
collected from 792 untransfected 
HEK cells and from between 269 
-  388 HEK cell transfected with 
each RyR2 cDNA.
* indicates a statistically
significant difference compared to 
WT RyR2.
# indicates a statistically
significant difference compared to 
the homotetrameric counterpart of 
heterotetrameric substitution
i.e. WT+GE vs GE or WT+LP vs 
LP or WT+LPGE vs LP.
¥ indicates a statistically
significant difference compared to 
the respective recombinant RyR2 
without G1885E co-expression, 
i.e. LP-GE vs LP or WT+LPGE vs 
WT+LP or LP+GE vs WT+LP
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4.3.2. Post-activation SVm is dependent on activating-caffeine concentration in 
ceils expressing WT+LP or WT+LPGE heterotetramers
Linear regression analysis was carried out to investigate whether post-activation SVm 
correlated with the concentration of caffeine (0.1-1 OmM) used to activate heterologously 
expressed recombinant RyR2 (Figure 4.12). The concentration of caffeine applied to 
untransfected HEK cells had no influence on the level of observed SVm during any 
period following caffeine addition (p = 0.14 - 0.87), which is not surprising as HEK ceils 
do not endogenously express RyR2 and do not exhibit ER Ca2* release in response to 
caffeine exposure. Similarly, the expression of WT RyR2 did not exhibit a link between 
activating-caffeine concentration and the level of post-activation SVm (p = 0.07 - 0.19), 
despite the addition of caffeine to cells expressing WT RyR2 resulting in the elevation of 
cytoplasmic Ca2*. In light of these differences in intracellular Ca2* handling phenotypes 
of untransfected HEK cells and those expressing recombinant RyR2, the comparison of 
post-caffeine activation SVm data produced in untransfected HEK cells will no longer be 
described in subsequent analysis.
No relationship between caffeine concentration and post-activation SVm was evident in 
cells expressing homotetrameric GE (p = 0.58 - 0.99) or LPGE (p = 0.2 - 0.92) However, 
a negative relationship was observed immediately after caffeine addition in cells 
expressing homotetrameric LP (p < 0.05), but not during the middle (p = 0.24) and late 
(p = 0.09) time periods. However, the expression of heterotetrameric WT+LP or 
WT+LPGE exhibited a robust positive relationship between activating caffeine 
concentration and the resulting level of post-activation SVm (p < 0.05, Figure 4.12). This 
implies that in cells expressing these RyR2s, increasing the concentration of caffeine, 
and therefore increasing the level of RyR2 activation, results in a greater level of post­
activation SVm. This relationship was observed during all periods following channel 
activation and there was no significant difference between the gradient of this 
relationship during early, middle or late periods in cells expressing either combination of 
RyR2s (p = 0.88 - 0.96). Similarly, the nature of these relationships was comparable 
between cells expressing WT+LP or WT+LPGE heterotetramers, suggesting that the 
presence of G1885E had little effect on these relationships. This relationship was not 
observed in cells expressing heterotetrameric LP+GE, suggesting that G1885E alters 
this relationship to varying degrees depending on the precise mode of L433P and 
G1885E co-expression.
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Figure 4.12. Linear regression analysis o f the relationship between activating caffeine 
concentration and post-activation SVm. Linear regression analysis was carried out to 
determine if the level of post-activation SVm was dependent on activating caffeine concentration. 
Linear regression line gradient (A), goodness-of-fit value (r2) and significance values (p) are 
indicated in the table in panel B. Asterisked data indicates a significant relationship between 
caffeine concentration and post-activation SVm. There was no significant difference between the 
gradients in early, medium and late in cells expressing the same RyR2 (p-values indicated in 
panel A). Data was collected from between 7 and 78 cells per experimental condition.
|Caffeinej vs post activation SVm
Caffeine
(mM) Early M iddle Late
HEK A -0 01 t 0 06 -0 0510 06 -01010 06
P 0 87 0 48 014
r 001 006 0.25
WT a 0 09 10.07 011 10 08 011 tO.08
p 0.21 0.21 048
r' 019 0119 0.07
GE A •0 001 t 0 07 0 021008 0.04 *0 06
P 0 99 082 058
1* 001 0007 004
LP A •01710.07 -0.11 0 14 •0.08 10.08
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r* 0 46 0 64 091
LP+GE A 0.07 i  0.08 011 10 07 0.14 tO 06
P 0 40 016 006
r* 0.09 023 0.40
4.3.3. L433P and G1885E decrease the level of post-activation SVm compared to 
WT RyR2
The level of post-activation SVm was measured to determine whether expression of 
L433P and/or G1885E altered the level of cytoplasmic Ca2+ signal variability following 
caffeine-evoked ER Ca2* release. SVm levels were recorded in cells expressing each 
RyR2, at each post-activation time point (early, middle and late), following activation with 
the range of caffeine concentrations (0.1-1 OmM). All raw SVm values are detailed in 
Appendix II, Tables 1 and 2.H eat maps were used to illustrate the statistical comparison 
of SVm levels in HEK cells expressing combinations of L433P and G1885E compared to 
WT RyR2 (Figure 4.13).
Despite the heterologous expression of mutant RyR2 having very little effect on 
cytoplasmic Ca2+ SVm under resting conditions, there was significant heterogeneity 
between the levels of cytoplasmic Ca2* SVm following caffeine-evoked channel 
activation in cells expressing each recombinant RyR (Figure 4.13). This suggests that 
differences in SVm only become apparent following RyR2 activation, which agrees with 
previous characterisation of CPVT-linked RyR2 mutations (George etal., 2006).
Although alterations in post-activation Ca2+ SVm were observed to varying degrees 
during all periods of cytoplasmic Ca2+ recovery, it appeared that the majority of SVm 
alteration occurred in the period immediately following channel activation. This suggests 
that the greatest perturbation of cytoplasmic Ca2* signal variability tends to occur at peak 
cytoplasmic Ca2* levels.
Rather surprisingly, the majority of mutant/SNP RyR2 appeared to cause a significant 
decrease in the level of post-activation SVm across the range of activating caffeine 
concentrations and cytoplasmic Ca2* recovery time periods, rather than an increase in 
signal variability observed in the heterologous expression of other CPVT-mutations in 
HEK cells and HL-1 immortalised cardiomyocytes (George etal., 2006).
Homotetrameric LP expression exhibited both increased and decreased SVm following 
activation with high and low concentrations of caffeine respectively. Given that a similar 
trend was observed in cells expressing homotetrameric LPGE, this could be attributable
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Figure 4.13. L433P and G1885E decrease the level of post-activation SVm. SVm data was expressed as a percentage o f that 
observed at the corresponding time point and activating caffeine concentration in HEK cells expressing WT RyR2. White-to-red 
transition indicates an increase in SVm whereas white-to-blue transition indicates a decrease in SVm compared to WT. Post­
activation data was divided into early (E, 0-30s), middle (30-60s) and late (L, 60-90s) periods. Only data that exhibited a significant 
difference to WT RyR2 (p < 0.05) is highlighted. White cells indicated that there was no significant difference compared to WT 
RyR2. Raw data and the results o f statistical comparison used to generate heat maps are presented in appendix II, Table 1.
to the increased and decreased Ca2* release magnitude observed at low and high 
activating caffeine concentrations respectively compared to WT RyR2 (Figure 3.17). 
Although the increase in post-activation SVm of L433P following activation with 0.1 mM 
caffeine could potentially be reconciled by the observed increase in Ca2* release 
magnitude causing an increase in cytoplasmic Ca2* flux under these experimental 
conditions (Figure 3.17), this increase in SVm was also observed in cells expressing 
homotetrameric GE which exhibited normal Ca2+ release magnitude, making this 
hypothesis unlikely. Furthermore, heterotetrameric WT+LP expression increased the 
magnitude of caffeine-evoked Ca2+ release (Figure 3.18) yet decreased post-activation 
SVm, making it unlikely that an increase in caffeine-evoked Ca2* release magnitude 
manifests as an increase in post-activation SVm.
There also appeared to be differences in post-activation SVm between cells expressing 
the same RyR2 in a homotetrameric or heterotetrameric fashion (i.e. GE vs WT+GE). 
Homotetrameric GE expression caused a significant increase in SVm at several 
activating caffeine concentrations, whereas heterotetrameric WT+GE expression 
resulted in a decrease in post-activation SVm. This observation was mirrored in LPGE 
expression, in that heterotetrameric WT+LPGE expression was largely similar to WT 
RyR2 in terms of post-activation SVm compared to WT RyR2, yet homotetrameric LPGE 
expression caused sporadic increases and decreases in post-activation SVm compared 
to WT RyR2 (Figure 4.13). This suggests that RyR2 substitutions can alter post­
activation Ca2* signal variability to a different extent, depending on the precise mode of 
mutation/polymorphism expression.
Expression of heterotetrameric LP+GE resulted in similar post-activation SVm levels to 
WT+LP, whereas the heterotetrameric expression of WT+LPGE resulted in SVm levels 
which were more similar to WT RyR2 (Figure 4.13), further suggesting that the whether 
G1885E is on the same or opposite subunit to the mutation alters its functional 
consequences on L433P. Although homotetrameric expression of LPGE presented SVm 
levels that were different to WT RyR2, there was little difference compared to those 
observed in cells expressing homotetrameric LP alone. Taken together, this suggests 
that G1885E only altered the post-activation SVm of heterotetrameric L433P when 
expressed on the same sub-unit as the mutation replicative of heterozygous in cis 
inheritance i.e. WT+LPGE, and had no effect on post-activation SVm of homotetrameric 
L433P i.e. LPGE.
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Figure 4.14. Behaviour of L433P is modified by G1885E and WT RyR2 
predominantly in the early phase of post-activation. Linear regression analysis 
was carried out to examine the nature o f the relationship between basal and post­
caffeine activation SVm. Relationship gradients observed in cells expressing L433P  
and/or G1885E were statistically compared those observed in cell expressing WT 
RyR2. The heat map in panel A illustrates statistically significant increases (white-to- 
red transition) and decreases (white-to-blue transition) compared to WT RyR2 (p < 
0.05). White shading indicates that there was no significant difference compared to 
WT RyR2 (p > 0.05). Raw data and the results o f statistical comparison used to 
generate heat maps are presented in appendix II. The heat-map scale is indicated in 
panel B. Panel C contains an example o f the method employed in statistical 
comparison o f regression line gradients o f two experimental conditions. Raw data is 
presented in Appendix II, Figures 1-2 and Tables 2-3.
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4.3.4. Linear regression analysis of basal and post-activation SVm
Although there appears to be little net change in cytoplasmic Ca2* levels under basal 
conditions in the experiments described here, the level of cytoplasmic Ca2* is maintained 
by a constant flux of Ca2* ions into and out of the cytoplasm by several mechanisms. 
Here it was hypothesised that the extent of cytoplasmic Ca2* signal variability under 
resting conditions predicts the magnitude of Ca2* signal variability during periods of 
elevated Ca2* following RyR2 activation and ER Ca2* release. To test whether this was 
the case, linear regression analysis was carried out to investigate the relationship 
between the observed levels of basal and post-activation SVm. In the case of the 
relationship between basal and post-activation SVm, a steeper positive gradient infers 
that for a given increase in basal SVm, there is a comparatively greater increase in post­
activation SVm (Figure 4.14C). In other words, a steep gradient means that the level of 
basal SVm is a more robust index of post-activation SVm.
The expression of WT RyR2 resulted in a strong positive relationship between the level 
of basal and post-activation SVm with all concentrations of activating-caffeine, indicating 
that increased basal SVm was associated with a higher SVm following caffeine-induced 
Ca2* release. There appeared to be no significant difference between the gradients of 
the linear regression line when examining the relationship between basal SVm and the 
level of SVm at each time point, i.e. 30,60 and 90 seconds post-activation (p = 0.06 - 
0.87, Figure 4.14). The observed relationship gradients are close to a value of 1 
following activation with the range of caffeine concentrations suggesting a strong 
coupling between basal and post activation SVm (Appendix II, Figures 1 and 2, Tables 2 
and 3), i.e. a doubling of basal SVm results in a doubling of post-activation SVm. This 
was the case following activation with the majority of caffeine concentrations, 
corroborating the caffeine concentration-independence of SVm observed in section 4.3.2 
and Figure 4.12.
This positive relationship between basal and post caffeine-activation SVm was also 
observed in cells expressing all combinations of L433P and G1885E. Although these 
mutations did not completely abolish this coupling, they appeared to alter the precise 
nature of this relationship (Figure 4.14). The majority of alterations to this relationship 
occurred during the early and middle phase of post-activation cytoplasmic Ca2* recovery. 
This suggests that the greatest perturbation of the relationship between basal and post­
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activation SVm occurs during the period of elevated cytoplasmic Ca2+ following channel 
activation and dissipates as cytoplasmic Ca2* concentration decreases to a resting 
homeostatic state. This could potentially further suggest that acute dysfunctional Ca2* 
release, as described in Chapter 3, is followed by relatively normal re-establishment of 
intracellular Ca2* homeostasis.
Consistent with the relative levels of SVm described in section 4.3.3, the co-expression 
of heterotetrameric WT+LP resulted in the most significant perturbation of the 
relationship between basal and post activation signal variability compared to WT RyR2. 
This mode of expression caused significant decreases in the gradient of this relationship, 
particularly during the early and middle phases of intracellular Ca2* recovery and 
suggests that in cells co-expressing WT+LP, an increase in basal SVm results in a 
smaller increase in post-activation SVm than that observed in cells expressing WT 
RyR2. Although decreases in the gradient of this relationship were observed in cells co­
expressing WT+LPGE or LP+GE when compared to WT RyR2, these decreases were to 
a lesser extent than those observed in cells expressing WT+LP. This suggests that the 
co-expression of G1885E had a significant effect on restoring the coupling between 
basal and post-activation SVm when expressed with L433P in a heterotetrameric fashion 
(WT+LPGE or LP+GE)
Interestingly, homotetrameric LP expression increased the gradient of the relationship 
between basal and post-activation SVm at just a single activating caffeine concentration, 
as did homotetrameric LPGE. However, LPGE resulted in both increases and decreases 
in relationship gradient at several sporadic activating caffeine concentrations, reaffirming 
the subtle modulatory effect of G1885E observed through heterotetrameric L433P and 
G1885E expression.
Statistical comparison of the steepness of the linear regression line of basal and post­
activation SVm revealed that homotetrameric GE expression exhibited an almost 
identical relationship to that observed in cells expressing WT RyR2 (Figure 4.14). 
Heterotetrameric WT+GE expression had more of an effect on the relationship between 
basal and post-activation SVm, causing both increases and decreases in the steepness 
of this relationship during the early phase of recovery, following activation of the channel 
with high concentrations of caffeine.
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4.4. Discussion
4.4.1. Untransfected HEK cells exhibit a fundamentally different resting 
phenotype compared to those expressing RyR2
Consistent with the basal cytoplasmic Ca2* quantification data detailed in section 3.3.8 
and previous published data (Tong et al.t 1999; George et a/., 2003b) the expression of 
recombinant RyR2 caused a significant increase in the basal Ca2+-dependent signal 
intensity compared to untransfected HEK cells (Figure 4.11 A). Although the expression 
of each recombinant RyR2 appeared to cause a significant decrease in basal Ca2* signal 
variability compared to untransfected HEK cells (Figure 4.11C), this is likely due to the 
significantly lower mean basal Ca2* signal intensity and increased basal SV observed in 
untransfected HEK cells (Figure 4.11A-B) from which SVm is derived. As untransfected 
HEK cells exhibit a fundamentally different intracellular Ca2* handling phenotype 
compared to those recombinantly expressing RyR2 (as described in section 4.3.1 and 
4.3.2), untransfected HEK cells were not included in this signal variability analysis.
4.4.2. Differences in cytoplasmic Ca2* SVm only manifest following RyR2 
activation
The observation that expression of RyR2 containing each combination of L433P and 
G1885E had little effect on basal Ca2* signal variability (Figure 4.11C) suggests that 
under basal conditions, i.e. without agonist-evoked channel activation, these 
substitutions have little effect on the level of cytoplasmic Ca2* influx and efflux compared 
to WT RyR2. This infers that expression of each RyR2 results in a similar intracellular 
Ca2* homeostatic environment at rest, which is consistent with data from a previous 
study investigating the effects of CPVT-linked RyR2 mutations on Ca2* signal variability 
(George et al., 2006). However, there was significantly greater heterogeneity in 
cytoplasmic Ca2* SVm following caffeine-mediated channel activation (Figure 4.13) 
suggesting that alterations in cytoplasmic Ca2* flux caused by L433P and G1885E only 
manifest following channel activation and subsequent ER Ca2* release. This is in 
agreement with some other in vitro and in vivo studies which indicate that the 
physiological effects of CPVT/ARVD2 linked mutations are only evident following 
increased levels of channel activation, be it through agonist-evoked or |3-AR activation
217
mechanisms (George et a/., 2006; Kannankeril et a/., 2006; Lehnart et a/., 2008), 
although there is increasing evidence that some mutations perturb basal Ca2* handling 
(Jiang etal., 2002; Fernandez-Velasco etal., 2009; Uchinoumi etal., 2010).
4.4.3. L433P and G1885E decrease post-activation Ca2* signal variability 
compared to WT RyR2
A surprising observation was that the majority of the permutations of recombinant RyR2 
examined here exhibited a decrease in post-activation cytoplasmic Ca2* signal variability 
(Figure 4.13), which disagrees with findings that two C-terminal mutations (R4496C and 
N4104K) significantly increased the cytoplasmic Ca2* signal variability following channel 
activation (George et a/., 2006). However this may be due to several differences in the 
experimental system or the nature of these particular mutations.
To further understand the effects of these amino acid substitutions on the level of post­
activation Ca2* signal variability, it would be extremely beneficial to determine the level of 
activity of the various cytoplasmic Ca2* removal proteins, i.e. PMCA, SERCA. This would 
potentially provide an indication of whether alterations in cytoplasmic Ca2* flux were due 
to altered activity of these removal proteins and whether this compensated for 
dysfunctional Ca2* release through mutant channels.
The level of post-activation Ca2* flux appeared to be independent of ER Ca2* store load 
or Ca2* release magnitude, as there was no obvious reconciliation between RyR2 
mutations that altered ER Ca2* load or Ca2* release magnitude and those that altered 
post-activation SVm (Figure 3.17-3.19, 3.23 and 4.13). i.e. both WT+GE and WT+LP 
cause a decrease in SVm, yet WT+LP exhibits an increase in ER Ca2* store whereas 
WT+GE exhibits an equivalent ER Ca2* store to WT RyR2. Furthermore, there did not 
appear to be any consistent trends between the level of cytoplasmic Ca2* signal 
variability and any of the measured Ca2* handling parameters detailed in chapter 3 
(Appendix 2 Figures 3-8), making it difficult to envisage a specific cause or effect of this 
alteration in cytoplasmic Ca2* flux. The absence of any obvious dependence of signal 
variability on intracellular Ca2* handling parameters also complicates the interpretation of 
why homotetrameric G1885E or L433P expression causes an increase in signal 
variability at some sporadic activating caffeine concentrations, yet most other
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combinations of L433P or G1885E expression cause a decrease in Ca2* signal 
variability.
Despite this, the expression of L433P and/or G1885E tends to alter post-activation 
signal variability predominantly during the period immediately after channel activation 
and to a lesser extent during the late period of cytoplasmic Ca2* recovery (Figure 4.13). 
This suggests that as the cytoplasmic Ca2* concentration approaches the pre-activation 
resting mean Ca2* level, the level of Ca2* flux also has a tendency to approach pre­
activation levels. However, due to the short amount of time over which post-activation 
SVm was recorded (90 secs), it is unknown whether the level of cytoplasmic Ca2* flux 
would reach the same pre-activation steady state equilibrium if post-activation data was 
collected over a longer time period.
4.4.4. Post-activation signal variability is dependent on the level of basal SVm 
and this relationship is altered by L433P
The observed relationship between basal and post-activation signal variability 
(summarised in Figure 4.14, raw data in Appendix II, Figures1-2 and Tables 2-3) 
suggests that increased basal signal variability translates to a more variable Ca2* signal 
following caffeine-evoked channel activation. Although this relationship was observed in 
cells expressing each recombinant RyR2, L433P and G1885E expression did appear to 
alter the precise nature of this relationship. In the majority of cases, the perturbation of 
this relationship tended to be rather sporadic i.e. alteration at a single caffeine 
concentration or a single time point.
Nevertheless, unlike the absolute SVm values, the relationship between basal and post­
activation Ca2* signal variability appeared to be somewhat associated with Ca2* release 
magnitude, in that WT+LP expression, which exhibited an increased ER Ca2* transient 
amplitude (Figure 3.18), resulted in a relatively smaller increase in signal variability 
following channel activation (Figure 4.14). On the contrary, RyR2 mutations that caused 
a decrease in ER Ca2* transient amplitude i.e. homotetrameric LP or LPGE (Figure 3.17) 
caused a relatively larger increase in post-activation Ca2* signal variability (Figure 4.14). 
Furthermore, this positive relationship was altered predominantly during the early and 
middle phase of cytoplasmic Ca2* recovery (Figure 4.14), reaffirming that the greatest
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perturbation of signal variability occurs during the period of elevated cytoplasmic Ca2* 
following RyR2 activation.
4.4.5. G1885E modulates post-activation SVm of cells expressing L433P
In addition to altering post-activation SVm and its dependence on the level of basal Ca2* 
signal variability when expressed alone, G1885E was shown to modulate both the 
relative levels of post-activation SVm (Figure 4.13 and Appendix II, Table 1) and the 
relationships between basal and post-activation SVm of cells expressing L433P (Figure 
4.14 and Appendix 2, Figures, 1-2 and Tables 2-3). The modulatory effects of G1885E 
were more pronounced when expressed with L433P in a heterotetrameric fashion 
(WT+LPGE or LP+GE), where the presence of G1885E partially restored post-activation 
SVm levels to those observed in WT RyR2. In contrast, homotetrameric LPGE 
expression exhibited SVm values and relationships that were very similar to those 
observed in cells expressing homotetrameric LP. This provides further evidence that 
G1885E modulates L433P channel function to varying degrees, depending on the 
precise mode of inheritance.
Homotetrameric GE expression resulted in identical relationships between basal and 
post-activation SVm compared to cells expressing WT RyR2, whereas the co-expression 
of WT+GE exhibited a slight, inconsistent, alteration of this relationship, providing further 
evidence that this polymorphism has little effect on RyR function when it is the only 
substitution present. However, when co-expressed with L433P (WT+LPGE or LP+GE), 
G1885E caused a significant reduction in the degree of perturbation of the relationship 
between basal and post-activation SVm. This provides further evidence that presence of 
G1885E causes subtle alterations in the effects of the L433P mutation, although the 
functional implications of the modulation of this relationship remain unknown.
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4.5 Chapter Summary
Most RyR2 variants expressed here displayed similar levels of basal Ca2* flux, 
suggesting the comparable net movement of Ca2* into and out of the cytoplasm under 
resting conditions, indicative of similar resting Ca2* homeostasis. Differences in 
cytoplasmic Ca2* flux caused by L433P and G1885E, were only evident following 
channel activation and ER Ca2* release which is consistent with other functional studies 
of RyR2 mutations.
Although the level of basal cytoplasmic Ca2* flux was not a determining factor of any of 
the measured Ca2* release parameters measured in Chapter 3, a positive relationship 
was observed between basal and post-activation Ca2* signal variability, supporting a role 
of L433P and G1885E in defective post-activation Ca2* handling.
Furthermore, L433P and G1885E expression appeared to mainly alter post-activation 
SVm levels and the relationship between basal and post-activation SVm during the early 
phase of cytoplasmic Ca2* recovery. This novel finding suggests that the effects of RyR2 
mutations on Ca2* flux were most pronounced immediately following channel activation 
when cytoplasmic Ca2* levels were at their peak, and reiterates that the defect in mutant 
RyR2 Ca2* handling may lie in the ‘inactivation’ or ‘recovery’ phase of the Ca2* transient.
Rather surprisingly, the majority of combinations of L433P and G1885E investigated 
here, appeared to cause a decrease in Ca2* signal variability following Ca2* release, 
although the mechanism by which this occurs and the functional consequences of this 
decrease in Ca2* signal intensity remain unknown. Furthermore, the alterations in SVm 
do not provide a clear mechanistic basis for the observed differences in Ca2* handling 
parameters detailed in Chapter 3.
In accordance with the caffeine-evoked Ca2* release data in Chapter 3, G1885E had 
little effect on SVm when expressed alone, yet modulated the effects of L433P. 
Furthermore, the precise mode of G1885E co-expression with L433P had a major effect 
on the extent to which G1885E would alter mutant channel function, with 
heterotetrameric expression of G1885E exhibiting the most profound modulatory effects 
on L433P SVm.
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As described in Chapter 3, although the majority of RyR2-expressing cells exhibited a 
characteristic steady basal Ca2* signal prior to caffeine addition, a proportion of the 
transfected cells exhibited spontaneous Ca2* release as Ca2* oscillations, similar to the 
“SOICR” phenomenon described by Jiang et al. In light of this, the next chapter of this 
thesis will detail the examination of these spontaneous Ca2* release events and any 
functional consequences L433P and G1885E expression may have on them.
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Chapter 5
Characterisation of spontaneous Ca2* 
release in HEK cells expressing L433P
and G1885E
5.1. Introduction
5.1.1. The implication of spontaneous Ca2+ release in heart failure
It is generally accepted that HF is characterised by decreased cardiac output, reduced 
contractility and impaired relaxation. VT is a major cause of death in HF (Bers, 2006) 
and is thought to be initiated by DADs, which arise due to spontaneous Ca2+ release 
from the SR via RyR2. The elevated cytoplasmic [Ca2+] resulting from spontaneous SR 
Ca2+ release is removed from the cell via the NCX in exchange for an inward 
depolarising Na+ current. The result of this inward Na+ current is a net gain in positive 
membrane potential during the repolarisation phase of the action potential (Schlotthauer 
& Bers, 2000). If the magnitude of this inward Na+ current is sufficient, it may lead to the 
onset of a DAD, which can lead to the premature initiation of action potentials in 
neighbouring cells and potentially result in the onset of VT (Figure 5.1, Marban, 2002).
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Figure 5.1. Comparison of a norm al action potential and an action potential 
exhibiting delayed after depolarisations (DADs). Panel a shows the representative 
action potentials at two neighbouring sites (1 and 2) in normal heart ventricular wall. 
Negatively polarised (resting) muscle is indicated in blue and depolarised tissue is 
indicated in red. Action potentials at both sites appear similar in duration and morphology. 
Panel b shows an action potential of failing heart in which DADs are occurring. During the 
repolarisation phase, spontaneous Ca2+ release occurs at site 1 and results in a DAD. 
This DAD causes the premature activation of an action potential at site 2 and can result in 
VT onset. From Marban (2002).
Data produced from several right ventricular apical tachypacing heart failure models has 
demonstrated similar functional perturbation of Ca2+ handling in the failing heart. Both 
individual myocytes and intact tissue from failing canine hearts demonstrated a decrease 
in the amplitude of the Ca2+ transient released from the SR during EC-coupling
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(Kubalova et al., 2005; Hoeker et al., 2009). This decrease in Ca2+ transient amplitude 
results in impaired contractility of the myocyte and has been attributed to increased 
diastolic Ca2+ leak and reduced Ca2+ sequestration in the SR. Isolated myocytes from 
failing hearts were also shown to exhibit a decreased level of SR Ca2\  potentially 
caused by the observed increase in Ca2+ spark/wave frequency (Kubalova et al., 2005; 
Hoeker et al., 2009).
5.1.2. Spontaneous Ca2* release in CPVT and ARVD2
CPVT and ARVD2 are both characterised by the onset of VT under periods of physical 
or emotional stress, when the level of circulating catecholamines is high and the p-AR 
pathway is activated (Leenhardt et al., 1995; Priori et al., 2002). In order for the heart to 
meet the higher metabolic demands during these periods of stress, cardiac output is 
increased by means of augmented Ca2* release from the SR during EC-coupling. In 
order to generate a larger magnitude of Ca2* release and increase contractile force, (3- 
AR stimulation causes the dissociation of PLN from SERCA, thereby increasing SERCA 
activity (Periasamy & Huke, 2001; Bers, 2008). This increases Ca2+ sequestration in to 
the SR, directly augmenting the amount of Ca2* available for release during the next 
action potential. However, if the level of intra-SR calcium reaches a particular threshold 
level, spontaneous Ca2* release from the SR can occur, a phenomenon referred to by 
one group as “store-overload induced Ca2* release” (SOICR, Jiang etai,  2004).
5.1.3. Role of RyR2 mutations in spontaneous Ca2* release
The development of CPVT/ARVD2 knock-in mouse models has made it possible to 
investigate the role of CPVT and ARVD2-linked RyR2 mutations in the development of 
DADs and triggered activity (Cerrone et al., 2005; Liu et al., 2006). Under non-stimulated 
conditions, myocytes isolated from the R4496C+/' knock-in mouse exhibited DADs in a 
small percentage of cells. p-AR stimulation caused a significant increase in the number 
of R4496C+/' myocytes that exhibited DADs (87%) and triggered activity (60%), and 
although p-AR stimulation also caused an increase in DADs in WT myocytes, it was to a 
lesser extent (11%) and no triggered activity was observed (Liu et al., 2006).
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A similar phenotype was observed in both the R176Q+/' and R2474S+/' knock-in mice, in 
that there was a higher incidence of spontaneous Ca2" release in myocytes isolated from 
the mutant mice compared to WT myocytes, under both resting conditions and following 
p-AR stimulation (Kannankeril et al., 2006; Lehnart et al., 2008; Uchinoumi ef al., 2010). 
The fact that P-AR stimulation exacerbates the level of DADs observed under resting 
conditions and results in an increase in triggered activity in R176Q+/', R2474S+/' and 
R4497C+/' mice (Kannankeril et al., 2006; Liu et al., 2006; Lehnart et al., 2008; 
Uchinoumi et al., 2010), suggests that this is a pathogenic mechanism by which RyR2 
mutations result in a CPVT-phenotype. Interestingly, the data produced from 
CPVT/ARVD2 knock-in mouse models corroborates data obtained from the 
characterisation of several disease-linked RyR2 mutations, including R4497C, in 
heterologous expression systems (Table 3.2).
Heterologous expression of a C-terminal CPVT-linked RyR2 mutation, V4653F, was 
shown to decrease the luminal Ca2" threshold at which spontaneous Ca2" release 
occurred, by increasing the sensitivity of the channel to activation by luminal Ca2" (Jones 
et al., 2008). This increased luminal Ca2" sensitivity manifested as an increase in the 
propensity for cells to exhibit spontaneous ER Ca2" release, which in the cardiac 
myocyte could lead to DADs. This reduced threshold for spontaneous SR Ca2" release 
and increased luminal Ca2" sensitivity was not limited to the V4653F CPVT-linked 
mutation and has been observed through the heterologous expression of mutations 
spanning the length of RyR2. Mutations from the N-terminal domain (R176Q/T2504M, 
L433P), central domains (S2246L, R2474) and C-terminal transmembrane domain 
(Q4201R, N4104K, R4496C, I4867M, N4865D) have all demonstrated increased luminal 
Ca2" sensitivity and a decreased luminal Ca2" threshold for spontaneous Ca2" release 
(Jiang et al., 2005; Jones et al., 2008), which manifests as an increased propensity for 
cells to exhibit spontaneous Ca2" release.
Chen and colleagues have proposed an attractive model for the mechanism by which 
CPVT/ARVD2-linked RyR2 mutations result in increased spontaneous Ca2" release 
(Figure 5.2, Jiang et al., 2004; reviewed by MacLennan & Chen, 2009). In their model 
they propose that under resting conditions, the level of free Ca2" in the SR is below the 
normal threshold at which spontaneous Ca2" release occurs through WT RyR2. 
Following p-AR stimulation, the level of free intra-SR Ca2" increases, but still remains 
below the critical threshold for spontaneous Ca2" release to occur. They propose that
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arrhythmia-linked RyR2 mutations reduce the threshold of luminal Ca2+ at which 
spontaneous Ca2+ release occurs and at rest, the level of Ca2+ in the SR remains below 
this threshold. However, during periods where SR Ca2+ is elevated as a result of 
increased (3-AR stimulation, the level of intra-SR Ca2+ surpasses this reduced threshold 
and results in spontaneous Ca2+ release, a phenomenon initially termed store-overload 
induced Ca2+ release or “SOICR”. However, since the inception of this model, this 
spontaneous Ca2+ release has been shown to be due to an increase in RyR2 luminal 
Ca2+ sensitivity, rather than ER Ca2+ store overload, suggesting that “SOICR” may not be 
the most accurate term for this phenomenon. This spontaneous Ca2+ release can 
potentially lead to the development of DADs and arrhythmia as discussed in section
5.1.1.
Lowered 
RyR SOICR 
threshold
B
Mutant
RyR
spillover
Cardiac  
arrhythmia 
or m uscle  
contracture
Free luminal 
[Ca*‘]
Mutant
RyR
Normal SOICR 
/” threshold
Mutation-lowered 
SOICR threshold
-  Drug-lowered 
SOICR threshold Little or 
no C o*i--------------    p, Hover
Caffeine
A t rest 
w ith  mutant 
RyR
lum inal
Normal SOICR 
* threehold
-  Free luminal Ca*‘
^  overload
v  Mutation-lowered 
\  SCHCR threshold /
Restng luminal Ca^* *
Catecholamine
increased 
SR Ca*’ 
loading
M u ta n t
RyR
spillover
Cardiac  
arrhythm ia  
or m uscle  
contracture
Figure 5.2. A model o f the SOICR m echanism  proposed for CPVT RyR2 mutations.
In myocytes expressing normal RyR2, under resting conditions, the level of free luminal 
Ca2+ (blue shading) in the SR store is below the normal threshold for spontaneous Ca2+ 
release (red dashed line), so SOICR does not occur as shown in panel B. It is proposed 
that CPVT-linked mutations reduce the threshold at which SOICR occurs (red solid line).
/3-AR stimulation increases the level of free luminal Ca2+ which remains below the normal 
SOICR threshold, so spontaneous Ca2+ release does not occur. The increased free 
luminal Ca2+ exceeds the mutation-lowered SOICR threshold and results in spontaneous 
Ca2+ release, as shown in panel C. Caffeine is proposed to act in a similar manner to RyR 
mutations by reducing the threshold at which SOICR occurs, which if below the level of 
free luminal Ca2+, can result in SOICR as shown in panel A. From MacLennan, (2009).
Although there remains great contention over whether the dissociation of FKBP12.6 has 
a role in CPVT/ARVD pathogenesis (section 1.3.4.3), there is increasing evidence that 
the interaction of FKBP12.6 with RyR2 has no effect on this spontaneous Ca2+ release 
propensity. Nevertheless, the investigation of the effects of CPVT/ARVD2 mutations on 
“SOICR” has only been described in HEK cells (Jiang et al., 2002; 2004; 2005; Jones et 
al., 2008), which do not endogenously express FKBP12.6, meaning that the role of
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FKBP12.6 in regulating this process remains unresolved. Acute and chronic treatment of 
the R4496C+/' mouse with K201 (JTV519), a compound proposed to restore FKBP12.6 
interaction with RyR2, did not prevent the DADs and triggered activity observed in these 
mice (Liu et al., 2006), although it did reduce Ca2* leak in an R2474S knock-in mouse 
model (Lehnart et al., 2008). Furthermore, the RyR2:FKBP12.6 interaction in these mice 
was identical to that observed in WT mice, both under resting or stimulated conditions 
(Liu et al., 2006). These observations were re-iterated through the heterologous 
expression of many CPVT/ARVD2-linked RyR2 mutations, which also demonstrated an 
equivalent FKBP12.6-RyR2 interaction in cells expressing WT or mutant RyR2, despite 
exhibiting an increase in spontaneous Ca2* release (Jiang et al., 2005; Jones et al., 
2008). Taken together with other experimental data (George et al., 2003a; Xiao et al., 
2007; Zissimopoulos et al., 2009), these findings suggest that the mechanism by which 
RyR2 mutations increase spontaneous Ca2* release propensity, resulting in DADs and 
triggered activity key to CPVT/ARVD2 pathogenesis, is in fact an FKBP12.6- 
independent mechanism.
Although the “SOICR” hypothesis is an attractive model for the mechanism by which 
gain-of-function RyR2 mutations can lead to arrhythmogenic disorders, it is unlikely that 
all disease-linked mutations act through this same pathogenic mechanism (section 
1.3.4). This is further highlighted by the fact that not all RyR2 mutations exhibit a similar 
degree of increased luminal Ca2* sensitivity, with some N-terminal mutations only 
exhibiting altered luminal Ca2* sensitivity when exposed to high luminal Ca2* 
concentrations (i.e. >10mM, Jiang et al., 2005) Furthermore, it is unlikely that mutations 
located in the cytoplasmic assembly alter luminal Ca2* sensitivity by direct perturbation 
of luminal Ca2* sensing, but instead may alter luminal Ca2* sensitivity through channel 
destabilisation or altered channel inactivation properties.
5.1.4. Loss-of-function RyR2 mutations
The majority of CPVT/ARVD2 linked RyR2 mutations that have been characterised in 
heterologous systems have demonstrated an increased sensitivity to activation by 
luminal Ca2*, manifesting as the increased occurrence of spontaneous basal Ca2* 
oscillations. However, recent evidence suggests that not all disease-linked RyR2 
mutations cause this gain-of-function phenotype in terms of spontaneous Ca2* release
2 2 8
(Jiang et al., 2007; Koop et al., 2008). A mutation in the RyR2 pore inner helix resulting 
in the substitution of a glycine residue in place of an alanine residue (A4860G) was 
shown to completely ablate basal spontaneous Ca2* release. The mutation reduced the 
sensitivity of the channel to activation by luminal Ca2*, caused an increase in the level of 
Ca2* in the ER store and decreased the level of basal activity as determined by 
[3H]Ryanodine binding (Jiang et al., 2007). Considering the non-polar nature of the 
substituted glycine residue and the position of the mutation deep within the inner-pore 
helix, it is unlikely that the A4860G mutation directly effects channel luminal Ca2* 
sensing, but likely affects the gating properties of the channel.
Interestingly, as well as altering RyR2 biophysical properties, as demonstrated using 
single channel analysis, the common G1885E and G1886S polymorphisms have also 
been shown to perturb spontaneous basal Ca2* release occurrence when expressed in a 
HEK cell system (Koop et al., 2008). Expression of mouse RyR2 containing either the 
G1885E or G1886S polymorphism resulted in an increase in the occurrence of 
spontaneous basal Ca2* release in the absence of altered Ca2* store-load. This lead the 
group to hypothesise that either polymorphism sensitises the channel to activation by 
luminal Ca2* and lowers the threshold at which spontaneous Ca2* release occurs (Figure 
5.3) and suggests that these two SNPs are not functionally benign when expressed as 
homotetramers containing either SNP. Furthermore, homotetrameric expression of both 
polymorphisms on the same RyR2 subunit caused near-complete ablation of 
spontaneous Ca2* release events (Koop et al., 2008). This demonstrates that the 
presence of both SNPs results in a very different phenotype to when either SNP is 
expressed alone, a similar phenomenon to that observed with SNPs in SCN5A and 
CASQ2 and with other rare RyR2 mutations (Postma et al., 2005; de la Fuente et al., 
2008; Medeiros-Domingo et al., 2009). Coupled with the observation that cells 
expressing both G1885E and G1886S exhibited an increased Ca2* store load, this 
suggests that expression of both G1885E and G1886S amino acid substitutions on 
every RyR2 subunit of the tetramer decreases the channel sensitivity to activation by 
luminal Ca2* and increases the threshold at which spontaneous Ca2* release occurs 
(Figure 5.3B). However, this mode of expression where both SNPs are present on all 
subunits of the tetramer (Koop et al., 2008) is not representative of the composite 
heterozygotic mode of G1885E and G1886S co-inheritance observed in the ARVD2 
patient in vivo (Milting et al., 2006), in which a mixture of channels containing both SNPs 
in varying stoichiometry would be expressed. Whether the mode of inheritance observed
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in vivo results in a similar loss-of-function remains to be determined, but highlights the 
importance of characterising SNPs and mutations when expressed in a manner 
replicative of the observed mode of disease-linked inheritance.
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Figure 5.3. G1885E and G1886S alter spontaneous Ca2+ release propensity. Cells expressing 
G1885E, G1886S or G1886D (mimicking constitutive phosphorylation at G1886S) exhibited
increased propensity for spontaneous Ca2+ release at all extracellular Ca2+ concentrations2+
([Ca2*Jo). Homotetrameric expression of G1885E/G1886S on the same subunits caused complete
ablation of spontaneous Ca2+ release as shown in panel A. Substitutions which caused an 
increase in spontaneous oscillation propensity exhibited a decreased ER Ca2+ level in oscillating 
cells compared to non-oscillating cells, whereas G1885E/G1886S exhibited an increase in ER 
Ca2+ load as shown in panel B. Adapted from Koop (2008).
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The G1886S substitution forms a putative PKC phosphorylation site in RyR2 (Milting et 
al., 2006), but this serine residue was not phosphorylated by PKA, PKC, PKG or 
CamKII, indicating that the functional consequences of this amino acid substitution are 
independent of RyR2 phosphorylation status. Given that disease-linked RyR2 mutations 
are responsible for both increasing (Jiang et al., 2005; Jones et al., 2008) and 
decreasing (Jiang et al., 2007; Koop et al., 2008) the luminal threshold for spontaneous 
Ca2* oscillations to occur, it is likely that any deviation from a normal threshold at which 
spontaneous Ca2* release occurs is likely to result in an arrhythmogenic phenotype. As 
such, a potential therapeutic strategy could potentially involve normalising the level of 
spontaneous Ca2* release to levels observed with WT RyR2, rather than completely 
preventing it, which may be pathogenic.
As detailed in the previous chapter, there is conflicting evidence over the precise 
functional consequences of the L433P ARVD2-linked RyR2 mutation with ambiguity as 
to whether L433P exhibits a decreased sensitivity to activation (Thomas et al., 2004; 
2005) or is a typical gain-of-function mutation (Jiang et al., 2005). However, the data 
presented in Chapter 3 is consistent with that of Thomas et al, who demonstrated that 
heterologous expression of human RyR2 harbouring the L433P mutation exhibited a 
decreased magnitude of caffeine-induced Ca2* release and a modest decrease in ER 
Ca2* store load compared to WT RyR2 (Thomas et al., 2004), suggesting this mutation 
results in ER Ca2* leak. Conversely, as well as demonstrating that L433P caused an 
increase in channel sensitivity to caffeine activation using ryanodine binding, Jiang et al 
also showed that the L433P mutation caused an increase in sensitivity to activation by 
luminal Ca2*, resulting in a substantial increase in the fraction of cells that exhibited 
spontaneous basal Ca2* release, both in RyR2 null cells and in cardiomycotes (Jiang et 
al., 2005). The group proposed that like other CPVT/ARVD2-linked mutations, the 
increase in luminal Ca2* sensitivity caused by the L433P mutation reduced the threshold 
at which spontaneous Ca2* release occurred, thus enhancing the propensity for DADs 
and triggered arrhythmias. There could be reconciliation between the data presented 
here and that of Jiang et al, in that the observed reduction in caffeine-evoked Ca2* 
release magnitude resulting from a decreased ER Ca2* load (Figure 3.23) could be 
attributed to an increased luminal Ca2* sensitivity or lower luminal threshold for 
spontaneous Ca2* release.
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5.1.5. Chapter aims
In Chapter 3, L433P was shown to decrease the caffeine sensitivity of channel activation 
and did not result in a typical gain-of-function intracellular Ca2* handling phenotype. 
Gain-of-function RyR2 mutations, which increase channel sensitivity to activation, also 
increase the propensity for cells to exhibit spontaneous ER Ca2* release (Jiang et al., 
2005). G1885E has been shown to alter the spontaneous Ca2* release incidence of HEK 
cells expressing another RyR2 SNP (Koop et al., 2008), G1886S. These spontaneous 
Ca2* release events occur as Ca2* ‘oscillations' in the absence of RyR2 agonists e.g. 
caffeine, apart from Ca2* in the external media. In Chapter 4, L433P and G1885E were 
shown to alter underlying Ca2* cycling following caffeine-evoked Ca2* release.
It is hypothesised that:
• Consistent with previous investigation of L433P and other CPVT/ARVD2-linked 
RyR2 mutations, L433P alters the incidence of spontaneous ER Ca2* release 
and is modulated by G1885E co-expression.
• L433P perturbs intracellular Ca2* handling of basal spontaneous Ca2* release 
events in a comparable manner to that of caffeine-evoked Ca2* release and is 
modulated by G1885E to varying degrees, depending on the mode of co­
expression.
• Analysis of spontaneous Ca2* release events may reveal further mechanisms of 
L433P Ca2* handling dysfunction arising from differences in channel 
activation/inactivation mechanisms between spontaneous and caffeine-evoked 
Ca2* release (Gaburjakova & Gaburjakova, 2006).
• Compensatory relationships between spontaneous Ca2* release and subsequent 
Ca2* extrusion exist in the absence of caffeine and such relationships are altered 
by L433P and G1885E expression.
In this chapter, the functional consequences of L433P and G1885E expression on 
spontaneous Ca2* oscillation propensity, intracellular Ca2* handling parameters of 
spontaneous Ca2* release and the relationships between such parameters will be 
examined.
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5.2. Methods
Single-cell Ca2* imaging experiments using confocal microscopy were carried out as 
detailed in section 2.2.2.3. Despite being collected in the same experiments described in 
Chapter 3 of this thesis, data acquired from cells that exhibited spontaneous basal Ca2* 
oscillations were omitted from the analysis detailed in Chapters 3 and 4. The omission of 
such data was deemed necessary due to differences in the nature of the basal Ca2* 
signal, which is critical in determining several Ca2* release parameters e.g. Ca2* release 
magnitude. Instead data from cells exhibiting spontaneous basal Ca2* oscillations in the 
absence of caffeine were analysed as a distinct data set, which will be the main focus of 
this chapter.
An example of a Ca2*-imaging trace of a cell exhibiting spontaneous Ca2* oscillations is 
shown in Figures 5.4 and 5.6. Spontaneous Ca2* oscillations were defined as the 
rhythmic increase and decrease in cytoplasmic Ca2* levels prior to agonist-evoked 
channel activation. In spontaneously oscillating cells, Ca2* oscillation morphology was 
highly comparable between that of sequential Ca2* oscillations within the same cell, but 
exhibited a different morphology to caffeine-evoked Ca2* release transients (Figure 5.6).
5.2.1. Propensity for spontaneous basal Ca2* release as Ca2* oscillations
The relative propensity for cells transfected with each RyR2 cDNA to exhibit 
spontaneous Ca2* release in the form of basal Ca2* oscillations was determined. The 
number of cells, both oscillating and non-oscillating, that exhibited an increase in 
cytosolic Ca2* immediately following caffeine addition (0.1-10mM) was recorded in a 
similar manner. The number of cells exhibiting spontaneous Ca2* oscillations or 
sensitivity to caffeine activation was expressed as a percentage of the total number of 
cells in the field of view. Transfection efficiency was determined as shown in Figure 3.10. 
The number of cells per field of view that exhibited caffeine sensitivity was expressed as 
a percentage of the total number of cells in that field of view. The percentage of 
oscillating, caffeine-sensitive cells per coverslip was calculated for cells transfected with 
each RyR2 cDNA to determine if L433P or G1885E altered spontaneous Ca2* release 
propensity.
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5.2.2. Measurement of spontaneous Ca2* release parameters
Semi-automated oscillation analysis software; SALVO (Synchrony -  Amplitude -  Length 
-  Variability of Oscillation, Silvester et al., 2009) was used to measure several Ca2+ 
handling parameters from single-cell Ca2+ imaging data (Figure 5.4). Raw Ca2+ imaging 
data was exported from Leica LAS AF software to a Microsoft Excel compatible format. 
Data was imported into SALVO and the beginning and the end of the Ca2+ oscillation 
(‘valleys’) and the highest point of the Ca2+ oscillation (‘peak’) were manually input into 
SALVO. Parameters that were determined by SALVO analysis and the method 
employed in calculating parameter values are detailed below:
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Figure 5.4. Measurement o f spontaneous Ca2+ oscillation parameters using 
SALVO. Synchrony -  Amplitude -  Length -  Variability of Oscillations (SALVO) 
software was used to measure several parameters of spontaneous Ca2+ oscillation 
parameters. SALVO is semi-automated and requires the start and the end of each 
oscillation to be indicated by the user.
Basal Signal Intensity
Basal signal intensity (F0) was measured by taking a mean average of the signal 
intensity at each time point that occurred between spontaneous Ca2+ oscillations. 
This is not to be confused with the mean signal intensity, which is the mean 
signal intensity over the entire time course, including that of Ca2+ oscillations.
Height and Magnitude
Oscillation height was determined by measuring the oscillation peak signal 
intensity (F) and subtracting the average inter-oscillation basal signal (F0) from
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this value, to obtain the magnitude of Ca2+ release (F-F0). To account for 
differences in basal signal intensity between cells, peak magnitude was 
normalised to the average basal signal intensity (F-F0 / F0).
Duration
The duration of the Ca2* oscillation was determined by subtracting the time at 
which spontaneous Ca2* release was initiated from the time at which signal 
intensity returned to F0. The duration of the spontaneous Ca2* oscillation was 
expressed in seconds (s).
Area
The area under the curve is calculated using the trapezoidal rule. To account for 
differences in mean basal signal intensity, the area under the curve is normalized 
to basal signal intensity (F0). The area under the curve is expressed as unit 
seconds (U s).
Rate o f Ca2* Release
The time taken to peak Ca2* {TReiease) was determined by subtracting the time at 
which spontaneous Ca2* release was initiated from the time at which peak signal 
intensity was reached. The rate of spontaneous Ca2* release was determined by 
dividing peak magnitude (F-F0 / F0) by the time taken to reach peak signal 
intensity ([F-F0 / F0] / TReiease) and is expressed as the change in signal intensity 
over time i.e dF I dt.
Rate o f Ca2* Removal
The time taken for signal intensity to return to basal levels (TRemovai) was 
determined by subtracting the time of peak signal intensity from the time at which 
signal intensity decreased to F0. To determine the rate of Ca2* removal from the 
cytosol, peak magnitude (F-F0 / F0) was divided by the time taken for signal 
intensity to decline back to that of the baseline [(F-F0 / F0) / TRem0vai]
Due to the relatively short time period over which Ca2* imaging data was collected prior 
to caffeine addition i.e. 60 seconds, it was not possible to carry out an accurate 
comparison of oscillation frequency between cells expressing each recombinant RyR2. 
Approximately 70% of oscillating cells exhibited 1 or 2 Ca2* oscillations in the 60 second
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period prior to caffeine activation and approximately 90% exhibited 3 Ca2+ oscillations in 
this same period. The low number of Ca2* oscillations observed could lead to artefactual 
conclusions being made with regards to oscillation frequency and was not included in 
the analysis detailed in this chapter.
5.2.3. Linear regression analysis of Ca2* release parameters
Linear regression analysis was used to identify whether any relationships existed 
between oscillation parameters. To examine this, Ca2* oscillation parameters were 
measured using SALVO as detailed in section 5.2.2. and parameter data from cells 
expressing each recombinant RyR2 were collated. Linear regression analysis was 
carried out between pairs of spontaneous Ca2* oscillation parameters as detailed in 
section 2.2.5, and was also used to identify whether there were any relationships 
between spontaneous Ca2* oscillation parameters and those of the subsequent caffeine- 
induced Ca2* release transient (Figure 5.5).
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Figure 5.5. Linear regression analysis o f spontaneous and caffeine-evoked Ca 
release parameters. The mean value o f a particular spontaneous Ca2* release parameter 
i.e. Ca2* release magnitude, was calculated from the basal Ca2* oscillations (panel A, x) 
and the same parameter was measured in the subsequent caffeine-evoked Ca2* release 
transient (panel A, y) in the same cell. Examples to illustrate the presence and absence of 
a significant relationship are presented in panel B. Data was presented as scatter-plots and 
linear regression analysis descriptive statistics were determined to ascertain whether 
relationships existed (I or did not exist (ii) between the same Ca2* handling parameter in 
spontaneous or caffeine-evoked Ca2* release.
However, caffeine applications were often made during periods of elevated cytoplasmic 
Ca2* resulting from prior spontaneous Ca2* release, meaning that those caffeine-evoked 
responses couldn’t always be accurately measured from a resting baseline (Figure 5.6).
ps
To negate this issue, only cells in which the caffeine response was observed when 
intracellular Ca2+ was at basal levels (Figure 5.6A), and not those where the response 
was observed partway through a Ca2+ oscillation (Figure 5.6B-C), were used in linear 
regression analysis of spontaneous and caffeine-evoked Ca2* release parameters.
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Figure 5.6. Caffeine causes further Ca2* release from the ER, even if applied during a 
spontaneous Ca2* oscillation. A proportion of HEK cells expressing each recombinant 
RyR2 exhibited spontaneous basal Ca2* oscillations prior to caffeine addition. Following 
activation of RyR2 with caffeine (dotted red line 0.1-10mM), no further Ca2* oscillations 
were observed and the Ca2*-dependent Fluo3 signal decreased to a resting level, as 
shown in panels A-C. Even if caffeine was added when intracellular Ca2* levels were 
partially declined (but still significantly greater than basal levels), further Ca2* was released 
from the ER store, as indicated in panel B. Similarly, when caffeine was added only a few 
seconds after the initiation of a spontaneous Ca2* release event, the caffeine evoked Ca2* 
release was much less obvious, as shown in panel C.
Due to the inherent variability of HEK cells, goodness-of-fit (r2) values tended to be 
relatively low and as such, a low arbitrary r2 threshold value of 0.3 was adopted to infer a 
weak relationship between two Ca2* oscillation parameters, data with a moderate fit to 
the regression model were characterised by r2 values between 0.5 and 0.7, and r2 values 
greater than 0.7 inferred a strong linear relationship between two given parameters. The 
relatively high number of oscillating cells expressing each construct (between 79-425 
cells) allowed the generation of stringent significance values {p-values) in terms of 
determining increasing/decreasing trends in the data.
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5.3. Results
5.3.1. RyR2 mutations and polymorphisms alter spontaneous Ca2* release 
propensity
As described in section 3.3.2, there was no significant difference between the average 
transfection efficiencies of ceils transfected with each RyR2 cDNA, either alone or co­
expressed with WT RyR2 (Figure 3.10, p > 0.05, ANOVA). Chapter 3 also provides 
evidence that the transfection efficiency of each RyR2 cDNA was comparable to that of 
WT RyR2 (Students t-test, p = 0.88, Figure 3.10).
Only HEK cells expressing functional RyR2 channels exhibit transient Ca2* release 
following exposure to caffeine (0.1-10mM). The percentage of cells responding to 
caffeine, which is indicative of functional RyR2 expression, was determined in HEK cells 
expressing each combination of WT RyR2, L433P and G1885E, both as homotetramers 
and heterotetramers (Figure 5.7A). In most cases, an equivalent number of cells 
expressing each combination of RyR2s containing combinations of L433P and G1885E 
substitutions, both alone and with WT RyR2, demonstrated a similar propensity to exhibit 
caffeine sensitivity compared to WT, although the heterotetrameric expression of WT+LP 
resulted in an increased number of caffeine-sensitive cells (p < 0.001, Figure 5.7A).
Surprisingly, the observed transfection efficiency, as determined by fluorescence 
microscopy, was approximately 5-10% lower than the percentage of cells responding to 
caffeine. This discrepancy was observed for cells transfected with each RyR2 cDNA and 
could possibly be attributable to cells expressing low levels of eGFP-tagged RyR2 not 
exhibiting sufficient eGFP fluorescence to allow detection using fluorescence 
microscopy, despite sufficient RyR2 being expressed to elicit caffeine-induced Ca2* 
release readily detectable by confocal Ca2* imaging.
Single-cell Ca2* imaging experiments demonstrated that a significant percentage of cells 
expressing each recombinant RyR2 exhibited spontaneous basal Ca2* oscillations under 
resting conditions, prior to agonist exposure (13-39%, Figure 5.7B). Despite the majority 
of recombinant RyR2s exhibiting similar numbers of caffeine-sensitive cells, there was 
greater variation in the propensity for cells expressing each RyR2 to exhibit spontaneous 
basal Ca2* oscillations (Figure 5.7B). In these experiments, the propensity of
spontaneous Ca2+ release refers to the percentage of cells exhibiting spontaneous Ca2+ 
oscillations, and should not be confused with the frequency of oscillations in a given cell.
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Figure 5.7. HEK cells expressing 
L433P and G1885E exhibit 
heterogeneity between
spontaneous Ca2+ release 
propensity. The percentage of all 
cells that exhibited caffeine 
sensitivity are indicated in panel A. 
The percentage of all cells that 
exhibited spontaneous basal Ca2* 
oscillations prior to caffeine-evoked 
Ca2* release is indicated in panel 
B. Data is plotted as the mean 
percentage ± S.E.M. The results of 
statistical comparison are indicated 
on the graphs according to the key 
in panel C. (brackets, p < 0.05, 
ANOVA). Caffeine sensitivity and 
oscillation propensity data was 
collected from between 39 and 75 
individual coverslips from between 
7 and 17 separate transfections.
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Q1885E expression did not alter the propensity of cells to exhibit spontaneous basal 
Ca2+ oscillations compared to WT RyR2, irrespective of whether it was expressed alone 
(GE, p = 0.83) or co-expressed with WT RyR2 (WT+GE, p = 0.46). The homotetrameric 
expression of LPGE resulted in a significant decrease in the propensity for cells to 
exhibit spontaneous Ca2+ release compared to WT RyR2 (Figure 5.7B, p < 0.05). 
However, this decrease was not observed in cells expressing homotetrameric LP (p < 
0.05), suggesting that G1885E modulates the spontaneous Ca2* release propensity of 
homotetrameric L433P. Furthermore, the expression of WT+LP heterotetramers caused 
a significant increase in spontaneous Ca2* release propensity compared to WT RyR2 (p 
< 0.001), which was surprising given that homotetrameric L433P had little effect on Ca2* 
oscillation propensity. Interestingly, this increase was not observed in cells co­
expressing WT+LPGE or LP+GE, providing evidence that G1885E also alters the 
spontaneous Ca2* release propensity of L433P heterotetramers when on the same or 
different subunit as the mutation.
5.3.2. Basal cytoplasmic Ca2* concentration is comparable in oscillating and non­
oscillating cells
Basal cytoplasmic Ca2* was measured to determine whether cytoplasmic Ca2* 
concentration influenced the propensity of cells expressing RyR2 to exhibit spontaneous 
Ca2* release. The average basal cytoplasmic Ca2* concentration of oscillating cells 
expressing each recombinant RyR2 was determined using the method detailed in 
section 3.2.6 and is presented in Figure 5.8.
In all instances, resting cytoplasmic Ca2* levels were equivalent between oscillating and 
non-oscillating cells expressing a particular recombinant RyR2. Oscillating cells 
expressing LP homotetramers exhibited a similar level of cytoplasmic Ca2* compared to 
WT RyR2 (p = 0.67), however LPGE homotetramers exhibited a significantly increased 
level of cytoplasmic Ca2* compared to LP (p < 0.05) and WT RyR2 (p < 0.001). This 
corroborates the observation in non-oscillating cells that homotetrameric LPGE 
expression results in the increase of cytoplasmic Ca2*. Although homotetrameric LPGE 
expression caused an increase in cytoplasmic Ca2* concentration (Figure 5.8) coupled 
with a decrease in spontaneous Ca2* release propensity (Figure 5.7B), a similar coupling 
was not observed as a result of the expression of other RyR2s that also altered Ca2*
oscillation propensity, i.e. WT+LP. This data suggests that the variation in propensity for 
cells expressing recombinant RyR2 to exhibit spontaneous Ca2+ release is independent 
of basal cytoplasmic Ca2+ concentration.
300
[= □ Non-oscillating cells (data from Chapter 3)
Oscillating cells
Figure 5.8. Basal cytoplasmic Ca2* levels are similar in oscillating and non­
oscillating cells, but vary between RyR2s. Data presented is the mean ± S.E.M. basal 
cytoplasmic Ca2* concentration, as determined by ionomycin and EGTA calibration 
described in section 3.2.6. Data was collected from between 8 and 74 transfected HEK 
cells and from 284 untransfected HEK cells from between 3 and 9 separate experiments. 
Asterisked data indicates a significant difference to WT RyR2 (p<0.05).
5.3.3. Oscillating cells exhibit equal or decreased ER Ca2+ store content 
compared to non-oscillating cells
Jiang et al proposed that CPVT/ARVD2-Iinked RyR2 mutations, including L433P and 
G1885E, increase the propensity for spontaneous Ca2+ release due to an increase in 
luminal Ca2+ sensitivity, which consequently results in decreased ER Ca2+ levels (Jiang 
et al., 2005; Koop et al., 2008). Thus, the ER Ca2+ levels of cells exhibiting spontaneous 
Ca2+ release were determined to see whether alterations in Ca2+ store load reconciled 
with the observed alterations in spontaneous Ca2+ release propensity.
ER Ca2+ levels of RyR2-expressing HEK-293 cells exhibiting spontaneous Ca2+ 
oscillations were determined as described in section 3.2.5. Untransfected HEK, cells did 
not exhibit spontaneous Ca2+ oscillations, and as such, only cells expressing RyR2
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exhibited these spontaneous Ca2+ release events. However, caffeine (0.5mM) was 
added to the cells prior to the administration of thapsigargin to allow direct comparison of 
the ER Ca2+ levels between oscillating and non-oscillating cells, as caffeine was used to 
identify RyR2-expressing, non-oscillating cells (section 3.2.5). If the caffeine or 
thapsigargin-evoked response occurred during a Ca2+ oscillation, this cell was excluded 
from analysis to allow accurate determination of Ca2+ release magnitude (see Figure 
5.6). The average ER Ca2+ store load of non-oscillating cells (data from section 3.3.7) 
and spontaneously oscillating cells is presented in Figure 5.9.
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Figure 5.9. Oscillating cells expressing WT+LP exhibit altered ER Ca2+ load. Data 
presented is the combined mean ± S.E.M. change in fluo3-AM signal intensity following 
addition of caffeine (0.5mM) immediately followed by thapsigargin (10pM). White bars 
represent the ER Ca2+ levels of non-oscillating cells. Grey bars represent the ER Ca2+ 
levels of spontaneously oscillating RyR2-expressing HEK-293 cells. Data was collected 
from between 12 and 69 transfected HEK cells and 284 untransfected HEK cells from 
between 3 and 9 separate experiments, f  denotes a significant difference between 
oscillating and non-oscillating cells transfected with the same RyR (p<0.05). Asterisked 
data indicates a significant difference to WT RyR2 (p<0.05)
Consistent with previous work, cells expressing WT RyR2 exhibited a similar ER Ca2+ 
store load in both oscillating and non-oscillating cells (Jiang et al., 2005; Koop et al.,
2008). Comparable ER Ca2+ levels in oscillating and non-oscillating cells were also 
observed in cells expressing each RyR2, although the expression of heterotetrameric
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WT+LP resulted in a significantly decreased level of ER Ca2* in oscillating cells 
compared to non-oscillating cells (p < 0.05). Although L433P or G1885E-containing 
RyR2s resulted in decreased ER Ca2* levels in oscillating cells compared to WT RyR2, 
there were no significant differences between ER Ca2* levels of oscillating cells 
expressing each RyR2 mutation/polymorphism.
The Ca2* store load of oscillating cells expressing heterotetrameric WT+LP was 
significantly decreased when compared to non-oscillating cells expressing WT+LP (p < 
0.05). The expression of heterotetrameric WT+LPGE or LP+GE resulted in an equivalent 
level of ER Ca2* compared to that of cells expressing WT+LP, indicating that G1885E 
did not modulate the ER store load of cells WT+LP heterotetramers. Homotetrameric 
expression of LPGE exhibited a decrease in ER Ca2* load in oscillating cells that was not 
observed in cells expressing LP homotetramers, suggesting that G1885E only 
modulates the store load of oscillating HEK cells expressing L433P in a homotetrameric 
fashion.
In these experiments, expression of RyR2 mutants which resulted in a decrease in 
spontaneous Ca2* oscillation propensity did not necessarily result in an increase in ER 
Ca2* levels (e.g. homotetrameric LPGE), and vice versa (e.g. heterotetrameric WT+LP), 
contrary to what would be expected according to the proposed SOICR model (Jiang, 
2004). The data from these experiments suggests that the variation in observed 
oscillation propensity can not be completely attributed to alterations in ER Ca2* load and 
that other contributory factors are likely involved i.e. Ca2* sensitivity, RyR2 stability etc.
5.3.4. Heterogeneity in basal spontaneous Ca2* oscillation parameters
To determine whether L433P and G1885E altered the Ca2* handling dynamics in the 
absence of agonist-evoked channel activation, several parameters of the spontaneous 
Ca2* oscillation were measured. This allowed comparison of intracellular Ca2* handling 
characteristics of cells that were undergoing basal Ca2*-cycling, with RyR2 switching 
between the open and closed states during CICR and subsequent store refilling. Single­
cell calcium imaging data was collected as described in section 2.2.2.3 and analysed 
using SALVO software as described in section 5.2.2.
5.3.4.1. Oscillation parameters: magnitude, duration and area
There appeared to be significant variation between several parameters of spontaneous 
basal Ca2" oscillations between cells expressing each RyR2 (Figure 5.10 and 5.11). 
Alteration of these parameters is indicative of altered intracellular Ca2+ handling following 
spontaneous Ca2* release, which could lead to the sustained elevation of cytoplasmic 
Ca2* concentration leading to premature inward Na* current and DAD onset in a cardiac 
setting.
Expression of GE homotetramers or WT+GE heterotetramers had little effect on the 
spatial parameters of intracellular Ca2* handling, although co-expression of WT+GE 
caused a small, but significant increase in Ca2* oscillation area compared to that of WT 
RyR2 (p < 0.05), an effect that was not evident when G1885E was expressed alone 
(Figure 5.10C). This is likely a cumulative effect of the observed marginal increase in 
oscillation magnitude (Figure 5.10A) and duration (Figure 5.1 OB) in cells expressing 
WT+GE heterotetramers.
Cells expressing homotetrameric LP or LPGE exhibited Ca2* oscillations with a similar 
magnitude (Figure 5.10A, p=0.53 and p=0.28 respectively), but significantly increased 
duration and area, compared to those observed in cells expressing WT RyR2 (Figure 
5.1 OB and C, p < 0.05). Oscillation magnitude, duration and area were similar between 
cells expressing homotetrameric LP or LPGE, indicating that G1885E has no effect on 
spontaneous Ca2* oscillation magnitude, duration or area when found with L433P on 
every subunit of the tetramer.
Expression of heterotetrameric WT+LP resulted in a significant increase in Ca2* 
oscillation magnitude compared to WT RyR2, a similar observation to that following 
caffeine-evoked Ca2* release (section 3.3.5). This increase in oscillation magnitude 
culminated in an increase in oscillation area, despite similar oscillation duration 
compared to WT. Despite both homotetrameric LP and heterotetrameric WT+LP 
expression altering magnitude and duration of oscillations in a different manner, both 
modes of L433P expression resulted in a similar increase in oscillation area, indicative of 
sustained elevated cytoplasmic Ca2* concentration following CICR, consistent with 
previous findings (Thomas et al., 2004; 2005). Similar observations were made through 
the expression of homotetrameric LPGE and heterotetrameric WT+LPGE compared to
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oscillation magnitude (panel A), 
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the oscillation trace (panel C). The 
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1
LP and WT+LP respectively, indicating that when G1885E co-expressed on the same 
subunit as L433P, the polymorphism has little effect on spontaneous Ca2* release 
parameters. However, expression of LP+GE heterotetramers resulted in oscillations with 
parameters that were not significantly different to those observed in cells expressing WT 
RyR2 or WT+LP. This suggests that L433P and G1885E co-expression on separate 
subunits partially normalises Ca2* oscillation area to that observed in WT RyR2.
5.3.4.2. Oscillation kinetic parameters: rates of Ca2* release and removal
Mechanisms other than RyR2 activation and inactivation are involved in regulating 
cytoplasmic Ca2* concentration following CICR, particularly in the removal of Ca2* from 
the cytoplasm (Figures 1.3 and 4.1). To further examine the effects of L433P and 
G1885E expression on Ca2* handling dynamics, the kinetic parameters of spontaneous 
Ca2* oscillations i.e. the rate of Ca2* release and the rate of subsequent Ca2* removal, 
were examined using SALVO software as detailed in section 5.2.2., the results of which 
are presented in Figure 5.11.
Homotetrameric expression of LP or LPGE caused a significant decrease in the rate of 
spontaneous Ca2* release compared to WT (p < 0.01, Figure 5.11 A) but did not alter the 
rate of Ca2* removal from the cytoplasm (Figure 5.11B), consistent with that of caffeine 
evoked Ca2* release (section 3.3.6). The similarity between the kinetic parameters 
observed in cells expressing LP or LPGE suggests that G1885E has little effect on the 
kinetic parameters of spontaneous Ca2* release in cells expressing homotetrameric 
L433P. G1885E expression caused a decrease in both the rate of spontaneous Ca2* 
release and the rate of subsequent Ca2* removal from the cytoplasm, although this was 
only observed when GE was expressed as homotetramers, and not when co-expressed 
with WT RyR2.
The expression of WT+LP resulted in a significant increase in both the rate of 
spontaneous Ca2* release (p < 0.01) and subsequent rate of Ca2* removal (p < 0.001), 
compared to both WT RyR2 or homotetrameric LP. This finding parallels that observed 
in the caffeine-evoked Ca2* release experiments detailed in section 3.3.6. Expression of 
WT+LPGE heterotetramers resulted in a similar rate of Ca2* release, but decreased rate 
of Ca2* removal compared to cells expressing WT+LP (Figure 5.11), suggesting G1885E
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has a greater modulatory effect on Ca2+ removal processes than spontaneous Ca2+ 
release. The co-expression of LP+GE on separate subunits produced kinetic parameters 
that were similar to those observed in cells expressing WT+LP, indicating that G1885E 
had little effect on kinetic parameters of spontaneous Ca2+ release when not on the 
same subunit as L433P.
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fTable 5.1 summarises the measured Ca2* oscillation parameters, as well as the results 
of statistical comparison between the mutant/polymorphism RyR2 and WT RyR2. In 
accordance with the agonist-evoked Ca2* release experiments detailed in Chapter 3, and 
the Ca2* flux analysis detailed in Chapter 4, the greatest perturbation of intracellular Ca2* 
handling parameters were observed following homotetrameric expression of LP or LPGE 
or the heterotetrameric expression of WT+LP.
However, as well as having a profound effect on spontaneous Ca2* release propensity in 
cells expressing L433P channels, it appears that G1885E exhibits a modulatory effect on 
L433P spontaneous Ca2* release parameters, but only following heterotetrameric 
LP+GE expression (Figures 5.10 and 5.11). In contrast, all measured oscillation 
parameters were comparable between cells expressing LP or LPGE homotetramers, 
suggesting G1885E did not alter the Ca2* handling parameters of L433P when both 
substitutions were found on every subunit of the tetramer. Although heterotetrameric 
expression of WT+LP or WT+LPGE both altered parameters of spontaneous Ca2* 
oscillations compared to WT RyR2, both modes of expression tended to augment Ca2* 
handling parameters to a similar extent, providing further evidence that the mode of 
L433P and G1885E co-expression was important in determining the extent to which 
G1885E altered L433P function.
There did not appear to be any resounding reconciliation between oscillation area and 
the kinetic parameters of Ca2* release, although some general observations were made. 
The heterotetrameric expression of WT+LP caused a significant increase in 
spontaneous Ca2* release magnitude, which was coupled with a significant increase in 
the rate of Ca2* removal. However, this increase in Ca2* removal rate was not sufficient 
to restore transient area to normal levels. Furthermore, homotetrameric expression of LP 
or LPGE caused a significant decrease in the rate of Ca2* removal, which likely 
contributed to the increased Ca2* oscillation area. To further examine these 
compensatory relationships, linear regression analysis on key oscillation parameters 
was carried out and is detailed below.
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Ca2* Store Load 
(F-Fe)/Fo
Basal Cytoplasmic 
[Ca2*] (nM)
Oscillation Parameter Measurements
RyR2 Oscillation Rate of Ca2* 
Release
AF-F.-F,/ 9
Rate of Ca2* 
Removal
AF-F,-FVsPropensity (% ± S.E.M) Non
OscVVWVW'
Osc Non Osc OscVSWAV
Magnitude
(F-F#)/F0
Duration
(*)
Area
(Us)
Wild Type 22.7 ±3 .0 1.51 ±  
0.19
1.53 ±  
0.12
108.7
±16.2
133.5 ±  
18.3
0.47 ±  
0.03
15.9 ±  
0.56
150.6 ±  
8.7
2.17 ±0.15 0.31 ±0.016
G1885E 21.9 ±2.1 1.57 ±  
0.26
1.12 ± 
0.11 *
88.5 ±  
16.8
109.8 ±  
8.6
0.43 ±  
0.03
17.0 ±  
0.49
151.2 ±  
6.0
1.61 ±0.11 * 0.25 ± 0.015 *
L433P 17.3 ±1 .7 1.24 ± 
0.04*
1.19 ±  
0.15
110.7 ±  
13.2
94.0 ±  
11.4
0.44 ±  
0.04
19.0 ± 
0.67*
166.9 ± 
7.8
1.34 + 0.12* 0.25 ±0.018
L433P-G1885E 12.8 ± 2.0 * 0.89 ± 
0.11*
0.97 ± 
0.2*
210.3 ± 
29.1 *
209.3 ± 
33.5*
0.42 ±  
0.03
19.5 ± 
0.91 *
192 ± 
13.2*
1.36 ±0.11 * 0.27 ±0.017
WT+G1885E 26.0 ±2 .9 1.27 ±  
0.18
0.89 ± 
0.15*
145.1 ±  
14.0
143.1 ±  
18.4
0.53 ±  
0.03
17.3 ±  
0.5
165 ± 
6.1 *
2.16 ±0.11 0.33 ±0.013
WT + L433P 38.6 ± 2.9 * 2.29 ± 
0.39*
1.32 ±  
0.21
180.0 ± 
28.0*
159.9 ± 
52.3
0.65 ± 
0.04*
15.6 ±  
0.57
176.9 + 
5.3*
2.82 ± 0 .1 2 * 0.57 ± 0.053 *
WT + 
L433P-G1885E
17.2 ±2 .6 1.11 ± 
0.06*
1.19 ±  
0.12
114.2 ±  
18.0
154 ±  
39.0
0.58 ± 
0.03*
18.5 ± 
0.67*
197.0 ± 
8.9*
2.74 ± 0.21 * 0.37 ±0 .01 9 *
L433P+G1886E 23.3 ±2 .7 1.21 ± 
0.14*
1.07 ± 
0.09*
114.2 ±  
18.5
128.7 ±  
9.1
0.55 ±  
0.03
16.4 ±  
0.64
181 ±  
8.9
2.32 ±0.16 0.45 ± 0.028 *
Table 5.1. A summary of the spontaneous Ca2* oscillation parameters observed in cells expressing each recombinant RyR2. Asterisked 
data indicates a significant difference to WT RyR2 (p<0.05). Red values indicate a significant increase and blue values indicate a significant 
decrease compared to WT RyR2.
5.3.5. Examination of the functional relationships between Ca2* oscillation 
parameters
Altered systolic Ca2+ transient amplitude has been implicated in HF and an increase in 
agonist-evoked ER Ca2+ release magnitude is well documented phenotypic 
manifestation of RyR2 CPVT-linked mutations examined in heterologous systems 
(George et a/., 2003a; Thomas et al., 2004; Jiang et al., 2005). Due to the vast network 
of Ca2* signalling proteins involved in intracellular Ca2* handling, compensatory 
mechanisms may come into effect to negate the detrimental effects of sustained 
elevated cytoplasmic Ca2+ concentrations following ER Ca2+ release, observed through 
the heterologous expression of RyR2 mutations. Given that L433P has been shown here 
to alter the magnitude of Ca2+ release, particularly when co-expressed with WT RyR2 
(Figures 3.17-3.19 and 5.10), linear regression analysis was employed to determine 
whether the magnitude of Ca2+ release influences other intracellular Ca2+ handling 
parameters following spontaneous Ca2+ release. For example, does increased 
spontaneous Ca2* release magnitude lead to a longer lasting period of elevated 
cytoplasmic Ca2*, does increased Ca2+ release result in a higher rate of Ca2+ removal 
from the cytoplasm etc. Subsequently, results of the linear regression analysis were 
used to determine if expression of the L433P mutation and/or the G1885E polymorphism 
perturbed any of these functional relationships.
5.3.5.1. Factors other than spontaneous Ca2* oscillation magnitude and 
duration determine Ca2* oscillation area
Although a positive linear relationship between spontaneous Ca2* oscillation magnitude 
and duration was observed in cells expressing each recombinant RyR2 (p < 0.05, apart 
from L433P p = 0.06, Figure 5.12A), data did not tend to fit the regression model very 
well (r2 = 0.04 -  0.18), indicating a lack of relationship between these two parameters. 
Unsurprisingly, this suggests that factors other than Ca2* release magnitude, likely to be 
Ca2* sequestration mechanisms, are major determinants of the duration of spontaneous 
Ca2* oscillations. However, expression of homotetrameric LPGE resulted in a moderate 
positive relationship between oscillation magnitude and duration (p < 0.0001, r2 = 0.37, A
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Figure 5.12. Spontaneous Ca2+ release magnitude does not determine oscillation duration.
Linear regression analysis was carried out to determine whether there were any relationships 
between the spatial parameters of spontaneous Ca2+ oscillations. Linear regression analysis was 
used to determine whether there were relationships between oscillation magnitude and duration 
(A), oscillation magnitude and area (B) or oscillation duration and area (C). Significance values 
(p) < 0.05 indicated that a significant relationship between two parameters existed. Plots 
highlighted in red indicate a significantly steeper gradient compared to WT whereas those 
highlighted in grey indicate no relationship was observed. An r  threshold value of 0.3 was 
employed to determine fitting data.
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= 18 ± 2.7), with a 2 to 3-fold steeper gradient than the other RyRs, indicating that an 
increase in Ca2* release magnitude results in a greater prolongation of the Ca2* 
oscillation than that observed in cells expressing the other RyR2s. This may indicate that 
homotetrameric expression of LPGE causes profound alterations in Ca2* sequestration 
following ER Ca2* release.
Expression of all RyR2s resulted in a significant, moderate, positive relationship between 
spontaneous Ca2* oscillation magnitude and area (p < 0.0001, r2 = 0.35 to 0.62, Figure 
5.12B), indicating that increasing spontaneous Ca2* release magnitude tended to result 
in an increase in the area of the oscillation. The linear regression line produced from 
cells expressing each recombinant RyR2 exhibited a similar gradient, apart from 
homotetrameric LPGE expression which resulted in significantly steeper (~2-fold) 
gradient, compared to that observed in cells expressing all other RyRs, again pointing 
towards an altered relationship between Ca2* release and subsequent Ca2* 
sequestration and extrusion.
Similarly, expression of all recombinant RyR2s resulted in a strong positive relationship 
between spontaneous Ca2* oscillation duration and area (Figure 5.12C, p < 0.0001, r* = 
0.68 to 0.86), suggesting that an increase in Ca2* oscillation duration tended to result in 
oscillations with a greater area. The presence of these relationships is not surprising, 
given the partial derivation of oscillation area from oscillation magnitude and duration. 
Nevertheless, this relationship was broadly comparable for each permutation of 
recombinant RyR2, although there were subtle differences between the steepness of the 
relationship gradient in cells expressing homotetrameric LPGE or heterotetrameric 
LP+GE or WT+LP when compared to WT RyR2, further contributing to the proposal that 
Ca2* removal from the cytoplasm is altered by these combinations of L433P and 
G1885E.
The modulatory effect of G1885E on L433P in terms of the relationships between these 
parameters was most pronounced when both substitutions were co-expressed in a 
homotetrameric fashion (LPGE). However, G1885E also modulated L433P function 
when the two substitutions were co-expressed as heterotetramers (WT+LPGE and 
LP+GE), although only the relationship between oscillation duration and area was 
altered.
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Although Ca2* oscillation area was, rather unsurprisingly, demonstrated to be dependent 
on both oscillation magnitude and duration, there was no apparent relationship between 
these two parameters. This suggests that factors other than oscillation magnitude are 
involved in determining the duration of the Ca2* oscillation, which is likely the rates of 
Ca2* release and subsequent removal.
5.3.5.2. L433P and G1885E expression alter the relationships between the
magnitude and kinetic parameters of spontaneous Ca2* release
Linear regression analysis was used to determine whether perturbation of Ca2* release 
magnitude, as shown in Figure 5.10, was coupled with a compensatory alteration in the 
kinetic parameters of intracellular Ca2* handling and subsequently, whether any such 
relationships were altered by L433P and/or G1885E expression (Figure 5.13). Linear 
regression analysis demonstrated that in RyR2-expressing cells, there were significant 
positive relationships between the magnitude and rate of spontaneous Ca2* release, 
suggesting that an increase in Ca2* release magnitude results in a higher rate of Ca2* 
release i.e. a steeper Ca2* transient (Figure 5.13A, p < 0.001, r2 = 0.29 to 0.58).
Similarly, a positive relationship was observed between the magnitude of Ca2* release 
and the rate of subsequent Ca2* removal from the cytoplasm (Figure 5.13B), suggesting 
that as the magnitude of Ca2* release increases, so too does the rate at which it is 
removed from the cytoplasm. This is likely due to a greater increase in cytoplasmic Ca2* 
concentration having a consequential effect of increasing the Ca2*-dependent activity of 
Ca2* extrusion mechanisms e.g. SERCA, PMCA.
Furthermore, in cells expressing each recombinant RyR2 there appeared to be a weak 
positive relationship between the rate of spontaneous Ca2* release and the rate of 
subsequent Ca2* removal from the cytoplasm (p<0.05, r2 = 0.18 to 0.48, Figure 5.13C), 
suggesting that an increase in the rate of Ca2* release results in a faster rate of Ca2* 
removal. The existence of this relationship could be somewhat consequential, in that a 
higher rate of Ca2* release tends to result from a greater magnitude of Ca2* release 
(Figure 5.13A) and similarly a higher magnitude of Ca2* release results in a higher rate 
of Ca2* removal (Figure 5.13B).
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Figure 5.13. Spontaneous Ca2* release magnitude is related to the rate o f Ca2* release and 
subsequent removal. Linear regression analysis was carried out to determine whether there 
was a relationship between the magnitude and rate of spontaneous Ca2* release as shown in 
panel A or the magnitude of Ca2* release and rate of subsequent Ca2* removal as shown in panel 
B. Similar analysis was carried out to determine whether the rate of Ca2* release was directly 
related to the rate of Ca2* removal as shown in panel C. Significance values (p) < 0.05 indicated 
that a significant relationship between two parameters existed. Plots highlighted in red indicate a 
significantly steeper gradient whereas those highlighted in green indicate a significantly shallower 
gradient compared to WT RyR2. Those highlighted in grey suggest no relationship was observed. 
An arbitrary r2 threshold value >0.3 was deemed to signify acceptable linkage. Asterisked 
gradients indicate those that are significantly different to WT.
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A somewhat surprising observation was that the rate of Ca2+ removal from the cytoplasm 
following spontaneous Ca2+ release did not exhibit a relationship with the duration or 
area of the Ca2+ oscillation in cells expressing any recombinant RyR2s (data not shown). 
This suggests that factors other than the rate of Ca2+ removal are important in 
determining the length of the Ca2+ oscillation. There was also no relationship between 
the rate of spontaneous Ca2+ release and the duration of the Ca2+ oscillation, which is 
less surprising given that the period over which Ca2+ release occurs accounts for only a 
fraction of the total length of the Ca2+ oscillation. There was also no significant 
relationship between the inter-oscillation duration and any other measured Ca2+ 
oscillation parameters. No significant relationships existed between the baseline Fluo3 
fluorescence and any spatial or kinetic parameters of the spontaneous Ca2+ oscillation.
Ampli tude & Temporal 
Parameters
Kinetic
Parameters
Magnitude
vs.
Area
Duration
vs.
Area
Magnitude
vs.
Duration
Magnitude 
vs. 
Rate of 
Release
Magnitude 
vs. 
Rate of 
Decay
Rate of 
Release 
vs. 
Rate of 
Removal
RyR2
WT
GE
LP T A
LPGE ▲ A A ▼
WT+GE
WT+LP
WT+LPGE A A
LP+GE A ▼
Table 5.2. Summary o f the relationships between magnitude, duration, area and 
kinetic parameters o f Ca2* oscillations. Green cells indicate a significant positive 
relationship exists between the indicated parameters (p<0.5) whereas red cells indicate the 
absence of a significant relationship (p>0.05). Arrows indicate the direction of statistically 
significant change in relationship gradient (p<0.05). Data used to generate this table is 
present in Figures 5.12 and 5.13.
The expression of L433P alone or in various combinations with G1885E only caused 
subtle alterations in relationships between oscillation magnitude, duration, area and 
kinetic parameters described above (summarised in Table 5.2). These alterations were 
most prevalent in cells expressing homotetrameric LPGE which abolished the 
relationship between Ca2+ release magnitude and the rate of subsequent Ca2+ removal
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and altered relationships between oscillation magnitude, duration and area. 
Homotetrameric expression of either LP or LPGE exhibited comparable decreases in the 
gradient of the relationship between the magnitude and rate of spontaneous Ca2* 
release, which may be attributable to the observed decrease in ER Ca2* levels (Figure 
5.9) in cells expressing these RyR2s. Despite severely augmenting the Ca2* release 
parameters (section 5.3.4), heterotetrameric WT+LP expression produced comparable 
relationships between Ca2* oscillation parameters compared to WT, which underwent 
subtle alterations in the gradient of the relationship following G1885E co-expression i.e 
WT+LPGE or LP+GE.
5.3.6. Linear regression analysis of spontaneous and caffeine-evoked Ca2* 
release parameters.
Linear regression analysis was also carried out to determine whether cells expressing 
each recombinant RyR2 exhibited any functional coupling between spontaneous Ca2* 
release parameters and those of caffeine-evoked Ca2* release. Data was grouped into 
caffeine dose ranges that induced sub-maximal activation (0.1-0.75mM), activation on 
the exponential phase of the dose response curve (1-2mM) and maximal activation (5- 
10mM), according to caffeine activation curves presented in Figure 3.17 and 3.18. This 
grouping of data was necessary due to a combination of factors:
• Certain recombinant RyR2s, particularly homotetrameric LP and LPGE, resulted 
in significantly fewer cells exhibiting basal Ca2* oscillations.
• Caffeine-activation of RyR2 often unavoidably occurred part-way through a Ca2* 
oscillation and these traces were excluded from subsequent analysis (Figure 
5.6B-C).
Thus, in some instances (e.g. LP: 0.1-0.75mM, n=10 cells and LPGE: 1-2mM, n=9 cells), 
sample number was very low and this adversely affected the rigour of linear regression 
analysis as shown in the data in Appendix II, Figures 9-13 and summarised in Figure 
5.14.
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5.3.6.1. L433P and G1885E have little effect on relationships between magnitude,
duration and area of spontaneous and caffeine-evoked Ca2* release
Linear regression analysis demonstrated that there was a strong, positive relationship 
between the magnitude of spontaneous Ca2* release and the magnitude of subsequent 
caffeine-evoked Ca2* release in oscillating HEK cells expressing each recombinant 
RyR2 (Figure 5.14). This is likely due to the apparent dependence of both modes of Ca2* 
release on the level of ER Ca2* store load. Furthermore, this relationship was observed 
in cells expressing each recombinant RyR2, despite an observed heterogeneity between 
the magnitude of spontaneous and caffeine-evoked Ca2* release between cells 
expressing different RyR2s (Figures 3.17-3.19 and 5.10). Although homotetrameric 
expression of LPGE appears to result in the ablation of the relationship between 
spontaneous and caffeine-evoked Ca2* release magnitude following activation with 1- 
2mM caffeine, this may be an artefact of the relatively low number of data points for this 
experimental condition (n=9). This is likely as a positive relationship was observed 
following activating with high and low activating caffeine concentrations.
There did not appear to be a relationship between the duration of the spontaneous Ca2* 
oscillation and the subsequent caffeine-evoked Ca2* release transient, which may be 
attributable to differences in the nature of Ca2* extrusion following spontaneous or 
caffeine-evoked Ca2* release. The continual presence of caffeine may alter RyR2 gating 
and consequentially ER store refilling compared to when intracellular Ca2* is undergoing 
spontaneous basal cycling.
There are obvious differences between the shapes of Fluo3-signal intensity traces 
representing spontaneous Ca2* oscillations and caffeine-evoked Ca2* transients and 
there was observed heterogeneity of Ca2* oscillation area in cells expressing each 
recombinant RyR2 (Figure 5.10). Despite this, expression of each recombinant RyR2 
resulted in a positive relationship between spontaneous Ca2* oscillation and caffeine- 
evoked Ca2* transient area to varying degrees, indicating that an increase in 
spontaneous Ca2* oscillation area was associated with an increase in the area of the 
subsequent caffeine-evoked Ca2* release transient. Although this relationship was 
observed in cells expressing each RyR2, there was a tendency for this relationship to be 
abolished following activation with maximal concentrations of caffeine in the majority of 
cases.
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Figure 5.14. Functional coupling between spontaneous and agonist evoked Ca2* release parameters. Linear regression analysis was 
carried out on like-parameters of spontaneous and caffeine-evoked Ca2+ release. The mean parameter of spontaneous Ca * release was 
compared against the same parameter of the caffeine evoked Ca2* transient in the same cells. Caffeine concentrations that evoked sub- 
maximal (0.1-0.75mM), exponential (1-2mM) or maximal (5-1 OmM) were applied to cells to activate RyR2, indicated by the^  arrow in each 
example trace. The gradient and robustness of observed relationships between spontaneous and caffeine evoked Ca release was 
summarised as matrix diagrams here and the raw data is presented in Appendix II, Figure 9. The goodness of fit of the data (r )  is indicated by 
the colour of the tabular cell (green > 0.1, orange 0 .5 -0 .7m and red 0.3 - 0.5). Black squares indicate non-fitting data (p>0.05) or the absence 
of a significant relationship. Arrows indicate a significant increase ( A)  or significant decrease (W) in relationship gradient compared to WT 
RYR2 (p < 0.05).
Despite the fact that expression of RyR2 containing the L433P mutation perturbed 
several intracellular Ca2* handling parameters, L433P appeared to have very little effect 
on the observed relationships between the magnitude, duration and area of spontaneous 
and agonist-evoked Ca2* release. Furthermore, there did not appear to be any 
noticeable differences between the relationships observed in cells expressing L433P 
alone or co-expressing L433P with G1885E, regardless of the precise mode of 
expression. This suggests that G1885E has very little effect on the relationships 
between spontaneous and caffeine-evoked Ca2* transient spatial parameters in cells 
expressing L433P.
5.3.6.2. L433P and G1885E have little effect on relationships between kinetic
parameters of spontaneous and caffeine-evoked Ca2* release
Expression of L433P and G1885E has been demonstrated to cause significant 
augmentation of the rate of Ca2* release and subsequent Ca2* removal, following both 
spontaneous (Figure 5.10) and agonist-evoked Ca2* release (Figures 3.20 and 3.22). To 
further examine functional coupling between spontaneous and caffeine-evoked Ca2* 
release and the effects of L433P and G1885E on these relationships, linear regression 
analysis of kinetic parameters of both modes of Ca2* release was carried out.
Cells expressing WT RyR2 exhibited a moderate positive relationship between the rates 
of spontaneous and caffeine-evoked Ca2* release. This relationship was also observed 
in cells expressing homotetrameric GE or heterotetrameric WT+GE, although the data 
was a poorer fit to the linear regression model. All modes of L433P expression, either 
alone (LP) or co-expressed with WT RyR2 or G1885E (WT+LP, LP+GE), caused near 
complete ablation of this relationship, suggesting that the presence of L433P is sufficient 
to cause severe perturbation of this relationship. Furthermore, there was little difference 
between the relationships observed in cells expressing L433P alone (LP or WT+LP) or 
co-expressing it with G1885E (LPGE, WT+LPGE or LP+GE), suggesting that this 
relationship is unaffected by G1885E co-expression.
In contrast to the weak relationships observed between the rates of spontaneous and 
caffeine-evoked Ca2* release only being observed in cells expressing WT RyR2 or 
G1885E, there appeared to be a moderate relationship between the rates of cytosolic
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Ca2* removal in cells expressing all recombinant RyR2s (Figure 5.14). This suggests 
that a higher rate of Ca2* removal following spontaneous Ca2* release tends to result in 
higher rate of Ca2* removal following caffeine-evoked channel activation. Interestingly, 
the gradient of the regression line of this relationship is relatively low in all cases (0.24 -  
0.31), indicating that an increase in rate of Ca2* removal following spontaneous Ca2* 
release only results in a comparably small increase in rate of removal following caffeine- 
evoked channel activation. This observation is possibly attributable to the fact that 
caffeine added as a bolus may alter post-activation gating, store refilling and cytoplasmic 
Ca2* removal. The only exception to the observation of this relationship was in cells 
expressing homotetrameric LP or LPGE following RyR2 activation with 1-2mM caffeine, 
although a positive relationship was observed following minimal and maximal caffeine 
exposure.
Taken together, this data suggests that L433P expression only has subtle effects on the 
functional coupling between spontaneous and agonist-evoked Ca2* release parameters, 
despite causing significant perturbation of the absolute values of these parameters. Cells 
expressing G1885E, exhibited similar relationships between spontaneous and caffeine- 
evoked Ca2* release parameters compared to WT RyR2 in all cases. This provides 
further evidence that G1885E does not result in gross alteration of RyR2 function. 
Furthermore, co-expression of G1885E with L433P tended to exhibit similar relationships 
between spontaneous and caffeine-evoked Ca2* release parameters to when L433P was 
expressed in the absence of G1885E. Taken together, these observations suggest that 
G1885E does not modulate the relationships between magnitude, duration, area and 
kinetic parameters of spontaneous and caffeine evoked Ca2* release in cells expressing 
WT RyR2 or L433P.
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5.4. Discussion
5.4.1. G1885E modulates the propensity for spontaneous Ca2* release from L433P 
RyR2.
Spontaneous Ca2* release from the ER is proposed to be causative of DADs which can 
lead to arrhythmia and SCD, characteristic of CPVT/ARVD2 (Liu et al., 2006). Here, it 
was observed that heterologous expression of RyR2 containing the L433P mutation and 
G1885E polymorphism, both on the same subunits (representative of in cis inheritance) 
and separate RyR2 subunits (representative of in trans inheritance), altered the 
propensity for cells to exhibit spontaneous Ca2* release, similar to the SOICR 
mechanism described by Chen and colleagues (Jiang et al., 2004; MacLennan & Chen,
2009).
In disagreement with the findings of Jiang et al, the homotetrameric expression of L433P 
did not produce a significant increase in spontaneous Ca2* release propensity, and a 
similar ER Ca2* level was observed in oscillating and non-oscillating cells expressing 
L433P. The reasons for these discrepancies are unknown but could be attributable to 
differences in experimental protocol (Jiang et al., 2005). The data produced here 
confirms that L433P does not exhibit the typical characteristics of a gain-of-function 
RyR2 mutation. Furthermore, the homotetrameric expression of LPGE exhibited a more 
severe phenotype than LP alone in terms of spontaneous Ca2* release propensity, 
providing further evidence that despite appearing functionally benign when expressed 
alone, G1885E modulates the severity of L433P dysfunction. This also adds strength to 
the argument that L433P and L433P-G1885E are not typical gain-of-function mutations, 
as other arrhythmogenic loss-of-function RyR2 mutations have been shown to result in a 
decrease (G1885E/G1886S, Koop et al., 2008) or complete ablation (A4860G, Jiang et 
al., 2007) of spontaneous Ca2* release. However, due to the autosomal dominant nature 
of RyR2 mutations (Tiso et al., 2001; Priori et al., 2002), homotetrameric expression of 
these substitutions is not the most physiologically accurate reflection of L433P/G1885E 
pathophysiology.
Co-expression of L433P with WT RyR2, which better reflects the autosomal dominant 
nature of CPVT/ARVD-linked RyR2 mutations, presented an extremely different 
phenotype to when L433P was expressed as homotetramers.This further highlights the 
functional importance of the precise mode of RyR2 mutation expression and the need to
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characterise disease-linked RyR2 mutations in a manner representative of the observed 
mode of inheritance in vivo. The observed increase in propensity for WT+LP expressing 
cells to exhibit spontaneous Ca2* release was more characteristic of gain-of-function 
mutations associated with CPVT/ARVD2 (Jiang et al., 2005).
The modulatory effect of G1885E was also evident when co-expressed with L433P in a 
manner representative of heterozygous inheritance (WT+LPGE or LP+GE), restoring the 
propensity for spontaneous Ca2* release to normal levels, suggesting that these modes 
of G1885E expression offer a protective effect with regards to normalising spontaneous 
Ca2* release propensity. However, WT+LPGE co-expression best represents the mode 
of L433P and G1885E inheritance in ARVD2-patients in which these substitutions were 
first identified (Tiso et al., 2001), yet results in similar spontaneous Ca2* release 
propensity to cells expressing WT RyR2. This makes it unlikely that altering 
spontaneous Ca2* release propensity is the mechanism by which heterotetrameric 
L433P-G1885E expression results in ARVD2 pathogenesis. However, whether similar 
findings are made when L433P and G1885E are expressed in a cardiac environment 
expressing the full complement of RyR2 accessory proteins remains to be determined.
Although when expressed alone, G1885E appears functionally benign in terms of 
spontaneous Ca2* release, it undoubtedly alters the propensity for cells expressing 
L433P to exhibit spontaneous Ca2* release and as such, modulates L433P channel 
activity in terms of one of the proposed pathogenic mechanisms of RyR2 mutations.
5.4.2. The role of ER Ca2* store load in spontaneous Ca2* release
The vast majority of functionally characterised CPVT mutations, display increased 
spontaneous Ca2* release coupled with decreased Ca2* in the ER/SR store of cells 
exhibiting spontaneous Ca2* oscillations (Jiang et al., 2004; Jiang et al., 2005), which is 
proposed to result from an increased sensitivity to channel activation by luminal Ca2* 
and a decreased threshold for spontaneous Ca2* release. Conversely, RyR2 mutations 
which display a decreased propensity to exhibit basal Ca2* oscillations, have been 
shown to exhibit increased ER Ca2* as a result of decreased luminal Ca2* sensitivity and 
an increase in the luminal threshold for spontaneous Ca2* release (Jiang et al., 2007; 
Koop et al., 2008).
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In the present experiments there was no evidence that basal cytoplasmic Ca2* 
concentration influenced the propensity for cells to exhibit spontaneous Ca2* release, as 
basal Ca2* levels were equivalent between oscillating and non-oscillating cells. Similarly, 
there was little evidence that spontaneous Ca2* release propensity was solely dependent 
on ER Ca2* store load, although several notable observations were made. Firstly, ER 
Ca2* levels were consistently lower in oscillating cells compared to non-oscillating cells 
expressing the same recombinant RyR2, which is consistent with previous data (Jiang et 
al., 2007; Koop et al., 2008) and supports the hypothesis that there is a luminal Ca2* 
threshold, above which spontaneous Ca2* release occurs. Secondly, there was 
significant heterogeneity between the ER Ca2* levels of cells expressing each 
recombinant RyR2, with the majority exhibiting a decrease in ER Ca2* compared to cells 
expressing WT RyR2. Finally, the level of ER Ca2* did not completely reconcile the 
heterogeneity in spontaneous Ca2* release propensity observed in cells expressing the 
different RyR2s, nor did it reconcile with any of the measured Ca2* oscillation 
parameters.
Unlike the majority of characterised CPVT-linked mutations which exhibit a decrease in 
ER Ca2* load and an increase in spontaneous Ca2* release (Jiang et al., 2005), here 
homotetrameric LPGE exhibited a decrease in ER Ca2* load coupled with a decrease in 
spontaneous Ca2* release propensity, if homotetrameric LPGE expression had simply 
lowered the luminal Ca2* threshold for spontaneous Ca2* release, an observed increase 
in spontaneous Ca2* release propensity would have been expected, although this was 
not the case. This could imply that expression of L433P-G1885E may cause a small, 
sustained Ca2* leak which is sufficient to cause ER Ca2* store depletion, yet not result in 
spontaneous Ca2* release through complete RyR2 activation. The existence of a 
underlying Ca2* leak that does not manifest as a transient Ca2* release event has 
recently been described (Santiago et al., 2010), adding plausibility to this hypothesis. 
Conversely, the significant increase in spontaneous Ca2* release propensity in cells 
expressing heterotetrameric WT+LP was coupled with a similar ER Ca2* load to WT 
RyR2 in oscillating cells, yet according to the model proposed by Chen et al, an increase 
in spontaneous Ca2* release propensity would be expected to be associated with a 
decreased ER Ca2* load. This suggests that although there are similarities with the 
findings presented here and that of Jiang et al, but the SOICR model doesn't reconcile 
completely with the intracellular Ca2* handling dysfunction resulting from L433P 
expression.
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Potentially, this may suggest that WT+LP co-expression has little effect on the luminal 
Ca2* threshold for spontaneous Ca2* release, but somehow results in increased ER Ca2* 
store refilling, accounting for the increase in ER Ca2* in non-oscillating cells and 
consequential increase in spontaneous Ca2* release propensity. However, it must be 
stressed that without measuring the activity of other proteins involved in ER Ca2* 
regulation, it is impossible to determine whether the altered ER Ca2* load is a direct 
result of RyR2 dysfunction or due to compensatory intracellular Ca2* handling by other 
proteins e.g. SERCA, PMCA.
5.4.3. Investigation of spontaneous Ca2* oscillation parameters reveals a possible 
mechanism of heterozygous WT+LPGE pathogenesis
In HEK cells expressing recombinant RyR2, spontaneous Ca2* release events manifest 
as basal Ca2* oscillations with a significantly different morphology to caffeine-induced 
Ca2* transients (Jiang et al., 2005; Jiang et al., 2007; Jones et al., 2008; Koop et al., 
2008). Consistent with published data, caffeine-induced Ca2* transients took longer to 
decrease to basal Ca2* levels compared to spontaneous Ca2* oscillations (Koop et al., 
2008). Similarly, the magnitude of spontaneous Ca2* release tended to be slightly lower 
than that observed following caffeine-evoked Ca2* release. Both of these observations 
are likely due to RyR2 inactivation due to decreased luminal Ca2* content and increased 
cytoplasmic Ca2* concentration following spontaneous Ca2* release, whereas RyR2 
activated by caffeine may alter processes of channel inactivation, cytoplasmic Ca2* 
removal and ER store refilling. Given that spontaneous Ca2* release events undergo 
basal Ca2* cycling that is not observed following caffeine-evoked activation of RyR2, the 
parameters of spontaneous Ca2* release were examined to identify whether they 
provided further indications of the mechanisms by which L433P and G1885E alter 
intracellular Ca2* handling properties.
In accordance with the caffeine-evoked Ca2* release data (Chapter 3), homotetrameric 
expression of LP or LPGE or the heterotetrameric expression of WT+LP caused the 
most significant perturbation of intracellular Ca2* handling dynamics following 
spontaneous Ca2* release. However, in contrast to the caffeine-evoked Ca2* release 
data, the heterotetrameric expression of WT+LPGE also resulted in significant alteration
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of several Ca2* handling parameters of spontaneous Ca2* release, that were not 
observed following caffeine activation.
Increased magnitude of ER/SR Ca2* release is a phenomenon commonly associated 
with arrhythmia-linked RyR2 mutations examined in heterologous systems (George et 
al., 2003a; Thomas et al., 2004; Jiang et al., 2005) and is proposed to result in a 
sustained elevation of cytoplasmic Ca2* levels which can contribute to DAD initiation and 
action potential prolongation. Interestingly, several modes of L433P/G1885E expression 
altered the magnitude and duration of spontaneous Ca2* release to varying degrees (LP, 
LPGE, WT+LP and WT+LPGE), but all of these culminated in a significantly increased 
oscillation area, which can be interpreted as a sustained elevation of cytoplasmic Ca2* 
concentration following ER Ca2* release.
Although, expression of WT+LP or WT+LPGE heterotetramers also results in an 
increased rate of Ca2* removal from the cell following spontaneous Ca2* release, this 
increase in rate of Ca2* removal was not sufficient to restore the oscillation area to 
normal levels. This suggests that heterozygous inheritance of either L433P or L433P- 
G1885E may lead to sustained elevated cytoplasmic Ca2* and DAD’s following RyR2 
activation. Given that WT+LPGE expression is most representative of the observed 
genotype in vivo (Tiso et al., 2001), this sustained elevation of cytoplasmic Ca2* caused 
by an increase in oscillation magnitude, duration and area could contribute to the 
pathogenesis of heterozygously inherited L433P-G1885E. Although heterotetrameric 
WT+LP and WT+LPGE expression also increased the rate of spontaneous Ca2* release, 
this only constitutes a small fraction of the Ca2* oscillation and has little impact on 
oscillation duration or area.
The measurement of spontaneous Ca2* oscillation parameters provides a possible 
mechanism by which WT+LPGE expression results in an arrhythmogenic phenotype, 
through the prolongation of cytoplasmic Ca2* elevation during spontaneous basal Ca2* 
cycling.
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5.4.4. G1885E preferentially modulates cytoplasmic Ca2* removal parameters of 
spontaneous Ca2* oscillations through WT+L433P channels
The measurement of spontaneous Ca2* release parameters provides further evidence 
that G1885E modulates L433P mutant channel function, both when co-expressed as 
homotetramers (LPGE) or in a heterotetrameric fashion (WT+LPGE, LP+GE). G1885E 
appeared to exacerbate the increase in Ca2* oscillation area when expressed with 
L433P in a homotetrameric (LPGE) or heterotetrameric (WT+LPGE) manner, which 
could potentially further increase the likelihood of DAD occurrence in vivo. In contrast, 
the expression of LP+GE heterotetramers resulted in similar Ca2* oscillation magnitude, 
duration and area compared to WT, suggesting that G1885E restored Ca2* oscillation 
area to normal levels when expressed in this composite heterotetrameric fashion. This 
could potentially indicate that inheritance of L433P and G1885E on distinct alleles may 
offer protection against prolongation of the Ca2* transient and DAD onset observed in 
WT+LP and WT+LPGE expression, although this would need to be investigated further 
in a cardiac cellular environment. Furthermore, this corroborates the finding that 
heterotetrameric LP+GE expression had little effect on caffeine-evoked Ca2* release 
parameters (section 3.3.5 and 3.3.6) and emphasises the importance of the precise 
mode of G1885E co-expression on the extent to which it modulates L433P function.
Although G1885E had little effect on the rate of Ca2* release through L433P channels, 
the expression of WT+LPGE or LP+GE heterotetramers partially restored the increased 
rate of cytoplasmic Ca2* removal caused by WT+LP expression to normal levels. This 
suggests that G1885E preferentially modulates L433P intracellular Ca2* handling during 
the period of cytoplasmic Ca2* removal, rather than the actual Ca2* release event itself. 
Given that G1885E is located within a region containing a low affinity cytoplasmic Ca2* 
binding site involved in RyR inactivation (Laver, 2007), the polymorphism may alter 
channel activation/inactivation properties, although this would need to be confirmed 
using single channel analysis.
In contrast, although expression of homotetrameric LPGE increased Ca2* oscillation 
area compared to homotetrameric LP, LP and LPGE exhibited similar rates of 
spontaneous Ca2* release and subsequent Ca2* removal, suggesting that G1885E has 
no modulatory effect on the kinetic Ca2* handling parameters of homotetrameric L433P. 
Similar to observations made through the characterisation of the effects of SCN5A SNPs
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on mutations in the same gene (Viswanathan et al., 2003; Poelzing et al., 2006), the 
precise mode of L433P and G1885E co-inheritance determines the extent to which the 
SNP modifies mutant channel function.
5.4.5. L433P and G1885E perturb functional coupling relationships between intra­
oscillation Ca2* handling parameters
Functional relationships were observed between several intracellular Ca2* handling 
parameters following spontaneous Ca2* release. As one would expect, both the 
magnitude of Ca2* release and the duration of the basal Ca2* oscillation were integral in 
determining the area of the spontaneous Ca2* oscillation. Conversely, the magnitude of 
spontaneous Ca2* release had little bearing on the duration of the Ca2* oscillation, 
suggesting that there were other determining factors involved. However, oscillation 
duration was not significantly associated with any of the other measured parameters, 
including the rate of Ca2* removal, suggesting that one factor alone does not determine 
the duration of the spontaneous Ca2* oscillation.
The magnitude of spontaneous Ca2* release was also a determining factor in the rate at 
which Ca2* was released from the ER and the rate at which it was subsequently 
removed from the cytosol, which is consistent with published data from a canine 
myocyte model (Hoeker et al., 2009). These observations are most likely due to an 
increased magnitude of Ca2* release creating a steeper luminal-to-cytosolic Ca2* 
gradient, increasing the rate of Ca2* release, whereas, a greater increase in cytoplasmic 
Ca2* concentration is likely to increase the Ca2*-dependent activity of Ca2* extrusion 
proteins, consequently increasing the rate at which Ca2* is removed from the cytoplasm. 
The observed co-dependence of both the rate of Ca2* release and subsequent removal 
on the magnitude of Ca2* release is likely to be attributable for the observed relationship 
between these two kinetic parameters. Taken together, this data suggests that in cells 
expressing the majority of RyR2s, a functional coupling exists between Ca2* release and 
Ca2* extrusion mechanisms during basal Ca2* cycling, as alterations in the magnitude of 
spontaneous Ca2* release appear to be compensated for by the activity of other 
intracellular Ca2* handing pathways. Furthermore, this coupling appears to be altered by 
L433P expression, and further modulated by the co-expression of G1885E.
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Expression of homotetrameric LPGE caused the greatest level of perturbation of intra- 
oscillation parameter relationships, causing complete ablation of the relationship 
between the magnitude of Ca2* release and its subsequent removal. Furthermore, 
homotetrameric LPGE expression altered the relationships between oscillation 
parameters that could contribute to transients with an increased area, suggesting that 
this mode of L433P and G1885E expression causes gross perturbation of intracellular 
Ca2* handling functional coupling, particularly of that involved with cytoplasmic Ca2* 
removal. The alteration of these intra-oscillation parameter relationships was less 
pronounced in cells expressing homotetrameric LP, suggesting that they are modulated 
by the presence of G1885E.
Despite the heterotetrameric expression of WT+LP causing severe alteration in Ca2* 
handling parameters, it did not disrupt the functional coupling between these 
parameters, suggesting an element of compensation in cytoplasmic Ca2* removal. 
However, the heterotetrameric expression of WT+LPGE or LP+GE altered the precise 
nature of these relationships compared to both WT or WT+LP, providing further 
evidence that G1885E has a role in modulating the functional coupling exhibited by 
L433P channels. Homotetrameric or heterotetrameric G1885E expression (GE or 
WT+GE) had no effect on any of the measured relationships between oscillation 
parameters, demonstrating that when expressed alone the polymorphism does not 
perturb the functional coupling of intracellular Ca2* handling, but modulates L433P 
function when co-expressed with the mutation.
5.4.6. L433P and G1885E co-expression alters the relationships between 
spontaneous and caffeine-evoked Ca2* release
Regression analysis was also used to determine whether there was any observable 
functional coupling between the like-parameters of spontaneous Ca2* release events 
and those of subsequent caffeine-evoked Ca2* release in the same cells. Given that 
caffeine is believed to sensitise the channel to activation by luminal or cytosolic Ca2* 
(Sitsapesan & Williams, 1990; Kong et al., 2008), one would expect the Ca2* handling 
parameters of these two modes of ER Ca2* release to be closely related. However, 
single channel analysis has revealed that caffeine and Ca2* are very different in their 
mechanisms of RyR2 activation, with caffeine increasing channel P0 by prolonging the
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duration of channel openings, whereas Ca2+ increases channel P0 by increasing the 
frequency of channel openings (Gaburjakova & Gaburjakova, 2006). Despite these 
differences in RyR2 activation mechanisms, the results of linear regression analysis 
confirmed that several parameters of spontaneous and caffeine-evoked Ca2+ release 
exhibited positive relationships e.g. magnitude, rate of Ca2+ removal, and that these 
relationships were not grossly altered by L433P and/or G1885E expression. Conversely, 
some parameters exhibited little or no relationship between those of spontaneous and 
caffeine-evoked Ca2+ release e.g. rate of Ca2+ release , duration, which may or not be 
due to differences in caffeine and Ca2+ activation properties.
Furthermore, L433P and G1885E appeared to have little effect on the relationships 
between spontaneous and caffeine-evoked Ca2+ release parameters. This could 
potentially be due to the greater level of systemic variation existing between the 
mechanisms of these two modes of Ca2+ release and subsequent Ca2+ removal masking 
any subtle alterations in coupling caused by RyR2 mutations.
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5.4.7. Chapter summary
The data presented here further demonstrates that the most substantial deviation from a 
“normal” intracellular Ca2* handling phenotype was observed following the 
homotetrameric expression of LP or LPGE, or the heterotetrameric expression of 
WT+L433P or WT+L433P-G1885E. These modes of expression altered spontaneous 
Ca2* release propensity and perturbed the magnitude, duration, area and kinetic Ca2* 
handling parameters of spontaneous Ca2* release and disrupted functional relationships 
between intra-oscillation Ca2* handling parameters
It also provides further evidence that alone, G1885E is predominantly functionally 
benign, yet it can modulate L433P channel function to different extents, depending on 
whether it is located on the same or different RyR2 subunits as the mutation. 
Furthermore, the extent to which G1885E altered L433P channel function depended on 
whether it was expressed as homotetramers i.e. decreased rate of Ca2* release, or as 
heterotetramers i.e. increased rate of Ca2* release. Interestingly, it appeared that 
G1885E tended to exhibit no-effect or an exacerbatory effect on L433P function when 
expressed in a homotetrameric fashion (LPGE), yet tended to have either no effect or a 
“normalising” effect on mutant channel function when expressed with L433P in a 
heterotetrameric manner (WT+LPGE or LP+GE).
Co-expression of L433P-G1885E with WT RyR2 (WT+LPGE), most representative of the 
ARVD2 genotype in vivo did not alter the propensity for spontaneous Ca2* release. 
However, this mode of L433P-G1885E expression altered intracellular Ca2* handling 
parameters in such a way that may result in a sustained elevation of cytoplasmic Ca2* 
following spontaneous Ca2* release, providing a potential mechanistic basis for 
WT+LPGE pathogenesis.
The investigation of intra-oscillation Ca2* handling parameter relationships revealed that 
expression of RyR2 containing L433P, with and without G1885E caused alterations in 
compensatory mechanisms of intracellular Ca2* handling, particularly through 
homotetrameric LPGE expression. Furthermore, G1885E exerted a subtle modulatory 
effect on the coupling observed with L433P, particularly of parameters involved in the 
‘recovery’ phase of the Ca2* oscillation, further indicating G1885E exerts its modulatory 
effects during the inactivation of RyR2.
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Although the examination of relationships between identical parameters of spontaneous 
and caffeine-evoked Ca2* release revealed that there was a degree of functional 
coupling between the two types of Ca2* release, these relationships were not greatly 
altered by L433P and/or G1885E expression.
Comparing the spontaneous Ca2* release data presented in this chapter with that of the 
caffeine-evoked Ca2* release experiments in chapter 3, demonstrates that although the 
majority of findings are reconciled between the two data sets, there are also some 
differences. These are likely to be a product of differences in activation and inactivation 
mechanisms following caffeine-mediated or spontaneous RyR2 activation. Importantly, 
this data in this chapter and the rest of this thesis demonstrates the modulatory effect of 
a relatively common RyR2 SNP on an ARVD2-linked mutation.
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Chapter 6
General Discussion
6.1. General Discussion
6.1.1. Precise mode of mutation expression is critical in determining the resulting 
Ca2* handling phenotype
This thesis supports the concept that L433P channels underpin very different 
phenotypes depending on whether they were expressed as homotetramers or 
heterotetramers consisting of both WT and L433P subunits. Homotetrameric L433P 
appeared to cause a decrease in channel sensitivity to activation, consistent with the 
findings of Thomas et al (2004), whereas heterotetrameric L433P (in combination with 
WT subunits) exhibited a gain-of-function Ca2* handling phenotype more typical of other 
CPVT/ARVD2 mutations (Chapters 3, 5). This observation is in contrast to the previous 
characterisation of heterotetrameric mutant RyR1 (Tong et al., 1999) and RyR2 
(Wehrens et al., 2003; Lehnart et al., 2008) in heterologous systems, which exhibited a 
‘diluted’ phenotype when co-expressed with WT RyR2, although the scope of these 
characterisations was limited.
The observation that L433P mutant co-expression with WT RyR2 results in a complex 
phenotype, that could not have been predicted from the analysis of either channel 
separately, highlights the inherent limitations in characterising mutant channels in a 
homotetrameric form. This is particularly pertinent with so-called ‘loss-of-function’ 
mutations e.g. A4860G, which exhibits a complete loss of luminal Ca2* sensitivity (Jiang 
et al., 2007), which would presumably result in an extremely lethal phenotype in vivo. 
However, unlike the experimental studies of Jiang and colleagues, only a proportion of 
RyR2 channels would be A4860G homotetramers given the autosomal dominant nature 
of such mutations, with heterotetrameric and WT channels also being expressed. This is 
further highlighted by the disparity in the results of biophysical characterisation of 
homotetrameric G1885E-G1886S channels, which abolished luminal Ca2* sensitivity 
(Koop et al., 2008) compared to composite heterotetrameric G1885E+G1886S channels 
(Milting et al., 2006) which resulted in channels exhibiting several sub-conductance 
states.
Taken together with the data presented here, this re-emphasises the need to 
characterise RyR2 mutations in a variety of experimental systems that allow 
investigation of the mutation in a manner representative of the heterozygous inheritance
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pattern observed in vivo i.e. knock-in mouse models (Cerrone et al., 2005; Kannankeril 
et al., 2006; Goddard et al., 2008; Lehnart et al., 2008; Fernandez-Velasco et al., 2009) 
or HL-1 cells (George et al., 2003a; 2006; 2007). Recombinant expression of mutant 
RyR2 in immortalised cardiomyocytes (HL-1) provides the means to examine the effects 
of heterotetramerisation on mutant channel function in a cardiac setting. However, the 
presence of endogenous RyR2 in such cells makes it likely there will be disparity 
between the relative expression levels of each RyR2 subunit type following recombinant 
RyR2 expression. The generation of heterozygous knock-in mouse models further 
alleviates this problem, allowing the investigation of heterotetramers in a mammalian 
cardiac system. However, considerations need to be made for species differences i.e. 
heart rate, cardiac output, arrhythmia susceptibility, variation in relative Ca2* 
homeostasis mechanisms e.g. SERCA, NCX (Cook et al., 2009). Furthermore, the 
genetic background of transgenic mice harbouring RyR2 mutations has been proposed 
to influence the resulting phenotype, with discrepancies between different mouse models 
carrying the same mutation being reported (Lehnart et al., 2008; Uchinoumi et al., 2010).
6.1.2. G1885E channels appear functionally normal yet G1885E exhibits a 
profound modulatory effect on L433P channel dysfunction
The majority of intracellular Ca2* handling parameters remained unaffected by G1885E 
expression (Chapters 3, 4 and 5), irrespective of whether it was expressed exclusively 
as G1885E homotetramers or as heterotetramers consisting of WT and G1885E 
subunits. This is entirely consistent with the view that G1885E is a SNP rather than a 
disease linked mutation, a notion which is reinforced by the prevalence of G1885E in the 
healthy population (Milting et al., 2006; Medeiros-Domingo et al., 2009). However, the 
data presented here shows that G1885E modulated nearly all of the examined Ca2* 
handling parameters of L433P channels, providing the first compelling evidence that a 
common RyR2 SNP can modulate the effects of an ARVD2-linked RyR2 mutation, 
similar to the phenomenon observed in cardiac Na* channelopathies (Viswanathan et 
al., 2003; Ye et al., 2003; Poelzing et al., 2006; Nof et al., 2010). This suggests that 
G1885E is a modifier of mutant channel function, rather than a dominant disease- 
causing mutation. Also consistent with the emergence of the role of SNPs in other 
cardiac channelopathies, was the observation that the precise mode of L433P and 
G1885E co-expression was critical in determining the extent to which G1885E altered
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L433P channel function, which is further highlighted by the disparity in findings by Koop 
et al and Milting et al.
6.1.3. Mutant dysfunction is most prominent in the decay phase of the Ca2* 
transient
A recurrent theme was the link between intracellular Ca2* handling dysfunction and 
alterations in the decay phase of the Ca2* transient (Chapters 3,4 and 5). RyR2 
containing the L433P mutation, in the presence and absence of G1885E, perturbed 
intracellular Ca2* parameters in such a way that could lead to prolongation of elevated 
cytoplasmic Ca2* levels (Chapter 5). This is entirely consistent with a previous 
characterisation of L433P, which demonstrated L433P reduced Ca2*-dependent 
inactivation (Thomas et al., 2005). This phenomenon has been associated with 
increased DAD occurrence and corroborates data generated in mutant RyR2 mouse 
models (Liu et al., 2006; Fernandez-Velasco et al., 2009), providing a potential 
mechanism for LP, LPGE, WT+LP and WT+LPGE pathogenesis. Although composite 
heterotetrameric expression of LP+GE perturbed several Ca2* release parameters, this 
appeared to be compensated for by altered Ca2* extrusion mechanism activity (Chapter 
5), resulting in the observation of a ‘normal’ post-activation cytoplasmic Ca2* profile, 
although further investigation is required to determine the exact nature of these extrusion 
and sequestration mechanisms.
6.1.4. The mode of G1885E and L433P co-expression determines the functionality 
of the resultant channels
The degree of modulation afforded by G1885E on L433P dysfunction depended heavily 
on the precise mode of co-expression, in a similar manner to that observed with SNPs 
and mutations in SCN5A (Viswanathan et al., 2003; Ye et al., 2003; Poelzing et al.,
2006). RyR2 homotetramers formed from subunits containing both substitutions 
(representative of *homozygous in cis’ inheritance) exhibited augmented dysfunction 
compared to homotetrameric L433P channels. Conversely, RyR2 heterotetrameric 
channels comprising of L433P and G1885E subunits (representative o f 'heterozygous in
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trans’ inheritance) or WT and L433P-G1885E subunits (representative of ‘heterozygous 
in cis’ inheritance) displayed a marked attenuation of L433P linked channel dysfunction.
Although both modes of heterotetrameric L433P and G1885E co-expression (WT+LPGE 
and LP+GE) appeared to exhibit a normalising effect on perturbed L433P Ca2+ handling, 
the extent of this also varied between the modes of heterotetrameric co-expression, with 
LP+GE expression exhibiting the most significant degree of modulation. Although a 
molecular basis for this observation remains unknown, a recent study examining intra­
molecular RyR2 interactions has provided a potential insight into these observed 
differences. The interaction between the N-terminal and central mutation domains in the 
RyR2 structure has been shown to be an intra-subunit interaction, as opposed to an 
interaction of these two domains of the same RyR2 subunit (Liu et al., 2005; Liu et al.,
2010). Given the relatively close proximity of DR3, which encompasses G1885E (Zhang 
et al., 2003), to the N-terminal mutation domain, which contains L433P (Wang et al.,
2007), it is plausible to speculate that there may be a certain degree of physical or 
allosteric interaction between the regions containing G1885E and L433P on separate 
subunits (LP+GE) compared to when they are expressed on the same subunits 
(WT+LPGE). However, whether DR3 interacts with the N-terminal domain to elicit 
channel modulation remains unknown.
Given that DR3 is proposed to contain a low-affinity Ca2+ binding site involved in channel 
inactivation (Hayek et al., 1999; Zhang et al., 2003), the insertion of a glycine for a 
negatively charged glutamate residue in this region may alter the inactivation properties 
of the mutant channel, which is consistent with a much of the data presented here 
suggesting that dysfunction arises during the recovery phase of the Ca2+ transient. 
However, the absence of dysfunctional Ca2+ removal in cells expressing G1885E alone, 
suggests that any alterations to Ca2+-dependent ‘inactivation’ caused by G1885E only 
manifest when L433P is also expressed. The examination of L433P and G1885E 
function in single channel bilayer studies would provide a valuable insight into the effects 
that these substitutions have on channel gating and conductance characteristics.
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6.1.5. Towards therapeutic benefit
Recently, it has been reported that the gene transfer of SERCA2a into a rat ischemic HF 
model offered significant long-term protection against HF onset and increased survival 
rates (Niwano, 2008), providing evidence of the potential benefits of gene therapy in 
treating cardiomyopathies. In the context of gene therapy and from a practical 
perspective, the transfer of an additional copy of a down-regulated gene i.e. SERCA2a 
or S100A1 (Hajjar, 2005) in HF, or a “rescuing” copy of a dysfunctional gene, is more 
feasible than attempting to modify a dysfunctional allele that is present in the patient i.e. 
in cis modification. The finding that G1885E co-expressed in ‘in trans' partly ameliorated 
the dysfunction of the autosomal-dominant L433P mutation (Chapter 3 and 5), provides 
the impetus for investigating this mode of complementation in the treatment of inherited 
RyR2-linked arrhythmias.
However, the modulatory effects of this SNP have only been described for two RyR2 
substitutions, L433P and G1886S (Chapter 3-5, Milting, 2006, Koop, 2008), and whether 
this SNP exerts a similar modulatory function on other RyR2 mutations, particularly 
those that are not found in close physical proximity, remains unknown. Furthermore, 
before the translational use of a ‘therapeutic’ polymorphism-based strategy could be 
considered, there would need to be a greater understanding of the mechanism of L433P 
(and RyR2 mutations in general) and how it is modulated by a common SNP (G1885E). 
The generation and characterisation of transgenic mice heterozygous for L433P or 
composite heterozygous for L433P and G1885E, could potentially elucidate whether this 
SNP afforded protective benefits on mutant RyR2 function in an intact mammalian 
system. This could provide an indication as to whether common RyR2 SNPs present a 
potential therapeutic tool for the treatment of genetic RyR2 dysfunction.
Another limiting factor is the rarity of individual mutations, with some particular mutations 
only being identified in a single family, making the development of “tailor-made” gene 
therapies unfeasible at present. However, if subsequent investigation of the effects of 
the more common RyR2 SNPs e.g. Q2958R (allelic frequency of between 26-34%) on 
RyR2 mutant channel function reveals that a single SNP can exert beneficial modulation 
of many different RyR2 mutations, development of such therapies may become more 
plausible.
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6.1.6. Further Work
In order to gain a better understanding of the mechanisms by which these substitutions 
result in an arrhythmia-linked phenotype and how G1885E can modulate dysfunctional 
L433P Ca2* handling, further work in other experimental systems is necessary. However, 
it has been suggested that the abundance of different investigative techniques used to 
examine RyR2 function, may contribute to the disparity in findings relating to the 
consequences of RyR2 mutations (George, 2008). This is likely further exacerbated by 
variation in the experimental tools used between research groups i.e antibody efficiency 
(Huke & Bers, 2008), transgenic mouse background (Lehnart et al., 2008; Uchinoumi et 
al., 2010), mode of recombinant expression (Thomas et al., 2004; Jiang et al., 2005), 
assay used etc. However, until comprehensive, standardised techniques become 
available to characterise the effects of RyR2 mutations on intracellular Ca2* handling 
dynamics, the complementary use of several of these experimental systems is the best 
means of mutant investigation.
Single channel analysis of RyR2 containing these substitutions would provide an insight 
into the effects of these substitutions on channel gating and conductance parameters. 
However, careful consideration would need to be given to the examination of 
heterotetrameric channels in these experiments due to the unknown stoichiometry of 
single RyR2 channels isolated from cells co-transfected with two distinct RyR2 cDNAs 
i.e. WT and L433P.
Although the use of an RyR-null HEK cell model provides more control over relative 
expression levels of distinct RyR2 subunits compared to other cell models which 
endogenously express RyR2, HEK cells lack many cardiac specific Ca2* handling and 
RyR2 accessory proteins. Given that the activity of these accessory proteins may or may 
not alter or be altered by the presence of L433P and G1885E, it would be beneficial to 
further examine the effects of these substitutions in a cellular environment more closely 
mimicking the scenario in vivo i.e. HL-1 cells, knock-in mouse models. Given the location 
of G1885E being in close proximity to the FKBP12.6, binding site, it would be of 
particular interest to determine if this SNP has any effect on FKBP12.6 binding affinity or 
activity, both in cell based experiments or single channel studies. It would also be 
extremely useful to determine the rates of the individual Ca2* extrusion mechanisms in
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cells expressing each recombinant RyR2, to confirm the existence and nature of 
compensatory Ca2* extrusion following dysfunctional Ca2* release.
Although the results presented here demonstrate that G1885E modulates L433P, the co­
inheritance of these substitutions has only been observed in a single family (Claycomb 
et al., 1998; Tiso et al., 2001; Bauce et al., 2002) suggesting that it is an extremely rare 
genotype. However, L433P has not been identified in a CPVT/ARVD patient in the 
absence of G1885E, suggesting that this like all other CPVT mutations, this is an 
extremely rare genotype. Given the increasing documentation of the co-inheritance of 
common SNPs with CPVT/ARVD2-linked RyR2 mutations (Medeiros Domingo, 2009), it 
would be interesting to determine whether any other SNPs exhibit similar functional 
modulation on co-inherited mutations or whether this phenomenon was unique to the 
combination of SNP/mutation examined here.
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Appendix I 
Cloning
A
L433Psite
I
HumanRyR2 GSIQHKMMHHEGHMDDGISLSRSQHEESRTARVmSTVFLgNRFIRGL13ftLSKKAKA5T 444
ChiapanseeRyR2 GSIQSKXnfilHEGHKDDGISLSRSQHEESRTRRVIRSTVFLENRFIRGtlALSKKRXRST 42B 
MousaRyR2 GSIQRKRIMHHEGaKQDGLRLSRSQHZESRTARVIRSTVFLENRFIRGLDRLSKKVKLPT 444
RatR;R2 GSIQRKAmHHKGHiaXGLNLSRSQHEESRXRRVIRSTVFLRfRFIRGLDhLSKRAKLPT 437
Gnin«»PigRyR2 GSIQRKXIMHMEGHKDDGLNLSR9QHEESRTXRVIRSTVFLENRFIRGLDALSKKVKVPA 390 
R*bbitRyR2 GSIQRRAIMHHEGlIMDDCLllI.SRflQHERSRTARVIRSTVFLENRFIRG&EfcLSKKAKASS 444 
CowRyR2 GS IQRKAIMOIRGHMinGI.NLSR9QHEESRTARVIRSTVFLFNRFIRGLI3M.SKKVXA.ST 428
DolphinRyR2 GSIQRKAIMHHEGHKEDGLNLSRSQHEESRTARVIRSTVFLFNRFIRGU3ALSKKAKA.ST 428 
Hors«RyR2 GSIQRKAIMHHEGHKDDCLHLSRSQHZRSRTRRVIRSTVFLENRFIRG&DRLSKKRXRST 428
C«nimRyR2 GSIQRKAIMHHEGHKEDGLIILSRSQHEESRTARVIRSTVFLENRFIRGLD&LSKKVRAST 347 
Oppo•snaRyR2 GSIQRKAIMI0IEGHKEDGL1ILSR9QHEESRTARVIRSTVFI.ENRFIRG&DALSKKVKSST 341 
Z«braFlnc9iRyR2 GSLQRKRIMHHXCBHEDGLTLSRSQNEESRIRRVIRSTVFLEIIRFrRGLOVLSKKVKSST 388 
ElephantRyR2 GSIQRKADOOOUaiKODGLNLSRSQHEESRTRRVIRSTVFLENRFIRGLDRZ^KKVKRSS 430 
GozillaRjR2 GSIQRKAIMHIIEG»inDGISLSRSQHEESRTftRVIRSTVFLENRFIRGLDRLSKiCAKRST 34S
HnnanRyRl GWLKKEAMUIQEGHIIDDALSLTRGQQEESQA&RIIIHSTNGLYNQFIKSUISFSGKPRGSG 428
HuaanRyR2 GSIQRKRIMHHEGBHCDGISLSRSQHZESRTRRVIRSTVFLENRFIRGLlALSXKAXRST 444
HraanRyR3 GPLKRKVIIHQEGHMDDGLTLQROQREESQAARI3RNTTALFSQFVS---- GNHRXAAP 420
G1885E site
4
HuaumRyR2 HILQLIEPSVFKEAATPEEESDTI£KELSVDDAKLQGAGEEEAKCGKRPKEGLLQjMXLPE 1900
Chiapans«ttRyR2 HILOLIEPSVFKEAATPEEESDTLEKELSVroAKLOGAGEEEAKCGXRPKEGLLQKKLPE 1884
MouseRyR2 KELQLIEPSVFKERAVPEEEGCTPEKEI SIEPAKLE— GEEEAKflGKRPKEGLLQMELPE 1899
RatRjR2 HILRLXEPSVFKEAATPEEEGGAPEKEISIDDSKI2— VKEEAKAGKRPKEGLIOKKLPE 1892
GtiinPigRjR2 HILQLIEPHVFEERACVEEEGDVIZKELSIEDSKIZGAGKEDVKVGKRPEEGLIfliatLPE 1846
RabbitRyR2 fflLQLXEPSVFKD&ATPEEEGDTIiEEEPSVEDTKXXGAGEEEAXMGKRPEEGLLGtlKLPE 1900
CowR$R2 HVLQLIEPSVFKERASPEEESEVAEKEPFVEDSKIZGAEEEEIIKBXKRPEEGLLQKKLPE 1884
DolphinRsR2 HCLQLXEPSVFKEAAGPEEEGES KKEPCAEDSK£EGAAEEEME0GERSKEGX>1QI1KLPE 1821
HorseRyR2 HILQLIEPSVFKERRSPEEESEAI2EEPGAEDSKIEGRGDEEAKEQERPEEGLLQKKLPE 1884
CanineRyR2 HILQLIEPSVFKE2UkTPDEErEAlEKEPCPEDSKSEG3^aEEEAKKVERPEEGLIGKKLPK 1803
Oppo ssoaRyR2 HILQLIEPSVFKERAIiKEEENEVXESELIITEDQGZEGGREEEIRaEKKPEEGLIQKKLPE 1979
ZebraFinchRyR2 HILQLlEPBVFKEMlSOEDElDFSEKEFSSnELKSEEG-EEErRBBgCPiXGlJiOMKLPE 1843
E1 e phantRyR2 HFLflIJEPSFFEIHATPEEI)6VVIgKELSTEDflElEGAGEEEMBflK3MtPEEGI»TflMKr«PE 1884
GorillaRsR2 HI LQLIEPSVFKIAATPEEES DT1£KELSVDDAKLQGAGEEEAKBGKRPKEGL1QKKLPE 1804
HuaanRyRl QnjaHEPEFFTEEEEEEDEEEEGEEEDEEEKEEIgEETROEiEEDEEKEEEEAAEGEKEE 1920
HtaaanRyR2 HELQLIEPSVFKEAATPEEESDTIEKELSVDDRKLQGAGEEEAKOGXRPEE -----1891
HuaanRyR3 QILLLIDPSVFGEHS AGTEEGAEKEEVTQVEEKAVEAG EKAffKEAPVK----------1792
- * • *  4f 4f 4f • *  - *
Figure 1. L433 and G1885 are conserved among species and isoforms RyR primary 
sequences were obtained from the ENSMBL database and underwent multiple sequence 
alignment using CLUSTALW as shown in panel A. Alignments of RyR2 sequence from multiple 
species confirmed that the Leucine at residue 433 was highly conserved across all species 
(upper panel) and was conserved between human RyR1 and RyR2 (lower panel) as shown in 
panel B. Sequence alignment demonstrated the glycine at residue 1885 was relatively conserved 
among mammals and occurred in a region of high sequence variability (DR3, upper panel). The 
glycine residue at 1885 was conserved between human RyR2 and RyR3 and occurs in a region 
of high variability between human RyR isoforms.
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Abbreviation Construct Description
WT RyR2 pcDNA3-eGFP-hRyR2 The pcDNA3 mammalian expression vector containing the cDNA 
encoding human RyR2 fused to eGFP at the N-terminus
SK1 pSL1180-SK1 The intermediate expression vector containing the SanDI/Kpn1  
RyR2 mutagenesis cassette.
n/a pSL1180-SK1-G1885E
The intermediate expression vector pSL1180, containing the 
SanDi/ Kpnl RyR2 mutagenesis cassette harbouring the 
G1885E-encoding nucleotide substitution
n/a SK1-G1885E The isolated SanDI/ Kpnl mutagenesis cassette containing the 
G1885E-encoding nucleotide substitution.
G1885E
or
GE
pcDNA3-eGFP-hRyR2-G1885E The pcDNA3 expression vector containing the cDNA encoding 
GFP-tagged, full length, human RyR2 containing the G1885E- 
encoding nucleotide substitution
L433P
or
LP
pcDNA3-eGFP-hRyR2-L433P The pcDNA3 expression vector containing the cDNA encoding 
GFP-tagged, full length, human RyR2 containing the L433P- 
encoding nucleotide substitution
L433P-G1885E
or
LPGE
pcDNA3-eGFP-hRyR2-L433P-G1885E The pcDNA3 expression vector containing the cDNA encoding 
GFP-tagged, full length, human RyR2 containing both the L433P 
and G1885E-encoding nucleotide substitutions.
Table 1. RyR2 cDNA nomenclature. A summary of the nomenclature of the various cDNA constructs used in the generation of full 
length eGFP-tagged, human RyR2 harbouring the L433P mutation and G1885E polymorphism.
SanDi
pSL1180-SK1 
5455bp
SK1
Kpnf
SanDi SanDi
pSL1180-SK1 - 
G1885E
5455bp
G1885E G1885E
SK1-G1885E 
2131 bp
SK1-G1885E SK1-G1885E
Kpnf
pcDNA3-eGFP-hRyR2 
21229bp
SanDi
RyR?
21229bp
pcDNA3-eGFP-hRyR2-'
L 433P  |  L433P
SanDi
Kpnf RyR2 Kpnf
pcDNA3-eGFP-hRyR2- 
G1885E
21229bp
SanDi
G1885E
RyR?
pcDNA3-eGFP-hRyR2- 
L433P-G1885E
21229bp
SanDi
G1885E
L433P
Kpnf RyR2 Kpnf
Figure 2. Schematic representation o f cDNA constructs produced from the cloning o f 
RyR2 containing L433P and/or G1885E. Schematic representations of the various cDNA 
plasmids produced during the generation of full length RyR2 plasmid cDNA containing 
combinations of L433P and G1885E encoding nucleotide substitutions. Thin black bars represent 
the vector sequence, red bars represent RyR2 encoding sequence and green arrows represent 
the eGFP coding sequence. The yellow rectangle represents the location of the point mutation 
encoding the indicated amino acid substitution.
282
B*0 r - ^ X 0^ 0^c - c to o o*~ oecro
. - C K c m o u w O  ---jc -o  a  xx<
Pvu
X  X  C Q  C D  U J  L U  C D
pcDNA3
5 . 4  k b
Smal
There is an ATG upstream 
of the Xba i site. Bsml
A-1$0226
Figure 3. Vectors used in the generation o f mutant eGFP- 
tagged human RyR2 cDNA constructs. The mammalian 
expression vector shown in panel A, pcDNA3, was used to clone 
full length RyR2 constructs. The pSL1180 super-linker vector, 
shown in panel B, was used as an intermediate vector to carry 
out site-directed mutagenesis on the RyR2 mutagenesis 
cassette, SK1. This vector was previously modified by the 
ase in agonist-evoked SR Ca2+ release !! ADDIN EN.CITE !! 
ADDIN EN.CITE. DATA r 1 ?! (Wright et al., 2008)1, which is
ck>TTATAATT/
PSL1180
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Name Sequence Nucleotide
substitution
Amino Acid 
Substitution
Length
(bp)
GC
content
Tm
fC )
Notes
G1885E For GAACOCGGCGAACGGGfGGAACCGAAGAAGGAG G5454A G1885E 33 636% 71
Forward 
primer for the 
mutagenesis 
of NRyR2 
(G1885E)
G1885E Rev CTCCTrCTTCGGTTCCfCCCGTrCGCCGGGTTC C5454T G1885E 33 636% 71
Reverse 
primer for the 
mutagenesis 
of hRyR2 
(G1885E)
Table 2. Site-directed mutagenesis primers. Mutagenesis primers used in the insertion of the G1885E encoding polymorphism in the SK1 
RyR2 mutagenesis cassette. Shaded nucleotides indicate those undergoing substitution. Nucleotide positions are derived from the RyR2 ATG 
start codon.
Name Sequence Primer Start 
Nucleotide
Primer
Direction
Length
(bp)
GC
content
Tm
fC )
Notes
B23F4 C AGTTGATTGAGCCC C5530 Forward 15 53.3% 46 Primer for G1885E 
mutagenesis verification
B23F3 TACAGTCCAGAGTTCCCAC T5332 Forward 19 52.6% 53 Primer for SanDi restriction 
site verification.
SPFOR7513-30 CAAGGCAGOCATGGTTTT C7392 Forward 18 50% 54 Primer for Kpnl restriction 
site verification
Table 3. Sequencing primers. Primers used in the direct automated sequencing of the G1885E SDM site and SK1 SanDi and Kpnl restriction 
sites in ligated full length eGFP-hRyR2 mutant constructs. Nucleotide positions are derived from the RyR2 ATG start codon.
Appendix II 
Experimental Data
HEK WT GE LP LP-GE
Caffeine
(mM)
B as a l
E a rly M id d le Lata
B a s a l
E a rly M id d le L ata
B as a l
E a rly M id d le Lata
B a s a l
E a rly M id d le L a te
B as a l
E a rly M id d le L a te
0.1 2.20 
± 0 0 7  
p<0.0001
2.21
± 0 0 7
p<00001
2.17
± 0 .07
p<0 0001
1.96 
± 0 0 6  
p<0 0001
1.35
± 0 1 1
1.34
±0.11
140
± 0 .1 2
1.28
± 0 .1 2
1 9 4  
± 0 1 0  
p=0 0004
183  
± 0 0 9  
P=0 002
193
± 0 0 9
p=0O01
1 85 
± 0 0 9  
p=0 0139
1 88 
± 0 1 5  
p±Q0127
185
± 0 1 4
p=0.014
186
± 0 1 3
p=0.0219
167
± 0 1 1
p=0.0278
1.61 
± 0 .09  
p=0 0907
1 4 8  
± 0 0 9  
p=0 3799
1.54
± 0 .1 0
p=04131
1 38 
± 0 0 9  
p=0 5970
0.25 1 87 
± 0  06 
p=0 065
193
± 0 0 6
p=0.0237
1.83
± 0 0 7
p=0,O158
1 66 
± 0 .05  
p=0 0IQ2
1.44
±0.11
1 43 
±0.11
1 46 
±0.11
1.28 
± 0  11
1 59 
± 0 .1 2  
p=0.8464
1 57 
±0.11  
p=0 9075
180  
±0.11  
Ps 
0 7097
1.39
±0.1
p=0.5593
1.88
± 0 .1 2
p=0.5813
1 68 
± 0 .1 4  
p=0.5378
1.72
± 0 1 1
p=0.385
1 54 
± 0 .0 9  
p=0.1925
1 73 
± 0  09 
p=0.3874
1 60 
± 0  08 
p=0.768
1.88
± 0 .0 8
p=0.4794
149
± 0 .0 8
P=
0258 8
0.5 1 83 
±  0 .05 p = 
0 5925
187
± 0 .0 4
p=tlJ3252
1.83 
± 0 04 p = 
0 3 46 9
1 80 
±0.04  
p=0 3222
1.78
±0.1
1 66 
±0.1
1.74
±0.11
1.51 
± 0  09
1.49
± 0 .12
p=0.0857
1.38
± 0 .1 2
p=00823
1.43 
±0 .12  
p=0 06
1.26
±0.1
p=0.0781
1.78 
±0 .14  
p=0 9862
161  
±0.11  
p=0 8012
1.71
± 0 1 1
p=0.8499
1.43 
±0 .1  
p±Q 5836
1.87 
±0 .12  
p=0 5809
1.49
± 0 1
p=0.3023
1 54 
±0 .1  
p=0.1919
1 40  
±0 .0 9  
p±0 4028
0.75 189 1.66 1.83 1.54 1.82
± 0 .0 8
1 73 
± 0 .0 9
1.76
±0 .0 9
1.56 
± 0  08
1.63 
± 0 1  
p±0 1610
1.51 1.59 1.41 2.07 2.00 201 1.73 14 6 1.33 14 2 12 4
± 0 05 
p=0.4539
± 0.05 
p=0.1688
± 0  05 
p=04493
±0 .04
p=0.8418 p=0 0860 p=0 2303 p=0 2303 p=0.3440 p=0 3329 p=0.3825 p=0 5007 ± 0 0 7
p=00013
± 0 0 8  
p±0 0001
±0 .0 6
p=0.0021
± 0 0 6  
p=0 0014
1 2.00
± 0 0 3
p<00001
1 99 
± 0  0 3 p  
<0 0001
196
± 0 0 3
p<0 0001
169
± 0 0 3
p<0 0001
1.40 
± 0  08
1.30
± 0 .0 8
1.27 
± 0  08
1.18
± 0 .07
1 59 
± 0  1 
p=0.1449
1.43 
± 0 .08  
p=0 2710
1.50 
±0 .09  
p=0 0599
1.29 
±0 .08  
p=0 2881
1.61
±0.1
p=0.0987
14 5  
± 0  09 
p±0 2374
151  
± 0 .0 8  
p=0 0442
1 3 7  
±0 .0 7  
p=0 0677
167  
± 0 1  
p±0 5251
1.51 
± 0  08 
p=0.7803
156  
± 0 0 9  
p = 0 1514
14 8  
± 0 .0 9  
p=0 4800
2 2 0 3  
± 0.04
p<00001
2.04 
± 0 0 4  
p<0 0001
1 98 
± 0 0 4  
p<0 0001
1 70 
±0 .0 4  
p<0 0001
1.51
± 0 .0 6
149
± 0 .0 5
1.52 
± 0  05
1.36
± 0 0 5
1 74 
± 0 0 7  
p=00040
1.61 
± 0  07 
p=0.1463
163  
± 0 .07  
p=0 2146
1.50 
± 0  06 
p=0 0582
17 5  
± 0 0 6  
p=0 0018
1.64 
± 0 8 7  
p=0 0798
1.7
± 0 0 6
p=00403
1 5 3  
± 0 0 5  
p=0 0255
1.59 
± 0 0 8  
p=0 2634
1.46
± 0 .0 8
p=0.7334
158  
±0 .09  
p=0 5811
1.43 
± 0  08 
p=04905
5 185
± 0 0 4
p= 0002
1 80 
± 0 0 4
p<0 0001
1 83 
± 0 0 4  
p=0.0007
1.35
± 0 .04
p=0.9341
1.60
± 0 .0 8
1 40 
± 0 .0 7
1.39 
± 0  06
1.35
± 0 .0 7
1.77 
± 0  06 
p=0 0808
16 4
±0 .07
p=0.0218
16 9  
± 0 0 6  
p=0 0008
15 3  
± 0 .0 5  
p=0 0421
15 2
± 0 .0 7
p=0.4127
143  
± 0  06 
p=0.7721
1.53
± 0 0 6
p=0.0923
1.37 
±0 .0 5  
p=0 8545
1.72 
± 0 .1 7  
p=0 5002
1.55
± 0 .1 8
p=0.3822
18 4
± 0 .1 8
p=0.1115
1.84 
± 0  16 
p=0.0899
7.5 2 0 4  
± 0  05 
p=00172
2 1 3
± 0 0 6
p=O0786
201  
± 0 0 8  
p=0 0483
1.89 
± 0  05 
p=0 6358
1.83
± 0 .0 6
1.71
± 0 .0 7
182
±0 .0 8
1.65 
± 0  06
181 
± 0  06 
p=0.7957
1.87 
± 0  05
p<0 0001
179  
± 0 0 5  
p=0 7828
1.80 
± 0  05 
p=0.5131
14 8
± 0 0 6
p<0.000l
13 2
±0 .0 5
p=0.6214
1.46
± 0 0 7
p=0.0008
131  
± 0 0 6  
p=0 0001
16 0  
± 0  08 
p=0 0377
1.52 
± 0 .0 7  
p<0 0001
157
± 0 .0 7
p=0.0214
1 4 3  
± 0 0 7  
p=0 0248
10 2.11 
± 0  04
p<0 0001
2 1 8
± 0 .0 4
p<0.C0Q1
2 0 6
± 0 0 4
p=00003
1.77
± 0 .0 7
p±0 0106
1.79
± 0 .0 7
1 76 
± 0 .0 8
1.79
±0 .0 6
1.58
± 0 0 1
1.92 
± 0  09 
p=0.3256
1.81 
±0.1  
p=0 6798
1.96
± 0 1
p=0.2135
1.71 
± 0  09 
p=0 2484
1.57 
± 0  09 
p=0.0618
144
±0 .0 8  
p=0 0036
152  
± 0 .0 8  
p=0 0133
1.37
± 0 0 7
p=00314
1.64
± 0 1 1
p=0.2743
1.51 
±0.11  
p=0 0535
1.85
± 0 .1 2
p=0.3063
1.52
± 0 1 2
p=0.6328
Table 1. Average basal and post-activation SVm values in cells expressing homotetrameric RyR2 and results o f statistical 
comparison with WT RyR2. The average basal and post-activation SVm values at each experimental condition were calculated and the mean 
± S.E.M SVm values are displayed. SVm values of untransfected HEK cells or cells expressing G1885E, L433P or L433P-G1885E were 
compared to the corresponding condition in cells expressing WT RyR2. Green shading indicates a significant difference to WT RyR (p < 0.05). 
Red shading indicates a significant difference between L433P and L433P-G1885E (p < 0.05). Data is represented as a heat map in Figure 4.13.
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Table 2. Average basal and post-activation SVm values o f cells expressing heterotetrameric RyR2 and results o f statistical 
comparison with WT RyR2. The average basal and post-activation SVm values at each experimental condition were calculated and the mean 
± S.E.M SVm values are displayed. SVm values of untransfected HEK cells or cells expressing G1885E, L433P or L433P-G1885E were 
compared to the corresponding condition in cells expressing WT RyR2. Green shading indicates a significant difference to WT RyR (p <  0.05). 
Red shading indicates a significant difference between L433P and L433P-G1885E (p <  0.05). Data is represented as a heat map in Figure 4.13.
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Figure 1. Linear regression analysis o f basal vs. post-activation SVm values o f untransfected and homotetrameric RyR2 expressing 
HEK cells. Linear regression analysis examining the relationships between basal and post-activation cytoplasmic Ca2+ SVm was carried out. 
Early (0-30secs), middle (30-60 secs) and late (60-90secs) were analysed. As detailed in section 2.2.5 and 4.2.3, the regression line gradient 
(A), goodness-of-fit value (r2)  and significance value testing whether the gradient is significantly different to 0 (p) were determined and are 
summarised in Appendix 2, Table 2. Asterisked data indicates a significant difference between the relationship gradients at each post­
activation time point (p<0.05).
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Figure 2. Linear regression analysis o f basal vs. post-activation SVm values o f HEK cells expressing heterotetrameric RyR2.
Linear regression analysis examining the relationships between basal and post-activation cytoplasmic Ca2+ SVm was carried out. Early (0- 
30secs), middle (30-60 secs) and late (60-90secs) were analysed. As detailed in sections 2.2.5 and 4.2.3, the regression line gradient (A), 
goodness-of-fit value (r2) and significance value testing whether the gradient is significantly different to 0 (p) were determined and are 
summarised in Appendix 2, Table 3. Asterisked data indicates a significant difference between the relationship gradients at each post­
activation time point (p<0.05).
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Table 3. Linear regression analysis o f basal vs. post-activation SVm values o f untransfected and homotetrameric RyR2 expressing 
HEK cells. Linear regression analysis examining the relationships between basal and post-activation cytoplasmic Ca2+ SVm was carried out, 
the results of which are presented here. As detailed in section 2.2.5 and 4.2.3, the regression line gradient (A), goodness-of-fit value (r )  and 
significance value testing whether the gradient is significantly different to 0 (p) were determined. Experimental conditions that produced a 
significantly different relationship gradient compared to the corresponding experimental condition in cells expressing WT RyR2 are highlighted 
in preen (p<0.05) and as such are presented on the heat map in Fipure 4.14.
WT WT + GE WT + LP WT + LPGE LP + GE
Basal SVm vs post-activation SVm Basal SVm vs post activation SVm Basal SVm vs post activation SVm Basal SVm vs post-activation SVm Basal SVm vs post-activation SVm
Caffeine
jmM) Early Late Early MMfelfc Late Early NbcMfc Late Early M rtd te Late Early MKidle Late
a 4.952*1 1822*84 48524.1 M 7 4 .1 ) 13*4117 * 3 4 4 3 1 4.5724.12 *73244 7 •492449 *742431 4.592*27 4432444 1.*12449 4.972487 1.442487
0 .1
t* 067 092 086 081 0 8 087 055 085 076 062 062 069 084 089 089
p 07012 04529 04395 002305 0 008677 02784 03913 09063 02784 066 06518 06573
a 4872487 l - K H J I 4.5«iS13 1.a i t  *.11 •872*1? 6.77*489 4432444 *7 2 2 *6 ( 6.9424.13 •4424.11 *7924.49 4.9624.47 1.452*47 4.442*47
A  OC r* 096 093 096 083 089 081 073 082 087 072 0.77 082 089 088 085U.aCD
P 0916 02967 05987 0049 0 7241 06405 09535 0 9424 0 7758 08387 008839 03504
A *922487 I T I i M ? *732*67 M ) 4 . * t *3 1 4 .1 * 6J?2*12 4412*13 •4926.11 *712*1 4.9*2*11 •4124.49 1J524.1t 1J224.17 1.4424.14
0.5
fl 061 088 085 083 084 083 082 079 083 079 083 088 084 084 078
P 03808 0 4552 03212 0 7049 09568 0 4017 03641 0 8601 0 2953 005294 0 09423 01687
A *.9 (t487 1811484 M M J S •811*12 *6726.14 * 8624.1 4.572489 *(324.49 * ( 1 2*4 4 6.5524.37 4.542*41 4.542*49 1.412*44 *9124.1 4.(42*44
rl 084 084 090 076 062 081 058 064 069 027 0 2 085 094 089 0 87
0.75
P 03757 007213 04227 0 001956 0002362 0002708 01082 006881 002066 07766 05214 005099
A *9 tr4 8 7 * 7 ( i4 8 7 •.(3 tt.1 1 *5924.1 i U 4 . i l 6.4? 26.14 4.572*1 *412444 6.422448 *742*11 4.(424.47 4.7(24.47 *752*66 4.712485
r1 085 078 077 047 047 058 027 055 069 085 073 084 0 72 074 079
1
P 000957 00648 03993 00003736 0 04752 01973 01961 04754 049S9 002S99 0 3397 05634
A 4852*44 *72*489 i K 4 . l l ( M 4 . « *7724.44 4.(62487 6.442686 •542*49 *54244 7 6.5524.11 4.(324.14 •4424.13 *4424.44 *7224.67 4.(12487
r1 063 063 064 079 061 060 036 0.42 054 047 042 047 0 74 073 067
2
P 002345 0 7256 09539 01051 02017 03756 0 4418 05619 01015 01053 09856 00758
A M 1 4 J I M ( ! M ( *71*484 68924.1 6852*1 •842484 6.(92487 *742444 *772446 *712*1 *712*11 *632*1 *7(2 4 8 7 6.592486 4.(22*46
r1 073 0.72 064 069 068 077 065 063 076 0.51 057 058 079 071 0745
P 04948 0 09286 02673 02546 04225 05999 04605 06723 05502 0642 04147 03611
A 4.7314.1? 4.M14.1 ? 6.7324.1 4.541*47 *632*67 1 3 4 4 3 4 4.53**48 •4424.64 *55244( *722*1 *522*11 4.552*11 *7424.47 6.(12*47 *532487
7.5
f* 051 064 060 052 058 060 055 057 065 070 OS 053 068 061 057
P 02406 002783 009774 01567 002139 01249 09*7 001189 02418 08263 0 02002 009816
A 6 8  726.1 68*24.11 6.75*484 M i t M l i ( t ! i * 1 4.(6248 7 t . » 2 t . t ( * 5 (2 * 6  ( 4432445 6.(42446 *622*46 4.7324.47 *572*1 4.(72484 4.592*44
10
r* 0.71 066 070 058 053 062 041 063 070 064* 063 065 053 071 067
P 004962 01515 04965 00001 00062 05038 0 049 003844 0825 003358 0123 01513
Table 4. Linear regression analysis o f basal vs. post-caffeine-activation SVm values in HEK cells expressing heterotetrameric RyR2.
Linear regression analysis examining the relationships between basal and post-activation cytoplasmic Ca2+ SVm was carried out, the results of 
which are presented here. As detailed in section 2.2.5 and 4.2.3, the regression line gradient (A), goodness-of-fit value (r2) and significance value 
testing whether the gradient is significantly different to 0 (p) were determined. Experimental conditions that produced a significantly different 
relationship gradient compared to the corresponding experimental condition in cells expressing WT RyR2 are highlighted in green (p<0.05) and 
as such are presented on the heat map in Ficjure 4.14.
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Figure 3. There is no relationship between basal SVm and magnitude o f caffeine-evoked Ca2+ release following homotetrameric RyR2 
expression. Linear regression analysis examining the relationships between basal SVm and caffeine-evoked Ca2+ release magnitude was 
carried out. As detailed in section 2.2.5 and 4.2.3, the regression line gradient (A), goodness-of-fit value (r2) and significance value testing 
whether the gradient is significantly different to 0 (p) were determine. Asterisked p-values indicate a linear regression line that was significantly 
different to 0 (p<0.05) whereas asterisked r2 values indicate data which was an acceptable fit to the linear regression model (r>0.3).
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Figure 4. There is no relationship between basal SVm and magnitude o f caffeine-evoked Ca2* release following heterotetrameric  
RyR2 expression. Linear regression analysis examining the relationships between basal SVm and caffeine-evoked Ca release 
magnitude was carried out. As detailed in section 2.2.5, the regression line gradient (A), goodness-of-fit value (r2) and significance value 
testing whether the gradient is significantly different to 0 (p) were determined. Asterisked p-values indicate a linear regression line that was 
significantly different to 0 (p<0.05) whereas asterisked r  values indicate data which was an acceptable fit to the linear regression model
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Figure 5. There is no relationship between basal SVm and rate o f caffeine-evoked Ca2+ release following homotetrameric RyR2 expression.
Linear regression analysis examining the relationships between basal SVm and the rate of caffeine-evoked Ca + release was carried out. As detailed 
in section 2.2.5, the regression line gradient (A), goodness-of-fit value (r2) and significance value testing whether the gradient is significantly different 
to 0 (p) were determined. Asterisked p-values indicate a linear regression line that was significantly different to 0 (p<0.05) whereas asterisked r  
values indicate data which was an acceDtable fit to the linear rearession model (r2>0.3).
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Figure 6. There is no relationship between basal SVm and rate o f caffeine-evoked Ca2+ release following heterotetrameric RyR2 expression.
Linear regression analysis examining the relationships between basal SVm and the rate of caffeine-evoked Ca2+ release was carried out. As detailed in 
section 2.2.5, the regression line gradient (A), goodness-of-fit value (r2) and significance value testing whether the gradient is significantly different to 
(p) were determined. Asterisked p-values indicate a linear regression line that was significantly different to 0 (p<0.05) whereas asterisked r  values 
indicate data which was an acceptable fit to the linear regression model (r2>0.3).
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Figure 7. There is no relationship between basal SVm and rate o f cytoplasmic Ca2* removal following caffeine-evoked Ca2* release in 
cells expressing homotetrameric RyR2. Linear regression analysis examining the relationships between basal SVm and the rate of cytoplasmic 
Ca2* removal following caffeine-evoked Ca2* release was carried out. As detailed in section 2.2.5, the regression line gradient (A ), g o o d n e s s -o f - f i t  
value (r2) and significance value testing whether the gradient is significantly different to 0 (p) were determined. Asterisked p-values indica e a 
linear regression line that was significantly different to 0 (p<0.05) whereas asterisked r2 values indicate data which was an acceptable fit to the 
linear regression model (r2>0.3).
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Figure 8. There is no relationship between basal SVm and rate o f cytoplasmic Ca2+ removal following caffeine-evoked Ca2+ release in cells 
expressing heterotetrameric RyR2. Linear regression analysis examining the relationships between basal SVm and the rate of cytoplasmic Ca 
removal following caffeine-evoked Ca2+ release was carried out. As detailed in section 2.2.5, the regression line gradient (A ), goodness-of-fit value ( ) 
and significance value testing whether the gradient is significantly different to 0 (p) were determined. Asterisked p-values indicate a linear regression ine 
that was significantly different to 0 (p<0.05) whereas asterisked r  values indicate data which was an acceptable fit to the linear regression model (r>0.J).
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Figure 9. Linear regression analysis o f spontaneous and caffeine-evoked Ca2+ release magnitude. Linear regression analysis was carried out 
to investigate relationships between the magnitude of spontaneous and caffeine-evoked Ca2+ release. Data was divided into groups by activating 
caffeine concentration (minimal: 0.1-0.75mM, exponential: 1-2mM and maximal: 5-1 OmM, see section 5.3.6). Data was obtained from between 9 an 
85 cells per experimental condition. As detailed in section 2.2.5, key linear regression parameters were determined including goodness-of-fit vaues 
(r2), whether the relationship was significantly different to 0 (p<0.05) and the gradient of the linear regression line (A ). Asterisked gradient va ues 
indicate a significant difference to WT RyR2. Data is summarised in Figure 5.14.
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Figure 10. Linear regression analysis o f spontaneous Ca2+ oscillation and caffeine-evoked Ca2+transient duration. Linear regression 
analysis was carried out to investigate relationships between the duration of spontaneous and caffeine-evoked Ca2+ release events. Data was 
divided into groups by activating caffeine concentration (minimal: 0.1-0.75mM, exponential: 1-2mM and maximal: 5-1 OmM, see section 5.3.6). 
Data was obtained from between 9 and 85 cells per experimental condition. As detailed in section 2.2.5, key linear regression parameters were 
determined including goodness-of-fit values (i ), whether the relationship was significantly different to 0 (p<0.05) and the gradient of the linear 
regression line (A). Asterisked gradient values indicate a significant difference to WT RyR2. Data is summarised in Figure 5.14.
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Figure 11. Linear regression analysis o f spontaneous Ca2+ oscillation and caffeine-evoked Ca2+transient area. Linear regression analysis was 
carried out to investigate relationships between the area of spontaneous and caffeine-evoked Ca2+ release events. Data was divided into groups by 
activating caffeine concentration (minimal: 0.1 -0.75mM, exponential: 1-2mM and maximal: 5-1 OmM, see section 5.3.6). Data was obtained from between 
9 and 85 cells per experimental condition. As detailed in section 2.2.5, key linear regression parameters were determined including goodness-of-fit values 
(r2), whether the relationship was significantly different to 0 (p<0.05) and the gradient of the linear regression line (A). Asterisked gradient values in ica e 
a significant difference to WT RyR2. Data is summarised in Figure 5.14.
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Figure 12. Linear regression analysis o f the rate o f spontaneous and caffeine-evoked Ca2+ release. Linear regression analysis was carried out 
to investigate relationships between the rate of spontaneous and caffeine-evoked Ca2+ release. Data was divided into groups by activating caffeine 
concentration (minimal: 0.1-0.75mM, exponential: 1-2mM and maximal: 5-1 OmM, see section 5.3.6). Data was obtained from between 9 and 85 cels 
per experimental condition. >As detailed in section 2.2.5, key linear regression parameters were determined including goodness-of-fit values ( ), 
whether the relationship was significantly different to 0 (p<0.05) and the gradient of the linear regression line (A). Asterisked gradient values indica e a 
significant difference to WT RyR2. Data is summarised in Figure 5.14.
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Figure 13. Linear regression analysis o f the rate o f cytoplasmic Ca2* removal following spontaneous and caffeine-evoked Ca2* release.
Linear regression analysis was carried out to investigate relationships between the rate of cytoplasmic Ca2* removal following spontaneous and 
caffeine-evoked Ca2* release. Data was divided into groups by activating caffeine concentration (minimal: 0.1-0.75mM, exponential: 1-2mM and 
maximal: 5-1 OmM, see section 5.3.6). Data was obtained from between 9 and 85 cells per experimental condition. As detailed in section 2.2.5, key 
linear regression parameters were determined including goodness-of-fit values (r2), whether the relationship was significantly different to 0 (P<0 )  
and the gradient of the linear regression line (A ). Asterisked gradient values indicate a significant difference to WT RyR2. Data is summarised in 
Figure 5.14.
References
Abriel H. (2010). Cardiac sodium channel Na(v)1.5 and interacting proteins: Physiology 
and pathophysiology. J Mol Cell Cardiol 48, 2-11.
Balser JR. (1999). Structure and function of the cardiac sodium channels. Cardiovasc 
Res 42, 327-338.
Baroudi G, Acharfi S, Larouche C & Chahine M. (2002). Expression and intracellular 
localization of an SCN5A double mutant R1232W/T1620M implicated in Brugada 
syndrome. Ciro Res 90, E11-16.
Bassani JW, Bassani RA & Bers DM. (1994). Relaxation in rabbit and rat cardiac cells: 
species-dependent differences in cellular mechanisms. J Physiol 476, 279-293.
Benitah JP, Alvarez JL & Gomez AM. (2010). L-type Ca(2+) current in ventricular 
cardiomyocytes. J Mol Cell Cardiol 48, 26-36.
Berridge MJ, Lipp P & Bootman MD. (2000). The versatility and universality of calcium 
signalling. Nat Rev Mol Cell Biol 1,11-21.
Bers DM. (2002). Cardiac excitation-contraction coupling. Nature 415,198-205.
Bers DM. (2006). Altered cardiac myocyte Ca regulation in heart failure. Physiology 
(Bethesda) 21, 380-387.
Bers DM. (2008). Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 
70, 23-49.
Bobe R, Bredoux R, Corvazier E, Andersen JP, Clausen JD, Dode L, Kovacs T & Enouf 
J. (2004). Identification, expression, function, and localization of a novel (sixth) 
isoform of the human sarco/endoplasmic reticulum Ca2+ATPase 3 gene. J Biol 
Chem 279, 24297-24306.
Bootman MD & Berridge MJ. (1995). The elemental principles of calcium signaling. Cell 
83, 675-678.
Bootman MD, Collins TJ, Peppiatt CM, Prothero LS, MacKenzie L, De Smet P, Travers 
M, Tovey SC, Seo JT, Berridge MJ, Ciccolini F & Lipp P. (2001). Calcium 
signalling - an overview. Semin Cell Dev Biol 12, 3-10.
Bootman MD, Higazi DR, Coombes S & Roderick HL. (2006). Calcium signalling during 
excitation-contraction coupling in mammalian atrial myocytes. J Cell Sci 119, 
3915-3925.
Cerrone M, Colombi B, Santoro M, di Barletta MR, Scelsi M, Villani L, Napolitano C & 
Priori SG. (2005). Bidirectional ventricular tachycardia and fibrillation elicited in a 
knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. 
Circ Res 96, e77-82.
Chalfie M, Tu Y, Euskirchen G, Ward WW & Prasher DC. (1994). Green fluorescent 
protein as a marker for gene expression. Science 263, 802-805.
Chen LY, Ballew JD, Herron KJ, Rodeheffer RJ & Olson TM. (2007). A common 
polymorphism in SCN5A is associated with lone atrial fibrillation. Clin Pharmacol 
Ther 81, 35-41.
Cheng H, Lederer WJ & Cannell MB. (1993). Calcium sparks: elementary events 
underlying excitation-contraction coupling in heart muscle. Science 262,740-744.
Chin D & Means AR. (2000). Calmodulin: a prototypical calcium sensor. Trends Cell Biol 
10, 322-328.
Ching LL, Williams AJ & Sitsapesan R. (2000). Evidence for Ca(2+) activation and 
inactivation sites on the luminal side of the cardiac ryanodine receptor complex. 
Circ Res 87, 201-206.
Chugun A, Sato O, Takeshima H & Ogawa Y. (2007). Mg2+ activates the ryanodine 
receptor type 2 (RyR2) at intermediate Ca2+ concentrations. Am J Physiol Cell 
Physiol 292, C535-544.
Cook SA, Clerk A & Sugden PH. (2009). Are transgenic mice the 'alkahest' to 
understanding myocardial hypertrophy and failure? J Mol Cell Cardiol 46, US- 
129.
Creighton W, Virmani R, Kutys R & Burke A. (2006). Identification of novel missense 
mutations of cardiac ryanodine receptor gene in exercise-induced sudden death 
at autopsy. J Mol Diagn 8, 62-67.
Cubitt AB, Heim R, Adams SR, Boyd AE, Gross LA & Tsien RY. (1995). Understanding, 
improving and using green fluorescent proteins. Trends Bbchem Sci 20, 448- 
455.
Davies KE & Nowak KJ. (2006). Molecular mechanisms of muscular dystrophies: old 
and new players. Nat Rev Mol Cell Biol 7, 762-773.
de la Fuente S, Van Langen IM, Postma AV, Bikker H & Meijer A. (2008). A case of 
catecholaminergic polymorphic ventricular tachycardia caused by two 
calsequestrin 2 mutations. Pacing Clin Electrophysiol 31, 916-919.
Di Leva F, Domi T, Fedrizzi L, Lim D & Carafoli E. (2008). The plasma membrane Ca2+ 
ATPase of animal cells: structure, function and regulation. Arch Biochem Biophys 
476, 65-74.
Diaz ME, Graham HK & Trafford AW. (2004). Enhanced sarcolemmal Ca2+ efflux 
reduces sarcoplasmic reticulum Ca2+ content and systolic Ca2+ in cardiac 
hypertrophy. Cardiovasc Res 62, 538-547.
Dibb KM, Graham HK, Venetucci LA, Eisner DA & Trafford AW. (2007). Analysis of 
cellular calcium fluxes in cardiac muscle to understand calcium homeostasis in 
the heart. Cell Calcium 42, 503-512.
Dirksen WP, Lacombe VA, Chi M, Kalyanasundaram A, Viatchenko-Karpinski S, 
Terentyev D, Zhou Z, Vedamoorthyrao S, Li N, Chiamvimonvat N, Carnes CA, 
Franzini-Armstrong C, Gyorke S & Periasamy M. (2007). A mutation in
305
calsequestrin, CASQ2D307H, impairs Sarcoplasmic Reticulum Ca2+ handling 
and causes complex ventricular arrhythmias in mice. Cardiovasc Res 75,69-78.
Du GG, Imredy JP & MacLennan DH. (1998). Characterization of recombinant rabbit 
cardiac and skeletal muscle Ca2+ release channels (ryanodine receptors) with a 
novel [3H]ryanodine binding assay. J Biol Chem 273, 33259-33266.
Du GG, Khanna VK, Guo X & MacLennan DH. (2004). Central core disease mutations 
R4892W, I4897T and G4898E in the ryanodine receptor isoform 1 reduce the 
Ca2+ sensitivity and amplitude of Ca2+-dependent Ca2+ release. Biochem J 
382, 557-564.
Fabiato A. (1985). Effects of ryanodine in skinned cardiac cells. Fed Proc 44, 2970- 
2976.
Femandez-Velasco M, Rueda A, Rizzi N, Benitah JP, Colombi B, Napolitano C, Priori 
SG, Richard S & Gomez AM. (2009). Increased Ca2+ sensitivity of the ryanodine 
receptor mutant RyR2R4496C underlies catecholaminergic polymorphic 
ventricular tachycardia. Circ Res 104, 201-209, 212p following 209.
Fill M & Copello JA. (2002). Ryanodine receptor calcium release channels. Physiol Rev 
82, 893-922.
Fry DL. (2008). Modulating Intracellular Ca2* Signalling Using Recombinant Fragments 
of the Human Cardiac Ryanodine Receptor (RyR2). PhD Thesis, Cardiff 
University, School of Medicine.
Gaburjakova J & Gaburjakova M. (2006). Comparison of the effects exerted by luminal 
Ca2+ on the sensitivity of the cardiac ryanodine receptor to caffeine and cytosolic 
Ca2+. J Membr Biol 212,17-28.
Gaburjakova J & Gaburjakova M. (2008). Effect of luminal Ca2+ on the stability of 
coupled gating between ryanodine receptors from the rat heart. Acta Physiol 
(Oxf) 193, 219-227.
Gee KR, Brown KA, Chen WN, Bishop-Stewart J, Gray D & Johnson I. (2000). Chemical 
and physiological characterization of fluo-4 Ca(2+)-indicator dyes. Cell Calcium 
27, 97-106.
George CH. (2008). Sarcoplasmic reticulum Ca2+ leak in heart failure: mere observation 
or functional relevance? Cardiovasc Res 77, 302-314.
George CH, Higgs GV & Lai FA. (2003a). Ryanodine receptor mutations associated with 
stress-induced ventricular tachycardia mediate increased calcium release in 
stimulated cardiomyocytes. Circ Res 93, 531-540.
George CH, Higgs GV, Mackrill JJ & Lai FA. (2003b). Dysregulated ryanodine receptors 
mediate cellular toxicity: restoration of normal phenotype by FKBP12.6. J Biol 
Chem 278, 28856-28864.
George CH, Jundi H, Thomas NL, Fry DL & Lai FA. (2007a). Ryanodine receptors and 
ventricular arrhythmias: emerging trends in mutations, mechanisms and 
therapies. J Mol Cell Cardiol 42, 34-50.
306
i
George CH, Jundi H, Walters N, Thomas NL, West RR & Lai FA. (2006). 
Arrhythmogenic mutation-linked defects in ryanodine receptor autoregulation 
reveal a novel mechanism of Ca2+ release channel dysfunction. Circ Res 98,88- 
97.
George CH, Rogers SA, Bertrand BM, Tunwell RE, Thomas NL, Steele DS, Cox EV, 
Pepper C, Hazeel CJ, Claycomb WC & Lai FA. (2007b). Alternative splicing of 
ryanodine receptors modulates cardiomyocyte Ca2+ signaling and susceptibility 
to apoptosis. Circ Res 100, 874-883.
George CH, Sorathia R, Bertrand BM & Lai FA. (2003c). In situ modulation of the human 
cardiac ryanodine receptor (hRyR2) by FKBP12.6. Biochem J 370, 579-589.
George CH, Yin CC & Lai FA. (2005). Toward a molecular understanding of the 
structure-function of ryanodine receptor Ca2+ release channels: perspectives 
from recombinant expression systems. Cell Biochem Biophys 42,197-222.
Ginsburg KS & Bers DM. (2005). Isoproterenol does not enhance Ca-dependent Na/Ca 
exchange current in intact rabbit ventricular myocytes. J Mol Cell Cardiol 39, 972- 
981.
Goddard CA, Ghais NS, Zhang Y, Williams AJ, Colledge WH, Grace AA & Huang CL. 
(2008). Physiological consequences of the P2328S mutation in the ryanodine 
receptor (RyR2) gene in genetically modified murine hearts. Acta Physiol (Oxf) 
194,123-140.
Graham FL, Smiley J, Russell WC & Nairn R. (1977). Characteristics of a human cell 
line transformed by DNA from human adenovirus type 5. J Gen Virol 36, 59-74.
Gramolini AO, Kislinger T, Asahi M, Li W, Emili A & MacLennan DH. (2004). Sarcolipin 
retention in the endoplasmic reticulum depends on its C-terminal RSYQY 
sequence and its interaction with sarco(endo)plasmic Ca(2+)-ATPases. Proc Natl 
Acad Sc iUS A 101,16807-16812.
Grynkiewicz G, Poenie M & Tsien RY. (1985). A new generation of Ca2+ indicators with 
greatly improved fluorescence properties. J Biol Chem 260, 3440-3450.
Gui J, Wang T, Jones RP, Trump D, Zimmer T & Lei M. (2010a). Multiple loss-of- 
function mechanisms contribute to SCN5A-related familial sick sinus syndrome. 
PLoS One 5, e10985.
Gui J, Wang T, Trump D, Zimmer T & Lei M. (2010b). Mutation-specific effects of 
polymorphism H558R in SCN5A-related sick sinus syndrome. J Cardiovasc 
Electrophysiol 21,564-573.
Gyorke S, Stevens SC & Terentyev D. (2009). Cardiac calsequestrin: quest inside the 
SR. J Physiol 587, 3091-3094.
Hayek SM, Zhao J, Bhat M, Xu X, Nagaraj R, Pan Z, Takeshima H & Ma J. (1999). A 
negatively charged region of the skeletal muscle ryanodine receptor is involved in 
Ca(2+)-dependent regulation of the Ca(2+) release channel. FEBS Lett 461,157- 
164.
307
Hayek SM, Zhu X, Bhat MB, Zhao J, Takeshima H, Valdivia HH & Ma J. (2000). 
Characterization of a calcium-regulation domain of the skeletal-muscle ryanodine 
receptor. Biochem J 351, 57-65.
Holmberg SR & Williams AJ. (1989). Single channel recordings from human cardiac 
sarcoplasmic reticulum. Circ Res 65,1445-1449.
Hu XF, Liang X, Chen KY, Zhu PH & Hu J. (2005). Depletion of FKBP does not affect 
the interaction between isolated ryanodine receptors. Biochem Biophys Res 
Commun 336,128-133.
Huke S & Bers DM. (2008). Ryanodine receptor phosphorylation at Serine 2030, 2808 
and 2814 in rat cardiomyocytes. Biochem Biophys Res Commun 376, 80-85.
Hunt DJ, Jones PP, Wang R, Chen W, Bolstad J, Chen K, Shimoni Y & Chen SR.
(2007). K201 (JTV519) suppresses spontaneous Ca2+ release and
[3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association. Biochem J 
404,431-438.
Hurtado C, Prociuk M, Maddaford TG, Dibrov E, Mesaeli N, Hryshko LV & Pierce GN.
(2006). Cells expressing unique Na+/Ca2+ exchange (NCX1) splice variants 
exhibit different susceptibilities to Ca2+ overload. Am J Physiol Heart Circ 
Physiol 290, H2155-2162.
Ikemoto N & Yamamoto T. (2000). Postulated role of inter-domain interaction within the 
ryanodine receptor in Ca(2+) channel regulation. Trends Cardiovasc Med 10, 
310-316.
Ikemoto N & Yamamoto T. (2002). Regulation of calcium release by interdomain 
interaction within ryanodine receptors. Front Biosci 7, d671-683.
Inui M, Saito A & Fleischer S. (1987). Isolation of the ryanodine receptor from cardiac 
sarcoplasmic reticulum and identity with the feet structures. J Biol Chem 262, 
15637-15642.
Iwasa H, Itoh T, Nagai R, Nakamura Y & Tanaka T. (2000). Twenty single nucleotide 
polymorphisms (SNPs) and their allelic frequencies in four genes that are 
responsible for familial long QT syndrome in the Japanese population. J Hum 
Genet 45,182-183.
Jiang D, Chen W, Wang R, Zhang L & Chen SR. (2007). Loss of luminal Ca2+ activation 
in the cardiac ryanodine receptor is associated with ventricular fibrillation and 
sudden death. Proc Natl Acad Sci U S A 104,18309-18314.
Jiang D, Chen W, Xiao J, Wang R, Kong H, Jones PP, Zhang L, Fruen B & Chen SR.
(2008). Reduced threshold for luminal Ca2+ activation of RyR1 underlies a 
causal mechanism of porcine malignant hyperthermia. J Biol Chem 283, 20813- 
20820.
Jiang D, Wang R, Xiao B, Kong H, Hunt DJ, Choi P, Zhang L & Chen SR. (2005). 
Enhanced store overload-induced Ca2+ release and channel sensitivity to
308
luminal Ca2+ activation are common defects of RyR2 mutations linked to 
ventricular tachycardia and sudden death. Circ Res 97,1173-1181.
Jiang D, Xiao B, Yang D, Wang R, Choi P, Zhang L, Cheng H & Chen SR. (2004). RyR2 
mutations linked to ventricular tachycardia and sudden death reduce the 
threshold for store-overload-induced Ca2+ release (SOICR). Proc Natl Acad Sci 
U S A  101,13062-13067.
Jiang D, Xiao B, Zhang L & Chen SR. (2002). Enhanced basal activity of a cardiac Ca2+ 
release channel (ryanodine receptor) mutant associated with ventricular 
tachycardia and sudden death. Circ Res 91, 218-225.
Jones PP, Jiang D, Bolstad J, Hunt DJ, Zhang L, Demaurex N & Chen SR. (2008). 
Endoplasmic reticulum Ca2+ measurements reveal that the cardiac ryanodine 
receptor mutations linked to cardiac arrhythmia and sudden death alter the 
threshold for store-overload-induced Ca2+ release. Biochem J 412,171-178.
Kannankeril PJ, Mitchell BM, Goonasekera SA, Chelu MG, Zhang W, Sood S, Kearney 
DL, Danila Cl, De Biasi M, Wehrens XH, Pautler RG, Roden DM, Taffet GE, 
Dirksen RT, Anderson ME & Hamilton SL. (2006). Mice with the R176Q cardiac 
ryanodine receptor mutation exhibit catecholamine-induced ventricular 
tachycardia and cardiomyopathy. Proc Natl Acad Sci U S A 103,12179-12184.
Kao JP, Harootunian AT & Tsien RY. (1989). Photochemically generated cytosolic 
calcium pulses and their detection by fluo-3. J Biol Chem 264, 8179-8184.
Kim E, Youn B, Kemper L, Campbell C, Milting H, Varsanyi M & Kang C. (2007). 
Characterization of human cardiac calsequestrin and its deleterious mutants. J 
Mol Biol 373,1047-1057.
Kong H, Jones PP, Koop A, Zhang L, Duff HJ & Chen SR. (2008). Caffeine induces 
Ca2+ release by reducing the threshold for luminal Ca2+ activation of the 
ryanodine receptor. Biochem J 414,441-452.
Koo SH, Teo WS, Ching CK, Chan SH & Lee EJ. (2007). Mutation screening in KCNQ1, 
HERG, KCNE1, KCNE2 and SCN5A genes in a long QT syndrome family. Ann 
Acad Med Singapore 36, 394-398.
Koop A, Goldmann P, Chen SR, Thieleczek R & Varsanyi M. (2008). ARVC-related 
mutations in divergent region 3 alter functional properties of the cardiac 
ryanodine receptor. Biophys J 94, 4668-4677.
Lahat H, Eldar M, Levy-Nissenbaum E, Bahan T, Friedman E, Khoury A, Lorber A, 
Kastner DL, Goldman B & Pras E. (2001a). Autosomal recessive catecholamine- 
or exercise-induced polymorphic ventricular tachycardia: clinical features and 
assignment of the disease gene to chromosome 1p13-21. Circulation 103, 2822- 
2827.
Lahat H, Pras E & Eldar M. (2002). Autosomal recessive catecholamine-induced 
polymorphic ventricular tachycardia. Exp Clin Cardiol 7,128-130.
Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, 
Khoury A, Lorber A, Goldman B, Lancet D & Eldar M. (2001b). A missense
309
mutation in a highly conserved region of CASQ2 is associated with autosomal 
recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin 
families from Israel. Am J Hum Genet 69,1378-1384.
Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, Donarum EA, 
Marino M, Tiso N, Viitasalo M, Toivonen L, Stephan DA & Kontula K. (2001). 
Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic 
ventricular tachycardia. Circulation 103,485-490.
Laitinen PJ, Swan H & Kontula K. (2003). Molecular genetics of exercise-induced 
polymorphic ventricular tachycardia: identification of three novel cardiac 
ryanodine receptor mutations and two common calsequestrin 2 amino-acid 
polymorphisms. EurJ Hum Genef 11, 888-891.
Laude AJ & Simpson AW. (2009). Compartmentalized signalling: Ca2+ compartments, 
microdomains and the many facets of Ca2+ signalling. FEBS J 276,1800-1816.
Laver DR. (2007). Ca2+ stores regulate ryanodine receptor Ca2+ release channels via 
luminal and cytosolic Ca2+ sites. Biophys J 92, 3541-3555.
Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD & Coumel P. (1995). 
Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year 
follow-up of 21 patients. Circulation 91,1512-1519.
Lehnart SE, Mongillo M, Bellinger A, Lindegger N, Chen BX, Hsueh W, Reiken S, 
Wronska A, Drew LJ, Ward CW, Lederer WJ, Kass RS, Morley G & Marks AR.
(2008). Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and 
sudden cardiac death in mice. J Clin Invest 118,2230-2245.
Li L, Chu G, Kranias EG & Bers DM. (1998). Cardiac myocyte calcium transport in 
phospholamban knockout mouse: relaxation and endogenous CaMKII effects. 
Am J Physiol 274, H1335-1347.
Liang X, Hu XF & Hu J. (2007). Dynamic interreceptor coupling: a novel working 
mechanism of two-dimensional ryanodine receptor array. Biophys J 92, 1215- 
1223.
Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano 
C, Lai FA & Priori SG. (2006). Arrhythmogenesis in catecholaminergic 
polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in 
mouse model. Circ Res 99, 292-298.
Liu Z, Wang R, Tian X, Zhong X, Gangopadhyay J, Cole R, Ikemoto N, Chen SR & 
Wagenknecht T. (2010). Dynamic, inter-subunit interactions between the N- 
terminal and central mutation regions of cardiac ryanodine receptor. J Cell Sci 
123, 1775-1784.
Liu Z, Wang R, Zhang J, Chen SR & Wagenknecht T. (2005). Localization of a disease- 
associated mutation site in the three-dimensional structure of the cardiac muscle 
ryanodine receptor. J Biol Chem 280, 37941-37947.
310
Liu Z, Zhang J, Li P, Chen SR & Wagenknecht T. (2002). Three-dimensional 
reconstruction of the recombinant type 2 ryanodine receptor and localization of 
its divergent region 1. J Biol Chem 277, 46712-46719.
Liu Z, Zhang J, Wang R, Wayne Chen SR & Wagenknecht T. (2004). Location of 
divergent region 2 on the three-dimensional structure of cardiac muscle 
ryanodine receptor/calcium release channel. J Mol Biol 338, 533-545.
Lytton J, Westlin M & Hanley MR. (1991). Thapsigargin inhibits the sarcoplasmic or 
endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem 266, 
17067-17071.
MacLennan DH & Chen SR. (2009). Store overload-induced Ca2+ release as a 
triggering mechanism for CPVT and MH episodes caused by mutations in RYR 
and CASQ genes. J Physiol 587, 3113-3115.
Marban E. (2002). Cardiac channelopathies. Nature 415, 213-218.
Marjamaa A, Laitinen-Forsblom P, Lahtinen AM, Viitasalo M, Toivonen L, Kontula K & 
Swan H. (2009a). Search for cardiac calcium cycling gene mutations in familial 
ventricular arrhythmias resembling catecholaminergic polymorphic ventricular 
tachycardia. BMC Med Genet 10,12.
Marjamaa A, Laitinen-Forsblom P, Wronska A, Toivonen L, Kontula K & Swan H. 
(2009b). Ryanodine receptor (RyR2) mutations in sudden cardiac death: Studies 
in extended pedigrees and phenotypic characterization in vitro. Int J Cardiol.
Marx SO & Marks AR. (2002). Regulation of the ryanodine receptor in heart failure. 
Basic Res Cardiol 97 Suppl 1,149-51.
Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N & Marks AR. 
(2000). PKA phosphorylation dissociates FKBP12.6 from the calcium release 
channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365- 
376.
Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, Hofman N, Bikker H, van Tintelen JP, 
Mannens MM, Wilde AA & Ackerman MJ. (2009). The RYR2-encoded ryanodine 
receptor/calcium release channel in patients diagnosed previously with either 
catecholaminergic polymorphic ventricular tachycardia or genotype negative, 
exercise-induced long QT syndrome: a comprehensive open reading frame 
mutational analysis. J Am Coll Cardiol 54, 2065-2074.
Meissner G. (2004). Molecular regulation of cardiac ryanodine receptor ion channel. Cell 
Calcium 35, 621-628.
Meur G, Parker AK, Gergely FV & Taylor CW. (2007). Targeting and retention of type 1 
ryanodine receptors to the endoplasmic reticulum. J Biol Chem 282, 23096- 
23103.
Niggli E & Shirokova N. (2007). A guide to sparkology: the taxonomy of elementary 
cellular Ca2+ signaling events. Cell Calcium 42, 379-387.
311
] Nof E, Cordeiro JM, Perez GJ, Scomik FS, Calloe K, Love B, Burashnikov E, Caceres
G, Gunsburg M & Antzelevitch C. (2010). A common single nucleotide 
polymorphism can exacerbate long-QT type 2 syndrome leading to sudden infant 
death. Circ Cardiovasc Genet 3,199-206.
Orlova EV, Serysheva, II, van Heel M, Hamilton SL & Chiu W. (1996). Two structural 
configurations of the skeletal muscle calcium release channel. Nat Struct Biol 3, 
547-552.
Periasamy M, Bhupathy P & Babu GJ. (2008). Regulation of sarcoplasmic reticulum 
Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology 
and pathology. Cardiovasc Res 77, 265-273.
Periasamy M & Huke S. (2001). SERCA pump level is a critical determinant of 
Ca(2+)homeostasis and cardiac contractility. J Mol Cell Cardiol 33,1053-1063.
Piacentino V, 3rd, Weber CR, Chen X, Weisser-Thomas J, Margulies KB, Bers DM & 
Houser SR. (2003). Cellular basis of abnormal calcium transients of failing 
human ventricular myocytes. Circ Res 92,651-658.
Pizzale S, Gollob MH, Gow R & Birnie DH. (2008). Sudden death in a young man with 
catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial 
fibrillation. J Cardiovasc Electrophysiol 19,1319-1321.
Poelzing S, Forleo C, Samodell M, Dudash L, Sorrentino S, Anaclerio M, Troccoli R, 
I lacoviello M, Romito R, Guida P, Chahine M, Pitzalis M & Deschenes I. (2006).
SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a 
separate gene. Circulation 114, 368-376.
Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, Dubosq- 
Bidot L, Sebillon P, Mannens MM, Guicheney P & Wilde AA. (2005). 
Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, 
bradycardia, and follow up of the patients. J Med Genet 42, 863-870.
Priori SG & Napolitano C. (2005). Cardiac and skeletal muscle disorders caused by 
mutations in the intracellular Ca2+ release channels. J Clin Invest 115, 2033- 
2038.
Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, Bloise R, 
Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G & Nastoli J. (2002a). 
Natural history of Brugada syndrome: insights for risk stratification and 
management. Circulation 105,1342-1347.
Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, 
Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A & DeLogu A. 
(2002b). Clinical and molecular characterization of patients with 
catecholaminergic polymorphic ventricular tachycardia. Circulation 106, 69-74.
Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V & Danieli 
} GA. (2001). Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie
| catecholaminergic polymorphic ventricular tachycardia. Circulation 103,196-200.
312
Purves WK, Sadava D, Orians GH & Heller HC. (2003). Life: The Science of Biology, 7th 
Edition.
Radermacher M, Rao V, Grassucci R, Frank J, Timerman AP, Fleischer S & 
Wagenknecht T. (1994). Cryo-electron microscopy and three-dimensional 
reconstruction of the calcium release channel/ryanodine receptor from skeletal 
muscle. J Cell Biol 127,411-423.
Rampazzo A, Nava A, Erne P, Eberhard M, Vian E, Slomp P, Tiso N, Thiene G & Danieli 
GA. (1995). A new locus for arrhythmogenic right ventricular cardiomyopathy 
(ARVD2) maps to chromosome 1q42-q43. Hum Mol Genet 4, 2151-2154.
Reppel M, Fleischmann BK, Reuter H, Pillekamp F, Schunkert H & Hescheler J. (2007). 
Regulation of Na+/Ca2+ exchange current in the normal and failing heart. Ann N 
Y Acad Sci 1099, 361-372.
Reuter H, Henderson SA, Han T, Mottino GA, Frank JS, Ross RS, Goldhaber Jl & 
Philipson KD. (2003). Cardiac excitation-contraction coupling in the absence of 
Na(+) - Ca2+ exchange. Cell Calcium 34,19-26.
Roses AD. (2000). Genetic susceptibility to cardiovascular diseases. Am Heart J 140, 
S45-47.
Rousseau E & Meissner G. (1989). Single cardiac sarcoplasmic reticulum Ca2+-release 
channel: activation by caffeine. Am J Physiol 256, H328-333.
Samso M & Wagenknecht T. (2002). Apocalmodulin and Ca2+-calmodulin bind to 
neighboring locations on the ryanodine receptor. J Biol Chem 277,1349-1353.
Sanguinetti MC, Curran ME, Spector PS & Keating MT. (1996). Spectrum of HERG K+- 
channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci U S A  
93, 2208-2212.
Santiago DJ, Curran JW, Bers DM, Lederer WJ, Stern MD, Rios E & Shannon TR. 
(2010). Ca sparks do not explain all ryanodine receptor-mediated SR Ca leak in 
mouse ventricular myocytes. Biophys J 98, 2111-2120.
Schaub MC, Hefti MA & Zaugg M. (2006). Integration of calcium with the signaling 
network in cardiac myocytes. J Mol Cell Cardiol 41,183-214.
Schlotthauer K & Bers DM. (2000). Sarcoplasmic reticulum Ca(2+) release causes 
myocyte depolarization. Underlying mechanism and threshold for triggered action 
potentials. Circ Res 87, 774-780.
Shimada T, Kawazato H, Yasuda A, Ono N & Sueda K. (2004). Cytoarchitecture and 
intercalated disks of the working myocardium and the conduction system in the 
mammalian heart. Anat Rec A Discov Mol Cell Evol Biol 280, 940-951.
Silvester NC, Barberini-Jammaers SR, Ashton PM, Jayanthi A, Yeung WY, Jundi H, 
Kotecha A, Lai FA & George CH. (2009). Investigating the Ca2+-cycling basis of 
rhythmicity and synchronicity in coupled cardiomyocyte monolayers. Biophysical 
Journal 96, 273a-274a.
313
Sitsapesan R & Williams AJ. (1990). Mechanisms of caffeine activation of single 
calcium-release channels of sheep cardiac sarcoplasmic reticulum. J Physiol 
423,425-439.
Sitsapesan R & Williams AJ. (1994). Regulation of the gating of the sheep cardiac 
sarcoplasmic reticulum Ca(2+)-release channel by luminal Ca2+. J Membr Biol 
137, 215-226.
Song LS, Guatimosim S, Gomez-Viquez L, Sobie EA, Ziman A, Hartmann H & Lederer 
WJ. (2005). Calcium biology of the transverse tubules in heart. Ann N Y Acad Sci 
1047, 99-111.
Sorrentino V & Volpe P. (1993). Ryanodine receptors: how many, where and why? 
Trends Pharmacol Sci 14, 98-103.
Stange M, Xu L, Balshaw D, Yamaguchi N & Meissner G. (2003). Characterization of 
recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) 
ryanodine receptor phosphorylation mutants. J Biol Chem 278, 51693-51702.
Stewart R, Zissimopoulos S & Lai FA. (2003). Oligomerization of the cardiac ryanodine 
receptor C-terminal tail. Biochem J 376, 795-799.
Takeshima H, Komazaki S, Hirose K, Nishi M, Noda T & lino M. (1998). Embryonic 
lethality and abnormal cardiac myocytes in mice lacking ryanodine receptor type 
2. E M B O J17, 3309-3316.
Tateishi H, Yano M, Mochizuki M, Suetomi T, Ono M, Xu X, Uchinoumi H, Okuda S, Oda 
T, Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N & Matsuzaki M.
(2009). Defective domain-domain interactions within the ryanodine receptor as a 
critical cause of diastolic Ca2+ leak in failing hearts. Cardiovasc Res 81, 536- 
545.
Tester DJ, Dura M, Carturan E, Reiken S, Wronska A, Marks AR & Ackerman MJ.
(2007). A mechanism for sudden infant death syndrome (SIDS): stress-induced 
leak via ryanodine receptors. Heart Rhythm 4, 733-739.
Tfelt-Hansen J, Winkel BG, Grunnet M & Jespersen T. (2010). Inherited cardiac 
diseases caused by mutations in the Nav1.5 sodium channel. J Cardiovasc 
Electrophysiol 21,107-115.
Thomas NL, George CH & Lai FA. (2004). Functional heterogeneity of ryanodine 
receptor mutations associated with sudden cardiac death. Cardiovasc Res 64, 
52-60.
Thomas NL, Lai FA & George CH. (2005). Differential Ca2+ sensitivity of RyR2 
mutations reveals distinct mechanisms of channel dysfunction in sudden cardiac 
death. Biochem Biophys Res Commun 331, 231-238.
Thomas NL, Maxwell C, Mukherjee S & Williams AJ. (2010). Ryanodine receptor 
mutations in arrhythmia: The continuing mystery of channel dysfunction. FEBS 
Lett 584, 2153-2160.
314
Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, 
Brahmbhatt B, Brown K, Bauce B, Muriago M, Basso C, Thiene G, Danieli GA & 
Rampazzo A. (2001). Identification of mutations in the cardiac ryanodine receptor 
gene in families affected with arrhythmogenic right ventricular cardiomyopathy 
type 2 (ARVD2). Hum Mol Genet 10,189-194.
Tong J, McCarthy TV & MacLennan DH. (1999). Measurement of resting cytosolic Ca2+ 
concentrations and Ca2+ store size in HEK-293 cells transfected with malignant 
hyperthermia or central core disease mutant Ca2+ release channels. J Biol 
Chem 274, 693-702.
Toyoshima C, Nakasako M, Nomura H & Ogawa H. (2000). Crystal structure of the 
calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature 405, 647- 
655.
Trafford AW, Diaz ME & Eisner DA. (2001). Coordinated control of cell Ca(2+) loading 
and triggered release from the sarcoplasmic reticulum underlies the rapid 
inotropic response to increased L-type Ca(2+) current. Circ Res 88,195-201.
Treinys R & Jurevicius J. (2008). L-type Ca2+ channels in the heart: structure and 
regulation. Medicina (Kaunas) 44, 491-499.
Treves S, Pouliquin R, Moccagatta L & Zorzato F. (2002). Functional properties of 
EGFP-tagged skeletal muscle calcium-release channel (ryanodine receptor) 
expressed in COS-7 cells: sensitivity to caffeine and 4-chloro-m-cresol. Cell 
Calcium 31,1-12.
Uchinoumi H, Yano M, Suetomi T, Ono M, Xu X, Tateishi H, Oda T, Okuda S, Doi M, 
Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N & Matsuzaki M.
(2010). Catecholaminergic polymorphic ventricular tachycardia is caused by 
mutation-linked defective conformational regulation of the ryanodine receptor. 
Circ Res 106,1413-1424.
Valdivia HH. (1998). Modulation of intracellular Ca2+ levels in the heart by sorcin and 
FKBP12, two accessory proteins of ryanodine receptors. Trends Pharmacol Sci 
19, 479-482.
van Noord C, Eijgelsheim M & Strieker BH. (2010). Drug- and non-drug-associated QT 
interval prolongation. BrJ Clin Pharmacol 70,16-23.
Verboomen H, Wuytack F, De Smedt H, Himpens B & Casteels R. (1992). Functional 
difference between SERCA2a and SERCA2b Ca2+ pumps and their modulation 
by phospholamban. Biochem J 286 ( Pt 2), 591-595.
Viswanathan PC, Benson DW & Balser JR. (2003). A common SCN5A polymorphism 
modulates the biophysical effects of an SCN5A mutation. J Clin Invest 111, 341- 
346.
Wakimoto H, Alcalai R, Song L, Arad M, Seidman CE, Seidman JG & Berul Cl. (2007). 
Prevention of fatal arrhythmia in a catecholaminergic polymorphoc ventricular 
tachycardia mouse model carrying calsequestrin-2 mutation. Circulation 116, 
216.
315
Walker CA & Spinale FG. (1999). The structure and function of the cardiac myocyte: a 
review of fundamental concepts. J Thorac Cardiovasc Sung 118, 375-382.
Wang R, Chen W, Cai S, Zhang J, Bolstad J, Wagenknecht T, Liu Z & Chen SR. (2007). 
Localization of an NH(2)-terminal disease-causing mutation hot spot to the 
"clamp" region in the three-dimensional structure of the cardiac ryanodine 
receptor. J Biol Chem 282,17785-17793.
Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, Sun J, Guatimosim 
S, Song LS, Rosemblit N, D'Armiento JM, Napolitano C, Memmi M, Priori SG, 
Lederer WJ & Marks AR. (2003). FKBP12.6 deficiency and defective calcium 
release channel (ryanodine receptor) function linked to exercise-induced sudden 
cardiac death. Cell 113, 829-840.
Wilton SB, Anderson TJ, Parboosingh J, Bridge PJ, Exner DV, Forrest D & Duff HJ.
(2008). Polymorphisms in multiple genes are associated with resting heart rate in 
a stepwise allele-dependent manner. Heart Rhythm 5, 694-700.
Xiao B, Masumiya H, Jiang D, Wang R, Sei Y, Zhang L, Murayama T, Ogawa Y, Lai FA, 
Wagenknecht T & Chen SR. (2002). Isoform-dependent formation of heteromeric 
Ca2+ release channels (ryanodine receptors). J Biol Chem 277,41778-41785.
Xu L & Meissner G. (1998). Regulation of cardiac muscle Ca2+ release channel by 
sarcoplasmic reticulum lumenal Ca2+. Biophys J 75, 2302-2312.
Xu X, Yano M, Uchinoumi H, Hino A, Suetomi T, Ono M, Tateishi H, Oda T, Okuda S, 
Doi M, Kobayashi S, Yamamoto T, Ikeda Y, Ikemoto N & Matsuzaki M. (2010). 
Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in 
CPVT-associated channel dysfunction. Biochem Biophys Res Commun 394, 
660-666.
Yang Z, Ikemoto N, Lamb GD & Steele DS. (2006). The RyR2 central domain peptide 
DPc10 lowers the threshold for spontaneous Ca2+ release in permeabilized 
cardiomyocytes. Cardiovasc Res 70,475-485.
Ye B, Valdivia CR, Ackerman MJ & Makielski JC. (2003). A common human SCN5A 
polymorphism modifies expression of an arrhythmia causing mutation. Physiol 
Genomics 12,187-193.
Yin CC, Blayney LM & Lai FA. (2005a). Physical coupling between ryanodine receptor- 
calcium release channels. J Mol Biol 349, 538-546.
Yin CC, Han H, Wei R & Lai FA. (2005b). Two-dimensional crystallization of the 
ryanodine receptor Ca2+ release channel on lipid membranes. J Struct Biol 149, 
219-224.
Zhang G, Gurtu V  & Kain SR. (1996). An enhanced green fluorescent protein allows 
sensitive detection of gene transfer in mammalian cells. Biochem Biophys Res 
Commun 227, 707-711.
Zhang J, Liu Z, Masumiya H, Wang R, Jiang D, Li F, Wagenknecht T & Chen SR. 
(2003). Three-dimensional localization of divergent region 3 of the ryanodine
316
receptor to the clamp-shaped structures adjacent to the FKBP binding sites. J 
Biol Chem 278,14211-14218.
Zhao M, Li P, Li X, Zhang L, Winkfein RJ & Chen SR. (1999). Molecular identification of 
the ryanodine receptor pore-forming segment J Biol Chem 274, 25971-25974.
Zimmer M. (2009). GFP: from jellyfish to the Nobel prize and beyond. Chem Soc Rev 38, 
2823-2832.
Zimmer T & Surber R. (2008). SCN5A channelopathies--an update on mutations and 
mechanisms. Prog Biophys Mol Biol 98,120-136.
Zissimopoulos S & Lai FA. (2005). Interaction of FKBP12.6 with the cardiac ryanodine 
receptor C-terminal domain. J Biol Chem 280, 5475-5485.
Zissimopoulos S, Thomas NL, Jamaluddin WW & Lai FA. (2009). FKBP12.6 binding of 
ryanodine receptors carrying mutations associated with arrhythmogenic cardiac 
disease. Biochem J 419, 273-278.
317
